{"version": "v2.0", "data": [{"id": "10907391_3_0", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_3_1", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_3_2", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_3_3", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_3_4", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_3_5", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_3_6", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_3_7", "context": "Physicians should be aware that PLP can occur after initiation of paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_3_8", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_3_9", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_3_10", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_3_11", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_3_12", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_3_13", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_3_14", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_3_15", "context": "Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6405633_1_16", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lithium; metoprolol"}, {"id": "6405633_1_17", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6405633_1_18", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6405633_1_19", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6405633_1_20", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6405633_1_21", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6405633_1_22", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "lithium tremor"}, {"id": "6405633_1_23", "context": "Treatment of lithium tremor with metoprolol.", "question": "potential therapeutic event. Treatment, metoprolol. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4044222_1_24", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Subject, A 54-year-old man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "54-year-old"}, {"id": "4044222_1_25", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Subject, A 54-year-old man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "4044222_1_26", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Subject, A 54-year-old man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4044222_1_27", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Subject, A 54-year-old man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4044222_1_28", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Subject, A 54-year-old man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4044222_1_29", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "4044222_1_30", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4044222_1_31", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4044222_1_32", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4044222_1_33", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4044222_1_34", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4044222_1_35", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4044222_1_36", "context": "A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12962465_2_37", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "12962465_2_38", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_2_39", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_2_40", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_2_41", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12962465_2_42", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_2_43", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_2_44", "context": "Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.", "question": "adverse event. Treatment, isoniazid therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_6_45", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Subject, prior cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_6_46", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Subject, prior cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_6_47", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Subject, prior cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15112258_6_48", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Subject, prior cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_6_49", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Subject, prior cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_6_50", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_6_51", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_6_52", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_6_53", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_6_54", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_6_55", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_6_56", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_6_57", "context": "The authors performed a literature search using PubMed and the search terms \"gemcitabine\" and \"radiation recall\" to find prior cases of radiation recall attributed to gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1893404_1_58", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carbamazepine"}, {"id": "1893404_1_59", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1893404_1_60", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1893404_1_61", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1893404_1_62", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1893404_1_63", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1893404_1_64", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1893404_1_65", "context": "Carbamazepine-induced Diabetes mellitus.", "question": "adverse event. Treatment, Carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_5_66", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Subject, She. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_5_67", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Subject, She. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "15827071_5_68", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Subject, She. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15827071_5_69", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Subject, She. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_5_70", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Subject, She. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_5_71", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_5_72", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_5_73", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_5_74", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "introduction"}, {"id": "15827071_5_75", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "8 days"}, {"id": "15827071_5_76", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_5_77", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_5_78", "context": "She displayed symptoms of ST 8 days after the introduction of linezolid.", "question": "adverse event. Treatment, 8 days after the introduction of linezolid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_2_79", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Naproxen"}, {"id": "9819544_2_80", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_2_81", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_2_82", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_2_83", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_2_84", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9819544_2_85", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_2_86", "context": "Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.", "question": "adverse event. Treatment, Naproxen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3159106_3_87", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "allopurinol"}, {"id": "3159106_3_88", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3159106_3_89", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3159106_3_90", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3159106_3_91", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3159106_3_92", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3159106_3_93", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3159106_3_94", "context": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.", "question": "adverse event. Treatment, allopurinol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8452107_2_95", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "piritrexim"}, {"id": "8452107_2_96", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_2_97", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_2_98", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8452107_2_99", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_2_100", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_2_101", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8452107_2_102", "context": "The pulmonary toxicity is probably induced by piritrexim.", "question": "adverse event. Treatment, piritrexim. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_1_103", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Interferon"}, {"id": "15944830_1_104", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_1_105", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_1_106", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_1_107", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_1_108", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_1_109", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_1_110", "context": "BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.", "question": "adverse event. Treatment, Interferon (IFN). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7986915_2_111", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Subject, a patient with a liver abscess due to Entamoeba histolytica. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7986915_2_112", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Subject, a patient with a liver abscess due to Entamoeba histolytica. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7986915_2_113", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Subject, a patient with a liver abscess due to Entamoeba histolytica. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7986915_2_114", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Subject, a patient with a liver abscess due to Entamoeba histolytica. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7986915_2_115", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Subject, a patient with a liver abscess due to Entamoeba histolytica. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7986915_2_116", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "7986915_2_117", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "21 g"}, {"id": "7986915_2_118", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7986915_2_119", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7986915_2_120", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7986915_2_121", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "14 days"}, {"id": "7986915_2_122", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "liver abscess; Entamoeba histolytica"}, {"id": "7986915_2_123", "context": "We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.", "question": "adverse event. Treatment, metronidazole therapy (total dose, 21 g over 14 days). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18159131_4_124", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Subject, a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18159131_4_125", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Subject, a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "18159131_4_126", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Subject, a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18159131_4_127", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Subject, a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "Japanese"}, {"id": "18159131_4_128", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Subject, a Japanese male patient who underwent a living-donor kidney transplantation; immunosuppression. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "kidney transplantation"}, {"id": "18159131_4_129", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tacrolimus; mycophenolate mofeti; prednisolone"}, {"id": "18159131_4_130", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18159131_4_131", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18159131_4_132", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18159131_4_133", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18159131_4_134", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18159131_4_135", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "immunosuppression"}, {"id": "18159131_4_136", "context": "We present a Japanese male patient who underwent a living-donor kidney transplantation having received tacrolimus, mycophenolate mofetil, and prednisolone for immunosuppression.", "question": "potential therapeutic event. Treatment, tacrolimus, mycophenolate mofetil, and prednisolone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tacrolimus; mycophenolate mofeti; prednisolone"}, {"id": "6430252_1_137", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gold; auranofin; tolmetin"}, {"id": "6430252_1_138", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6430252_1_139", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6430252_1_140", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6430252_1_141", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6430252_1_142", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6430252_1_143", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6430252_1_144", "context": "Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.", "question": "adverse event. Treatment, auranofin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_3_145", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Subject, three cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2690546_3_146", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Subject, three cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2690546_3_147", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Subject, three cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "2690546_3_148", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Subject, three cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2690546_3_149", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Subject, three cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2690546_3_150", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "2690546_3_151", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_3_152", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_3_153", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_3_154", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_3_155", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_3_156", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_3_157", "context": "We report three cases of amiodarone-induced torsades de pointe.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11720625_1_158", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disopyramide; clarithromycin"}, {"id": "11720625_1_159", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_1_160", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_1_161", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_1_162", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_1_163", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_1_164", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11720625_1_165", "context": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin.", "question": "adverse event. Treatment, drug interaction between disopyramide and clarithromycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "disopyramide; clarithromycin"}, {"id": "12053072_2_166", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12053072_2_167", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12053072_2_168", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12053072_2_169", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12053072_2_170", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12053072_2_171", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12053072_2_172", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "144 mg/m2"}, {"id": "12053072_2_173", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12053072_2_174", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12053072_2_175", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_2_176", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12053072_2_177", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "carcinoma of the ascending colon"}, {"id": "12053072_2_178", "context": "We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.", "question": "adverse event. Treatment, mitomycin C (total dose 144 mg/m2). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23006440_5_179", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23006440_5_180", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23006440_5_181", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23006440_5_182", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23006440_5_183", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23006440_5_184", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-FU; PHT"}, {"id": "23006440_5_185", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23006440_5_186", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23006440_5_187", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23006440_5_188", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23006440_5_189", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23006440_5_190", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23006440_5_191", "context": "In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.", "question": "adverse event. Treatment, 5-FU increased PHT, which in turn may have increased the PB concentration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "5-FU; PHT"}, {"id": "16181292_2_192", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone; photodynamic"}, {"id": "16181292_2_193", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16181292_2_194", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16181292_2_195", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16181292_2_196", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16181292_2_197", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16181292_2_198", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "exudative age-related macular degeneration"}, {"id": "16181292_2_199", "context": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.", "question": "adverse event. Treatment, intravitreal triamcinolone; photodynamic. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "triamcinolone; photodynamic"}, {"id": "10715308_12_200", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Subject, patients with advanced NSCLC. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10715308_12_201", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Subject, patients with advanced NSCLC. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10715308_12_202", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Subject, patients with advanced NSCLC. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10715308_12_203", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Subject, patients with advanced NSCLC. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10715308_12_204", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Subject, patients with advanced NSCLC. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10715308_12_205", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine"}, {"id": "10715308_12_206", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_12_207", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_12_208", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_12_209", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_12_210", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_12_211", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced NSCLC"}, {"id": "10715308_12_212", "context": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.", "question": "potential therapeutic event. Treatment, tirapazamine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9619226_1_213", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulprostone"}, {"id": "9619226_1_214", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9619226_1_215", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9619226_1_216", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9619226_1_217", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9619226_1_218", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9619226_1_219", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9619226_1_220", "context": "Cardiac arrest associated with sulprostone use during caesarean section.", "question": "adverse event. Treatment, sulprostone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11807466_1_221", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11807466_1_222", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11807466_1_223", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11807466_1_224", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11807466_1_225", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11807466_1_226", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11807466_1_227", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11807466_1_228", "context": "Linear IgA bullous dermatosis occurring after carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12053072_1_229", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Erythropoietin"}, {"id": "12053072_1_230", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12053072_1_231", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12053072_1_232", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12053072_1_233", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_1_234", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12053072_1_235", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "mitomycin-induced hemolytic-uremic syndrome"}, {"id": "12053072_1_236", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "potential therapeutic event. Treatment, Erythropoietin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12053072_1_237", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin"}, {"id": "12053072_1_238", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12053072_1_239", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12053072_1_240", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12053072_1_241", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12053072_1_242", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12053072_1_243", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12053072_1_244", "context": "Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.", "question": "adverse event. Treatment, mitomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_9_245", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Subject, 11 percent of patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8305778_9_246", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Subject, 11 percent of patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8305778_9_247", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Subject, 11 percent of patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "11 percent"}, {"id": "8305778_9_248", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Subject, 11 percent of patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8305778_9_249", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Subject, 11 percent of patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8305778_9_250", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "8305778_9_251", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_9_252", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8305778_9_253", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8305778_9_254", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_9_255", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8305778_9_256", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8305778_9_257", "context": "Hypothyroidism, occurring in up to 11 percent of patients treated with amiodarone, can also alter drug metabolism and sensitize the central nervous system, thus increasing the potential for toxicity.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3513544_2_258", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Subject, a renal transplant patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_2_259", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Subject, a renal transplant patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_2_260", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Subject, a renal transplant patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_2_261", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Subject, a renal transplant patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_2_262", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Subject, a renal transplant patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3513544_2_263", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine A; chronic steroid"}, {"id": "3513544_2_264", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_2_265", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_2_266", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_2_267", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_2_268", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_2_269", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal transplant"}, {"id": "3513544_2_270", "context": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.", "question": "adverse event. Treatment, Cyclosporine A while on chronic steroid therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "Cyclosporine A; chronic steroid"}, {"id": "1827039_1_271", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyproterone acetate"}, {"id": "1827039_1_272", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_1_273", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_1_274", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_1_275", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_1_276", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_1_277", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_1_278", "context": "Severe hepatocellular dysfunction following cyproterone acetate therapy.", "question": "adverse event. Treatment, cyproterone acetate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11672959_2_279", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulphasalazine"}, {"id": "11672959_2_280", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11672959_2_281", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11672959_2_282", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11672959_2_283", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11672959_2_284", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11672959_2_285", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11672959_2_286", "context": "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called \"3-week sulphasalazine syndrome\", a rare, but often fatal, immunoallergic reaction to sulphasalazine.", "question": "adverse event. Treatment, sulphasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6405633_2_287", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Subject, Two patients with bipolar affective disorder and a history of bronchospastic phenomena. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6405633_2_288", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Subject, Two patients with bipolar affective disorder and a history of bronchospastic phenomena. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6405633_2_289", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Subject, Two patients with bipolar affective disorder and a history of bronchospastic phenomena. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "6405633_2_290", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Subject, Two patients with bipolar affective disorder and a history of bronchospastic phenomena. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6405633_2_291", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Subject, Two patients with bipolar affective disorder and a history of bronchospastic phenomena. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "a history of bronchospastic phenomena"}, {"id": "6405633_2_292", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium carbonate"}, {"id": "6405633_2_293", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6405633_2_294", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6405633_2_295", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6405633_2_296", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6405633_2_297", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6405633_2_298", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bipolar affective disorder"}, {"id": "6405633_2_299", "context": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.", "question": "adverse event. Treatment, lithium carbonate therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_1_300", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Subject, chronically hypoperfused kidneys. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6344831_1_301", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Subject, chronically hypoperfused kidneys. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6344831_1_302", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Subject, chronically hypoperfused kidneys. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6344831_1_303", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Subject, chronically hypoperfused kidneys. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6344831_1_304", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Subject, chronically hypoperfused kidneys. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronically hypoperfused kidneys"}, {"id": "6344831_1_305", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_1_306", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_1_307", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_1_308", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_1_309", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_1_310", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_1_311", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6344831_1_312", "context": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.", "question": "adverse event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2154663_3_313", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Subject, a patient with metastatic breast cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2154663_3_314", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Subject, a patient with metastatic breast cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2154663_3_315", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Subject, a patient with metastatic breast cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2154663_3_316", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Subject, a patient with metastatic breast cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2154663_3_317", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Subject, a patient with metastatic breast cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2154663_3_318", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aminoglutethimide"}, {"id": "2154663_3_319", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_3_320", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2154663_3_321", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2154663_3_322", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_3_323", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2154663_3_324", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic breast cancer"}, {"id": "2154663_3_325", "context": "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.", "question": "adverse event. Treatment, radiotherapy-enhanced aminoglutethimide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_8_326", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "25540831_8_327", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "25540831_8_328", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "25540831_8_329", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "25540831_8_330", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "25540831_8_331", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic drugs"}, {"id": "25540831_8_332", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_8_333", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_8_334", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_8_335", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_8_336", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_8_337", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_8_338", "context": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome.", "question": "adverse event. Treatment, serotonergic drugs. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "946400_3_339", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methyldopa"}, {"id": "946400_3_340", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_3_341", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_3_342", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_3_343", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "946400_3_344", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_3_345", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "946400_3_346", "context": "Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.", "question": "adverse event. Treatment, methyldopa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_2_347", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Subject, eight patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_2_348", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Subject, eight patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_2_349", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Subject, eight patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "eight"}, {"id": "6507240_2_350", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Subject, eight patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_2_351", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Subject, eight patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_2_352", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_2_353", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single 200 mg"}, {"id": "6507240_2_354", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_2_355", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "6507240_2_356", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_2_357", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_2_358", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_2_359", "context": "In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.", "question": "adverse event. Treatment, a single 200 mg intravenous dose of lorcainide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2234880_1_360", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Nitrendipine"}, {"id": "2234880_1_361", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2234880_1_362", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2234880_1_363", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2234880_1_364", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2234880_1_365", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2234880_1_366", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2234880_1_367", "context": "Nitrendipine-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3501467_1_368", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Subject, a patient with definite seronegative rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3501467_1_369", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Subject, a patient with definite seronegative rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3501467_1_370", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Subject, a patient with definite seronegative rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3501467_1_371", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Subject, a patient with definite seronegative rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3501467_1_372", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Subject, a patient with definite seronegative rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3501467_1_373", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "3501467_1_374", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3501467_1_375", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3501467_1_376", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3501467_1_377", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3501467_1_378", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3501467_1_379", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "3501467_1_380", "context": "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.", "question": "adverse event. Treatment, gold therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_4_381", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Subject, he. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12763355_4_382", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Subject, he. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12763355_4_383", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Subject, he. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12763355_4_384", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Subject, he. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12763355_4_385", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Subject, he. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12763355_4_386", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SASP; 5-aminosalicylic acid"}, {"id": "12763355_4_387", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_4_388", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_4_389", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_4_390", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_4_391", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_4_392", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_4_393", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "adverse event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_4_394", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "5-aminosalicylic acid; SASP"}, {"id": "12763355_4_395", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_4_396", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12763355_4_397", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12763355_4_398", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_4_399", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12763355_4_400", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "skin eruptions"}, {"id": "12763355_4_401", "context": "When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.", "question": "potential therapeutic event. Treatment, SASP was changed to 5-aminosalicylic acid (5-ASA). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17697264_2_402", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus"}, {"id": "17697264_2_403", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17697264_2_404", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17697264_2_405", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17697264_2_406", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17697264_2_407", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17697264_2_408", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17697264_2_409", "context": "One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.", "question": "adverse event. Treatment, tacrolimus; after lung transplantation (LT). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_4_410", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Subject, an NHL patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16948177_4_411", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Subject, an NHL patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16948177_4_412", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Subject, an NHL patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16948177_4_413", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Subject, an NHL patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16948177_4_414", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Subject, an NHL patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16948177_4_415", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_4_416", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_4_417", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_4_418", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_4_419", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_4_420", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_4_421", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "NHL"}, {"id": "16948177_4_422", "context": "We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).", "question": "adverse event. Treatment, rituximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11720625_4_423", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Subject, 76-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "76-year-old"}, {"id": "11720625_4_424", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Subject, 76-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11720625_4_425", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Subject, 76-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11720625_4_426", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Subject, 76-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11720625_4_427", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Subject, 76-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11720625_4_428", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "long-term disopyramide; clarithromycin"}, {"id": "11720625_4_429", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_4_430", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_4_431", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_4_432", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_4_433", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_4_434", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic bronchitis"}, {"id": "11720625_4_435", "context": "We describe a case of TdP caused by a drug interaction in a 76-year-old woman taking long-term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis.", "question": "adverse event. Treatment, long-term disopyramide; clarithromycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "long-term disopyramide; clarithromycin"}, {"id": "14971874_2_436", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Subject, rheumatoid arthritis patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14971874_2_437", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Subject, rheumatoid arthritis patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14971874_2_438", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Subject, rheumatoid arthritis patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14971874_2_439", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Subject, rheumatoid arthritis patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14971874_2_440", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Subject, rheumatoid arthritis patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14971874_2_441", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "14971874_2_442", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14971874_2_443", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14971874_2_444", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14971874_2_445", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14971874_2_446", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14971874_2_447", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "14971874_2_448", "context": "Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.", "question": "adverse event. Treatment, infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18006091_2_449", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "18006091_2_450", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18006091_2_451", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18006091_2_452", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18006091_2_453", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18006091_2_454", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18006091_2_455", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18006091_2_456", "context": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_1_457", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Subject, three adolescent patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "11008259_1_458", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Subject, three adolescent patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11008259_1_459", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Subject, three adolescent patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11008259_1_460", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Subject, three adolescent patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11008259_1_461", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Subject, three adolescent patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11008259_1_462", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_1_463", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_1_464", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_1_465", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_1_466", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_1_467", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_1_468", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_1_469", "context": "Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.", "question": "adverse event. Treatment, tiagabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_5_470", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_5_471", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_5_472", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_5_473", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_5_474", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_5_475", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_5_476", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_5_477", "context": "We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.", "question": "adverse event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_3_478", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; amoxapine"}, {"id": "6625005_3_479", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_3_480", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_3_481", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_3_482", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_3_483", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_3_484", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_3_485", "context": "The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.", "question": "adverse event. Treatment, discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19934385_3_486", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Subject, A 34-year-old HIV-infected man. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "34-year-old"}, {"id": "19934385_3_487", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Subject, A 34-year-old HIV-infected man. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "19934385_3_488", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Subject, A 34-year-old HIV-infected man. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19934385_3_489", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Subject, A 34-year-old HIV-infected man. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19934385_3_490", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Subject, A 34-year-old HIV-infected man. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "disseminated Histoplasma capsulatum infection"}, {"id": "19934385_3_491", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "efavirenz; antiretroviral"}, {"id": "19934385_3_492", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19934385_3_493", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19934385_3_494", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19934385_3_495", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19934385_3_496", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19934385_3_497", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "HIV"}, {"id": "19934385_3_498", "context": "A 34-year-old HIV-infected man who had recently initiated efavirenz-based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection.", "question": "potential therapeutic event. Treatment, initiated efavirenz-based antiretroviral therapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "efavirenz; antiretroviral"}, {"id": "2154663_1_499", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Aminoglutethimide"}, {"id": "2154663_1_500", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_1_501", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2154663_1_502", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2154663_1_503", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_1_504", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2154663_1_505", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2154663_1_506", "context": "Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.", "question": "potential therapeutic event. Treatment, Aminoglutethimide was discontinued until completion of radiotherapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15941649_4_507", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Subject, two children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "15941649_4_508", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Subject, two children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15941649_4_509", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Subject, two children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15941649_4_510", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Subject, two children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15941649_4_511", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Subject, two children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15941649_4_512", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15941649_4_513", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_4_514", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_4_515", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_4_516", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_4_517", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_4_518", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_4_519", "context": "We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.", "question": "adverse event. Treatment, exposed prenatally to VGB; VGB. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2572964_2_520", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Subject, Two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2572964_2_521", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Subject, Two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2572964_2_522", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Subject, Two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "2572964_2_523", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Subject, Two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2572964_2_524", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Subject, Two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2572964_2_525", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "depot neuroleptics; betel nut"}, {"id": "2572964_2_526", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2572964_2_527", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2572964_2_528", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2572964_2_529", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2572964_2_530", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2572964_2_531", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic schizophrenic"}, {"id": "2572964_2_532", "context": "Two cases are described of chronic schizophrenic patients maintained on depot neuroleptics, who developed severe extrapyramidal symptoms following a period of heavy betel nut consumption.", "question": "adverse event. Treatment, heavy betel nut consumption; depot neuroleptics. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "160443_1_533", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Subject, younger individuals. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "younger"}, {"id": "160443_1_534", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Subject, younger individuals. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "160443_1_535", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Subject, younger individuals. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "160443_1_536", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Subject, younger individuals. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "160443_1_537", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Subject, younger individuals. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "160443_1_538", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clioquinol"}, {"id": "160443_1_539", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "160443_1_540", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "160443_1_541", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intake"}, {"id": "160443_1_542", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "160443_1_543", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "160443_1_544", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "160443_1_545", "context": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.", "question": "adverse event. Treatment, intake of clioquinol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_2_546", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Subject, a patient with severe renovascular hypertension. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6344831_2_547", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Subject, a patient with severe renovascular hypertension. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "6344831_2_548", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Subject, a patient with severe renovascular hypertension. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6344831_2_549", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Subject, a patient with severe renovascular hypertension. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6344831_2_550", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Subject, a patient with severe renovascular hypertension. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6344831_2_551", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_2_552", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_2_553", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_2_554", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_2_555", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_2_556", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_2_557", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renovascular hypertension"}, {"id": "6344831_2_558", "context": "In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.", "question": "adverse event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1834424_1_559", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Subject, A 30-year-old pharmacist. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "30-year-old"}, {"id": "1834424_1_560", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Subject, A 30-year-old pharmacist. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1834424_1_561", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Subject, A 30-year-old pharmacist. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1834424_1_562", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Subject, A 30-year-old pharmacist. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1834424_1_563", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Subject, A 30-year-old pharmacist. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1834424_1_564", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "4-chloro-7-nitrobenzofurazan"}, {"id": "1834424_1_565", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1834424_1_566", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1834424_1_567", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1834424_1_568", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1834424_1_569", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1834424_1_570", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1834424_1_571", "context": "A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan (NBD-Cl). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_1_572", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15760792_1_573", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_1_574", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_1_575", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_1_576", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_1_577", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_1_578", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15760792_1_579", "context": "CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.", "question": "adverse event. Treatment, PTU. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7887138_1_580", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "7887138_1_581", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7887138_1_582", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7887138_1_583", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7887138_1_584", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "15-year"}, {"id": "7887138_1_585", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7887138_1_586", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7887138_1_587", "context": "A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_2_588", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Subject, two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8627446_2_589", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Subject, two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8627446_2_590", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Subject, two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "8627446_2_591", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Subject, two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8627446_2_592", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Subject, two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8627446_2_593", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_2_594", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_2_595", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_2_596", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_2_597", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_2_598", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_2_599", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis"}, {"id": "8627446_2_600", "context": "We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.", "question": "adverse event. Treatment, methotrexate therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_6_601", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_6_602", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_6_603", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_6_604", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_6_605", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_6_606", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_6_607", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_6_608", "context": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_5_609", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "24927617_5_610", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_5_611", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_5_612", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_5_613", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_5_614", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_5_615", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24927617_5_616", "context": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "question": "adverse event. Treatment, simvastatin and all antiviral drugs. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_1_617", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "6614033_1_618", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_1_619", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6614033_1_620", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6614033_1_621", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_1_622", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6614033_1_623", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_1_624", "context": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2461837_2_625", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Subject, a patient with acquired immune deficiency syndrome (AIDS). What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2461837_2_626", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Subject, a patient with acquired immune deficiency syndrome (AIDS). What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2461837_2_627", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Subject, a patient with acquired immune deficiency syndrome (AIDS). What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2461837_2_628", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Subject, a patient with acquired immune deficiency syndrome (AIDS). What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2461837_2_629", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Subject, a patient with acquired immune deficiency syndrome (AIDS). What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2461837_2_630", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "2461837_2_631", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2461837_2_632", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2461837_2_633", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2461837_2_634", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2461837_2_635", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2461837_2_636", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acquired immune deficiency syndrome"}, {"id": "2461837_2_637", "context": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).", "question": "adverse event. Treatment, bleomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_2_638", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Subject, a patient with autoimmune hepatitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8551001_2_639", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Subject, a patient with autoimmune hepatitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8551001_2_640", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Subject, a patient with autoimmune hepatitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8551001_2_641", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Subject, a patient with autoimmune hepatitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8551001_2_642", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Subject, a patient with autoimmune hepatitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8551001_2_643", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "8551001_2_644", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_2_645", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_2_646", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_2_647", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_2_648", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_2_649", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "thiopurine methyltransferase deficiency; autoimmune hepatitis"}, {"id": "8551001_2_650", "context": "Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.", "question": "adverse event. Treatment, Azathioprine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_2_651", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "8645078_2_652", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_2_653", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_2_654", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_2_655", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_2_656", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_2_657", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_2_658", "context": "Captopril-associated \"pseudocholangitis'.", "question": "adverse event. Treatment, Captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6628806_1_659", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Subject, psoriasis; a 47-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "47-year-old"}, {"id": "6628806_1_660", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Subject, psoriasis; a 47-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6628806_1_661", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Subject, psoriasis; a 47-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6628806_1_662", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Subject, psoriasis; a 47-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6628806_1_663", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Subject, psoriasis; a 47-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6628806_1_664", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etretinate; methotrexate"}, {"id": "6628806_1_665", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6628806_1_666", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6628806_1_667", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6628806_1_668", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6628806_1_669", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6628806_1_670", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "severe psoriasis"}, {"id": "6628806_1_671", "context": "A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.", "question": "adverse event. Treatment, combination therapy with methotrexate and etretinate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; etretinate"}, {"id": "1988604_2_672", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Thrombin"}, {"id": "1988604_2_673", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1988604_2_674", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1988604_2_675", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1988604_2_676", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1988604_2_677", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1988604_2_678", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "intractable arterial hemorrhage"}, {"id": "1988604_2_679", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "potential therapeutic event. Treatment, Thrombin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1988604_2_680", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Subject, one patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1988604_2_681", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Subject, one patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1988604_2_682", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Subject, one patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "one"}, {"id": "1988604_2_683", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Subject, one patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1988604_2_684", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Subject, one patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1988604_2_685", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Thrombin"}, {"id": "1988604_2_686", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1988604_2_687", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1988604_2_688", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1988604_2_689", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1988604_2_690", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1988604_2_691", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "intractable arterial hemorrhage"}, {"id": "1988604_2_692", "context": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.", "question": "adverse event. Treatment, Thrombin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12439602_2_693", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carboplatin"}, {"id": "12439602_2_694", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12439602_2_695", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12439602_2_696", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12439602_2_697", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12439602_2_698", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12439602_2_699", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12439602_2_700", "context": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.", "question": "adverse event. Treatment, Carboplatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23471710_1_701", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Helicobacter pylori triple-drug; insulin detemir drug"}, {"id": "23471710_1_702", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23471710_1_703", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23471710_1_704", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23471710_1_705", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23471710_1_706", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23471710_1_707", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23471710_1_708", "context": "Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.", "question": "adverse event. Treatment, Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "insulin detemir drug; Helicobacter pylori triple-drug"}, {"id": "18765315_3_709", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_3_710", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_3_711", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_3_712", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusions"}, {"id": "18765315_3_713", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_3_714", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_3_715", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_3_716", "context": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.", "question": "adverse event. Treatment, rituximab infusions. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12196060_12_717", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; isradipine"}, {"id": "12196060_12_718", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_12_719", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_12_720", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_12_721", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_12_722", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_12_723", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_12_724", "context": "Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed.", "question": "adverse event. Treatment, Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; isradipine"}, {"id": "11819156_2_725", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Subject, A patient suffering from a rare enzyme deficiency. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11819156_2_726", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Subject, A patient suffering from a rare enzyme deficiency. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11819156_2_727", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Subject, A patient suffering from a rare enzyme deficiency. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11819156_2_728", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Subject, A patient suffering from a rare enzyme deficiency. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11819156_2_729", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Subject, A patient suffering from a rare enzyme deficiency. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11819156_2_730", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "11819156_2_731", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "one single dose"}, {"id": "11819156_2_732", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11819156_2_733", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11819156_2_734", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11819156_2_735", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11819156_2_736", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "enzyme deficiency"}, {"id": "11819156_2_737", "context": "A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.", "question": "adverse event. Treatment, one single dose of haloperidol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_3_738", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "8645078_3_739", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_3_740", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_3_741", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_3_742", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_3_743", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_3_744", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_3_745", "context": "Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.", "question": "adverse event. Treatment, Captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16446228_1_746", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Subject, a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16446228_1_747", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Subject, a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16446228_1_748", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Subject, a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16446228_1_749", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Subject, a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16446228_1_750", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Subject, a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16446228_1_751", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "corticosteroids"}, {"id": "16446228_1_752", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_1_753", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16446228_1_754", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16446228_1_755", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_1_756", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16446228_1_757", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16446228_1_758", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "potential therapeutic event. Treatment, withdrawal of the drug and treatment with corticosteroids. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16446228_1_759", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16446228_1_760", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_1_761", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16446228_1_762", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16446228_1_763", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_1_764", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16446228_1_765", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "sirolimus-associated interstitial pneumonitis"}, {"id": "16446228_1_766", "context": "Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.", "question": "adverse event. Treatment, sirolimus. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_1_767", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_1_768", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_1_769", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_1_770", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_1_771", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_1_772", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3586163_1_773", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3586163_1_774", "context": "Other upper tract neoplasms after cyclophosphamide are reviewed.", "question": "adverse event. Treatment, cyclophosphamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "647693_1_775", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Subject, Four patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "647693_1_776", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Subject, Four patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "647693_1_777", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Subject, Four patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Four"}, {"id": "647693_1_778", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Subject, Four patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "647693_1_779", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Subject, Four patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "647693_1_780", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "647693_1_781", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "647693_1_782", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "647693_1_783", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "647693_1_784", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "647693_1_785", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "1 year"}, {"id": "647693_1_786", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "647693_1_787", "context": "Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.", "question": "adverse event. Treatment, high-dose tamoxifen for greater than 1 year. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_3_788", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12390172_3_789", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12390172_3_790", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12390172_3_791", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12390172_3_792", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12390172_3_793", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_3_794", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_3_795", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_3_796", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_3_797", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_3_798", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_3_799", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_3_800", "context": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_1_801", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Subject, Greenlandic patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11590881_1_802", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Subject, Greenlandic patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11590881_1_803", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Subject, Greenlandic patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11590881_1_804", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Subject, Greenlandic patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Greenlandic"}, {"id": "11590881_1_805", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Subject, Greenlandic patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11590881_1_806", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carbamazepine"}, {"id": "11590881_1_807", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11590881_1_808", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11590881_1_809", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11590881_1_810", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_1_811", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11590881_1_812", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_1_813", "context": "Carbamazepine induced right bundle branch block in a Greenlandic patient.", "question": "adverse event. Treatment, Carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17068466_2_814", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Subject, Both cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17068466_2_815", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Subject, Both cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17068466_2_816", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Subject, Both cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17068466_2_817", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Subject, Both cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17068466_2_818", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Subject, Both cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17068466_2_819", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "moxifloxacin"}, {"id": "17068466_2_820", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_2_821", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "frequent"}, {"id": "17068466_2_822", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "17068466_2_823", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_2_824", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_2_825", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_2_826", "context": "RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.", "question": "adverse event. Treatment, weeks of frequent topical dosing with moxifloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8844232_2_827", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8844232_2_828", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8844232_2_829", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8844232_2_830", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8844232_2_831", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8844232_2_832", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "3,4-methylenedioxymet-amphetamine"}, {"id": "8844232_2_833", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8844232_2_834", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8844232_2_835", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8844232_2_836", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8844232_2_837", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8844232_2_838", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8844232_2_839", "context": "We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.", "question": "adverse event. Treatment, 3,4-methylenedioxymet-amphetamine Ecstasy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_7_840", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Subject, the patient had tolerated lisinopril before. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14964753_7_841", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Subject, the patient had tolerated lisinopril before. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14964753_7_842", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Subject, the patient had tolerated lisinopril before. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14964753_7_843", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Subject, the patient had tolerated lisinopril before. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14964753_7_844", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Subject, the patient had tolerated lisinopril before. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "tolerated lisinopril"}, {"id": "14964753_7_845", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ramipril"}, {"id": "14964753_7_846", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_7_847", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_7_848", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_7_849", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_7_850", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_7_851", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_7_852", "context": "Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.", "question": "adverse event. Treatment, Ramipril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_6_853", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_6_854", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_6_855", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_6_856", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_6_857", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_6_858", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_6_859", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_6_860", "context": "To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1628669_1_861", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Subject, A 7-year-old girl. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "7-year-old"}, {"id": "1628669_1_862", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Subject, A 7-year-old girl. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "1628669_1_863", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Subject, A 7-year-old girl. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1628669_1_864", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Subject, A 7-year-old girl. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1628669_1_865", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Subject, A 7-year-old girl. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1628669_1_866", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine; prednisone; azathioprine; prednisone"}, {"id": "1628669_1_867", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1628669_1_868", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1628669_1_869", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1628669_1_870", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1628669_1_871", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "3.5 years"}, {"id": "1628669_1_872", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic auto-immune haemolytic anaemia"}, {"id": "1628669_1_873", "context": "A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.", "question": "adverse event. Treatment, 3.5 years of almost continuous treatment with azathioprine and/or prednisone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "azathioprine; prednisone"}, {"id": "10485779_2_874", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ritonavir; substrates of this enzyme"}, {"id": "10485779_2_875", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10485779_2_876", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10485779_2_877", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10485779_2_878", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10485779_2_879", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10485779_2_880", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10485779_2_881", "context": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme, and ritonavir's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions.", "question": "adverse event. Treatment, ritonavir's concomitant administration with the substrates of this enzyme. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "substrates of this enzyme; ritonavir"}, {"id": "10510017_3_882", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Subject, children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "10510017_3_883", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Subject, children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_3_884", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Subject, children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_3_885", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Subject, children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_3_886", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Subject, children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_3_887", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_3_888", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_3_889", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_3_890", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_3_891", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_3_892", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_3_893", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_3_894", "context": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308511_1_895", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8308511_1_896", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308511_1_897", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308511_1_898", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308511_1_899", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308511_1_900", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308511_1_901", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308511_1_902", "context": "Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.", "question": "adverse event. Treatment, Unintended exposure to acyclovir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_6_903", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACE inhibitors"}, {"id": "14964753_6_904", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_6_905", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_6_906", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_6_907", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_6_908", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_6_909", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_6_910", "context": "The ACE inhibitors can cause various skin side effects; however, it rarely causes cutaneous vasculitis.", "question": "adverse event. Treatment, ACE inhibitors. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10633877_2_911", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "10633877_2_912", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10633877_2_913", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10633877_2_914", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10633877_2_915", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10633877_2_916", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10633877_2_917", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10633877_2_918", "context": "Salicylate intoxication was excluded, and theophylline was finally incriminated.", "question": "adverse event. Treatment, theophylline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_4_919", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Subject, an 8-year-old boy on chronic peritoneal dialysis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "8-year-old"}, {"id": "15028328_4_920", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Subject, an 8-year-old boy on chronic peritoneal dialysis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "15028328_4_921", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Subject, an 8-year-old boy on chronic peritoneal dialysis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_4_922", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Subject, an 8-year-old boy on chronic peritoneal dialysis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_4_923", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Subject, an 8-year-old boy on chronic peritoneal dialysis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_4_924", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PPA"}, {"id": "15028328_4_925", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_4_926", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_4_927", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_4_928", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 months"}, {"id": "15028328_4_929", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_4_930", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_4_931", "context": "We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.", "question": "adverse event. Treatment, PPA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_1_932", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Subject, pediatric patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "15028328_1_933", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Subject, pediatric patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15028328_1_934", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Subject, pediatric patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_1_935", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Subject, pediatric patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_1_936", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Subject, pediatric patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_1_937", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylpropanolamine"}, {"id": "15028328_1_938", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_1_939", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_1_940", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_1_941", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_1_942", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_1_943", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_1_944", "context": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.", "question": "adverse event. Treatment, phenylpropanolamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16164579_2_945", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "irbesartan"}, {"id": "16164579_2_946", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16164579_2_947", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16164579_2_948", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16164579_2_949", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16164579_2_950", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16164579_2_951", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16164579_2_952", "context": "To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.", "question": "adverse event. Treatment, irbesartan. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_2_953", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Subject, two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_2_954", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Subject, two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_2_955", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Subject, two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15944830_2_956", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Subject, two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_2_957", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Subject, two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_2_958", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon"}, {"id": "15944830_2_959", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_2_960", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_2_961", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_2_962", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_2_963", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_2_964", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_2_965", "context": "Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.", "question": "adverse event. Treatment, interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_3_966", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Subject, a 13-year-old female with a right frontal high-grade glioma and complex partial seizures. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "13-year-old"}, {"id": "16939867_3_967", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Subject, a 13-year-old female with a right frontal high-grade glioma and complex partial seizures. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "16939867_3_968", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Subject, a 13-year-old female with a right frontal high-grade glioma and complex partial seizures. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16939867_3_969", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Subject, a 13-year-old female with a right frontal high-grade glioma and complex partial seizures. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16939867_3_970", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Subject, a 13-year-old female with a right frontal high-grade glioma and complex partial seizures. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "right frontal high-grade glioma"}, {"id": "16939867_3_971", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_3_972", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_3_973", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_3_974", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_3_975", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_3_976", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16939867_3_977", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "23 months; complex partial seizures"}, {"id": "16939867_3_978", "context": "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.", "question": "adverse event. Treatment, 23 months of lamotrigine monotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_2_979", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Subject, Patient 1. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9491301_2_980", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Subject, Patient 1. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_2_981", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Subject, Patient 1. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9491301_2_982", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Subject, Patient 1. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_2_983", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Subject, Patient 1. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9491301_2_984", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_2_985", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_2_986", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_2_987", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous; injection"}, {"id": "9491301_2_988", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_2_989", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_2_990", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_2_991", "context": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.", "question": "adverse event. Treatment, intravenous heroin injection. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3718111_1_992", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Subject, He. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3718111_1_993", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Subject, He. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "3718111_1_994", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Subject, He. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3718111_1_995", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Subject, He. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3718111_1_996", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Subject, He. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3718111_1_997", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "timolol"}, {"id": "3718111_1_998", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_1_999", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_1_1000", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_1_1001", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_1_1002", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_1_1003", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3718111_1_1004", "context": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.", "question": "adverse event. Treatment, timolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_1_1005", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11247558_1_1006", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11247558_1_1007", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11247558_1_1008", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11247558_1_1009", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11247558_1_1010", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_1_1011", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11247558_1_1012", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11247558_1_1013", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_1_1014", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_1_1015", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11247558_1_1016", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11247558_1_1017", "context": "Ischaemic colitis in a patient taking meloxicam.", "question": "adverse event. Treatment, meloxicam. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17937473_2_1018", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Leflunomide"}, {"id": "17937473_2_1019", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_2_1020", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_2_1021", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_2_1022", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_2_1023", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_2_1024", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "17937473_2_1025", "context": "Leflunomide-associated infections in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11903249_1_1026", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Subject, two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11903249_1_1027", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Subject, two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11903249_1_1028", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Subject, two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11903249_1_1029", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Subject, two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11903249_1_1030", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Subject, two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11903249_1_1031", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alfa; ribavirin"}, {"id": "11903249_1_1032", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_1_1033", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_1_1034", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_1_1035", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_1_1036", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_1_1037", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus infection"}, {"id": "11903249_1_1038", "context": "Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.", "question": "adverse event. Treatment, interferon alfa and ribavirin treatment of hepatitis C virus infection. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "alfa; ribavirin"}, {"id": "7632529_2_1039", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Subject, a child. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "7632529_2_1040", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Subject, a child. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7632529_2_1041", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Subject, a child. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7632529_2_1042", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Subject, a child. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7632529_2_1043", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Subject, a child. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7632529_2_1044", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "7632529_2_1045", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7632529_2_1046", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7632529_2_1047", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7632529_2_1048", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7632529_2_1049", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7632529_2_1050", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7632529_2_1051", "context": "Acute renal failure in a child associated with acyclovir.", "question": "adverse event. Treatment, acyclovir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18622319_4_1052", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Bevacizumab"}, {"id": "18622319_4_1053", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_4_1054", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18622319_4_1055", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18622319_4_1056", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_4_1057", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18622319_4_1058", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "angiogenesis"}, {"id": "18622319_4_1059", "context": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis.", "question": "potential therapeutic event. Treatment, Bevacizumab is a recently developed monoclonal antibody. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7387219_3_1060", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Subject, Two patients with rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7387219_3_1061", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Subject, Two patients with rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7387219_3_1062", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Subject, Two patients with rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "7387219_3_1063", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Subject, Two patients with rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7387219_3_1064", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Subject, Two patients with rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7387219_3_1065", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_3_1066", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_3_1067", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_3_1068", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_3_1069", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_3_1070", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_3_1071", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "7387219_3_1072", "context": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17310853_1_1073", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Subject, a patient with metastatic gastrointestinal stromal tumor. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17310853_1_1074", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Subject, a patient with metastatic gastrointestinal stromal tumor. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17310853_1_1075", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Subject, a patient with metastatic gastrointestinal stromal tumor. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17310853_1_1076", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Subject, a patient with metastatic gastrointestinal stromal tumor. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17310853_1_1077", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Subject, a patient with metastatic gastrointestinal stromal tumor. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17310853_1_1078", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "17310853_1_1079", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17310853_1_1080", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17310853_1_1081", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17310853_1_1082", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17310853_1_1083", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17310853_1_1084", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic gastrointestinal stromal tumor"}, {"id": "17310853_1_1085", "context": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.", "question": "adverse event. Treatment, imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_2_1086", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_2_1087", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19296063_2_1088", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_2_1089", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_2_1090", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_2_1091", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_2_1092", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_2_1093", "context": "However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7897759_2_1094", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propoxyphene"}, {"id": "7897759_2_1095", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7897759_2_1096", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7897759_2_1097", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7897759_2_1098", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7897759_2_1099", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7897759_2_1100", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7897759_2_1101", "context": "Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.", "question": "adverse event. Treatment, Propoxyphene. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_11_1102", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Subject, Simvastatin plasma concentration increased 30 times in this patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "24927617_11_1103", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Subject, Simvastatin plasma concentration increased 30 times in this patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "24927617_11_1104", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Subject, Simvastatin plasma concentration increased 30 times in this patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "24927617_11_1105", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Subject, Simvastatin plasma concentration increased 30 times in this patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "24927617_11_1106", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Subject, Simvastatin plasma concentration increased 30 times in this patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "Simvastatin plasma concentration increased 30 times"}, {"id": "24927617_11_1107", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "24927617_11_1108", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_11_1109", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_11_1110", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_11_1111", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_11_1112", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_11_1113", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24927617_11_1114", "context": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "question": "adverse event. Treatment, statin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11171531_3_1115", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Subject, a painter. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11171531_3_1116", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Subject, a painter. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11171531_3_1117", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Subject, a painter. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11171531_3_1118", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Subject, a painter. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11171531_3_1119", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Subject, a painter. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11171531_3_1120", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lead"}, {"id": "11171531_3_1121", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11171531_3_1122", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11171531_3_1123", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11171531_3_1124", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11171531_3_1125", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11171531_3_1126", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11171531_3_1127", "context": "Poorly controlled hypertension in a painter with chronic lead toxicity.", "question": "adverse event. Treatment, lead. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_4_1128", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "9695308_4_1129", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_4_1130", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_4_1131", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_4_1132", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_4_1133", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_4_1134", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_4_1135", "context": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.", "question": "adverse event. Treatment, PTU. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12561997_1_1136", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12561997_1_1137", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12561997_1_1138", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12561997_1_1139", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12561997_1_1140", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12561997_1_1141", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12561997_1_1142", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12561997_1_1143", "context": "Gelatinous transformation of bone marrow following chemotherapy for myeloma.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_2_1144", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15279668_2_1145", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15279668_2_1146", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15279668_2_1147", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15279668_2_1148", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15279668_2_1149", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine; cytarabine; FLA (fludarabine and cytarabine)"}, {"id": "15279668_2_1150", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_2_1151", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_2_1152", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15279668_2_1153", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_2_1154", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_2_1155", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_2_1156", "context": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA (fludarabine and cytarabine) regime.", "question": "adverse event. Treatment, fludarabine and cytarabine; FLA (fludarabine and cytarabine) regime. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "fludarabine; cytarabine"}, {"id": "7174620_2_1157", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7174620_2_1158", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7174620_2_1159", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7174620_2_1160", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7174620_2_1161", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7174620_2_1162", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7174620_2_1163", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7174620_2_1164", "context": "The course of delirium due to lithium intoxication.", "question": "adverse event. Treatment, lithium intoxication. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_10_1165", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "21350204_10_1166", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_10_1167", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_10_1168", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_10_1169", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_10_1170", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_10_1171", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21350204_10_1172", "context": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6).", "question": "adverse event. Treatment, Preadmission warfarin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507380_11_1173", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Subject, a patient undergoing treatment for IFN-induced hypertriglyceridemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507380_11_1174", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Subject, a patient undergoing treatment for IFN-induced hypertriglyceridemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507380_11_1175", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Subject, a patient undergoing treatment for IFN-induced hypertriglyceridemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16507380_11_1176", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Subject, a patient undergoing treatment for IFN-induced hypertriglyceridemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507380_11_1177", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Subject, a patient undergoing treatment for IFN-induced hypertriglyceridemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507380_11_1178", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa 11; gemfibrozil"}, {"id": "16507380_11_1179", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg"}, {"id": "16507380_11_1180", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507380_11_1181", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_11_1182", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_11_1183", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_11_1184", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "IFN-induced hypertriglyceridemia"}, {"id": "16507380_11_1185", "context": "In this case of a possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID in a patient undergoing treatment for IFN-induced hypertriglyceridemia, the Naranjo Adverse Drug Reactions (ADR) Probability Scale score was 7 (ie, ADR possibly related to treatment).", "question": "adverse event. Treatment, IFN alfa 11 MU TIW; gemfibrozil 600 mg BID. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "IFN alfa 11; gemfibrozil"}, {"id": "11554897_5_1186", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "11554897_5_1187", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11554897_5_1188", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_5_1189", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_5_1190", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_5_1191", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_5_1192", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_5_1193", "context": "Stupor from lamotrigine toxicity.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_2_1194", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxygen; bleomycin"}, {"id": "2417800_2_1195", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_2_1196", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_2_1197", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_2_1198", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_2_1199", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_2_1200", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_2_1201", "context": "Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.", "question": "adverse event. Treatment, bleomycin and oxygen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "oxygen; bleomycin"}, {"id": "9426968_2_1202", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha 2a"}, {"id": "9426968_2_1203", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9426968_2_1204", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9426968_2_1205", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9426968_2_1206", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9426968_2_1207", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "the second month"}, {"id": "9426968_2_1208", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic active hepatitis C"}, {"id": "9426968_2_1209", "context": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "question": "adverse event. Treatment, during the second month of interferon alpha 2a therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_2_1210", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Vardenafil"}, {"id": "16244351_2_1211", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_2_1212", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16244351_2_1213", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral"}, {"id": "16244351_2_1214", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_2_1215", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16244351_2_1216", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "erectile dysfunction"}, {"id": "16244351_2_1217", "context": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction.", "question": "potential therapeutic event. Treatment, Vardenafil is a new oral phosphodiesterase inhibitor. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17959575_16_1218", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Subject, A patient with CHF and ESRD. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_16_1219", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Subject, A patient with CHF and ESRD. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_16_1220", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Subject, A patient with CHF and ESRD. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_16_1221", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Subject, A patient with CHF and ESRD. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_16_1222", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Subject, A patient with CHF and ESRD. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "ESRD"}, {"id": "17959575_16_1223", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_16_1224", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_16_1225", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "continuous"}, {"id": "17959575_16_1226", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "i.v"}, {"id": "17959575_16_1227", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_16_1228", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_16_1229", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CHF"}, {"id": "17959575_16_1230", "context": "CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v.", "question": "adverse event. Treatment, dobutamine by continuous i.v. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_1_1231", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine"}, {"id": "2568058_1_1232", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_1_1233", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_1_1234", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_1_1235", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2568058_1_1236", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_1_1237", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2568058_1_1238", "context": "Nail-changes induced by penicillamine.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_4_1239", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Subject, The fourth patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_4_1240", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Subject, The fourth patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_4_1241", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Subject, The fourth patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_4_1242", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Subject, The fourth patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_4_1243", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Subject, The fourth patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_4_1244", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_4_1245", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "20-mg"}, {"id": "18562412_4_1246", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "18562412_4_1247", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_4_1248", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_4_1249", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_4_1250", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_4_1251", "context": "The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.", "question": "adverse event. Treatment, 20-mg daily olanzapine dosage. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_1_1252", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Naproxen"}, {"id": "9819544_1_1253", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_1_1254", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_1_1255", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_1_1256", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_1_1257", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9819544_1_1258", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_1_1259", "context": "Naproxen-associated sudden sensorineural hearing loss.", "question": "adverse event. Treatment, Naproxen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_3_1260", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Retinoic acid"}, {"id": "15719254_3_1261", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_3_1262", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_3_1263", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_3_1264", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_3_1265", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_3_1266", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_3_1267", "context": "Retinoic acid may increase the risk of bone marrow transplant nephropathy.", "question": "adverse event. Treatment, Retinoic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_13_1268", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_13_1269", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_13_1270", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_13_1271", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_13_1272", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 1-3 days"}, {"id": "15827071_13_1273", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_13_1274", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_13_1275", "context": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1-3 days.", "question": "adverse event. Treatment, introduction of linezolid, generally within 1-3 days. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_2_1276", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Subject, children. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "10465148_2_1277", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Subject, children. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10465148_2_1278", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Subject, children. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10465148_2_1279", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Subject, children. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10465148_2_1280", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Subject, children. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10465148_2_1281", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate; cytosine arabinoside"}, {"id": "10465148_2_1282", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_2_1283", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10465148_2_1284", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "Intrathecal chemotherapy"}, {"id": "10465148_2_1285", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_2_1286", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10465148_2_1287", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "central nervous system leukemia"}, {"id": "10465148_2_1288", "context": "Intrathecal chemotherapy with methotrexate or cytosine arabinoside is the standard approach to prophylaxis and treatment of central nervous system leukemia in children.", "question": "potential therapeutic event. Treatment, Intrathecal chemotherapy with methotrexate or cytosine arabinoside. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15827071_10_1289", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_10_1290", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15827071_10_1291", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15827071_10_1292", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_10_1293", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_10_1294", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_10_1295", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_10_1296", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_10_1297", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_10_1298", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_10_1299", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_10_1300", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_10_1301", "context": "The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment.", "question": "adverse event. Treatment, linezolid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_1_1302", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Subject, premature infants. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "infants"}, {"id": "9527943_1_1303", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Subject, premature infants. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_1_1304", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Subject, premature infants. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9527943_1_1305", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Subject, premature infants. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_1_1306", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Subject, premature infants. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "premature"}, {"id": "9527943_1_1307", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "9527943_1_1308", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_1_1309", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_1_1310", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_1_1311", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_1_1312", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_1_1313", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_1_1314", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "adverse event. Treatment, dexamethasone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_1_1315", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Subject, premature infants. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "infants"}, {"id": "9527943_1_1316", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Subject, premature infants. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9527943_1_1317", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Subject, premature infants. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9527943_1_1318", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Subject, premature infants. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9527943_1_1319", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Subject, premature infants. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "premature"}, {"id": "9527943_1_1320", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "beta-blockade"}, {"id": "9527943_1_1321", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_1_1322", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9527943_1_1323", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9527943_1_1324", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_1_1325", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9527943_1_1326", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy"}, {"id": "9527943_1_1327", "context": "Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.", "question": "potential therapeutic event. Treatment, beta-blockade. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7235792_1_1328", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_1_1329", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_1_1330", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_1_1331", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_1_1332", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7235792_1_1333", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_1_1334", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_1_1335", "context": "Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.", "question": "adverse event. Treatment, bretylium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_4_1336", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Subject, three cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16531969_4_1337", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Subject, three cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16531969_4_1338", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Subject, three cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "16531969_4_1339", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Subject, three cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16531969_4_1340", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Subject, three cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16531969_4_1341", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN beta"}, {"id": "16531969_4_1342", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_4_1343", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_4_1344", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_4_1345", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_4_1346", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_4_1347", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16531969_4_1348", "context": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.", "question": "adverse event. Treatment, IFN beta. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_2_1349", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_2_1350", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_2_1351", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_2_1352", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_2_1353", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_2_1354", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_2_1355", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_2_1356", "context": "RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.", "question": "adverse event. Treatment, FK506. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_2_1357", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine"}, {"id": "11984077_2_1358", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_2_1359", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_2_1360", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_2_1361", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_2_1362", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_2_1363", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11984077_2_1364", "context": "The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.", "question": "adverse event. Treatment, amifostine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_5_1365", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_5_1366", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_5_1367", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_5_1368", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_5_1369", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_5_1370", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_5_1371", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_5_1372", "context": "Nonconvulsive status epilepticus due to ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16122280_3_1373", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Subject, infectious patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16122280_3_1374", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Subject, infectious patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16122280_3_1375", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Subject, infectious patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16122280_3_1376", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Subject, infectious patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16122280_3_1377", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Subject, infectious patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "infectious"}, {"id": "16122280_3_1378", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "16122280_3_1379", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "800mg"}, {"id": "16122280_3_1380", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once daily"}, {"id": "16122280_3_1381", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral"}, {"id": "16122280_3_1382", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16122280_3_1383", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "5-10 days"}, {"id": "16122280_3_1384", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "community-acquired upper and lower respiratory tract infections"}, {"id": "16122280_3_1385", "context": "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.", "question": "potential therapeutic event. Treatment, oral telithromycin 800mg once daily for 5-10 days. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2549018_2_1386", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Subject, Five patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_2_1387", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Subject, Five patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_2_1388", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Subject, Five patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Five"}, {"id": "2549018_2_1389", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Subject, Five patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_2_1390", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Subject, Five patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2549018_2_1391", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_2_1392", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_2_1393", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_2_1394", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_2_1395", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_2_1396", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_2_1397", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_2_1398", "context": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_6_1399", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_6_1400", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_6_1401", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_6_1402", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_6_1403", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_6_1404", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_6_1405", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_6_1406", "context": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12196060_1_1407", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Phenytoin; isradipine"}, {"id": "12196060_1_1408", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_1_1409", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_1_1410", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_1_1411", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_1_1412", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_1_1413", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_1_1414", "context": "Phenytoin/isradipine interaction causing severe neurologic toxicity.", "question": "adverse event. Treatment, Phenytoin/isradipine interaction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "isradipine; Phenytoin"}, {"id": "3609047_3_1415", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3609047_3_1416", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "single oral dose; 1400 mg; 30 mg kg-1"}, {"id": "3609047_3_1417", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3609047_3_1418", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3609047_3_1419", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3609047_3_1420", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3609047_3_1421", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "prevention of paroxysmal atrial flutter"}, {"id": "3609047_3_1422", "context": "We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.", "question": "adverse event. Treatment, a single oral dose of amiodarone (1400 mg or 30 mg kg-1). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14660304_2_1423", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Subject, children with acute lymphoblastic leukemia. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "14660304_2_1424", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Subject, children with acute lymphoblastic leukemia. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "14660304_2_1425", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Subject, children with acute lymphoblastic leukemia. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14660304_2_1426", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Subject, children with acute lymphoblastic leukemia. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14660304_2_1427", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Subject, children with acute lymphoblastic leukemia. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14660304_2_1428", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "prednisone"}, {"id": "14660304_2_1429", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14660304_2_1430", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14660304_2_1431", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14660304_2_1432", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14660304_2_1433", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14660304_2_1434", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute lymphoblastic leukemia"}, {"id": "14660304_2_1435", "context": "Traditionally, children with acute lymphoblastic leukemia receive prednisone, as part of multiagent remission-induction chemotherapy.", "question": "potential therapeutic event. Treatment, prednisone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15760792_3_1436", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propylthiouracil"}, {"id": "15760792_3_1437", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_3_1438", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_3_1439", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_3_1440", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_3_1441", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_3_1442", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15760792_3_1443", "context": "Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.", "question": "adverse event. Treatment, Propylthiouracil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_1_1444", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_1_1445", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_1_1446", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_1_1447", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9466030_1_1448", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9466030_1_1449", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_1_1450", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_1_1451", "context": "Acute respiratory depression as a complication of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7420580_2_1452", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Subject, a patient with an embryonal teratocarcinoma of the testicle. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7420580_2_1453", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Subject, a patient with an embryonal teratocarcinoma of the testicle. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7420580_2_1454", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Subject, a patient with an embryonal teratocarcinoma of the testicle. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7420580_2_1455", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Subject, a patient with an embryonal teratocarcinoma of the testicle. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7420580_2_1456", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Subject, a patient with an embryonal teratocarcinoma of the testicle. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7420580_2_1457", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vinblastine"}, {"id": "7420580_2_1458", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high dose"}, {"id": "7420580_2_1459", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7420580_2_1460", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7420580_2_1461", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7420580_2_1462", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7420580_2_1463", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "embryonal teratocarcinoma of the testicle"}, {"id": "7420580_2_1464", "context": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.", "question": "adverse event. Treatment, a high dose of vinblastine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_4_1465", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "8864370_4_1466", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_4_1467", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_4_1468", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_4_1469", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_4_1470", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_4_1471", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_4_1472", "context": "Methotrexate-induced liver cirrhosis.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17195428_2_1473", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "17195428_2_1474", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17195428_2_1475", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17195428_2_1476", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17195428_2_1477", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17195428_2_1478", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17195428_2_1479", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17195428_2_1480", "context": "A case of oculogyric crisis induced by metoclopramide is described in this paper.", "question": "adverse event. Treatment, metoclopramide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12806509_1_1481", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Subject, case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12806509_1_1482", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Subject, case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12806509_1_1483", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Subject, case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12806509_1_1484", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Subject, case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12806509_1_1485", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Subject, case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12806509_1_1486", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hepatitis B vaccination"}, {"id": "12806509_1_1487", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12806509_1_1488", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12806509_1_1489", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12806509_1_1490", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12806509_1_1491", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12806509_1_1492", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12806509_1_1493", "context": "Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.", "question": "adverse event. Treatment, hepatitis B vaccination. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_5_1494", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_5_1495", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_5_1496", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_5_1497", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_5_1498", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_5_1499", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_5_1500", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_5_1501", "context": "The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12661801_3_1502", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbimazole; recombinant human granulocyte colony stimulating factor"}, {"id": "12661801_3_1503", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_3_1504", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12661801_3_1505", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12661801_3_1506", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12661801_3_1507", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12661801_3_1508", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12661801_3_1509", "context": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).", "question": "adverse event. Treatment, carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "recombinant human granulocyte colony stimulating factor; carbimazole"}, {"id": "16459502_1_1510", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16459502_1_1511", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16459502_1_1512", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16459502_1_1513", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical"}, {"id": "16459502_1_1514", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16459502_1_1515", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16459502_1_1516", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16459502_1_1517", "context": "Cutaneous mycobacterial infection post intravesical BCG installation.", "question": "adverse event. Treatment, intravesical BCG installation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_2_1518", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Subject, the patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19690222_2_1519", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Subject, the patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19690222_2_1520", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Subject, the patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19690222_2_1521", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Subject, the patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19690222_2_1522", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Subject, the patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19690222_2_1523", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dalteparin"}, {"id": "19690222_2_1524", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "3 doses"}, {"id": "19690222_2_1525", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_2_1526", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_2_1527", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_2_1528", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_2_1529", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_2_1530", "context": "On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.", "question": "adverse event. Treatment, 3 doses of dalteparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23774436_2_1531", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gatifloxacin; rifampin; isoniazid; pyrazinamide"}, {"id": "23774436_2_1532", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23774436_2_1533", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23774436_2_1534", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23774436_2_1535", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23774436_2_1536", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23774436_2_1537", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "23774436_2_1538", "context": "A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB).", "question": "potential therapeutic event. Treatment, gatifloxacin; rifampin; isoniazid; pyrazinamide. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "isoniazid; pyrazinamide"}, {"id": "9619226_2_1539", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulprostone"}, {"id": "9619226_2_1540", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9619226_2_1541", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9619226_2_1542", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9619226_2_1543", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9619226_2_1544", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9619226_2_1545", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9619226_2_1546", "context": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.", "question": "adverse event. Treatment, sulprostone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12661801_1_1547", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Subject, 72-year-old woman with a history of thyrotoxicosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "72-year-old"}, {"id": "12661801_1_1548", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Subject, 72-year-old woman with a history of thyrotoxicosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12661801_1_1549", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Subject, 72-year-old woman with a history of thyrotoxicosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12661801_1_1550", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Subject, 72-year-old woman with a history of thyrotoxicosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12661801_1_1551", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Subject, 72-year-old woman with a history of thyrotoxicosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "thyrotoxicosis"}, {"id": "12661801_1_1552", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12661801_1_1553", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_1_1554", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12661801_1_1555", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12661801_1_1556", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "two weeks"}, {"id": "12661801_1_1557", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12661801_1_1558", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12661801_1_1559", "context": "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.", "question": "adverse event. Treatment, two weeks after starting carbimazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_5_1560", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Subject, she. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8700794_5_1561", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Subject, she. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "8700794_5_1562", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Subject, she. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8700794_5_1563", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Subject, she. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8700794_5_1564", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Subject, she. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8700794_5_1565", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_5_1566", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_5_1567", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_5_1568", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8700794_5_1569", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_5_1570", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_5_1571", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_5_1572", "context": "Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.", "question": "adverse event. Treatment, desmopressin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_1_1573", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FLA"}, {"id": "15279668_1_1574", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_1_1575", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_1_1576", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15279668_1_1577", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_1_1578", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_1_1579", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_1_1580", "context": "Fatal peripheral neuropathy following FLA chemotherapy.", "question": "adverse event. Treatment, FLA chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_1_1581", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sitagliptin; lovastatin"}, {"id": "19249953_1_1582", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_1_1583", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_1_1584", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_1_1585", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_1_1586", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_1_1587", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_1_1588", "context": "Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.", "question": "adverse event. Treatment, potential sitagliptin-lovastatin interaction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lovastatin; sitagliptin"}, {"id": "8305778_3_1589", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Subject, A 78-year-old man with a history of congestive heart failure and coronary artery disease. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "78-year-old"}, {"id": "8305778_3_1590", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Subject, A 78-year-old man with a history of congestive heart failure and coronary artery disease. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "8305778_3_1591", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Subject, A 78-year-old man with a history of congestive heart failure and coronary artery disease. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8305778_3_1592", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Subject, A 78-year-old man with a history of congestive heart failure and coronary artery disease. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8305778_3_1593", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Subject, A 78-year-old man with a history of congestive heart failure and coronary artery disease. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "congestive heart failure; coronary artery disease"}, {"id": "8305778_3_1594", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "8305778_3_1595", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_3_1596", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8305778_3_1597", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8305778_3_1598", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_3_1599", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8305778_3_1600", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "sustained ventricular tachycardia"}, {"id": "8305778_3_1601", "context": "A 78-year-old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia.", "question": "potential therapeutic event. Treatment, amiodarone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8645078_1_1602", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Subject, A patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8645078_1_1603", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Subject, A patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8645078_1_1604", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Subject, A patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8645078_1_1605", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Subject, A patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8645078_1_1606", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Subject, A patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8645078_1_1607", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "8645078_1_1608", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_1_1609", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_1_1610", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_1_1611", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_1_1612", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_1_1613", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_1_1614", "context": "A patient with severe cholestatic jaundice induced by captopril is presented.", "question": "adverse event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_3_1615", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_3_1616", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_3_1617", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_3_1618", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_3_1619", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_3_1620", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_3_1621", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_3_1622", "context": "Three distinct types of minocycline-induced cutaneous pigmentation have been described.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_4_1623", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_4_1624", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_4_1625", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_4_1626", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_4_1627", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_4_1628", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "first"}, {"id": "18765315_4_1629", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_4_1630", "context": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.", "question": "adverse event. Treatment, first rituximab infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12635752_1_1631", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Subject, 12th week of pregnancy. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12635752_1_1632", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Subject, 12th week of pregnancy. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12635752_1_1633", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Subject, 12th week of pregnancy. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12635752_1_1634", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Subject, 12th week of pregnancy. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12635752_1_1635", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Subject, 12th week of pregnancy. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "pregnancy"}, {"id": "12635752_1_1636", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "12635752_1_1637", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_1_1638", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12635752_1_1639", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12635752_1_1640", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_1_1641", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12635752_1_1642", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12635752_1_1643", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12635752_1_1644", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Subject, 12th week of pregnancy. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12635752_1_1645", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Subject, 12th week of pregnancy. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12635752_1_1646", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Subject, 12th week of pregnancy. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12635752_1_1647", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Subject, 12th week of pregnancy. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12635752_1_1648", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Subject, 12th week of pregnancy. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "pregnancy"}, {"id": "12635752_1_1649", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12635752_1_1650", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_1_1651", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12635752_1_1652", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12635752_1_1653", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_1_1654", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12635752_1_1655", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Antithyroid"}, {"id": "12635752_1_1656", "context": "Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).", "question": "potential therapeutic event. Treatment, carbimazole (CBZ). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9695308_2_1657", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "9695308_2_1658", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_2_1659", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_2_1660", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_2_1661", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_2_1662", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_2_1663", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_2_1664", "context": "Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.", "question": "adverse event. Treatment, propylthiouracil therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12399645_2_1665", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Subject, plasma osmolality. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12399645_2_1666", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Subject, plasma osmolality. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12399645_2_1667", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Subject, plasma osmolality. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12399645_2_1668", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Subject, plasma osmolality. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12399645_2_1669", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Subject, plasma osmolality. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "plasma osmolality"}, {"id": "12399645_2_1670", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_2_1671", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_2_1672", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12399645_2_1673", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12399645_2_1674", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_2_1675", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12399645_2_1676", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ADH hypersecretion"}, {"id": "12399645_2_1677", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "potential therapeutic event. Treatment, mizoribin withdrawal. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12399645_2_1678", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bredinin"}, {"id": "12399645_2_1679", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_2_1680", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_2_1681", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_2_1682", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_2_1683", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_2_1684", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_2_1685", "context": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.", "question": "adverse event. Treatment, bredinin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_1_1686", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Heparin"}, {"id": "10510017_1_1687", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_1_1688", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_1_1689", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_1_1690", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_1_1691", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_1_1692", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_1_1693", "context": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "question": "adverse event. Treatment, anticoagulation therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18991509_1_1694", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Subject, an HIV type 1-infected patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18991509_1_1695", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Subject, an HIV type 1-infected patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18991509_1_1696", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Subject, an HIV type 1-infected patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18991509_1_1697", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Subject, an HIV type 1-infected patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18991509_1_1698", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Subject, an HIV type 1-infected patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18991509_1_1699", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "epidural triamcinolone; ritonavir-lopinavir"}, {"id": "18991509_1_1700", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18991509_1_1701", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18991509_1_1702", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injections"}, {"id": "18991509_1_1703", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18991509_1_1704", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18991509_1_1705", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV type 1"}, {"id": "18991509_1_1706", "context": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.", "question": "adverse event. Treatment, receiving therapy with ritonavir-lopinavir; epidural triamcinolone injections. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "epidural triamcinolone; ritonavir-lopinavir"}, {"id": "18622319_2_1707", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "the more recent antiangiogenic therapy"}, {"id": "18622319_2_1708", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_2_1709", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_2_1710", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_2_1711", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_2_1712", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_2_1713", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignancies"}, {"id": "18622319_2_1714", "context": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies.", "question": "adverse event. Treatment, the more recent antiangiogenic therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7459812_2_1715", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "7459812_2_1716", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7459812_2_1717", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7459812_2_1718", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7459812_2_1719", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "9 to 12 days"}, {"id": "7459812_2_1720", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7459812_2_1721", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7459812_2_1722", "context": "Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.", "question": "adverse event. Treatment, the chlorambucil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_2_1723", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_2_1724", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_2_1725", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_2_1726", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_2_1727", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_2_1728", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_2_1729", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19648225_2_1730", "context": "Possible mechanisms for damage to the urothelium by ketamine are suggested.", "question": "adverse event. Treatment, ketamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19217693_2_1731", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Subject, a patient with diabetes. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19217693_2_1732", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Subject, a patient with diabetes. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19217693_2_1733", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Subject, a patient with diabetes. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19217693_2_1734", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Subject, a patient with diabetes. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19217693_2_1735", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Subject, a patient with diabetes. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "diabetes"}, {"id": "19217693_2_1736", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "19217693_2_1737", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19217693_2_1738", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19217693_2_1739", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19217693_2_1740", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19217693_2_1741", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19217693_2_1742", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "19217693_2_1743", "context": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.", "question": "adverse event. Treatment, etanercept. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_1_1744", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "polyethylene glycol-modified interferon alfa."}, {"id": "15965422_1_1745", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_1_1746", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_1_1747", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "15965422_1_1748", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_1_1749", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_1_1750", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_1_1751", "context": "Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.", "question": "adverse event. Treatment, injection of polyethylene glycol-modified interferon alfa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_3_1752", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_3_1753", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_3_1754", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_3_1755", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_3_1756", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_3_1757", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "3586163_3_1758", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nonHodgkin's lymphoma"}, {"id": "3586163_3_1759", "context": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.", "question": "adverse event. Treatment, chronic cyclophosphamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18359591_1_1760", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Subject, two patients with active UC. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18359591_1_1761", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Subject, two patients with active UC. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18359591_1_1762", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Subject, two patients with active UC. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "18359591_1_1763", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Subject, two patients with active UC. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18359591_1_1764", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Subject, two patients with active UC. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18359591_1_1765", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "18359591_1_1766", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18359591_1_1767", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18359591_1_1768", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "18359591_1_1769", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18359591_1_1770", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18359591_1_1771", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "active UC"}, {"id": "18359591_1_1772", "context": "In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.", "question": "adverse event. Treatment, oral microemulsion form of cyclosporine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_5_1773", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Subject, the patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9681092_5_1774", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Subject, the patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9681092_5_1775", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Subject, the patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9681092_5_1776", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Subject, the patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9681092_5_1777", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Subject, the patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9681092_5_1778", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "droperidol"}, {"id": "9681092_5_1779", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_5_1780", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9681092_5_1781", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9681092_5_1782", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_5_1783", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9681092_5_1784", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_5_1785", "context": "Prior to surgery, the patient received droperidol, an agent known to prolong the QT interval.", "question": "potential therapeutic event. Treatment, droperidol; Prior to surgery. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20110001_4_1786", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Subject, a patient affected by CML. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_4_1787", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Subject, a patient affected by CML. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_4_1788", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Subject, a patient affected by CML. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_4_1789", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Subject, a patient affected by CML. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_4_1790", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Subject, a patient affected by CML. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_4_1791", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "20110001_4_1792", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20110001_4_1793", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_4_1794", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_4_1795", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20110001_4_1796", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_4_1797", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CML"}, {"id": "20110001_4_1798", "context": "OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.", "question": "adverse event. Treatment, imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17907595_6_1799", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Subject, Patient 1. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17907595_6_1800", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Subject, Patient 1. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17907595_6_1801", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Subject, Patient 1. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "1"}, {"id": "17907595_6_1802", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Subject, Patient 1. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17907595_6_1803", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Subject, Patient 1. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17907595_6_1804", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; phenytoin therapy"}, {"id": "17907595_6_1805", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17907595_6_1806", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17907595_6_1807", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17907595_6_1808", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "36 days"}, {"id": "17907595_6_1809", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17907595_6_1810", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17907595_6_1811", "context": "The FK 506 dose was constant within 21 days after discontinuing phenytoin in Patient 1 who had 36 days of phenytoin therapy.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_14_1812", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11597289_14_1813", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11597289_14_1814", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11597289_14_1815", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11597289_14_1816", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11597289_14_1817", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "concomitant heparin; antithrombin III"}, {"id": "11597289_14_1818", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11597289_14_1819", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11597289_14_1820", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11597289_14_1821", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_14_1822", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11597289_14_1823", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11597289_14_1824", "context": "In patients receiving antithrombin III and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin III group vs 13.5% for placebo group; P<.001).", "question": "adverse event. Treatment, antithrombin III and concomitant heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "antithrombin III; concomitant heparin"}, {"id": "968449_2_1825", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Subject, 2 patients with polycythaemia vera (PV). What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "968449_2_1826", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Subject, 2 patients with polycythaemia vera (PV). What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "968449_2_1827", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Subject, 2 patients with polycythaemia vera (PV). What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "2"}, {"id": "968449_2_1828", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Subject, 2 patients with polycythaemia vera (PV). What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "968449_2_1829", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Subject, 2 patients with polycythaemia vera (PV). What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "968449_2_1830", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_2_1831", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "968449_2_1832", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "968449_2_1833", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "968449_2_1834", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "968449_2_1835", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "968449_2_1836", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "polycythaemia vera (PV)"}, {"id": "968449_2_1837", "context": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera (PV) at the time of diagnosis and several times subsequently during therapy with chlorambucil.", "question": "potential therapeutic event. Treatment, chlorambucil. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2429270_4_1838", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Procainamide"}, {"id": "2429270_4_1839", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_4_1840", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_4_1841", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_4_1842", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_4_1843", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_4_1844", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wolff-Parkinson-White syndrome"}, {"id": "2429270_4_1845", "context": "Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.", "question": "adverse event. Treatment, Procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_10_1846", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sitagliptin; lovastatin"}, {"id": "19249953_10_1847", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_10_1848", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_10_1849", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_10_1850", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_10_1851", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_10_1852", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_10_1853", "context": "To our knowledge, however, this is the first case report of a possible sitagliptin-lovastatin interaction that may have caused rhabdomyolysis.", "question": "adverse event. Treatment, sitagliptin-lovastatin interaction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lovastatin; sitagliptin"}, {"id": "897744_2_1854", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Subject, A drug addict. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "897744_2_1855", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Subject, A drug addict. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "897744_2_1856", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Subject, A drug addict. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "897744_2_1857", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Subject, A drug addict. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "897744_2_1858", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Subject, A drug addict. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "drug addict"}, {"id": "897744_2_1859", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin"}, {"id": "897744_2_1860", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_2_1861", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_2_1862", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_2_1863", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_2_1864", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_2_1865", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "staphylococcal endocarditis"}, {"id": "897744_2_1866", "context": "A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.", "question": "adverse event. Treatment, methicillin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7035691_3_1867", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Subject, a patient with decreased renal function. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7035691_3_1868", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Subject, a patient with decreased renal function. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7035691_3_1869", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Subject, a patient with decreased renal function. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7035691_3_1870", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Subject, a patient with decreased renal function. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7035691_3_1871", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Subject, a patient with decreased renal function. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "decreased renal function"}, {"id": "7035691_3_1872", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "captopril"}, {"id": "7035691_3_1873", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_3_1874", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7035691_3_1875", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7035691_3_1876", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_3_1877", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7035691_3_1878", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypertension associated with chronic renal failure"}, {"id": "7035691_3_1879", "context": "Although inhibition of the angiotensin-converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure, care should be taken when captopril is administered initially to a patient with decreased renal function, under the conditions of sodium and water depletion.", "question": "potential therapeutic event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7907218_1_1880", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Subject, Two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7907218_1_1881", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Subject, Two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7907218_1_1882", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Subject, Two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "7907218_1_1883", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Subject, Two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7907218_1_1884", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Subject, Two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7907218_1_1885", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluphenazine decanoate"}, {"id": "7907218_1_1886", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7907218_1_1887", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7907218_1_1888", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7907218_1_1889", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7907218_1_1890", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7907218_1_1891", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7907218_1_1892", "context": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.", "question": "adverse event. Treatment, fluphenazine decanoate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_2_1893", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "10348150_2_1894", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_2_1895", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_2_1896", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_2_1897", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_2_1898", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_2_1899", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10348150_2_1900", "context": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2196696_1_1901", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Disulfiram"}, {"id": "2196696_1_1902", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_1_1903", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_1_1904", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_1_1905", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2196696_1_1906", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_1_1907", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_1_1908", "context": "Disulfiram-induced hepatitis.", "question": "adverse event. Treatment, Disulfiram. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_13_1909", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_13_1910", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_13_1911", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_13_1912", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_13_1913", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_13_1914", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_13_1915", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_13_1916", "context": "The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_2_1917", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18487000_2_1918", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "sibutramine"}, {"id": "18487000_2_1919", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_2_1920", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_2_1921", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_2_1922", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_2_1923", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18487000_2_1924", "context": "The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20979526_8_1925", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FHP"}, {"id": "20979526_8_1926", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20979526_8_1927", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20979526_8_1928", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20979526_8_1929", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20979526_8_1930", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20979526_8_1931", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20979526_8_1932", "context": "Because at the end of the first month the patient's platelet counts were normal and the thrombocytopenia developed after the co-medication with conventional drugs, it was suspected that the thrombocytopenia might not be attributed to the use of FHP.", "question": "adverse event. Treatment, FHP. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_3_1933", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Subject, Two cases of childhood-onset schizophrenia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "childhood"}, {"id": "12625995_3_1934", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Subject, Two cases of childhood-onset schizophrenia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_3_1935", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Subject, Two cases of childhood-onset schizophrenia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "12625995_3_1936", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Subject, Two cases of childhood-onset schizophrenia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_3_1937", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Subject, Two cases of childhood-onset schizophrenia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_3_1938", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "12625995_3_1939", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_3_1940", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_3_1941", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_3_1942", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_3_1943", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_3_1944", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "12625995_3_1945", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_3_1946", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Subject, Two cases of childhood-onset schizophrenia. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "childhood"}, {"id": "12625995_3_1947", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Subject, Two cases of childhood-onset schizophrenia. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12625995_3_1948", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Subject, Two cases of childhood-onset schizophrenia. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "Two"}, {"id": "12625995_3_1949", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Subject, Two cases of childhood-onset schizophrenia. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12625995_3_1950", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Subject, Two cases of childhood-onset schizophrenia. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12625995_3_1951", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "beta-blocker"}, {"id": "12625995_3_1952", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_3_1953", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12625995_3_1954", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12625995_3_1955", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_3_1956", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12625995_3_1957", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "clozapine-induced akathisia responsive"}, {"id": "12625995_3_1958", "context": "Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.", "question": "potential therapeutic event. Treatment, beta-blocker treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11688826_2_1959", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Subject, a pulmonary adenocarcinoma patient with a malignant pleural effusion. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11688826_2_1960", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Subject, a pulmonary adenocarcinoma patient with a malignant pleural effusion. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11688826_2_1961", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Subject, a pulmonary adenocarcinoma patient with a malignant pleural effusion. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11688826_2_1962", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Subject, a pulmonary adenocarcinoma patient with a malignant pleural effusion. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11688826_2_1963", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Subject, a pulmonary adenocarcinoma patient with a malignant pleural effusion. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "malignant pleural effusion"}, {"id": "11688826_2_1964", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "11688826_2_1965", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_2_1966", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_2_1967", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_2_1968", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_2_1969", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_2_1970", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary adenocarcinoma"}, {"id": "11688826_2_1971", "context": "Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.", "question": "adverse event. Treatment, cisplatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_2_1972", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_2_1973", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_2_1974", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_2_1975", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "12546343_2_1976", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "immediate"}, {"id": "12546343_2_1977", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_2_1978", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_2_1979", "context": "He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.", "question": "adverse event. Treatment, MTX infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20110001_1_1980", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_1_1981", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_1_1982", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_1_1983", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_1_1984", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_1_1985", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "20110001_1_1986", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "400 mg/d"}, {"id": "20110001_1_1987", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_1_1988", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_1_1989", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "12 months"}, {"id": "20110001_1_1990", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_1_1991", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20110001_1_1992", "context": "CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.", "question": "adverse event. Treatment, 12 months; imatinib 400 mg/d. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_2_1993", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Subject, 1.4% of MS patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16531969_2_1994", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Subject, 1.4% of MS patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16531969_2_1995", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Subject, 1.4% of MS patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "1.4%"}, {"id": "16531969_2_1996", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Subject, 1.4% of MS patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16531969_2_1997", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Subject, 1.4% of MS patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16531969_2_1998", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN beta"}, {"id": "16531969_2_1999", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_2_2000", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_2_2001", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_2_2002", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_2_2003", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_2_2004", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MS"}, {"id": "16531969_2_2005", "context": "Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.", "question": "adverse event. Treatment, IFN beta. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_6_2006", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Subject, a girl of 6. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "6"}, {"id": "17329303_6_2007", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Subject, a girl of 6. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "17329303_6_2008", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Subject, a girl of 6. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17329303_6_2009", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Subject, a girl of 6. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17329303_6_2010", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Subject, a girl of 6. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17329303_6_2011", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "risperidone"}, {"id": "17329303_6_2012", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_6_2013", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17329303_6_2014", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17329303_6_2015", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_6_2016", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17329303_6_2017", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ADHD; borderline intellectual functioning"}, {"id": "17329303_6_2018", "context": "The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred.", "question": "potential therapeutic event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12196060_2_2019", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Subject, a young man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12196060_2_2020", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Subject, a young man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12196060_2_2021", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Subject, a young man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12196060_2_2022", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Subject, a young man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12196060_2_2023", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Subject, a young man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12196060_2_2024", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isradipine; phenytoin"}, {"id": "12196060_2_2025", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12196060_2_2026", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12196060_2_2027", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12196060_2_2028", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12196060_2_2029", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12196060_2_2030", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12196060_2_2031", "context": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.", "question": "adverse event. Treatment, phenytoin; isradipine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; isradipine"}, {"id": "16446228_2_2032", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16446228_2_2033", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16446228_2_2034", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16446228_2_2035", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16446228_2_2036", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16446228_2_2037", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16446228_2_2038", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16446228_2_2039", "context": "Reversible sirolimus-associated pneumonitis after heart transplantation.", "question": "adverse event. Treatment, sirolimus. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2063999_2_2040", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Subject, a girl. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2063999_2_2041", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Subject, a girl. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "2063999_2_2042", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Subject, a girl. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2063999_2_2043", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Subject, a girl. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2063999_2_2044", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Subject, a girl. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2063999_2_2045", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hopantenate"}, {"id": "2063999_2_2046", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2063999_2_2047", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2063999_2_2048", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2063999_2_2049", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2063999_2_2050", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2063999_2_2051", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2063999_2_2052", "context": "We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).", "question": "adverse event. Treatment, calcium hopantenate (HOPA). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_7_2053", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Subject, he; night leg cramps. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11126885_7_2054", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Subject, he; night leg cramps. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "11126885_7_2055", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Subject, he; night leg cramps. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11126885_7_2056", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Subject, he; night leg cramps. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11126885_7_2057", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Subject, he; night leg cramps. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11126885_7_2058", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_7_2059", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_7_2060", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_7_2061", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11126885_7_2062", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "over the next four weeks"}, {"id": "11126885_7_2063", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_7_2064", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "night leg cramps"}, {"id": "11126885_7_2065", "context": "Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.", "question": "adverse event. Treatment, continued to take quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10327035_1_2066", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Subject, a young adult with metastastic gastric cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young adult"}, {"id": "10327035_1_2067", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Subject, a young adult with metastastic gastric cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10327035_1_2068", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Subject, a young adult with metastastic gastric cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10327035_1_2069", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Subject, a young adult with metastastic gastric cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10327035_1_2070", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Subject, a young adult with metastastic gastric cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10327035_1_2071", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10327035_1_2072", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1500 mg/m2"}, {"id": "10327035_1_2073", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10327035_1_2074", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10327035_1_2075", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10327035_1_2076", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10327035_1_2077", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastastic gastric cancer"}, {"id": "10327035_1_2078", "context": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "question": "adverse event. Treatment, a moderate dose of methotrexate (1500 mg/m2) (MTX). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24927617_1_2079", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Subject, hepatitis C virus infected patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "24927617_1_2080", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Subject, hepatitis C virus infected patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "24927617_1_2081", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Subject, hepatitis C virus infected patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "24927617_1_2082", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Subject, hepatitis C virus infected patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "24927617_1_2083", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Subject, hepatitis C virus infected patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "24927617_1_2084", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "telaprevir; simvastatin"}, {"id": "24927617_1_2085", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_1_2086", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24927617_1_2087", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24927617_1_2088", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_1_2089", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24927617_1_2090", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus"}, {"id": "24927617_1_2091", "context": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.", "question": "adverse event. Treatment, telaprevir and simvastatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "telaprevir; simvastatin"}, {"id": "15779196_1_2092", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15779196_1_2093", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15779196_1_2094", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15779196_1_2095", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15779196_1_2096", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15779196_1_2097", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Zoledronic acid"}, {"id": "15779196_1_2098", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15779196_1_2099", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15779196_1_2100", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "15779196_1_2101", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Four days after"}, {"id": "15779196_1_2102", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15779196_1_2103", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15779196_1_2104", "context": "Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.", "question": "adverse event. Treatment, Four days after intravenous Zoledronic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_3_2105", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucytosine"}, {"id": "7117795_3_2106", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_3_2107", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_3_2108", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_3_2109", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_3_2110", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_3_2111", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_3_2112", "context": "Ulcerating enteritis associated with flucytosine therapy.", "question": "adverse event. Treatment, flucytosine therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_2_2113", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15681911_2_2114", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15681911_2_2115", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15681911_2_2116", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15681911_2_2117", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15681911_2_2118", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_2_2119", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_2_2120", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_2_2121", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15681911_2_2122", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_2_2123", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_2_2124", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_2_2125", "context": "OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_5_2126", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_5_2127", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_5_2128", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_5_2129", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_5_2130", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_5_2131", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_5_2132", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_5_2133", "context": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.", "question": "adverse event. Treatment, imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8840640_2_2134", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetrimide; chlorhexidine"}, {"id": "8840640_2_2135", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8840640_2_2136", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8840640_2_2137", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "solution"}, {"id": "8840640_2_2138", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8840640_2_2139", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8840640_2_2140", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hydatid cyst"}, {"id": "8840640_2_2141", "context": "Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.", "question": "adverse event. Treatment, cetrimide-chlorhexidine solution. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "chlorhexidine; cetrimide"}, {"id": "7685228_1_2142", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Subject, granulocyte colony-stimulating factor. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7685228_1_2143", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Subject, granulocyte colony-stimulating factor. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7685228_1_2144", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Subject, granulocyte colony-stimulating factor. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7685228_1_2145", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Subject, granulocyte colony-stimulating factor. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7685228_1_2146", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Subject, granulocyte colony-stimulating factor. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7685228_1_2147", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "7685228_1_2148", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_1_2149", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7685228_1_2150", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7685228_1_2151", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_1_2152", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7685228_1_2153", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7685228_1_2154", "context": "Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, gold; granulocyte colony-stimulating factor (G-CSF). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "946400_2_2155", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methyldopa"}, {"id": "946400_2_2156", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_2_2157", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_2_2158", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_2_2159", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "946400_2_2160", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_2_2161", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "946400_2_2162", "context": "Methyldopa-induced liver injury.", "question": "adverse event. Treatment, Methyldopa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14971874_1_2163", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "14971874_1_2164", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14971874_1_2165", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14971874_1_2166", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14971874_1_2167", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14971874_1_2168", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14971874_1_2169", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pathophysiology of sleep apnea"}, {"id": "14971874_1_2170", "context": "After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.", "question": "adverse event. Treatment, infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_4_2171", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Subject, One patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_4_2172", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Subject, One patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_4_2173", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Subject, One patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "6507240_4_2174", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Subject, One patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_4_2175", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Subject, One patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_4_2176", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydrochlorothiazide"}, {"id": "6507240_4_2177", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_4_2178", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_4_2179", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_4_2180", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_4_2181", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_4_2182", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypertension"}, {"id": "6507240_4_2183", "context": "One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.", "question": "adverse event. Treatment, hydrochlorothiazide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_3_2184", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Subject, patients with malignant disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_3_2185", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Subject, patients with malignant disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_3_2186", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Subject, patients with malignant disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1624172_3_2187", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Subject, patients with malignant disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_3_2188", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Subject, patients with malignant disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_3_2189", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_3_2190", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_3_2191", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_3_2192", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_3_2193", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_3_2194", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_3_2195", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignant disease"}, {"id": "1624172_3_2196", "context": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_9_2197", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Subject, a patient with pancreatic adenocarcinoma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_9_2198", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Subject, a patient with pancreatic adenocarcinoma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_9_2199", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Subject, a patient with pancreatic adenocarcinoma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15112258_9_2200", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Subject, a patient with pancreatic adenocarcinoma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_9_2201", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Subject, a patient with pancreatic adenocarcinoma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_9_2202", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_9_2203", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_9_2204", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_9_2205", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_9_2206", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_9_2207", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_9_2208", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pancreatic adenocarcinoma"}, {"id": "15112258_9_2209", "context": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_8_2210", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_8_2211", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_8_2212", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_8_2213", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "tablet"}, {"id": "11126885_8_2214", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_8_2215", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_8_2216", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11126885_8_2217", "context": "Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine tablet. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_4_2218", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Subject, Case 1. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "968449_4_2219", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Subject, Case 1. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "968449_4_2220", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Subject, Case 1. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "1"}, {"id": "968449_4_2221", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Subject, Case 1. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "968449_4_2222", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Subject, Case 1. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "968449_4_2223", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "myelosuppressive"}, {"id": "968449_4_2224", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_4_2225", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_4_2226", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_4_2227", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "25 months"}, {"id": "968449_4_2228", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_4_2229", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "968449_4_2230", "context": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no. 12, del (12) (p11), in 60% of the diploid cells.", "question": "adverse event. Treatment, 25 months of myelosuppressive therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1893404_2_2231", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1893404_2_2232", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1893404_2_2233", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1893404_2_2234", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1893404_2_2235", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1893404_2_2236", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "1893404_2_2237", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1893404_2_2238", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1893404_2_2239", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1893404_2_2240", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1893404_2_2241", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1893404_2_2242", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1893404_2_2243", "context": "Diabetes Mellitus was observed in a patient given carbamazepine.", "question": "adverse event. Treatment, carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_3_2244", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Subject, patients with schizophrenia. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25295553_3_2245", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Subject, patients with schizophrenia. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "25295553_3_2246", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Subject, patients with schizophrenia. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "25295553_3_2247", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Subject, patients with schizophrenia. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25295553_3_2248", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Subject, patients with schizophrenia. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "schizophrenia"}, {"id": "25295553_3_2249", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "25295553_3_2250", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_3_2251", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_3_2252", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_3_2253", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_3_2254", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_3_2255", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Anxiety"}, {"id": "25295553_3_2256", "context": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.", "question": "potential therapeutic event. Treatment, pregabalin has been suggested as an off-label add-on treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8996514_2_2257", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "8996514_2_2258", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8996514_2_2259", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8996514_2_2260", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8996514_2_2261", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8996514_2_2262", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8996514_2_2263", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neurocysticercosis"}, {"id": "8996514_2_2264", "context": "Large cerebral infarction during praziquantel therapy in neurocysticercosis.", "question": "adverse event. Treatment, praziquantel. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18556970_2_2265", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Subject, a 13 year-old male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "13 year-old"}, {"id": "18556970_2_2266", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Subject, a 13 year-old male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18556970_2_2267", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Subject, a 13 year-old male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18556970_2_2268", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Subject, a 13 year-old male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18556970_2_2269", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Subject, a 13 year-old male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18556970_2_2270", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Increlex"}, {"id": "18556970_2_2271", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18556970_2_2272", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18556970_2_2273", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18556970_2_2274", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18556970_2_2275", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18556970_2_2276", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18556970_2_2277", "context": "We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.", "question": "adverse event. Treatment, Increlex. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_1_2278", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-beta"}, {"id": "16531969_1_2279", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_1_2280", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_1_2281", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_1_2282", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_1_2283", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_1_2284", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple sclerosis"}, {"id": "16531969_1_2285", "context": "Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.", "question": "adverse event. Treatment, interferon-beta (IFN-beta). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_1_2286", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Subject, pediatric. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "9925865_1_2287", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Subject, pediatric. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9925865_1_2288", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Subject, pediatric. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9925865_1_2289", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Subject, pediatric. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9925865_1_2290", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Subject, pediatric. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9925865_1_2291", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_1_2292", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_1_2293", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_1_2294", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_1_2295", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_1_2296", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_1_2297", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_1_2298", "context": "CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.", "question": "adverse event. Treatment, mineral oil aspiration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_12_2299", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Subject, patients with acute ischemic stroke. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_12_2300", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Subject, patients with acute ischemic stroke. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_12_2301", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Subject, patients with acute ischemic stroke. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21350204_12_2302", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Subject, patients with acute ischemic stroke. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_12_2303", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Subject, patients with acute ischemic stroke. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_12_2304", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "21350204_12_2305", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_12_2306", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_12_2307", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21350204_12_2308", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_12_2309", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_12_2310", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute ischemic stroke"}, {"id": "21350204_12_2311", "context": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.", "question": "potential therapeutic event. Treatment, taking warfarin with an international normalized ratio <1.7; tissue plasminogen activator treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "17157086_4_2312", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Subject, she. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17157086_4_2313", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Subject, she. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17157086_4_2314", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Subject, she. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17157086_4_2315", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Subject, she. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17157086_4_2316", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Subject, she. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17157086_4_2317", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "montelukast"}, {"id": "17157086_4_2318", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_4_2319", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17157086_4_2320", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17157086_4_2321", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "5 years"}, {"id": "17157086_4_2322", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17157086_4_2323", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "chronic asthma"}, {"id": "17157086_4_2324", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "potential therapeutic event. Treatment, a leukotriene receptor antagonist (montelukast) for 5 years. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17157086_4_2325", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Subject, two recent cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17157086_4_2326", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Subject, two recent cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17157086_4_2327", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Subject, two recent cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "17157086_4_2328", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Subject, two recent cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17157086_4_2329", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Subject, two recent cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17157086_4_2330", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Garcinia Cambogia"}, {"id": "17157086_4_2331", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_4_2332", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_4_2333", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_4_2334", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_4_2335", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_4_2336", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_4_2337", "context": "Because of chronic asthma, she had been receiving a leukotriene receptor antagonist (montelukast) for 5 years before the current presentation; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control; one of these included Garcinia Cambogia, a possible cause of two recent cases of hepatitis in the USA; in addition, both formulas contained a citrus derivative that interferes cytochrome functions.", "question": "adverse event. Treatment, Garcinia Cambogia. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2204409_1_2338", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Subject, 13-year-old girl who. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "13-year-old"}, {"id": "2204409_1_2339", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Subject, 13-year-old girl who. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "2204409_1_2340", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Subject, 13-year-old girl who. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2204409_1_2341", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Subject, 13-year-old girl who. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2204409_1_2342", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Subject, 13-year-old girl who. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2204409_1_2343", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "radiotherapy; methotrexate; intrathecal methotrexate"}, {"id": "2204409_1_2344", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "500 mg/m2; 12 mg"}, {"id": "2204409_1_2345", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2204409_1_2346", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "2204409_1_2347", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_1_2348", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2204409_1_2349", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2204409_1_2350", "context": "An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.", "question": "adverse event. Treatment, standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11514944_1_2351", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Accutane"}, {"id": "11514944_1_2352", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11514944_1_2353", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11514944_1_2354", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11514944_1_2355", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11514944_1_2356", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11514944_1_2357", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe, recalcitrant nodular acne"}, {"id": "11514944_1_2358", "context": "BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, Accutane. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12452753_5_2359", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with breast cancer who had allergic reactions to capecitabine. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_5_2360", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with breast cancer who had allergic reactions to capecitabine. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12452753_5_2361", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with breast cancer who had allergic reactions to capecitabine. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_5_2362", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with breast cancer who had allergic reactions to capecitabine. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_5_2363", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with breast cancer who had allergic reactions to capecitabine. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_5_2364", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluorouracil"}, {"id": "12452753_5_2365", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_5_2366", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_5_2367", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_5_2368", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_5_2369", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_5_2370", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "12452753_5_2371", "context": "OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7797283_1_2372", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Subject, two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7797283_1_2373", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Subject, two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7797283_1_2374", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Subject, two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "7797283_1_2375", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Subject, two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7797283_1_2376", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Subject, two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7797283_1_2377", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "7797283_1_2378", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7797283_1_2379", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7797283_1_2380", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7797283_1_2381", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7797283_1_2382", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7797283_1_2383", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7797283_1_2384", "context": "Esophageal candidiasis following omeprazole therapy: a report of two cases.", "question": "adverse event. Treatment, omeprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11059196_2_2385", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Subject, a 10-year-old boy with ulcerative colitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "10-year-old"}, {"id": "11059196_2_2386", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Subject, a 10-year-old boy with ulcerative colitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "11059196_2_2387", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Subject, a 10-year-old boy with ulcerative colitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11059196_2_2388", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Subject, a 10-year-old boy with ulcerative colitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11059196_2_2389", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Subject, a 10-year-old boy with ulcerative colitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11059196_2_2390", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "11059196_2_2391", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11059196_2_2392", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "long-term treatment"}, {"id": "11059196_2_2393", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11059196_2_2394", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11059196_2_2395", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11059196_2_2396", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "11059196_2_2397", "context": "We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.", "question": "adverse event. Treatment, long-term treatment with 5-aminosalicylic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_8_2398", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; extended-release niacin"}, {"id": "22010004_8_2399", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_8_2400", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_8_2401", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_8_2402", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_8_2403", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_8_2404", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_8_2405", "context": "The mechanism of niacin-induced coagulopathy is theorized to be related to diminished coagulation factors, and limited data suggest that this may be more pronounced with extended-release niacin.", "question": "adverse event. Treatment, niacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_6_2406", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_6_2407", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_6_2408", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_6_2409", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16449538_6_2410", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_6_2411", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_6_2412", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_6_2413", "context": "OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.", "question": "adverse event. Treatment, infusion of ifosfamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24679099_8_2414", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "24679099_8_2415", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_8_2416", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_8_2417", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_8_2418", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_8_2419", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_8_2420", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24679099_8_2421", "context": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_2_2422", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_2_2423", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_2_2424", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_2_2425", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_2_2426", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_2_2427", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_2_2428", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_2_2429", "context": "Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.", "question": "adverse event. Treatment, semi-synthetic tetracycline derivative antibiotic, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_2_2430", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Pregabalin"}, {"id": "25295553_2_2431", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_2_2432", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_2_2433", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_2_2434", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_2_2435", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_2_2436", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "generalized anxiety disorder"}, {"id": "25295553_2_2437", "context": "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder.", "question": "potential therapeutic event. Treatment, Pregabalin is an antiepileptic drug with anti-anxiety properties. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16615675_4_2438", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_4_2439", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_4_2440", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_4_2441", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_4_2442", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_4_2443", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "16615675_4_2444", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_4_2445", "context": "We report a case of chronic use of HCQ associated with torsade de pointes.", "question": "adverse event. Treatment, chronic use of HCQ. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_18_2446", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Subject, a patient with end-stage renal disease (ESRD). What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_18_2447", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Subject, a patient with end-stage renal disease (ESRD). What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_18_2448", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Subject, a patient with end-stage renal disease (ESRD). What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_18_2449", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Subject, a patient with end-stage renal disease (ESRD). What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_18_2450", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Subject, a patient with end-stage renal disease (ESRD). What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "end-stage renal disease (ESRD)"}, {"id": "17959575_18_2451", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_18_2452", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_18_2453", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17959575_18_2454", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_18_2455", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_18_2456", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_18_2457", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17959575_18_2458", "context": "PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.", "question": "adverse event. Treatment, continuous i.v. infusion of dobutamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15235919_3_2459", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Subject, a 29-year-old male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "29-year-old"}, {"id": "15235919_3_2460", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Subject, a 29-year-old male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15235919_3_2461", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Subject, a 29-year-old male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "male"}, {"id": "15235919_3_2462", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Subject, a 29-year-old male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15235919_3_2463", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Subject, a 29-year-old male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15235919_3_2464", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_3_2465", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_3_2466", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_3_2467", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_3_2468", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 weeks before"}, {"id": "15235919_3_2469", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_3_2470", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_3_2471", "context": "The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12806509_2_2472", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Subject, 3 years-old boy. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "3 years-old"}, {"id": "12806509_2_2473", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Subject, 3 years-old boy. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "12806509_2_2474", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Subject, 3 years-old boy. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12806509_2_2475", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Subject, 3 years-old boy. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12806509_2_2476", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Subject, 3 years-old boy. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "a viral respiratory infecction"}, {"id": "12806509_2_2477", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hepatitis B vaccination"}, {"id": "12806509_2_2478", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12806509_2_2479", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12806509_2_2480", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12806509_2_2481", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12806509_2_2482", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12806509_2_2483", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12806509_2_2484", "context": "In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.", "question": "adverse event. Treatment, hepatitis B vaccination. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_6_2485", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_6_2486", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_6_2487", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9925865_6_2488", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9925865_6_2489", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_6_2490", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9925865_6_2491", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ELP"}, {"id": "9925865_6_2492", "context": "Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.", "question": "potential therapeutic event. Treatment, stopping the use of mineral oil. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17710018_3_2493", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_3_2494", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17710018_3_2495", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_3_2496", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17710018_3_2497", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_3_2498", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_3_2499", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_3_2500", "context": "PET scintigraphy of etoposide-induced pulmonary toxicity.", "question": "adverse event. Treatment, etoposide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11807466_2_2501", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11807466_2_2502", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11807466_2_2503", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11807466_2_2504", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11807466_2_2505", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11807466_2_2506", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11807466_2_2507", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11807466_2_2508", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11807466_2_2509", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "starting"}, {"id": "11807466_2_2510", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11807466_2_2511", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11807466_2_2512", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11807466_2_2513", "context": "We report a patient who experienced LABD shortly after starting carbamazepine therapy.", "question": "adverse event. Treatment, starting carbamazepine therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1759924_1_2514", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "1759924_1_2515", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1759924_1_2516", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1759924_1_2517", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1759924_1_2518", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1759924_1_2519", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1759924_1_2520", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1759924_1_2521", "context": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.", "question": "adverse event. Treatment, Fulminant metoclopramide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_1_2522", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_1_2523", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_1_2524", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_1_2525", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_1_2526", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_1_2527", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_1_2528", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pain"}, {"id": "19648225_1_2529", "context": "Can ketamine prescribed for pain cause damage to the urinary tract?", "question": "adverse event. Treatment, ketamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1450506_3_2530", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "1450506_3_2531", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_3_2532", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_3_2533", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_3_2534", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_3_2535", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_3_2536", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_3_2537", "context": "Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).", "question": "adverse event. Treatment, IFN. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2924444_8_2538", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_8_2539", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_8_2540", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_8_2541", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_8_2542", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_8_2543", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_8_2544", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_8_2545", "context": "We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17952482_1_2546", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Subject, 58-year-old woman with rheumatoid arthritis (RA). What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "58-year-old"}, {"id": "17952482_1_2547", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Subject, 58-year-old woman with rheumatoid arthritis (RA). What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "17952482_1_2548", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Subject, 58-year-old woman with rheumatoid arthritis (RA). What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17952482_1_2549", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Subject, 58-year-old woman with rheumatoid arthritis (RA). What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17952482_1_2550", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Subject, 58-year-old woman with rheumatoid arthritis (RA). What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17952482_1_2551", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "17952482_1_2552", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_1_2553", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_1_2554", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_1_2555", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 weeks after"}, {"id": "17952482_1_2556", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_1_2557", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis (RA)"}, {"id": "17952482_1_2558", "context": "A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.", "question": "adverse event. Treatment, 3 weeks after treatment with sulfasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3449312_1_2559", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gold"}, {"id": "3449312_1_2560", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3449312_1_2561", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3449312_1_2562", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3449312_1_2563", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3449312_1_2564", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3449312_1_2565", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3449312_1_2566", "context": "Gold-induced aplastic anemia.", "question": "adverse event. Treatment, Gold. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15176542_1_2567", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Subject, One patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15176542_1_2568", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Subject, One patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15176542_1_2569", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Subject, One patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15176542_1_2570", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Subject, One patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15176542_1_2571", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Subject, One patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15176542_1_2572", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "15176542_1_2573", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15176542_1_2574", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15176542_1_2575", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15176542_1_2576", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15176542_1_2577", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15176542_1_2578", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15176542_1_2579", "context": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy.", "question": "adverse event. Treatment, a complication of heparin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6478628_1_2580", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "6478628_1_2581", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6478628_1_2582", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6478628_1_2583", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6478628_1_2584", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6478628_1_2585", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6478628_1_2586", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6478628_1_2587", "context": "Mammary gigantism is a rare complication of D-penicillamine treatment.", "question": "adverse event. Treatment, D-penicillamine treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_8_2588", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclobenzaprine; tricyclic antidepressants"}, {"id": "9681092_8_2589", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_8_2590", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_8_2591", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_8_2592", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_8_2593", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_8_2594", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_8_2595", "context": "Cyclobenzaprine shares anticholinergic effects, tachycardia, and dysrhythmic potential with the tricyclic antidepressants (TCAs).", "question": "adverse event. Treatment, Cyclobenzaprine; with the tricyclic antidepressants (TCAs). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15235919_2_2596", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_2_2597", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_2_2598", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_2_2599", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_2_2600", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15235919_2_2601", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_2_2602", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_2_2603", "context": "The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_3_2604", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_3_2605", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_3_2606", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_3_2607", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "nebulised"}, {"id": "9466030_3_2608", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9466030_3_2609", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_3_2610", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_3_2611", "context": "PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11554897_3_2612", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Subject, A 55-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "55-year-old"}, {"id": "11554897_3_2613", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Subject, A 55-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11554897_3_2614", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Subject, A 55-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11554897_3_2615", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Subject, A 55-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11554897_3_2616", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Subject, A 55-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11554897_3_2617", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine; valproic acid"}, {"id": "11554897_3_2618", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "11554897_3_2619", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_3_2620", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "tablets"}, {"id": "11554897_3_2621", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_3_2622", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_3_2623", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_3_2624", "context": "METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.", "question": "adverse event. Treatment, overdose with lamotrigine (LTG) and valproic acid (VPA) tablets. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lamotrigine; valproic acid"}, {"id": "16099004_1_2625", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine; phenytoin"}, {"id": "16099004_1_2626", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_1_2627", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_1_2628", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_1_2629", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_1_2630", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_1_2631", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16099004_1_2632", "context": "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.", "question": "adverse event. Treatment, quinine; phenytoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "11978156_1_2633", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_1_2634", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_1_2635", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_1_2636", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_1_2637", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_1_2638", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_1_2639", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_1_2640", "context": "CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3549808_1_2641", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, One of the subjects. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3549808_1_2642", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, One of the subjects. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3549808_1_2643", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, One of the subjects. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "3549808_1_2644", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, One of the subjects. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3549808_1_2645", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, One of the subjects. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3549808_1_2646", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "3549808_1_2647", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3549808_1_2648", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3549808_1_2649", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "3549808_1_2650", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3549808_1_2651", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3549808_1_2652", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3549808_1_2653", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3549808_1_2654", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, the other. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3549808_1_2655", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, the other. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3549808_1_2656", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, the other. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3549808_1_2657", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, the other. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3549808_1_2658", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Subject, the other. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3549808_1_2659", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "3549808_1_2660", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3549808_1_2661", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3549808_1_2662", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "3549808_1_2663", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3549808_1_2664", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3549808_1_2665", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3549808_1_2666", "context": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.", "question": "adverse event. Treatment, extemporaneous topical minoxidil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_1_2667", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_1_2668", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_1_2669", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_1_2670", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_1_2671", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_1_2672", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_1_2673", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_1_2674", "context": "CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6628806_2_2675", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; etretinate"}, {"id": "6628806_2_2676", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6628806_2_2677", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6628806_2_2678", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6628806_2_2679", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6628806_2_2680", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6628806_2_2681", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "6628806_2_2682", "context": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.", "question": "adverse event. Treatment, methotrexate and etretinate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; etretinate"}, {"id": "19934385_2_2683", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Subject, an HIV-infected male. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "19934385_2_2684", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Subject, an HIV-infected male. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "19934385_2_2685", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Subject, an HIV-infected male. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19934385_2_2686", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Subject, an HIV-infected male. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19934385_2_2687", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Subject, an HIV-infected male. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19934385_2_2688", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "itraconazole; ritonavir; lopinavir"}, {"id": "19934385_2_2689", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19934385_2_2690", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19934385_2_2691", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19934385_2_2692", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19934385_2_2693", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19934385_2_2694", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "histoplasmosis; HIV"}, {"id": "19934385_2_2695", "context": "To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis.", "question": "potential therapeutic event. Treatment, lopinavir/ritonavir and itraconazole concentrations. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "lopinavir; ritonavir; itraconazole"}, {"id": "11476690_1_2696", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin; gentamycin"}, {"id": "11476690_1_2697", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11476690_1_2698", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11476690_1_2699", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11476690_1_2700", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11476690_1_2701", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11476690_1_2702", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Ulcer"}, {"id": "11476690_1_2703", "context": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days.", "question": "adverse event. Treatment, tobramycin and gentamycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "gentamycin; tobramycin"}, {"id": "12149193_3_2704", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide; cytotoxic"}, {"id": "12149193_3_2705", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_3_2706", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_3_2707", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12149193_3_2708", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_3_2709", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_3_2710", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "refractory multiple myeloma (MM)"}, {"id": "12149193_3_2711", "context": "Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT.", "question": "adverse event. Treatment, single-agent thalidomide; combination with cytotoxic chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "thalidomide; cytotoxic"}, {"id": "2357706_3_2712", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_3_2713", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_3_2714", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_3_2715", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_3_2716", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_3_2717", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_3_2718", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_3_2719", "context": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_4_2720", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Subject, a postmenopausal patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7789881_4_2721", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Subject, a postmenopausal patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7789881_4_2722", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Subject, a postmenopausal patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7789881_4_2723", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Subject, a postmenopausal patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7789881_4_2724", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Subject, a postmenopausal patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "postmenopausal"}, {"id": "7789881_4_2725", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_4_2726", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_4_2727", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_4_2728", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_4_2729", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_4_2730", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_4_2731", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast carcinoma"}, {"id": "7789881_4_2732", "context": "Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.", "question": "adverse event. Treatment, tamoxifen therapy 5 years after mastectomy for breast carcinoma.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_1_2733", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "intravesical"}, {"id": "2104570_1_2734", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_1_2735", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_1_2736", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "2104570_1_2737", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_1_2738", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_1_2739", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bladder carcinoma"}, {"id": "2104570_1_2740", "context": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.", "question": "adverse event. Treatment, intravesical chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_1_2741", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ciprofloxacin"}, {"id": "15463865_1_2742", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_1_2743", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_1_2744", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_1_2745", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_1_2746", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_1_2747", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15463865_1_2748", "context": "Ciprofloxacin-induced renal insufficiency in cystic fibrosis.", "question": "adverse event. Treatment, Ciprofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_3_2749", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carmustine wafers"}, {"id": "15701285_3_2750", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_3_2751", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_3_2752", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15701285_3_2753", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_3_2754", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_3_2755", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignant glioma"}, {"id": "15701285_3_2756", "context": "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.", "question": "adverse event. Treatment, the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_5_2757", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Didanosine"}, {"id": "11573852_5_2758", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_5_2759", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_5_2760", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_5_2761", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_5_2762", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_5_2763", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_5_2764", "context": "Didanosine also has a potential for inducing seizures.", "question": "adverse event. Treatment, Didanosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12880504_2_2765", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "12880504_2_2766", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12880504_2_2767", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12880504_2_2768", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12880504_2_2769", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12880504_2_2770", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12880504_2_2771", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12880504_2_2772", "context": "Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.", "question": "adverse event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15362597_1_2773", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin; glyburide"}, {"id": "15362597_1_2774", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15362597_1_2775", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15362597_1_2776", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15362597_1_2777", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15362597_1_2778", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15362597_1_2779", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15362597_1_2780", "context": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction.", "question": "adverse event. Treatment, ciprofloxacin and glyburide interaction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "18556970_1_2781", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant insulin-like growth factor-I"}, {"id": "18556970_1_2782", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18556970_1_2783", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18556970_1_2784", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18556970_1_2785", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18556970_1_2786", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18556970_1_2787", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18556970_1_2788", "context": "Anaphylactic reaction to recombinant insulin-like growth factor-I.", "question": "adverse event. Treatment, recombinant insulin-like growth factor-I. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_1_2789", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tissue plasminogen activator; warfarin"}, {"id": "21350204_1_2790", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_1_2791", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_1_2792", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_1_2793", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_1_2794", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_1_2795", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ischemic strokes"}, {"id": "21350204_1_2796", "context": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.", "question": "adverse event. Treatment, Subtherapeutic warfarin; treated with tissue plasminogen activator. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; tissue plasminogen activator"}, {"id": "10510017_2_2797", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, Pediatric. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "Pediatric"}, {"id": "10510017_2_2798", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, Pediatric. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10510017_2_2799", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, Pediatric. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10510017_2_2800", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, Pediatric. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10510017_2_2801", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, Pediatric. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10510017_2_2802", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Danaparoid"}, {"id": "10510017_2_2803", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_2_2804", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10510017_2_2805", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10510017_2_2806", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_2_2807", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10510017_2_2808", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "heparin-induced thrombocytopenia"}, {"id": "10510017_2_2809", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10510017_2_2810", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Subject, Pediatric. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "Pediatric"}, {"id": "10510017_2_2811", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Subject, Pediatric. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_2_2812", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Subject, Pediatric. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_2_2813", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Subject, Pediatric. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_2_2814", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Subject, Pediatric. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_2_2815", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_2_2816", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_2_2817", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_2_2818", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_2_2819", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_2_2820", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_2_2821", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_2_2822", "context": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_4_2823", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Teicoplanin; vancomycin"}, {"id": "17426073_4_2824", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_4_2825", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_4_2826", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_4_2827", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17426073_4_2828", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_4_2829", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_4_2830", "context": "Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.", "question": "adverse event. Treatment, Teicoplanin; followed vancomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "Teicoplanin; vancomycin"}, {"id": "946400_1_2831", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Subject, A 55-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "55-year-old"}, {"id": "946400_1_2832", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Subject, A 55-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "946400_1_2833", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Subject, A 55-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "946400_1_2834", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Subject, A 55-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "946400_1_2835", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Subject, A 55-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "946400_1_2836", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methyldopa"}, {"id": "946400_1_2837", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "946400_1_2838", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "946400_1_2839", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "946400_1_2840", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "12 weeks"}, {"id": "946400_1_2841", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "946400_1_2842", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypertension"}, {"id": "946400_1_2843", "context": "A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.", "question": "adverse event. Treatment, methyldopa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "644545_1_2844", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclophosphamide"}, {"id": "644545_1_2845", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "644545_1_2846", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "644545_1_2847", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "644545_1_2848", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "644545_1_2849", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "644545_1_2850", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "644545_1_2851", "context": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.", "question": "adverse event. Treatment, Cyclophosphamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_1_2852", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Subject, 6%-10% of patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7117795_1_2853", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Subject, 6%-10% of patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7117795_1_2854", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Subject, 6%-10% of patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "6%-10%"}, {"id": "7117795_1_2855", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Subject, 6%-10% of patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7117795_1_2856", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Subject, 6%-10% of patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7117795_1_2857", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Flucytosine"}, {"id": "7117795_1_2858", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_1_2859", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_1_2860", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_1_2861", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_1_2862", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_1_2863", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_1_2864", "context": "Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.", "question": "adverse event. Treatment, Flucytosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4051280_1_2865", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Subject, his hyperadrenergic state. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4051280_1_2866", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Subject, his hyperadrenergic state. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "his"}, {"id": "4051280_1_2867", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Subject, his hyperadrenergic state. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4051280_1_2868", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Subject, his hyperadrenergic state. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4051280_1_2869", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Subject, his hyperadrenergic state. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4051280_1_2870", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "4051280_1_2871", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4051280_1_2872", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4051280_1_2873", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "IV"}, {"id": "4051280_1_2874", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4051280_1_2875", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4051280_1_2876", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperadrenergic state"}, {"id": "4051280_1_2877", "context": "IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.", "question": "adverse event. Treatment, IV propranolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_3_2878", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_3_2879", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_3_2880", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_3_2881", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_3_2882", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_3_2883", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_3_2884", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7789881_3_2885", "context": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3513544_1_2886", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Subject, renal transplant patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_1_2887", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Subject, renal transplant patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_1_2888", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Subject, renal transplant patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_1_2889", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Subject, renal transplant patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_1_2890", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Subject, renal transplant patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3513544_1_2891", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "3513544_1_2892", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_1_2893", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_1_2894", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_1_2895", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_1_2896", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_1_2897", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal transplant"}, {"id": "3513544_1_2898", "context": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.", "question": "adverse event. Treatment, cyclosporine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_3_2899", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-ASA"}, {"id": "12763355_3_2900", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_3_2901", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_3_2902", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_3_2903", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_3_2904", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_3_2905", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_3_2906", "context": "This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.", "question": "adverse event. Treatment, 5-ASA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18622319_1_2907", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab"}, {"id": "18622319_1_2908", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_1_2909", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_1_2910", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_1_2911", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_1_2912", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_1_2913", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18622319_1_2914", "context": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.", "question": "adverse event. Treatment, antiangiogenic bevacizumab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_3_2915", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tricyclic antidepressants; serotonin selective reuptake inhibitors"}, {"id": "10442258_3_2916", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_3_2917", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_3_2918", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_3_2919", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_3_2920", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_3_2921", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_3_2922", "context": "There are a few case reports on hair loss associated with tricyclic antidepressants and serotonin selective reuptake inhibitors (SSRIs), but none deal specifically with paroxetine.", "question": "adverse event. Treatment, tricyclic antidepressants and serotonin selective reuptake inhibitors. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "tricyclic antidepressants; serotonin selective reuptake inhibitors"}, {"id": "11903249_2_2923", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; interferon alfa; ribavirin"}, {"id": "11903249_2_2924", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_2_2925", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_2_2926", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_2_2927", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_2_2928", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_2_2929", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11903249_2_2930", "context": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.", "question": "adverse event. Treatment, interferon alfa and more recently with the combination of interferon alfa plus ribavirin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "20065266_2_2931", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, A 37-year-old African- American man with G6PD deficiency. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "37-year-old"}, {"id": "20065266_2_2932", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, A 37-year-old African- American man with G6PD deficiency. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "20065266_2_2933", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, A 37-year-old African- American man with G6PD deficiency. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_2_2934", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, A 37-year-old African- American man with G6PD deficiency. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "African- American"}, {"id": "20065266_2_2935", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, A 37-year-old African- American man with G6PD deficiency. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "G6PD deficiency"}, {"id": "20065266_2_2936", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim-sulfamethoxazole"}, {"id": "20065266_2_2937", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_2_2938", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_2_2939", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_2_2940", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_2_2941", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_2_2942", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_2_2943", "context": "CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20009973_1_2944", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "All-trans retinoic acid"}, {"id": "20009973_1_2945", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20009973_1_2946", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20009973_1_2947", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20009973_1_2948", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20009973_1_2949", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20009973_1_2950", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20009973_1_2951", "context": "All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.", "question": "adverse event. Treatment, All-trans retinoic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_4_2952", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Oxygen; bleomycin"}, {"id": "2417800_4_2953", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_4_2954", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_4_2955", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_4_2956", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_4_2957", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_4_2958", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_4_2959", "context": "Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.", "question": "adverse event. Treatment, Oxygen potentiation of bleomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "bleomycin; Oxygen"}, {"id": "11554897_1_2960", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "LTG"}, {"id": "11554897_1_2961", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "11554897_1_2962", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_1_2963", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_1_2964", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_1_2965", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_1_2966", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_1_2967", "context": "CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.", "question": "adverse event. Treatment, LTG overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_7_2968", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "danazol; simvastatin"}, {"id": "14712320_7_2969", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_7_2970", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_7_2971", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_7_2972", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_7_2973", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_7_2974", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_7_2975", "context": "In this report, we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin.", "question": "adverse event. Treatment, interaction between danazol and simvastatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "danazol; simvastatin"}, {"id": "14660304_1_2976", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Subject, two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14660304_1_2977", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Subject, two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14660304_1_2978", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Subject, two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "14660304_1_2979", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Subject, two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14660304_1_2980", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Subject, two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14660304_1_2981", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "14660304_1_2982", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14660304_1_2983", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14660304_1_2984", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "14660304_1_2985", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14660304_1_2986", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14660304_1_2987", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14660304_1_2988", "context": "Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.", "question": "adverse event. Treatment, dexamethasone; all remission-induction chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19531696_3_2989", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Subject, A 56-year-old white male. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "56-year-old"}, {"id": "19531696_3_2990", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Subject, A 56-year-old white male. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "19531696_3_2991", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Subject, A 56-year-old white male. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19531696_3_2992", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Subject, A 56-year-old white male. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "19531696_3_2993", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Subject, A 56-year-old white male. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19531696_3_2994", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "19531696_3_2995", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19531696_3_2996", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19531696_3_2997", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19531696_3_2998", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19531696_3_2999", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19531696_3_3000", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19531696_3_3001", "context": "A 56-year-old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement.", "question": "potential therapeutic event. Treatment, chronic warfarin therapy for 11 years after mechanical heart valve replacement. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12962465_3_3002", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isoniazid"}, {"id": "12962465_3_3003", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_3_3004", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_3_3005", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_3_3006", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12962465_3_3007", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_3_3008", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_3_3009", "context": "Isoniazid associated, painful, bilateral gynaecomastia.", "question": "adverse event. Treatment, Isoniazid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2924444_5_3010", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_5_3011", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_5_3012", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_5_3013", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_5_3014", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_5_3015", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_5_3016", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_5_3017", "context": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.", "question": "adverse event. Treatment, the L-thyroxine therapy.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20154441_1_3018", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylephedrine; Chinese herbal drugs"}, {"id": "20154441_1_3019", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20154441_1_3020", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20154441_1_3021", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20154441_1_3022", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20154441_1_3023", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20154441_1_3024", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20154441_1_3025", "context": "Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.", "question": "adverse event. Treatment, Combining methylephedrine and Chinese herbal drugs. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "methylephedrine; Chinese herbal drugs"}, {"id": "18025525_11_3026", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "voriconazole; efavirenz; efavirenz; voriconazole"}, {"id": "18025525_11_3027", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "200 mg; 400 mg"}, {"id": "18025525_11_3028", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18025525_11_3029", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18025525_11_3030", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18025525_11_3031", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18025525_11_3032", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18025525_11_3033", "context": "Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.", "question": "adverse event. Treatment, Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz; efavirenz on voriconazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "voriconazole; efavirenz"}, {"id": "22010004_12_3034", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Subject, this patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22010004_12_3035", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Subject, this patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22010004_12_3036", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Subject, this patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_12_3037", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Subject, this patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22010004_12_3038", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Subject, this patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_12_3039", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; warfarin"}, {"id": "22010004_12_3040", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_12_3041", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_12_3042", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_12_3043", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_12_3044", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_12_3045", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_12_3046", "context": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin.", "question": "adverse event. Treatment, interaction between niacin and warfarin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "niacin; warfarin"}, {"id": "12692521_2_3047", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Subject, two cases in which both patients suffered with CLS. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12692521_2_3048", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Subject, two cases in which both patients suffered with CLS. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12692521_2_3049", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Subject, two cases in which both patients suffered with CLS. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "12692521_2_3050", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Subject, two cases in which both patients suffered with CLS. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12692521_2_3051", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Subject, two cases in which both patients suffered with CLS. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12692521_2_3052", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "granulocyte colony-stimulating facto"}, {"id": "12692521_2_3053", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12692521_2_3054", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12692521_2_3055", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12692521_2_3056", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12692521_2_3057", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12692521_2_3058", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12692521_2_3059", "context": "We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.", "question": "adverse event. Treatment, granulocyte colony-stimulating factor. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_1_3060", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Subject, woman. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_1_3061", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Subject, woman. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "woman"}, {"id": "12452753_1_3062", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Subject, woman. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_1_3063", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Subject, woman. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_1_3064", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Subject, woman. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12452753_1_3065", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "diphenhydramine"}, {"id": "12452753_1_3066", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_1_3067", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_1_3068", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_1_3069", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "1 week"}, {"id": "12452753_1_3070", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_1_3071", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_1_3072", "context": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.", "question": "potential therapeutic event. Treatment, diphenhydramine for 1 week. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18812562_5_3073", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "everolimus; mycophenolate mofetil; cyclosporine; fluconazole"}, {"id": "18812562_5_3074", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "0.75 mg every 12 hours; 400 mg, followed by 100 mg every 24 hours"}, {"id": "18812562_5_3075", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18812562_5_3076", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral; Intravenous"}, {"id": "18812562_5_3077", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18812562_5_3078", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18812562_5_3079", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nephrotoxicity"}, {"id": "18812562_5_3080", "context": "Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours according to impaired renal function, was immediately started; to avoid further nephrotoxicity, immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours.", "question": "potential therapeutic event. Treatment, Intravenous fluconazole 400 mg, followed by 100 mg every 24 hours; immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "cyclosporine; mycophenolate mofetil; fluconazole; everolimus"}, {"id": "1827039_2_3081", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 3 patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1827039_2_3082", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 3 patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1827039_2_3083", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 3 patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "1827039_2_3084", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 3 patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1827039_2_3085", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 3 patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1827039_2_3086", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CPA"}, {"id": "1827039_2_3087", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_2_3088", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_2_3089", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_2_3090", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_2_3091", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_2_3092", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_2_3093", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1827039_2_3094", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 2. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1827039_2_3095", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 2. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1827039_2_3096", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 2. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "1827039_2_3097", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 2. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1827039_2_3098", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Subject, 2. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1827039_2_3099", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CPA"}, {"id": "1827039_2_3100", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1827039_2_3101", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1827039_2_3102", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1827039_2_3103", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1827039_2_3104", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1827039_2_3105", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1827039_2_3106", "context": "We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.", "question": "adverse event. Treatment, CPA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_2_3107", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Subject, she. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12702914_2_3108", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Subject, she. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "12702914_2_3109", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Subject, she. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12702914_2_3110", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Subject, she. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12702914_2_3111", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Subject, she. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12702914_2_3112", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_2_3113", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_2_3114", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_2_3115", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_2_3116", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_2_3117", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_2_3118", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12702914_2_3119", "context": "Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.", "question": "adverse event. Treatment, insulin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_3_3120", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Subject, a continuous ambulatory peritoneal dialysis (CAPD) patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_3_3121", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Subject, a continuous ambulatory peritoneal dialysis (CAPD) patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_3_3122", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Subject, a continuous ambulatory peritoneal dialysis (CAPD) patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_3_3123", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Subject, a continuous ambulatory peritoneal dialysis (CAPD) patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_3_3124", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Subject, a continuous ambulatory peritoneal dialysis (CAPD) patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "continuous ambulatory peritoneal dialysis (CAPD)"}, {"id": "15053046_3_3125", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_3_3126", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_3_3127", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_3_3128", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_3_3129", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_3_3130", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15053046_3_3131", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia"}, {"id": "15053046_3_3132", "context": "We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_8_3133", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Subject, In both cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17667887_8_3134", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Subject, In both cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_8_3135", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Subject, In both cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "17667887_8_3136", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Subject, In both cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_8_3137", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Subject, In both cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_8_3138", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; atypical antipsychotic"}, {"id": "17667887_8_3139", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_8_3140", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_8_3141", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_8_3142", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_8_3143", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_8_3144", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17667887_8_3145", "context": "In both cases, we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic.", "question": "adverse event. Treatment, a combination of an antidepressant and an atypical antipsychotic. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "antidepressant; atypical antipsychotic"}, {"id": "3620420_6_3146", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporin"}, {"id": "3620420_6_3147", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_6_3148", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3620420_6_3149", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3620420_6_3150", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_6_3151", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3620420_6_3152", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3620420_6_3153", "context": "Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.", "question": "adverse event. Treatment, Cyclosporin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_7_3154", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_7_3155", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_7_3156", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_7_3157", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_7_3158", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_7_3159", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_7_3160", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_7_3161", "context": "She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication.", "question": "adverse event. Treatment, switching to methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_8_3162", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Subject, three cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_8_3163", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Subject, three cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_8_3164", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Subject, three cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11573852_8_3165", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Subject, three cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_8_3166", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Subject, three cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_8_3167", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_8_3168", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_8_3169", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_8_3170", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_8_3171", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_8_3172", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_8_3173", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_8_3174", "context": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16355099_1_3175", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Heparin"}, {"id": "16355099_1_3176", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16355099_1_3177", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16355099_1_3178", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16355099_1_3179", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16355099_1_3180", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16355099_1_3181", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16355099_1_3182", "context": "Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.", "question": "adverse event. Treatment, Heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17473920_1_3183", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Subject, human-immunodeficiency-virus-infected patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17473920_1_3184", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Subject, human-immunodeficiency-virus-infected patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17473920_1_3185", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Subject, human-immunodeficiency-virus-infected patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17473920_1_3186", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Subject, human-immunodeficiency-virus-infected patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17473920_1_3187", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Subject, human-immunodeficiency-virus-infected patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17473920_1_3188", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "nevirapine; methadone"}, {"id": "17473920_1_3189", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17473920_1_3190", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once daily"}, {"id": "17473920_1_3191", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17473920_1_3192", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17473920_1_3193", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17473920_1_3194", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "human-immunodeficiency-virus"}, {"id": "17473920_1_3195", "context": "Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.", "question": "potential therapeutic event. Treatment, methadone; nevirapine once daily. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "nevirapine; methadone"}, {"id": "3449312_2_3196", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Subject, Three patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3449312_2_3197", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Subject, Three patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3449312_2_3198", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Subject, Three patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "3449312_2_3199", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Subject, Three patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3449312_2_3200", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Subject, Three patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3449312_2_3201", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold salt"}, {"id": "3449312_2_3202", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3449312_2_3203", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3449312_2_3204", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3449312_2_3205", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3449312_2_3206", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3449312_2_3207", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "3449312_2_3208", "context": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.", "question": "adverse event. Treatment, gold salt. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12092878_2_3209", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Subject, patient with non-haemorrhagic hypovolaemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12092878_2_3210", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Subject, patient with non-haemorrhagic hypovolaemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12092878_2_3211", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Subject, patient with non-haemorrhagic hypovolaemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12092878_2_3212", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Subject, patient with non-haemorrhagic hypovolaemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12092878_2_3213", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Subject, patient with non-haemorrhagic hypovolaemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12092878_2_3214", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gelofusine"}, {"id": "12092878_2_3215", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12092878_2_3216", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12092878_2_3217", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12092878_2_3218", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12092878_2_3219", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12092878_2_3220", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "non-haemorrhagic hypovolaemia"}, {"id": "12092878_2_3221", "context": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.", "question": "adverse event. Treatment, Gelofusine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6344831_3_3222", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "6344831_3_3223", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6344831_3_3224", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6344831_3_3225", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6344831_3_3226", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6344831_3_3227", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6344831_3_3228", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6344831_3_3229", "context": "Nonoliguric acute renal failure after captopril therapy.", "question": "adverse event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19217693_3_3230", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Subject, a patient with type 2 diabetes mellitus. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19217693_3_3231", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Subject, a patient with type 2 diabetes mellitus. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19217693_3_3232", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Subject, a patient with type 2 diabetes mellitus. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19217693_3_3233", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Subject, a patient with type 2 diabetes mellitus. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19217693_3_3234", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Subject, a patient with type 2 diabetes mellitus. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19217693_3_3235", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept; insulin"}, {"id": "19217693_3_3236", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19217693_3_3237", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19217693_3_3238", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19217693_3_3239", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19217693_3_3240", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19217693_3_3241", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "type 2 diabetes mellitus; severe plaque psoriasis"}, {"id": "19217693_3_3242", "context": "We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.", "question": "adverse event. Treatment, the antitumor necrosis factor-alpha blocking agent etanercept; previous insulin regimen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "insulin; etanercept"}, {"id": "12540009_4_3243", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Subject, a young nondiabetic man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12540009_4_3244", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Subject, a young nondiabetic man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12540009_4_3245", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Subject, a young nondiabetic man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12540009_4_3246", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Subject, a young nondiabetic man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12540009_4_3247", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Subject, a young nondiabetic man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "nondiabetic"}, {"id": "12540009_4_3248", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12540009_4_3249", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12540009_4_3250", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12540009_4_3251", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12540009_4_3252", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12540009_4_3253", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12540009_4_3254", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12540009_4_3255", "context": "We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.", "question": "adverse event. Treatment, doxycycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_7_3256", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Subject, AIDS patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_7_3257", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Subject, AIDS patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_7_3258", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Subject, AIDS patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_7_3259", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Subject, AIDS patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_7_3260", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Subject, AIDS patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "AIDS"}, {"id": "11573852_7_3261", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_7_3262", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_7_3263", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_7_3264", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_7_3265", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_7_3266", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_7_3267", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_7_3268", "context": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_1_3269", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "897744_1_3270", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_1_3271", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_1_3272", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_1_3273", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_1_3274", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_1_3275", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "897744_1_3276", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, heroin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_1_3277", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin"}, {"id": "897744_1_3278", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_1_3279", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_1_3280", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_1_3281", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_1_3282", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_1_3283", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "heroin-related infective endocarditis"}, {"id": "897744_1_3284", "context": "Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.", "question": "adverse event. Treatment, methicillin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1834424_2_3285", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "4-chloro-7-nitrobenzofurazan"}, {"id": "1834424_2_3286", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1834424_2_3287", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1834424_2_3288", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1834424_2_3289", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1834424_2_3290", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1834424_2_3291", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1834424_2_3292", "context": "Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.", "question": "adverse event. Treatment, 4-chloro-7-nitrobenzofurazan. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_2_3293", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Subject, a 5-year-old girl. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "5-year-old"}, {"id": "16816519_2_3294", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Subject, a 5-year-old girl. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "16816519_2_3295", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Subject, a 5-year-old girl. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16816519_2_3296", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Subject, a 5-year-old girl. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16816519_2_3297", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Subject, a 5-year-old girl. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16816519_2_3298", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "16816519_2_3299", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_2_3300", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_2_3301", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16816519_2_3302", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_2_3303", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_2_3304", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_2_3305", "context": "We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "pyridostigmine; pyridoxine"}, {"id": "9925865_3_3306", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_3_3307", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_3_3308", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_3_3309", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_3_3310", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_3_3311", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_3_3312", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_3_3313", "context": "Lipoid pneumonia: a silent complication of mineral oil aspiration.", "question": "adverse event. Treatment, mineral oil aspiration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10610018_1_3314", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Subject, four patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10610018_1_3315", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Subject, four patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10610018_1_3316", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Subject, four patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "four"}, {"id": "10610018_1_3317", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Subject, four patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10610018_1_3318", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Subject, four patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10610018_1_3319", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "risperidone"}, {"id": "10610018_1_3320", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_1_3321", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10610018_1_3322", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10610018_1_3323", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_1_3324", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10610018_1_3325", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Elevated serum triglycerides with clozapine"}, {"id": "10610018_1_3326", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "potential therapeutic event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10610018_1_3327", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "10610018_1_3328", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_1_3329", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10610018_1_3330", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10610018_1_3331", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_1_3332", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10610018_1_3333", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10610018_1_3334", "context": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_3_3335", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_3_3336", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_3_3337", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_3_3338", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_3_3339", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_3_3340", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_3_3341", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_3_3342", "context": "Seizures associated with fluoxetine therapy.", "question": "adverse event. Treatment, fluoxetine therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18006091_1_3343", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "18006091_1_3344", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18006091_1_3345", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18006091_1_3346", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18006091_1_3347", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18006091_1_3348", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18006091_1_3349", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18006091_1_3350", "context": "Sustained monomorphic ventricular tachycardia after adenosine infusion.", "question": "adverse event. Treatment, adenosine infusion.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7632529_1_3351", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Subject, A 9-year-old boy. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "9-year-old"}, {"id": "7632529_1_3352", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Subject, A 9-year-old boy. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "7632529_1_3353", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Subject, A 9-year-old boy. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7632529_1_3354", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Subject, A 9-year-old boy. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7632529_1_3355", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Subject, A 9-year-old boy. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7632529_1_3356", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "intravenous acyclovir"}, {"id": "7632529_1_3357", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "30 mg/kg"}, {"id": "7632529_1_3358", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "per day"}, {"id": "7632529_1_3359", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7632529_1_3360", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7632529_1_3361", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "6 days"}, {"id": "7632529_1_3362", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "herpetic encephalitis"}, {"id": "7632529_1_3363", "context": "A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.", "question": "adverse event. Treatment, intravenous acyclovir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18476934_3_3364", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Subject, a 4-year-old girl. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "4-year-old"}, {"id": "18476934_3_3365", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Subject, a 4-year-old girl. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "18476934_3_3366", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Subject, a 4-year-old girl. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18476934_3_3367", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Subject, a 4-year-old girl. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18476934_3_3368", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Subject, a 4-year-old girl. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18476934_3_3369", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxybutynin"}, {"id": "18476934_3_3370", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18476934_3_3371", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18476934_3_3372", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18476934_3_3373", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10 days"}, {"id": "18476934_3_3374", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18476934_3_3375", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "enuresis"}, {"id": "18476934_3_3376", "context": "We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.", "question": "adverse event. Treatment, oxybutynin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_1_3377", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Subject, a patient with renal insufficiency. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16580907_1_3378", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Subject, a patient with renal insufficiency. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16580907_1_3379", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Subject, a patient with renal insufficiency. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_1_3380", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Subject, a patient with renal insufficiency. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_1_3381", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Subject, a patient with renal insufficiency. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_1_3382", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "16580907_1_3383", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_1_3384", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_1_3385", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_1_3386", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_1_3387", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_1_3388", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_1_3389", "context": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2.", "question": "adverse event. Treatment, interaction of cetirizine and pilsicainide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "10465148_4_3390", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Subject, three children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "10465148_4_3391", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Subject, three children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10465148_4_3392", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Subject, three children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "10465148_4_3393", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Subject, three children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10465148_4_3394", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Subject, three children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10465148_4_3395", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_4_3396", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_4_3397", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_4_3398", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_4_3399", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_4_3400", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_4_3401", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_4_3402", "context": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_3_3403", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Subject, 2 patients who presented to the emergency department with pre-excited atrial fibrillation. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11428480_3_3404", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Subject, 2 patients who presented to the emergency department with pre-excited atrial fibrillation. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11428480_3_3405", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Subject, 2 patients who presented to the emergency department with pre-excited atrial fibrillation. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "11428480_3_3406", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Subject, 2 patients who presented to the emergency department with pre-excited atrial fibrillation. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11428480_3_3407", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Subject, 2 patients who presented to the emergency department with pre-excited atrial fibrillation. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11428480_3_3408", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "11428480_3_3409", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "12 mg"}, {"id": "11428480_3_3410", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_3_3411", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_3_3412", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_3_3413", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_3_3414", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pre-excited atrial fibrillation"}, {"id": "11428480_3_3415", "context": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.", "question": "adverse event. Treatment, 12 mg of adenosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_5_3416", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17083890_5_3417", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17083890_5_3418", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17083890_5_3419", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17083890_5_3420", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17083890_5_3421", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17083890_5_3422", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_5_3423", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_5_3424", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "17083890_5_3425", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_5_3426", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_5_3427", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_5_3428", "context": "During administration of chemotherapy, the patient progressively developed a complex association of Beau's lines, transverse melanonychia, Muehrcke's lines, and diffuse hyperpigmentation of the skin.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_1_3429", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine; adriamycin; dexamethasone"}, {"id": "17083890_1_3430", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_1_3431", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_1_3432", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_1_3433", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_1_3434", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_1_3435", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "17083890_1_3436", "context": "Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.", "question": "adverse event. Treatment, vincristine, adriamycin, dexamethasone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10633877_3_3437", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Subject, a child. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "10633877_3_3438", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Subject, a child. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10633877_3_3439", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Subject, a child. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10633877_3_3440", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Subject, a child. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10633877_3_3441", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Subject, a child. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10633877_3_3442", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Theophylline"}, {"id": "10633877_3_3443", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10633877_3_3444", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10633877_3_3445", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10633877_3_3446", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10633877_3_3447", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10633877_3_3448", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10633877_3_3449", "context": "Theophylline intoxication mimicking diabetic ketoacidosis in a child.", "question": "adverse event. Treatment, Theophylline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_3_3450", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_3_3451", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_3_3452", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_3_3453", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_3_3454", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_3_3455", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "18492617_3_3456", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_3_3457", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_3_3458", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_3_3459", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_3_3460", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_3_3461", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neuropathic pain"}, {"id": "18492617_3_3462", "context": "We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_2_3463", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with mild allergic reactions to capecitabine. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12452753_2_3464", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with mild allergic reactions to capecitabine. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12452753_2_3465", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with mild allergic reactions to capecitabine. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12452753_2_3466", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with mild allergic reactions to capecitabine. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12452753_2_3467", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Subject, a patient with mild allergic reactions to capecitabine. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_2_3468", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluorouracil"}, {"id": "12452753_2_3469", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_2_3470", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_2_3471", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_2_3472", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_2_3473", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_2_3474", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_2_3475", "context": "CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, fluorouracil treatment with careful monitoring. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16313549_1_3476", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16313549_1_3477", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16313549_1_3478", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16313549_1_3479", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16313549_1_3480", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16313549_1_3481", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "16313549_1_3482", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16313549_1_3483", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16313549_1_3484", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16313549_1_3485", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16313549_1_3486", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16313549_1_3487", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "16313549_1_3488", "context": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, bisphosphonate treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_1_3489", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "G-CSF"}, {"id": "9681211_1_3490", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_1_3491", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_1_3492", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_1_3493", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681211_1_3494", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_1_3495", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681211_1_3496", "context": "Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.", "question": "adverse event. Treatment, G-CSF. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4018433_1_3497", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Subject, A case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4018433_1_3498", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Subject, A case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4018433_1_3499", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Subject, A case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4018433_1_3500", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Subject, A case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4018433_1_3501", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Subject, A case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4018433_1_3502", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridoxine"}, {"id": "4018433_1_3503", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4018433_1_3504", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4018433_1_3505", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4018433_1_3506", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4018433_1_3507", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4018433_1_3508", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4018433_1_3509", "context": "A case of pyridoxine-dependent seizures is reported.", "question": "adverse event. Treatment, pyridoxine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2417800_1_3510", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Subject, A case of a 53-year-old man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "53-year-old"}, {"id": "2417800_1_3511", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Subject, A case of a 53-year-old man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "2417800_1_3512", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Subject, A case of a 53-year-old man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2417800_1_3513", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Subject, A case of a 53-year-old man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2417800_1_3514", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Subject, A case of a 53-year-old man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2417800_1_3515", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin; oxygen"}, {"id": "2417800_1_3516", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "moderate"}, {"id": "2417800_1_3517", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_1_3518", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_1_3519", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_1_3520", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_1_3521", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_1_3522", "context": "A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.", "question": "adverse event. Treatment, bleomycin and moderate oxygen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "bleomycin; oxygen"}, {"id": "14530108_1_3523", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14530108_1_3524", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14530108_1_3525", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14530108_1_3526", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14530108_1_3527", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14530108_1_3528", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_1_3529", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_1_3530", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_1_3531", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_1_3532", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_1_3533", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_1_3534", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_1_3535", "context": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.", "question": "adverse event. Treatment, FK506. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_3_3536", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Subject, hepatitis C patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_3_3537", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Subject, hepatitis C patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_3_3538", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Subject, hepatitis C patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_3_3539", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Subject, hepatitis C patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_3_3540", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Subject, hepatitis C patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_3_3541", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon; ribavirin"}, {"id": "20020238_3_3542", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_3_3543", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_3_3544", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_3_3545", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_3_3546", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_3_3547", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "20020238_3_3548", "context": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.", "question": "adverse event. Treatment, pegylated interferon and ribavirin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "pegylated interferon; ribavirin"}, {"id": "16615675_1_3549", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Subject, her. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16615675_1_3550", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Subject, her. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "her"}, {"id": "16615675_1_3551", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Subject, her. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16615675_1_3552", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Subject, her. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16615675_1_3553", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Subject, her. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16615675_1_3554", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_1_3555", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_1_3556", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_1_3557", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_1_3558", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_1_3559", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16615675_1_3560", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_1_3561", "context": "After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.", "question": "adverse event. Treatment, HCQ. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_2_3562", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_2_3563", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_2_3564", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_2_3565", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_2_3566", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_2_3567", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_2_3568", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_2_3569", "context": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3159106_1_3570", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Subject, a black African. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3159106_1_3571", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Subject, a black African. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3159106_1_3572", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Subject, a black African. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3159106_1_3573", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Subject, a black African. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "black African"}, {"id": "3159106_1_3574", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Subject, a black African. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3159106_1_3575", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "allopurinol"}, {"id": "3159106_1_3576", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3159106_1_3577", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3159106_1_3578", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3159106_1_3579", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3159106_1_3580", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3159106_1_3581", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3159106_1_3582", "context": "A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.", "question": "adverse event. Treatment, allopurinol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_5_3583", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Subject, he. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "14964753_5_3584", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Subject, he. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "he"}, {"id": "14964753_5_3585", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Subject, he. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14964753_5_3586", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Subject, he. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14964753_5_3587", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Subject, he. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14964753_5_3588", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "steroids"}, {"id": "14964753_5_3589", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "a course"}, {"id": "14964753_5_3590", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14964753_5_3591", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14964753_5_3592", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_5_3593", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14964753_5_3594", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "rash"}, {"id": "14964753_5_3595", "context": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly.", "question": "potential therapeutic event. Treatment, a course of steroids. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15961942_1_3596", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ribavirin; interferon-alfa"}, {"id": "15961942_1_3597", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15961942_1_3598", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15961942_1_3599", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15961942_1_3600", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15961942_1_3601", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15961942_1_3602", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "15961942_1_3603", "context": "Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.", "question": "adverse event. Treatment, interferon-alfa; ribavirin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "ribavirin; interferon-alfa"}, {"id": "9517515_2_3604", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Subject, patients with hairy cell leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9517515_2_3605", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Subject, patients with hairy cell leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9517515_2_3606", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Subject, patients with hairy cell leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9517515_2_3607", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Subject, patients with hairy cell leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9517515_2_3608", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Subject, patients with hairy cell leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9517515_2_3609", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "9517515_2_3610", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9517515_2_3611", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9517515_2_3612", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9517515_2_3613", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9517515_2_3614", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9517515_2_3615", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukemia"}, {"id": "9517515_2_3616", "context": "Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.", "question": "adverse event. Treatment, chemotherapy or interferon alfa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8840640_1_3617", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Subject, A patient with a large hydatid cyst of the left lobe of the liver. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8840640_1_3618", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Subject, A patient with a large hydatid cyst of the left lobe of the liver. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8840640_1_3619", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Subject, A patient with a large hydatid cyst of the left lobe of the liver. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8840640_1_3620", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Subject, A patient with a large hydatid cyst of the left lobe of the liver. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8840640_1_3621", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Subject, A patient with a large hydatid cyst of the left lobe of the liver. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "a large hydatid cyst of the left lobe of the liver"}, {"id": "8840640_1_3622", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetrimide-chlorhexidine"}, {"id": "8840640_1_3623", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "rather liberal use"}, {"id": "8840640_1_3624", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8840640_1_3625", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "a scolicidal agent"}, {"id": "8840640_1_3626", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8840640_1_3627", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8840640_1_3628", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8840640_1_3629", "context": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.", "question": "adverse event. Treatment, rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_12_3630", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Subject, five pediatric patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_12_3631", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Subject, five pediatric patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_12_3632", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Subject, five pediatric patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "8329789_12_3633", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Subject, five pediatric patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_12_3634", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Subject, five pediatric patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_12_3635", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_12_3636", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "4.6 and 40.8 mg/kg/d"}, {"id": "8329789_12_3637", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_12_3638", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_12_3639", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_12_3640", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_12_3641", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_12_3642", "context": "INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.", "question": "adverse event. Treatment, between 4.6 and 40.8 mg/kg/d of amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16521231_2_3643", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Subject, a patient with Crohn's disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16521231_2_3644", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Subject, a patient with Crohn's disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16521231_2_3645", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Subject, a patient with Crohn's disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16521231_2_3646", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Subject, a patient with Crohn's disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16521231_2_3647", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Subject, a patient with Crohn's disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16521231_2_3648", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16521231_2_3649", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16521231_2_3650", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16521231_2_3651", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16521231_2_3652", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "fourth"}, {"id": "16521231_2_3653", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16521231_2_3654", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16521231_2_3655", "context": "In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.", "question": "adverse event. Treatment, fourth infusion of infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_4_3656", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Subject, 232 MM patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_4_3657", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Subject, 232 MM patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_4_3658", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Subject, 232 MM patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "232"}, {"id": "12149193_4_3659", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Subject, 232 MM patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_4_3660", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Subject, 232 MM patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_4_3661", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; thalidomide"}, {"id": "12149193_4_3662", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_4_3663", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_4_3664", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_4_3665", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_4_3666", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_4_3667", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MM"}, {"id": "12149193_4_3668", "context": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.", "question": "adverse event. Treatment, chemotherapy; thalidomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; thalidomide"}, {"id": "17109650_2_3669", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17109650_2_3670", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17109650_2_3671", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17109650_2_3672", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17109650_2_3673", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17109650_2_3674", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17109650_2_3675", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17109650_2_3676", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17109650_2_3677", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17109650_2_3678", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17109650_2_3679", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17109650_2_3680", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17109650_2_3681", "context": "Valvular heart disease in a patient taking benfluorex.", "question": "adverse event. Treatment, benfluorex. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_3_3682", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Subject, The fifth patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_3_3683", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Subject, The fifth patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_3_3684", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Subject, The fifth patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_3_3685", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Subject, The fifth patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_3_3686", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Subject, The fifth patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_3_3687", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_3_3688", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_3_3689", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_3_3690", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_3_3691", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_3_3692", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_3_3693", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_3_3694", "context": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.", "question": "adverse event. Treatment, olanzapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_11_3695", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Subject, cardiac arrhythmias in children. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "8329789_11_3696", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Subject, cardiac arrhythmias in children. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8329789_11_3697", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Subject, cardiac arrhythmias in children. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8329789_11_3698", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Subject, cardiac arrhythmias in children. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8329789_11_3699", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Subject, cardiac arrhythmias in children. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8329789_11_3700", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Hydrocortisone"}, {"id": "8329789_11_3701", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_11_3702", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_11_3703", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_11_3704", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_11_3705", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_11_3706", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "incidence of mortality"}, {"id": "8329789_11_3707", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "potential therapeutic event. Treatment, Hydrocortisone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8329789_11_3708", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Subject, cardiac arrhythmias in children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "8329789_11_3709", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Subject, cardiac arrhythmias in children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_11_3710", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Subject, cardiac arrhythmias in children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_11_3711", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Subject, cardiac arrhythmias in children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_11_3712", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Subject, cardiac arrhythmias in children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_11_3713", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_11_3714", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdoses"}, {"id": "8329789_11_3715", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_11_3716", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_11_3717", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_11_3718", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_11_3719", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cardiac arrhythmias"}, {"id": "8329789_11_3720", "context": "Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.", "question": "adverse event. Treatment, amphotericin B overdoses. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_1_3721", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Subject, 11 children and 2 adults. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children; adults"}, {"id": "8700794_1_3722", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Subject, 11 children and 2 adults. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8700794_1_3723", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Subject, 11 children and 2 adults. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "11; 2"}, {"id": "8700794_1_3724", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Subject, 11 children and 2 adults. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8700794_1_3725", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Subject, 11 children and 2 adults. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8700794_1_3726", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_1_3727", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_1_3728", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_1_3729", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intranasal"}, {"id": "8700794_1_3730", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_1_3731", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_1_3732", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_1_3733", "context": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.", "question": "adverse event. Treatment, intranasal desmopressin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7387219_1_3734", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_1_3735", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_1_3736", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_1_3737", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_1_3738", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_1_3739", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_1_3740", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "7387219_1_3741", "context": "Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_1_3742", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_1_3743", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_1_3744", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_1_3745", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_1_3746", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_1_3747", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_1_3748", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "juvenile rheumatoid arthritis"}, {"id": "8627446_1_3749", "context": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_6_3750", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8305778_6_3751", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8305778_6_3752", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8305778_6_3753", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8305778_6_3754", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_6_3755", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8305778_6_3756", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8305778_6_3757", "context": "Amiodarone is a Class III antiarrhythmic with an adverse-effect profile involving many different organ systems.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_2_3758", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17083890_2_3759", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_2_3760", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_2_3761", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "17083890_2_3762", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_2_3763", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_2_3764", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_2_3765", "context": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes.", "question": "adverse event. Treatment, chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7117795_2_3766", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucytosine"}, {"id": "7117795_2_3767", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7117795_2_3768", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7117795_2_3769", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7117795_2_3770", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7117795_2_3771", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7117795_2_3772", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7117795_2_3773", "context": "This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.", "question": "adverse event. Treatment, flucytosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_1_3774", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_1_3775", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_1_3776", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_1_3777", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_1_3778", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "968449_1_3779", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_1_3780", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "polycythaemia vera"}, {"id": "968449_1_3781", "context": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.", "question": "adverse event. Treatment, chlorambucil therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_6_3782", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_6_3783", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_6_3784", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_6_3785", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_6_3786", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_6_3787", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_6_3788", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_6_3789", "context": "With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.", "question": "adverse event. Treatment, IFN. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_1_3790", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vardenafil"}, {"id": "16244351_1_3791", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_1_3792", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16244351_1_3793", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16244351_1_3794", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_1_3795", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16244351_1_3796", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16244351_1_3797", "context": "Atrial fibrillation after vardenafil therapy.", "question": "adverse event. Treatment, vardenafil therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16122280_19_3798", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Subject, patients with community-acquired pneumonia. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16122280_19_3799", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Subject, patients with community-acquired pneumonia. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16122280_19_3800", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Subject, patients with community-acquired pneumonia. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16122280_19_3801", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Subject, patients with community-acquired pneumonia. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16122280_19_3802", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Subject, patients with community-acquired pneumonia. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16122280_19_3803", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "16122280_19_3804", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "800 mg"}, {"id": "16122280_19_3805", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once-daily"}, {"id": "16122280_19_3806", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16122280_19_3807", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16122280_19_3808", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16122280_19_3809", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "S. pneumoniae; Haemophilus influenzae; Staphylococcus aureus; pneumonia"}, {"id": "16122280_19_3810", "context": "In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.", "question": "potential therapeutic event. Treatment, telithromycin 800 mg once-daily dose. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11247558_4_3811", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_4_3812", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "11247558_4_3813", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11247558_4_3814", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_4_3815", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_4_3816", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11247558_4_3817", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11247558_4_3818", "context": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.", "question": "adverse event. Treatment, meloxicam. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3152997_1_3819", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "3152997_1_3820", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3152997_1_3821", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3152997_1_3822", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3152997_1_3823", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3152997_1_3824", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3152997_1_3825", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3152997_1_3826", "context": "Atrial fibrillation following methylprednisolone pulse therapy.", "question": "adverse event. Treatment, methylprednisolone pulse therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2113320_2_3827", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "2113320_2_3828", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2113320_2_3829", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2113320_2_3830", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2113320_2_3831", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2113320_2_3832", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2113320_2_3833", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wegener's granulomatosis"}, {"id": "2113320_2_3834", "context": "Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.", "question": "adverse event. Treatment, cyclophosphamide treatment with response to carbon dioxide laser therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_2_3835", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Subject, a patient with neuropathic pain. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_2_3836", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Subject, a patient with neuropathic pain. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_2_3837", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Subject, a patient with neuropathic pain. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_2_3838", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Subject, a patient with neuropathic pain. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_2_3839", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Subject, a patient with neuropathic pain. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_2_3840", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pregabalin"}, {"id": "18492617_2_3841", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_2_3842", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_2_3843", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_2_3844", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_2_3845", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_2_3846", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neuropathic pain"}, {"id": "18492617_2_3847", "context": "Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.", "question": "adverse event. Treatment, Pregabalin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12663440_12_3848", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, a small subgroup of patients defined by rhodamine 123 efflux. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12663440_12_3849", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, a small subgroup of patients defined by rhodamine 123 efflux. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_12_3850", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, a small subgroup of patients defined by rhodamine 123 efflux. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "a small subgroup"}, {"id": "12663440_12_3851", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, a small subgroup of patients defined by rhodamine 123 efflux. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_12_3852", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, a small subgroup of patients defined by rhodamine 123 efflux. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "rhodamine 123 efflux"}, {"id": "12663440_12_3853", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_12_3854", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_12_3855", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_12_3856", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_12_3857", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_12_3858", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_12_3859", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo AML"}, {"id": "12663440_12_3860", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12663440_12_3861", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, adult patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "adult"}, {"id": "12663440_12_3862", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, adult patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_12_3863", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, adult patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12663440_12_3864", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, adult patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_12_3865", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Subject, adult patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12663440_12_3866", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_12_3867", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_12_3868", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_12_3869", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_12_3870", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_12_3871", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_12_3872", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo AML"}, {"id": "12663440_12_3873", "context": "We conclude that quinine does not improve the survival of adult patients with de novo AML, even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux.", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14530108_4_3874", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_4_3875", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_4_3876", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_4_3877", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_4_3878", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_4_3879", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_4_3880", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_4_3881", "context": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated.", "question": "adverse event. Treatment, FK506. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17301517_2_3882", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Subject, patients with diabetic risk factors. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17301517_2_3883", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Subject, patients with diabetic risk factors. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17301517_2_3884", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Subject, patients with diabetic risk factors. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17301517_2_3885", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Subject, patients with diabetic risk factors. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17301517_2_3886", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Subject, patients with diabetic risk factors. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "diabetic risk factors"}, {"id": "17301517_2_3887", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "perospirone hydrochloride"}, {"id": "17301517_2_3888", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17301517_2_3889", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17301517_2_3890", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17301517_2_3891", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17301517_2_3892", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17301517_2_3893", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17301517_2_3894", "context": "The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.", "question": "adverse event. Treatment, perospirone hydrochloride or other atypical antipsychotics. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_1_3895", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sibutramine"}, {"id": "18487000_1_3896", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18487000_1_3897", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_1_3898", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_1_3899", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_1_3900", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_1_3901", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18487000_1_3902", "context": "Severe symptomatic hyponatremia during sibutramine therapy: a case report.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15779196_2_3903", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Subject, prostate cancer patient with extensive osteoblastic bone metastases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15779196_2_3904", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Subject, prostate cancer patient with extensive osteoblastic bone metastases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15779196_2_3905", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Subject, prostate cancer patient with extensive osteoblastic bone metastases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15779196_2_3906", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Subject, prostate cancer patient with extensive osteoblastic bone metastases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15779196_2_3907", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Subject, prostate cancer patient with extensive osteoblastic bone metastases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15779196_2_3908", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Zoledronic acid"}, {"id": "15779196_2_3909", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15779196_2_3910", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15779196_2_3911", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15779196_2_3912", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15779196_2_3913", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15779196_2_3914", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "prostate cancer; extensive osteoblastic bone metastases"}, {"id": "15779196_2_3915", "context": "Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.", "question": "adverse event. Treatment, Zoledronic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_9_3916", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Subject, MM patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_9_3917", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Subject, MM patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_9_3918", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Subject, MM patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_9_3919", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Subject, MM patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_9_3920", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Subject, MM patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_9_3921", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide; doxorubicin"}, {"id": "12149193_9_3922", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_9_3923", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_9_3924", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_9_3925", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_9_3926", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_9_3927", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MM"}, {"id": "12149193_9_3928", "context": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.", "question": "adverse event. Treatment, thalidomide and doxorubicin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "thalidomide; doxorubicin"}, {"id": "19653965_1_3929", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Subject, HIV-positive individuals. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19653965_1_3930", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Subject, HIV-positive individuals. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19653965_1_3931", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Subject, HIV-positive individuals. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19653965_1_3932", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Subject, HIV-positive individuals. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19653965_1_3933", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Subject, HIV-positive individuals. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19653965_1_3934", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir"}, {"id": "19653965_1_3935", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19653965_1_3936", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19653965_1_3937", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19653965_1_3938", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19653965_1_3939", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19653965_1_3940", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV"}, {"id": "19653965_1_3941", "context": "These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.", "question": "adverse event. Treatment, lopinavir/ritonavir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lopinavir; ritonavir"}, {"id": "11200291_1_3942", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11200291_1_3943", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11200291_1_3944", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11200291_1_3945", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11200291_1_3946", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11200291_1_3947", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept; methotrexate"}, {"id": "11200291_1_3948", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11200291_1_3949", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11200291_1_3950", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11200291_1_3951", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11200291_1_3952", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11200291_1_3953", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "11200291_1_3954", "context": "Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.", "question": "adverse event. Treatment, etanercept plus methotrexate for rheumatoid arthritis. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "etanercept; methotrexate"}, {"id": "17083890_4_3955", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Subject, a 52-year-old male. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "52-year-old"}, {"id": "17083890_4_3956", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Subject, a 52-year-old male. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "17083890_4_3957", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Subject, a 52-year-old male. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17083890_4_3958", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Subject, a 52-year-old male. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17083890_4_3959", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Subject, a 52-year-old male. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17083890_4_3960", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "vincristine; adriamycin; dexamathasone"}, {"id": "17083890_4_3961", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_4_3962", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17083890_4_3963", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17083890_4_3964", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_4_3965", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "5-monthly"}, {"id": "17083890_4_3966", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "stage III multiple myeloma"}, {"id": "17083890_4_3967", "context": "We describe a 52-year-old male diagnosed with stage III multiple myeloma, who was treated with 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone).", "question": "potential therapeutic event. Treatment, 5-monthly cycles of VAD (vincristine, adriamycin and dexamathasone). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "vincristine; adriamycin; dexamathasone"}, {"id": "15965422_4_3968", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "standard interferon alfa; pegylated interferon alfa-2b"}, {"id": "15965422_4_3969", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_4_3970", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_4_3971", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "15965422_4_3972", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_4_3973", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_4_3974", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_4_3975", "context": "We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.", "question": "adverse event. Treatment, standard interferon alfa; pegylated interferon alfa-2b. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_9_3976", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 1739 patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_9_3977", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 1739 patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_9_3978", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 1739 patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "1739"}, {"id": "21350204_9_3979", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 1739 patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_9_3980", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 1739 patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_9_3981", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tissue plasminogen activator"}, {"id": "21350204_9_3982", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_9_3983", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_9_3984", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "21350204_9_3985", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_9_3986", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_9_3987", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21350204_9_3988", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, intravenous tissue plasminogen activator. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21350204_9_3989", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 125 (7.2%). What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21350204_9_3990", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 125 (7.2%). What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21350204_9_3991", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 125 (7.2%). What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21350204_9_3992", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 125 (7.2%). What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21350204_9_3993", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Subject, 125 (7.2%). What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21350204_9_3994", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "21350204_9_3995", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_9_3996", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21350204_9_3997", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21350204_9_3998", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_9_3999", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21350204_9_4000", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute ischemic stroke"}, {"id": "21350204_9_4001", "context": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7.", "question": "potential therapeutic event. Treatment, warfarin before admission. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7495990_1_4002", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "naloxone"}, {"id": "7495990_1_4003", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7495990_1_4004", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7495990_1_4005", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7495990_1_4006", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7495990_1_4007", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7495990_1_4008", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7495990_1_4009", "context": "Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.", "question": "adverse event. Treatment, Used injudiciously, naloxone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_3_4010", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_3_4011", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_3_4012", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_3_4013", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8700794_3_4014", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_3_4015", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_3_4016", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_3_4017", "context": "When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.", "question": "adverse event. Treatment, desmopressin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_4_4018", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy"}, {"id": "2104570_4_4019", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_4_4020", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_4_4021", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "Intravesical"}, {"id": "2104570_4_4022", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_4_4023", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_4_4024", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2104570_4_4025", "context": "Intravesical chemotherapy may be associated with a risk of secondary malignancy.", "question": "adverse event. Treatment, Intravesical chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_9_4026", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_9_4027", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_9_4028", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_9_4029", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_9_4030", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_9_4031", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_9_4032", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_9_4033", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, discontinuation of methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_9_4034", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Subject, two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17329303_9_4035", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Subject, two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17329303_9_4036", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Subject, two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "17329303_9_4037", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Subject, two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_9_4038", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Subject, two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_9_4039", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17329303_9_4040", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_9_4041", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_9_4042", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_9_4043", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_9_4044", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_9_4045", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_9_4046", "context": "In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "897744_3_4047", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methicillin; antibiotic; nephrotoxic agents"}, {"id": "897744_3_4048", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "897744_3_4049", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "897744_3_4050", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "897744_3_4051", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "897744_3_4052", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "897744_3_4053", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "endocarditis"}, {"id": "897744_3_4054", "context": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement, emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear.", "question": "adverse event. Treatment, methicillin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_2_4055", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Subject, most patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8864370_2_4056", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Subject, most patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8864370_2_4057", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Subject, most patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8864370_2_4058", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Subject, most patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8864370_2_4059", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Subject, most patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8864370_2_4060", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "8864370_2_4061", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_2_4062", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_2_4063", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_2_4064", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_2_4065", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_2_4066", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_2_4067", "context": "CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.", "question": "adverse event. Treatment, MTX. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24679099_4_4068", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide; Chinese herbal formula"}, {"id": "24679099_4_4069", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_4_4070", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_4_4071", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_4_4072", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_4_4073", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_4_4074", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "glioblastoma"}, {"id": "24679099_4_4075", "context": "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.", "question": "adverse event. Treatment, temozolomide; a popular Chinese herbal formula. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "temozolomide; Chinese herbal formula"}, {"id": "11978156_3_4076", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Subject, He. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11978156_3_4077", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Subject, He. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "11978156_3_4078", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Subject, He. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11978156_3_4079", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Subject, He. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11978156_3_4080", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Subject, He. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11978156_3_4081", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_3_4082", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "60 mg"}, {"id": "11978156_3_4083", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "11978156_3_4084", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11978156_3_4085", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_3_4086", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "day 2"}, {"id": "11978156_3_4087", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_3_4088", "context": "He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).", "question": "adverse event. Treatment, oral lansoprazole 60 mg twice daily. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8207519_1_4089", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Subject, She. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "She"}, {"id": "8207519_1_4090", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Subject, She. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8207519_1_4091", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Subject, She. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8207519_1_4092", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Subject, She. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8207519_1_4093", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Subject, She. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8207519_1_4094", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "8207519_1_4095", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "450-mg"}, {"id": "8207519_1_4096", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8207519_1_4097", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "bolus injection"}, {"id": "8207519_1_4098", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8207519_1_4099", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8207519_1_4100", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8207519_1_4101", "context": "She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.", "question": "adverse event. Treatment, 450-mg bolus injection of morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_4_4102", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Subject, six patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2357706_4_4103", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Subject, six patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2357706_4_4104", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Subject, six patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "six"}, {"id": "2357706_4_4105", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Subject, six patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2357706_4_4106", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Subject, six patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2357706_4_4107", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_4_4108", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_4_4109", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_4_4110", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_4_4111", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_4_4112", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_4_4113", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "depression; gastrointestinal symptoms"}, {"id": "2357706_4_4114", "context": "We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_4_4115", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "38-year-old"}, {"id": "15827071_4_4116", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "15827071_4_4117", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_4_4118", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "15827071_4_4119", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15827071_4_4120", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "venlafaxine"}, {"id": "15827071_4_4121", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "300 mg/day"}, {"id": "15827071_4_4122", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15827071_4_4123", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15827071_4_4124", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_4_4125", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "one year"}, {"id": "15827071_4_4126", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15827071_4_4127", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, venlafaxine 300 mg/day for one year. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15827071_4_4128", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "38-year-old"}, {"id": "15827071_4_4129", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "15827071_4_4130", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_4_4131", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "15827071_4_4132", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Subject, A 38-year-old white female. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15827071_4_4133", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid"}, {"id": "15827071_4_4134", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "600 mg"}, {"id": "15827071_4_4135", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "every 12 hours"}, {"id": "15827071_4_4136", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenously"}, {"id": "15827071_4_4137", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_4_4138", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15827071_4_4139", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection"}, {"id": "15827071_4_4140", "context": "A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection.", "question": "potential therapeutic event. Treatment, linezolid 600 mg intravenously every 12 hours. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7448830_1_4141", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Subject, patients with metastatic breast cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7448830_1_4142", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Subject, patients with metastatic breast cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7448830_1_4143", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Subject, patients with metastatic breast cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7448830_1_4144", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Subject, patients with metastatic breast cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7448830_1_4145", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Subject, patients with metastatic breast cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7448830_1_4146", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hycanthone"}, {"id": "7448830_1_4147", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7448830_1_4148", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7448830_1_4149", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7448830_1_4150", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7448830_1_4151", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7448830_1_4152", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic breast cancer"}, {"id": "7448830_1_4153", "context": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer.", "question": "adverse event. Treatment, hycanthone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16237130_2_4154", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "16237130_2_4155", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16237130_2_4156", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16237130_2_4157", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16237130_2_4158", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16237130_2_4159", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16237130_2_4160", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16237130_2_4161", "context": "The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.", "question": "adverse event. Treatment, capecitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7545251_1_4162", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Chlormadinone acetate; androgen blockade"}, {"id": "7545251_1_4163", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7545251_1_4164", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7545251_1_4165", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7545251_1_4166", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7545251_1_4167", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7545251_1_4168", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced prostate cancer"}, {"id": "7545251_1_4169", "context": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.", "question": "potential therapeutic event. Treatment, Chlormadinone acetate; androgen blockade. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "androgen blockade; Chlormadinone acetate"}, {"id": "18562412_2_4170", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_2_4171", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_2_4172", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_2_4173", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_2_4174", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_2_4175", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_2_4176", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_2_4177", "context": "Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.", "question": "adverse event. Treatment, olanzapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_8_4178", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydrocortisone"}, {"id": "8329789_8_4179", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_8_4180", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_8_4181", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_8_4182", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_8_4183", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_8_4184", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cardiac arrhythmias"}, {"id": "8329789_8_4185", "context": "Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.", "question": "potential therapeutic event. Treatment, hydrocortisone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14530108_6_4186", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Subject, a case of RTA. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14530108_6_4187", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Subject, a case of RTA. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14530108_6_4188", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Subject, a case of RTA. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14530108_6_4189", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Subject, a case of RTA. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14530108_6_4190", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Subject, a case of RTA. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14530108_6_4191", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_6_4192", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_6_4193", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_6_4194", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_6_4195", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_6_4196", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_6_4197", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_6_4198", "context": "We report a case of RTA secondary to FK506 administration in liver transplantation.", "question": "adverse event. Treatment, FK506 administration in liver transplantation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_1_4199", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Subject, a patient with end-stage renal disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17959575_1_4200", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Subject, a patient with end-stage renal disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17959575_1_4201", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Subject, a patient with end-stage renal disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17959575_1_4202", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Subject, a patient with end-stage renal disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17959575_1_4203", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Subject, a patient with end-stage renal disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17959575_1_4204", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_1_4205", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_1_4206", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17959575_1_4207", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_1_4208", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_1_4209", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17959575_1_4210", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "end-stage renal disease"}, {"id": "17959575_1_4211", "context": "Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.", "question": "adverse event. Treatment, continuous dobutamine infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_2_4212", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Subject, humans. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "6614033_2_4213", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Subject, humans. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "6614033_2_4214", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Subject, humans. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "6614033_2_4215", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Subject, humans. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "6614033_2_4216", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Subject, humans. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "6614033_2_4217", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "salt"}, {"id": "6614033_2_4218", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_2_4219", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6614033_2_4220", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6614033_2_4221", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_2_4222", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6614033_2_4223", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_2_4224", "context": "Amphotericin B nephrotoxicity in humans decreased by salt repletion.", "question": "potential therapeutic event. Treatment, salt repletion. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8638872_2_4225", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "8638872_2_4226", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8638872_2_4227", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8638872_2_4228", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8638872_2_4229", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8638872_2_4230", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8638872_2_4231", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8638872_2_4232", "context": "Only a few reports of overt jaundice are associated with streptokinase.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12885108_1_4233", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rosiglitazone"}, {"id": "12885108_1_4234", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12885108_1_4235", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12885108_1_4236", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12885108_1_4237", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12885108_1_4238", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12885108_1_4239", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12885108_1_4240", "context": "Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.", "question": "adverse event. Treatment, rosiglitazone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11388112_2_4241", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Subject, the first case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11388112_2_4242", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Subject, the first case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11388112_2_4243", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Subject, the first case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11388112_2_4244", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Subject, the first case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11388112_2_4245", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Subject, the first case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11388112_2_4246", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "evofloxacin"}, {"id": "11388112_2_4247", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11388112_2_4248", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11388112_2_4249", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11388112_2_4250", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11388112_2_4251", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11388112_2_4252", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11388112_2_4253", "context": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.", "question": "adverse event. Treatment, oral use of levofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8104147_2_4254", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Subject, an 81-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "81-year-old"}, {"id": "8104147_2_4255", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Subject, an 81-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "8104147_2_4256", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Subject, an 81-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8104147_2_4257", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Subject, an 81-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8104147_2_4258", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Subject, an 81-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8104147_2_4259", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ibopamine"}, {"id": "8104147_2_4260", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "100 mg"}, {"id": "8104147_2_4261", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8104147_2_4262", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8104147_2_4263", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8104147_2_4264", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8104147_2_4265", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic congestive heart failure"}, {"id": "8104147_2_4266", "context": "Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.", "question": "adverse event. Treatment, adjunctive ibopamine 100 mg t.i.d.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_4_4267", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_4_4268", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_4_4269", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_4_4270", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_4_4271", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_4_4272", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_4_4273", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12702914_4_4274", "context": "We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.", "question": "adverse event. Treatment, insulin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "278642_1_4275", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "278642_1_4276", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "278642_1_4277", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "278642_1_4278", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "278642_1_4279", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "278642_1_4280", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "278642_1_4281", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "278642_1_4282", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "278642_1_4283", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "278642_1_4284", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "278642_1_4285", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "278642_1_4286", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "stage II breast cancer."}, {"id": "278642_1_4287", "context": "Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.", "question": "adverse event. Treatment, receiving chlorambucil as long-term adjuvant chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7889679_1_4288", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocil; diuron; aminotriazole"}, {"id": "7889679_1_4289", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7889679_1_4290", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7889679_1_4291", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7889679_1_4292", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7889679_1_4293", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7889679_1_4294", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7889679_1_4295", "context": "We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.", "question": "adverse event. Treatment, herbicides containing bromocil, diuron and aminotriazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "diuron; bromocil; aminotriazole"}, {"id": "19097599_1_4296", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "19097599_1_4297", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19097599_1_4298", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19097599_1_4299", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19097599_1_4300", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19097599_1_4301", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19097599_1_4302", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19097599_1_4303", "context": "Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.", "question": "adverse event. Treatment, imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_2_4304", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Subject, A 61-year-old patient who had been treated with lisinopril in the past without any problems. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "61-year-old"}, {"id": "14964753_2_4305", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Subject, A 61-year-old patient who had been treated with lisinopril in the past without any problems. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "14964753_2_4306", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Subject, A 61-year-old patient who had been treated with lisinopril in the past without any problems. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "14964753_2_4307", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Subject, A 61-year-old patient who had been treated with lisinopril in the past without any problems. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "14964753_2_4308", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Subject, A 61-year-old patient who had been treated with lisinopril in the past without any problems. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "14964753_2_4309", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_2_4310", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_2_4311", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14964753_2_4312", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14964753_2_4313", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_2_4314", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14964753_2_4315", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "left ventricular dysfunction"}, {"id": "14964753_2_4316", "context": "A 61-year-old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction.", "question": "potential therapeutic event. Treatment, ramipril. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9760614_2_4317", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tPA"}, {"id": "9760614_2_4318", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9760614_2_4319", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9760614_2_4320", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intracameral; injections"}, {"id": "9760614_2_4321", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9760614_2_4322", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9760614_2_4323", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9760614_2_4324", "context": "However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.", "question": "adverse event. Treatment, repeated intracameral tPA injections. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9934637_3_4325", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Subject, a vitiligo patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9934637_3_4326", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Subject, a vitiligo patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9934637_3_4327", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Subject, a vitiligo patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9934637_3_4328", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Subject, a vitiligo patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9934637_3_4329", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Subject, a vitiligo patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "vitiligo"}, {"id": "9934637_3_4330", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "8-methoxypsoralen"}, {"id": "9934637_3_4331", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9934637_3_4332", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_3_4333", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "9934637_3_4334", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_3_4335", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_3_4336", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_3_4337", "context": "In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.", "question": "adverse event. Treatment, topical use of 8-methoxypsoralen solution as a suntanning agent. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_3_4338", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Subject, patients with tachyarrhythmias. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7474364_3_4339", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Subject, patients with tachyarrhythmias. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7474364_3_4340", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Subject, patients with tachyarrhythmias. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7474364_3_4341", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Subject, patients with tachyarrhythmias. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7474364_3_4342", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Subject, patients with tachyarrhythmias. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7474364_3_4343", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "7474364_3_4344", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7474364_3_4345", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_3_4346", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7474364_3_4347", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7474364_3_4348", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_3_4349", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tachyarrhythmias"}, {"id": "7474364_3_4350", "context": "The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_1_4351", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin"}, {"id": "11642488_1_4352", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_1_4353", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11642488_1_4354", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_1_4355", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_1_4356", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11642488_1_4357", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_1_4358", "context": "Cicatricial entropion associated with chronic dipivefrin application.", "question": "adverse event. Treatment, chronic dipivefrin application. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7174620_1_4359", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Subject, Nine delirious patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7174620_1_4360", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Subject, Nine delirious patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7174620_1_4361", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Subject, Nine delirious patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Nine"}, {"id": "7174620_1_4362", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Subject, Nine delirious patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7174620_1_4363", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Subject, Nine delirious patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "delirious"}, {"id": "7174620_1_4364", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7174620_1_4365", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7174620_1_4366", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7174620_1_4367", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7174620_1_4368", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7174620_1_4369", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7174620_1_4370", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7174620_1_4371", "context": "Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_1_4372", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Subject, a chronic lymphocytic leukemia patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19423476_1_4373", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Subject, a chronic lymphocytic leukemia patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19423476_1_4374", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Subject, a chronic lymphocytic leukemia patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19423476_1_4375", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Subject, a chronic lymphocytic leukemia patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19423476_1_4376", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Subject, a chronic lymphocytic leukemia patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19423476_1_4377", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_1_4378", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_1_4379", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_1_4380", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_1_4381", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_1_4382", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_1_4383", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocytic leukemia"}, {"id": "19423476_1_4384", "context": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.", "question": "adverse event. Treatment, alemtuzumab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_2_4385", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cholestyramine"}, {"id": "6597713_2_4386", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_2_4387", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_2_4388", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_2_4389", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_2_4390", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_2_4391", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_2_4392", "context": "Cholestyramine induced hyperchloremic metabolic acidosis.", "question": "adverse event. Treatment, Cholestyramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11406880_2_4393", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "11406880_2_4394", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_2_4395", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_2_4396", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_2_4397", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_2_4398", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_2_4399", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11406880_2_4400", "context": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine, which are attributed to active metabolites.", "question": "adverse event. Treatment, morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_3_4401", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_3_4402", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_3_4403", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_3_4404", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_3_4405", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_3_4406", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_3_4407", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16948177_3_4408", "context": "This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.", "question": "adverse event. Treatment, single-agent rituximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_5_4409", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_5_4410", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_5_4411", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_5_4412", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_5_4413", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_5_4414", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_5_4415", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_5_4416", "context": "The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.", "question": "adverse event. Treatment, FK506. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11518127_1_4417", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Subject, A 62-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "62-year-old"}, {"id": "11518127_1_4418", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Subject, A 62-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "11518127_1_4419", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Subject, A 62-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11518127_1_4420", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Subject, A 62-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11518127_1_4421", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Subject, A 62-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11518127_1_4422", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "11518127_1_4423", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11518127_1_4424", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11518127_1_4425", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11518127_1_4426", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11518127_1_4427", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "2 months"}, {"id": "11518127_1_4428", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11518127_1_4429", "context": "A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.", "question": "adverse event. Treatment, treated with pranlukast for 2 months. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11359026_2_4430", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valacyclovir"}, {"id": "11359026_2_4431", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11359026_2_4432", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11359026_2_4433", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11359026_2_4434", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11359026_2_4435", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11359026_2_4436", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11359026_2_4437", "context": "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.", "question": "adverse event. Treatment, valacyclovir in peritoneal dialysis. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20065266_3_4438", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Subject, He. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_3_4439", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Subject, He. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "20065266_3_4440", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Subject, He. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_3_4441", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Subject, He. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_3_4442", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Subject, He. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_3_4443", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "20065266_3_4444", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_3_4445", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_3_4446", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_3_4447", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_3_4448", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "eight days"}, {"id": "20065266_3_4449", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_3_4450", "context": "He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole for approximately eight days. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "10970989_2_4451", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Subject, an AIDS patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10970989_2_4452", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Subject, an AIDS patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10970989_2_4453", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Subject, an AIDS patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10970989_2_4454", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Subject, an AIDS patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10970989_2_4455", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Subject, an AIDS patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10970989_2_4456", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "stavudine; lamivudine"}, {"id": "10970989_2_4457", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10970989_2_4458", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10970989_2_4459", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10970989_2_4460", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10970989_2_4461", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10970989_2_4462", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "10970989_2_4463", "context": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "stavudine; lamivudine"}, {"id": "15235919_1_4464", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "15235919_1_4465", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15235919_1_4466", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15235919_1_4467", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15235919_1_4468", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15235919_1_4469", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15235919_1_4470", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15235919_1_4471", "context": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11171531_2_4472", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lead"}, {"id": "11171531_2_4473", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11171531_2_4474", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11171531_2_4475", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "11171531_2_4476", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11171531_2_4477", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11171531_2_4478", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11171531_2_4479", "context": "It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.", "question": "adverse event. Treatment, lead exposure. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15489872_1_4480", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Subject, allogeneic bone marrow transplant recipient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15489872_1_4481", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Subject, allogeneic bone marrow transplant recipient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15489872_1_4482", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Subject, allogeneic bone marrow transplant recipient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15489872_1_4483", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Subject, allogeneic bone marrow transplant recipient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15489872_1_4484", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Subject, allogeneic bone marrow transplant recipient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "allogeneic bone marrow transplant"}, {"id": "15489872_1_4485", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ganciclovir; foscarnet; cidofovir"}, {"id": "15489872_1_4486", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15489872_1_4487", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15489872_1_4488", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15489872_1_4489", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15489872_1_4490", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15489872_1_4491", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "CMV infection"}, {"id": "15489872_1_4492", "context": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.", "question": "potential therapeutic event. Treatment, sequential therapy with ganciclovir, foscarnet, and cidofovir. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "ganciclovir; foscarnet; cidofovir"}, {"id": "11518127_2_4493", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ONO-1078"}, {"id": "11518127_2_4494", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11518127_2_4495", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11518127_2_4496", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11518127_2_4497", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11518127_2_4498", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11518127_2_4499", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11518127_2_4500", "context": "Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.", "question": "adverse event. Treatment, ONO-1078 (pranlukast). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_2_4501", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_2_4502", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_2_4503", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_2_4504", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_2_4505", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_2_4506", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon"}, {"id": "20020238_2_4507", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_2_4508", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_2_4509", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_2_4510", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_2_4511", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_2_4512", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20020238_2_4513", "context": "CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.", "question": "adverse event. Treatment, pegylated interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11335880_1_4514", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Subject, our patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_1_4515", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Subject, our patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_1_4516", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Subject, our patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_1_4517", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Subject, our patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_1_4518", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Subject, our patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "a specific genetic predisposition (DR5) for this pathology"}, {"id": "11335880_1_4519", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-alpha"}, {"id": "11335880_1_4520", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_1_4521", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_1_4522", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_1_4523", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_1_4524", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_1_4525", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic C hepatitis"}, {"id": "11335880_1_4526", "context": "CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.", "question": "adverse event. Treatment, IFN-alpha. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18472517_2_4527", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Subject, a female patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18472517_2_4528", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Subject, a female patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "18472517_2_4529", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Subject, a female patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18472517_2_4530", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Subject, a female patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18472517_2_4531", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Subject, a female patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18472517_2_4532", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "enalaprilat"}, {"id": "18472517_2_4533", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18472517_2_4534", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18472517_2_4535", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18472517_2_4536", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within minutes"}, {"id": "18472517_2_4537", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18472517_2_4538", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18472517_2_4539", "context": "We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.", "question": "adverse event. Treatment, i.v. enalaprilat injection. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_4_4540", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Subject, 2 patients with prior amputation. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10907391_4_4541", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Subject, 2 patients with prior amputation. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10907391_4_4542", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Subject, 2 patients with prior amputation. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "10907391_4_4543", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Subject, 2 patients with prior amputation. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10907391_4_4544", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Subject, 2 patients with prior amputation. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "prior amputation"}, {"id": "10907391_4_4545", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_4_4546", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_4_4547", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_4_4548", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_4_4549", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_4_4550", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_4_4551", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_4_4552", "context": "We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.", "question": "adverse event. Treatment, paclitaxel therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11191005_1_4553", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "losartan"}, {"id": "11191005_1_4554", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11191005_1_4555", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11191005_1_4556", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11191005_1_4557", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11191005_1_4558", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11191005_1_4559", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11191005_1_4560", "context": "There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.", "question": "adverse event. Treatment, angiotensin II receptor antagonist, losartan. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_1_4561", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_1_4562", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_1_4563", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_1_4564", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_1_4565", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_1_4566", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11468878_1_4567", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11468878_1_4568", "context": "Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.", "question": "adverse event. Treatment, metformin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15468380_2_4569", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, one patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15468380_2_4570", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, one patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15468380_2_4571", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, one patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15468380_2_4572", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, one patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15468380_2_4573", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, one patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15468380_2_4574", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_2_4575", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_2_4576", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_2_4577", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_2_4578", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_2_4579", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_2_4580", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "necrotizing vasculitis"}, {"id": "15468380_2_4581", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15468380_2_4582", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, preexisting mononeuritis multiplex in the other. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15468380_2_4583", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, preexisting mononeuritis multiplex in the other. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15468380_2_4584", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, preexisting mononeuritis multiplex in the other. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15468380_2_4585", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, preexisting mononeuritis multiplex in the other. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15468380_2_4586", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Subject, preexisting mononeuritis multiplex in the other. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "preexisting mononeuritis multiplex"}, {"id": "15468380_2_4587", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_2_4588", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_2_4589", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_2_4590", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_2_4591", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_2_4592", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_2_4593", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "necrotizing vasculitis"}, {"id": "15468380_2_4594", "context": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3586163_2_4595", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "3586163_2_4596", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3586163_2_4597", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3586163_2_4598", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3586163_2_4599", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3586163_2_4600", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3586163_2_4601", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3586163_2_4602", "context": "Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.", "question": "adverse event. Treatment, cyclophosphamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8864370_1_4603", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "8864370_1_4604", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8864370_1_4605", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_1_4606", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_1_4607", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_1_4608", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_1_4609", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriatics"}, {"id": "8864370_1_4610", "context": "BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.", "question": "adverse event. Treatment, Methotrexate (MTX). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_5_4611", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluconazole"}, {"id": "19071894_5_4612", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_5_4613", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_5_4614", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_5_4615", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_5_4616", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_5_4617", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_5_4618", "context": "The infection proceeded even after treatment with fluconazole.", "question": "adverse event. Treatment, fluconazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9861579_1_4619", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Subject, a 41-year-old female patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "41-year-old"}, {"id": "9861579_1_4620", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Subject, a 41-year-old female patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "9861579_1_4621", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Subject, a 41-year-old female patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9861579_1_4622", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Subject, a 41-year-old female patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9861579_1_4623", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Subject, a 41-year-old female patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9861579_1_4624", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mirtazapine"}, {"id": "9861579_1_4625", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9861579_1_4626", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9861579_1_4627", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9861579_1_4628", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9861579_1_4629", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9861579_1_4630", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "major depression"}, {"id": "9861579_1_4631", "context": "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.", "question": "adverse event. Treatment, mirtazapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_9_4632", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "16816519_9_4633", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_9_4634", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_9_4635", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16816519_9_4636", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "7 days"}, {"id": "16816519_9_4637", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_9_4638", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_9_4639", "context": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks.", "question": "potential therapeutic event. Treatment, pyridoxine and pyridostigmine treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "pyridoxine; pyridostigmine"}, {"id": "20065266_4_4640", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_4_4641", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20065266_4_4642", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_4_4643", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_4_4644", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_4_4645", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim-sulfamethoxazole"}, {"id": "20065266_4_4646", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_4_4647", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_4_4648", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_4_4649", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_4_4650", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_4_4651", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_4_4652", "context": "PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12432978_2_4653", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Subject, a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12432978_2_4654", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Subject, a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12432978_2_4655", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Subject, a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12432978_2_4656", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Subject, a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12432978_2_4657", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Subject, a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12432978_2_4658", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clomipramine; interferon beta-1a"}, {"id": "12432978_2_4659", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12432978_2_4660", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12432978_2_4661", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12432978_2_4662", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12432978_2_4663", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12432978_2_4664", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Tourette's syndrome; Asperger's syndrome; multiple sclerosis"}, {"id": "12432978_2_4665", "context": "Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.", "question": "adverse event. Treatment, interferon beta-1a and clomipramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon beta-1a; clomipramine"}, {"id": "8961730_1_4666", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "8961730_1_4667", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8961730_1_4668", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8961730_1_4669", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8961730_1_4670", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8961730_1_4671", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8961730_1_4672", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8961730_1_4673", "context": "Psychotic disorder associated with isoniazid.", "question": "adverse event. Treatment, isoniazid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_3_4674", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_3_4675", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1 mg/kg"}, {"id": "8551001_3_4676", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_3_4677", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_3_4678", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "56 days"}, {"id": "8551001_3_4679", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_3_4680", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_3_4681", "context": "The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.", "question": "adverse event. Treatment, 56 days therapy; The azathioprine dose was low (1 mg/kg). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_5_4682", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paroxetine"}, {"id": "10442258_5_4683", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_5_4684", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_5_4685", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_5_4686", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_5_4687", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_5_4688", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_5_4689", "context": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "question": "adverse event. Treatment, paroxetine.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_5_4690", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12546343_5_4691", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12546343_5_4692", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12546343_5_4693", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12546343_5_4694", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12546343_5_4695", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_5_4696", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_5_4697", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_5_4698", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_5_4699", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_5_4700", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_5_4701", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_5_4702", "context": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.", "question": "adverse event. Treatment, MTX. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18445989_2_4703", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Clomiphene"}, {"id": "18445989_2_4704", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18445989_2_4705", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18445989_2_4706", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18445989_2_4707", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18445989_2_4708", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18445989_2_4709", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anovulation"}, {"id": "18445989_2_4710", "context": "Clomiphene is a first line treatment for anovulation, a common cause of infertility.", "question": "potential therapeutic event. Treatment, Clomiphene. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3290702_2_4711", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Subject, A new case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3290702_2_4712", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Subject, A new case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3290702_2_4713", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Subject, A new case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3290702_2_4714", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Subject, A new case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3290702_2_4715", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Subject, A new case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3290702_2_4716", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "human growth hormone"}, {"id": "3290702_2_4717", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3290702_2_4718", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3290702_2_4719", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3290702_2_4720", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3290702_2_4721", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3290702_2_4722", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3290702_2_4723", "context": "A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.", "question": "adverse event. Treatment, human growth hormone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_2_4724", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_2_4725", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_2_4726", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_2_4727", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_2_4728", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_2_4729", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "prolonged"}, {"id": "16939867_2_4730", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16939867_2_4731", "context": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19047493_1_4732", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "19047493_1_4733", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "small doses"}, {"id": "19047493_1_4734", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19047493_1_4735", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19047493_1_4736", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19047493_1_4737", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19047493_1_4738", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19047493_1_4739", "context": "Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.", "question": "adverse event. Treatment, haloperidol; small doses. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_9_4740", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Subject, patients with renal insufficiency. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16580907_9_4741", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Subject, patients with renal insufficiency. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16580907_9_4742", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Subject, patients with renal insufficiency. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_9_4743", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Subject, patients with renal insufficiency. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_9_4744", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Subject, patients with renal insufficiency. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_9_4745", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cetirizine"}, {"id": "16580907_9_4746", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_9_4747", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_9_4748", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_9_4749", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_9_4750", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_9_4751", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_9_4752", "context": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers, such an interaction should be considered, especially in patients with renal insufficiency who are receiving pilsicainide.", "question": "adverse event. Treatment, cetirizine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_1_4753", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_1_4754", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_1_4755", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_1_4756", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_1_4757", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_1_4758", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_1_4759", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "non-Hodgkin's lymphoma"}, {"id": "16948177_1_4760", "context": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.", "question": "adverse event. Treatment, rituximab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_1_4761", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast; pranlukast"}, {"id": "9792602_1_4762", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_1_4763", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9792602_1_4764", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9792602_1_4765", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9792602_1_4766", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9792602_1_4767", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9792602_1_4768", "context": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.", "question": "adverse event. Treatment, pranlukast. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_4_4769", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12546343_4_4770", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "12546343_4_4771", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_4_4772", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_4_4773", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_4_4774", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_4_4775", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_4_4776", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "adverse event. Treatment, high-dose methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_4_4777", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12546343_4_4778", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_4_4779", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12546343_4_4780", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12546343_4_4781", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_4_4782", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12546343_4_4783", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "systemic anaphylaxis"}, {"id": "12546343_4_4784", "context": "Successful desensitization to high-dose methotrexate after systemic anaphylaxis.", "question": "potential therapeutic event. Treatment, high-dose methotrexate. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7468565_4_4785", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "barbiturates"}, {"id": "7468565_4_4786", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_4_4787", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_4_4788", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_4_4789", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_4_4790", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_4_4791", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_4_4792", "context": "The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.", "question": "adverse event. Treatment, barbiturates. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19838099_1_4793", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Subject, 2 patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19838099_1_4794", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Subject, 2 patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19838099_1_4795", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Subject, 2 patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "19838099_1_4796", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Subject, 2 patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19838099_1_4797", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Subject, 2 patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19838099_1_4798", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dasatinib"}, {"id": "19838099_1_4799", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19838099_1_4800", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19838099_1_4801", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19838099_1_4802", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19838099_1_4803", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19838099_1_4804", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19838099_1_4805", "context": "Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.", "question": "adverse event. Treatment, dasatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2523364_1_4806", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocriptine"}, {"id": "2523364_1_4807", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2523364_1_4808", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2523364_1_4809", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2523364_1_4810", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2523364_1_4811", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2523364_1_4812", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2523364_1_4813", "context": "Morphea after bromocriptine therapy.", "question": "adverse event. Treatment, bromocriptine therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_2_4814", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Subject, a young boy. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12390172_2_4815", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Subject, a young boy. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "12390172_2_4816", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Subject, a young boy. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12390172_2_4817", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Subject, a young boy. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12390172_2_4818", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Subject, a young boy. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12390172_2_4819", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_2_4820", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_2_4821", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_2_4822", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_2_4823", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_2_4824", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_2_4825", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_2_4826", "context": "PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2196696_3_4827", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2196696_3_4828", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2196696_3_4829", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2196696_3_4830", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2196696_3_4831", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2196696_3_4832", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "2196696_3_4833", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_3_4834", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_3_4835", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_3_4836", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2196696_3_4837", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_3_4838", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_3_4839", "context": "We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.", "question": "adverse event. Treatment, disulfiram. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_4_4840", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8739289_4_4841", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8739289_4_4842", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8739289_4_4843", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8739289_4_4844", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "underlying chronic NDI"}, {"id": "8739289_4_4845", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_4_4846", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_4_4847", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_4_4848", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_4_4849", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_4_4850", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "8739289_4_4851", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_4_4852", "context": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.", "question": "adverse event. Treatment, chronic lithium therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20009973_2_4853", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Subject, a patient with newly diagnosed acute promyelocytic leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20009973_2_4854", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Subject, a patient with newly diagnosed acute promyelocytic leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20009973_2_4855", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Subject, a patient with newly diagnosed acute promyelocytic leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20009973_2_4856", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Subject, a patient with newly diagnosed acute promyelocytic leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20009973_2_4857", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Subject, a patient with newly diagnosed acute promyelocytic leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20009973_2_4858", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "all-trans retinoic acid"}, {"id": "20009973_2_4859", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20009973_2_4860", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20009973_2_4861", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20009973_2_4862", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20009973_2_4863", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20009973_2_4864", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute promyelocytic leukemia"}, {"id": "20009973_2_4865", "context": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.", "question": "adverse event. Treatment, all-trans retinoic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_2_4866", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Subject, a 25-year-old man with osteosarcoma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "22550162_2_4867", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Subject, a 25-year-old man with osteosarcoma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "22550162_2_4868", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Subject, a 25-year-old man with osteosarcoma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22550162_2_4869", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Subject, a 25-year-old man with osteosarcoma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22550162_2_4870", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Subject, a 25-year-old man with osteosarcoma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "osteosarcoma"}, {"id": "22550162_2_4871", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; omeprazole"}, {"id": "22550162_2_4872", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_2_4873", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_2_4874", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_2_4875", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_2_4876", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_2_4877", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_2_4878", "context": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma.", "question": "adverse event. Treatment, methotrexate and omeprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; omeprazole"}, {"id": "18562412_1_4879", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_1_4880", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_1_4881", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_1_4882", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_1_4883", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_1_4884", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_1_4885", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_1_4886", "context": "Increasing the olanzapine dosage severely aggravated the symptoms of RLS.", "question": "adverse event. Treatment, Increasing the olanzapine dosage. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_2_4887", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Subject, a case of 48-year-old woman with seizure disorder. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "48-year-old"}, {"id": "19512997_2_4888", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Subject, a case of 48-year-old woman with seizure disorder. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "19512997_2_4889", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Subject, a case of 48-year-old woman with seizure disorder. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19512997_2_4890", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Subject, a case of 48-year-old woman with seizure disorder. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19512997_2_4891", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Subject, a case of 48-year-old woman with seizure disorder. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19512997_2_4892", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "divalproex sodium"}, {"id": "19512997_2_4893", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_2_4894", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_2_4895", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_2_4896", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_2_4897", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_2_4898", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "seizure disorder"}, {"id": "19512997_2_4899", "context": "We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.", "question": "adverse event. Treatment, divalproex sodium (Depakote). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19531696_2_4900", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; marijuana"}, {"id": "19531696_2_4901", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19531696_2_4902", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19531696_2_4903", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "smoking"}, {"id": "19531696_2_4904", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19531696_2_4905", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19531696_2_4906", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19531696_2_4907", "context": "To report a probable interaction between warfarin and marijuana smoking, resulting in increased international normalized ratio (INR) values and bleeding complications.", "question": "adverse event. Treatment, interaction between warfarin and marijuana smoking. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; marijuana"}, {"id": "19653965_2_4908", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Subject, two patients with HIV infection. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19653965_2_4909", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Subject, two patients with HIV infection. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19653965_2_4910", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Subject, two patients with HIV infection. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "19653965_2_4911", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Subject, two patients with HIV infection. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19653965_2_4912", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Subject, two patients with HIV infection. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19653965_2_4913", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir"}, {"id": "19653965_2_4914", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19653965_2_4915", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19653965_2_4916", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19653965_2_4917", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19653965_2_4918", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19653965_2_4919", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV infection"}, {"id": "19653965_2_4920", "context": "Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.", "question": "adverse event. Treatment, lopinavir/ritonavir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lopinavir; ritonavir"}, {"id": "11688826_1_4921", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CDDP"}, {"id": "11688826_1_4922", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_1_4923", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_1_4924", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_1_4925", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_1_4926", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_1_4927", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11688826_1_4928", "context": "Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.", "question": "adverse event. Treatment, CDDP. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_1_4929", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_1_4930", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_1_4931", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_1_4932", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_1_4933", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_1_4934", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_1_4935", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_1_4936", "context": "Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.", "question": "adverse event. Treatment, heparin-dependent antibodies (HDAs). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_3_4937", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Subject, 69-year-old white female. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "69-year-old"}, {"id": "22010004_3_4938", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Subject, 69-year-old white female. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "22010004_3_4939", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Subject, 69-year-old white female. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_3_4940", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Subject, 69-year-old white female. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "22010004_3_4941", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Subject, 69-year-old white female. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_3_4942", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "extended-release niacin; warfarin"}, {"id": "22010004_3_4943", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1000 mg; 2.5 mg"}, {"id": "22010004_3_4944", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily; daily"}, {"id": "22010004_3_4945", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_3_4946", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_3_4947", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_3_4948", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_3_4949", "context": "A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.", "question": "adverse event. Treatment, anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk); dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "extended-release niacin; warfarin"}, {"id": "17346586_1_4950", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "17346586_1_4951", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17346586_1_4952", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17346586_1_4953", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenously"}, {"id": "17346586_1_4954", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17346586_1_4955", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17346586_1_4956", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17346586_1_4957", "context": "The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.", "question": "adverse event. Treatment, bisphosphonate treatment (particularly when it is administered intravenously). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18160579_1_4958", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetylsalicylic acid"}, {"id": "18160579_1_4959", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18160579_1_4960", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18160579_1_4961", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18160579_1_4962", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18160579_1_4963", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18160579_1_4964", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18160579_1_4965", "context": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, acetylsalicylic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7387219_2_4966", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Subject, These cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7387219_2_4967", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Subject, These cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7387219_2_4968", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Subject, These cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7387219_2_4969", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Subject, These cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7387219_2_4970", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Subject, These cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7387219_2_4971", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "D-penicillamine"}, {"id": "7387219_2_4972", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7387219_2_4973", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7387219_2_4974", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7387219_2_4975", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7387219_2_4976", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7387219_2_4977", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7387219_2_4978", "context": "These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.", "question": "adverse event. Treatment, D-penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12962465_1_4979", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "RH"}, {"id": "12962465_1_4980", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12962465_1_4981", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12962465_1_4982", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12962465_1_4983", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "After four months"}, {"id": "12962465_1_4984", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12962465_1_4985", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12962465_1_4986", "context": "After four months, while receiving RH, he developed painful bilateral gynaecomastia.", "question": "adverse event. Treatment, receiving RH. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_5_4987", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "16580907_5_4988", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16580907_5_4989", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_5_4990", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16580907_5_4991", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16580907_5_4992", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_5_4993", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_5_4994", "context": "The plasma concentrations of both drugs were significantly increased during the coadministration, and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued, which suggested that the fainting was induced by the pharmacokinetic drug interaction.", "question": "adverse event. Treatment, pilsicainide; cetirizine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "11573852_6_4995", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Subject, an AIDS patent. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_6_4996", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Subject, an AIDS patent. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_6_4997", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Subject, an AIDS patent. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_6_4998", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Subject, an AIDS patent. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_6_4999", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Subject, an AIDS patent. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_6_5000", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_6_5001", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_6_5002", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_6_5003", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "11573852_6_5004", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_6_5005", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_6_5006", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "11573852_6_5007", "context": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "question": "adverse event. Treatment, amphotericin B infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_3_5008", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Creon 10; Viokase; Pancrease MT 16"}, {"id": "9651465_3_5009", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_3_5010", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_3_5011", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_3_5012", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9651465_3_5013", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_3_5014", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_3_5015", "context": "The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.", "question": "adverse event. Treatment, different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_1_5016", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_1_5017", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_1_5018", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_1_5019", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_1_5020", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_1_5021", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_1_5022", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_1_5023", "context": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19047493_2_5024", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19047493_2_5025", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19047493_2_5026", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19047493_2_5027", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19047493_2_5028", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19047493_2_5029", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "haloperidol"}, {"id": "19047493_2_5030", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19047493_2_5031", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19047493_2_5032", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19047493_2_5033", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19047493_2_5034", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19047493_2_5035", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obsessive nocturnal thoughts and auditory disturbances"}, {"id": "19047493_2_5036", "context": "This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.", "question": "adverse event. Treatment, haloperido. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_3_5037", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_3_5038", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_3_5039", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_3_5040", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_3_5041", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_3_5042", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_3_5043", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_3_5044", "context": "In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.", "question": "adverse event. Treatment, imatinib therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_4_5045", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Subject, a typical case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "25540831_4_5046", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Subject, a typical case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "25540831_4_5047", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Subject, a typical case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "25540831_4_5048", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Subject, a typical case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "25540831_4_5049", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Subject, a typical case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "25540831_4_5050", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tramadol; Citalopram"}, {"id": "25540831_4_5051", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_4_5052", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_4_5053", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_4_5054", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_4_5055", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_4_5056", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_4_5057", "context": "We report a typical case of transient serotonin syndrome secondary to tramadol-Citalopram combination.", "question": "adverse event. Treatment, tramadol-Citalopram combination. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "tramadol; Citalopram"}, {"id": "22550162_9_5058", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Subject, the patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22550162_9_5059", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Subject, the patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22550162_9_5060", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Subject, the patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22550162_9_5061", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Subject, the patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22550162_9_5062", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Subject, the patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22550162_9_5063", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; omeprazole"}, {"id": "22550162_9_5064", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_9_5065", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_9_5066", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_9_5067", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_9_5068", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_9_5069", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_9_5070", "context": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.", "question": "adverse event. Treatment, methotrexate; and omeprazole use. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; omeprazole"}, {"id": "3620420_5_5071", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Subject, patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_5_5072", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Subject, patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_5_5073", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Subject, patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_5_5074", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Subject, patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_5_5075", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Subject, patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_5_5076", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Systemic cyclosporin"}, {"id": "3620420_5_5077", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "10 mg/kg/day"}, {"id": "3620420_5_5078", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_5_5079", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_5_5080", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_5_5081", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_5_5082", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3620420_5_5083", "context": "Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy.", "question": "potential therapeutic event. Treatment, Systemic cyclosporin (10 mg/kg/day). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6578007_2_5084", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Subject, a 59-year-old patient with chronic myeloid leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "59-year-old"}, {"id": "6578007_2_5085", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Subject, a 59-year-old patient with chronic myeloid leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6578007_2_5086", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Subject, a 59-year-old patient with chronic myeloid leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6578007_2_5087", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Subject, a 59-year-old patient with chronic myeloid leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6578007_2_5088", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Subject, a 59-year-old patient with chronic myeloid leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6578007_2_5089", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "melphalan; busulfan"}, {"id": "6578007_2_5090", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6578007_2_5091", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6578007_2_5092", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6578007_2_5093", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "short term"}, {"id": "6578007_2_5094", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6578007_2_5095", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "6578007_2_5096", "context": "We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.", "question": "adverse event. Treatment, short term and sequential treatment with melphalan and busulfan. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "melphalan; busulfan"}, {"id": "12702914_1_5097", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Subject, a patient with liver dysfunction. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12702914_1_5098", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Subject, a patient with liver dysfunction. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12702914_1_5099", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Subject, a patient with liver dysfunction. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12702914_1_5100", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Subject, a patient with liver dysfunction. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12702914_1_5101", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Subject, a patient with liver dysfunction. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12702914_1_5102", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "12702914_1_5103", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12702914_1_5104", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_1_5105", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_1_5106", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_1_5107", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_1_5108", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "liver dysfunction"}, {"id": "12702914_1_5109", "context": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?", "question": "adverse event. Treatment, insulin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_2_5110", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Subject, patients with chronic hepatitis C. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_2_5111", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Subject, patients with chronic hepatitis C. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_2_5112", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Subject, patients with chronic hepatitis C. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1624172_2_5113", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Subject, patients with chronic hepatitis C. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_2_5114", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Subject, patients with chronic hepatitis C. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_2_5115", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_2_5116", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_2_5117", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_2_5118", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_2_5119", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_2_5120", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_2_5121", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "1624172_2_5122", "context": "Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_3_5123", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Depakote"}, {"id": "19512997_3_5124", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_3_5125", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_3_5126", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_3_5127", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_3_5128", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_3_5129", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19512997_3_5130", "context": "Withdrawal of Depakote resulted in resolution of the effusion.", "question": "adverse event. Treatment, Withdrawal of Depakote. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_1_5131", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Adenosine"}, {"id": "11428480_1_5132", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11428480_1_5133", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_1_5134", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_1_5135", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_1_5136", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_1_5137", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11428480_1_5138", "context": "Adenosine-induced ventricular fibrillation.", "question": "adverse event. Treatment, Adenosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23774436_1_5139", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Subject, pulmonary tuberculosis patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23774436_1_5140", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Subject, pulmonary tuberculosis patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23774436_1_5141", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Subject, pulmonary tuberculosis patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23774436_1_5142", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Subject, pulmonary tuberculosis patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23774436_1_5143", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Subject, pulmonary tuberculosis patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23774436_1_5144", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gatifloxacin"}, {"id": "23774436_1_5145", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23774436_1_5146", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23774436_1_5147", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23774436_1_5148", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23774436_1_5149", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23774436_1_5150", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pulmonary tuberculosis"}, {"id": "23774436_1_5151", "context": "Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.", "question": "potential therapeutic event. Treatment, gatifloxacin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14723711_5_5152", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Subject, two patients with acne vulgaris. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14723711_5_5153", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Subject, two patients with acne vulgaris. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14723711_5_5154", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Subject, two patients with acne vulgaris. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "14723711_5_5155", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Subject, two patients with acne vulgaris. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14723711_5_5156", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Subject, two patients with acne vulgaris. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14723711_5_5157", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_5_5158", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_5_5159", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_5_5160", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_5_5161", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_5_5162", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_5_5163", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acne vulgaris"}, {"id": "14723711_5_5164", "context": "We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7720517_2_5165", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Budesonide"}, {"id": "7720517_2_5166", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7720517_2_5167", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7720517_2_5168", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7720517_2_5169", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7720517_2_5170", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7720517_2_5171", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "asthma and rhinitis."}, {"id": "7720517_2_5172", "context": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis.", "question": "potential therapeutic event. Treatment, Budesonide. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3620420_1_5173", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Cyclosporin"}, {"id": "3620420_1_5174", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_1_5175", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_1_5176", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_1_5177", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_1_5178", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_1_5179", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Mooren's ulcer"}, {"id": "3620420_1_5180", "context": "Cyclosporin therapy in Mooren's ulcer.", "question": "potential therapeutic event. Treatment, Cyclosporin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11359026_3_5181", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Subject, She. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11359026_3_5182", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Subject, She. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "11359026_3_5183", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Subject, She. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11359026_3_5184", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Subject, She. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11359026_3_5185", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Subject, She. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11359026_3_5186", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valacyclovir"}, {"id": "11359026_3_5187", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "adjustment dosage"}, {"id": "11359026_3_5188", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11359026_3_5189", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11359026_3_5190", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11359026_3_5191", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11359026_3_5192", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cutaneous zoster infection"}, {"id": "11359026_3_5193", "context": "She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.", "question": "adverse event. Treatment, adjustment dosage of valacyclovir. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_3_5194", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Subject, Nine eyes from 6 patients, 74 years to 90 years of age. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "74 years to 90 years"}, {"id": "11642488_3_5195", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Subject, Nine eyes from 6 patients, 74 years to 90 years of age. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11642488_3_5196", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Subject, Nine eyes from 6 patients, 74 years to 90 years of age. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "6"}, {"id": "11642488_3_5197", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Subject, Nine eyes from 6 patients, 74 years to 90 years of age. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11642488_3_5198", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Subject, Nine eyes from 6 patients, 74 years to 90 years of age. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11642488_3_5199", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin"}, {"id": "11642488_3_5200", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_3_5201", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice-a-day"}, {"id": "11642488_3_5202", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_3_5203", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_3_5204", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "2 years"}, {"id": "11642488_3_5205", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_3_5206", "context": "Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.", "question": "adverse event. Treatment, at least 2 years of twice-a-day application of dipivefrin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_3_5207", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, two patients with chronic myelocytic leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15965422_3_5208", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, two patients with chronic myelocytic leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15965422_3_5209", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, two patients with chronic myelocytic leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15965422_3_5210", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, two patients with chronic myelocytic leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15965422_3_5211", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, two patients with chronic myelocytic leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15965422_3_5212", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alfa-2b"}, {"id": "15965422_3_5213", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "different doses"}, {"id": "15965422_3_5214", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "weekly"}, {"id": "15965422_3_5215", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "subcutaneous injections"}, {"id": "15965422_3_5216", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_3_5217", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_3_5218", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myelocytic leukemia"}, {"id": "15965422_3_5219", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_3_5220", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, 3 patients with chronic hepatitis C. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15965422_3_5221", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, 3 patients with chronic hepatitis C. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15965422_3_5222", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, 3 patients with chronic hepatitis C. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15965422_3_5223", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, 3 patients with chronic hepatitis C. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15965422_3_5224", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Subject, 3 patients with chronic hepatitis C. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15965422_3_5225", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alfa-2b; ribavirin"}, {"id": "15965422_3_5226", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_3_5227", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_3_5228", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15965422_3_5229", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_3_5230", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_3_5231", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "15965422_3_5232", "context": "We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.", "question": "adverse event. Treatment, pegylated interferon alfa-2b in association with oral ribavirin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "pegylated interferon alfa-2b; ribavirin"}, {"id": "20180933_2_5233", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Artemether-lumefantrine"}, {"id": "20180933_2_5234", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20180933_2_5235", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_2_5236", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20180933_2_5237", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_2_5238", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20180933_2_5239", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "uncomplicated malaria"}, {"id": "20180933_2_5240", "context": "Artemether-lumefantrine (AL) is first-line treatment for uncomplicated malaria in many African countries.", "question": "potential therapeutic event. Treatment, Artemether-lumefantrine (AL). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17329303_10_5241", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone; methylphenidate"}, {"id": "17329303_10_5242", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_10_5243", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_10_5244", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_10_5245", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_10_5246", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_10_5247", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_10_5248", "context": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate.", "question": "adverse event. Treatment, risperidone; switching to methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3508194_1_5249", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium nitroprusside"}, {"id": "3508194_1_5250", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3508194_1_5251", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3508194_1_5252", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "3508194_1_5253", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3508194_1_5254", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3508194_1_5255", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3508194_1_5256", "context": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.", "question": "adverse event. Treatment, sodium nitroprusside infusion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_2_5257", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_2_5258", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_2_5259", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_2_5260", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_2_5261", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_2_5262", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_2_5263", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7789881_2_5264", "context": "This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7420580_1_5265", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vinblastine"}, {"id": "7420580_1_5266", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high dose"}, {"id": "7420580_1_5267", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7420580_1_5268", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7420580_1_5269", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7420580_1_5270", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7420580_1_5271", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7420580_1_5272", "context": "Inappropriate antidiuretic hormone secretion after high dose vinblastine.", "question": "adverse event. Treatment, high dose vinblastine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17373180_2_5273", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "17373180_2_5274", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17373180_2_5275", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17373180_2_5276", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17373180_2_5277", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17373180_2_5278", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17373180_2_5279", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "severe psoriasis"}, {"id": "17373180_2_5280", "context": "Osteomyelitis occurring during infliximab treatment of severe psoriasis.", "question": "adverse event. Treatment, infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8452107_3_5281", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Subject, a patient with transitional cell carcinoma of the renal pelvis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8452107_3_5282", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Subject, a patient with transitional cell carcinoma of the renal pelvis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8452107_3_5283", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Subject, a patient with transitional cell carcinoma of the renal pelvis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8452107_3_5284", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Subject, a patient with transitional cell carcinoma of the renal pelvis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8452107_3_5285", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Subject, a patient with transitional cell carcinoma of the renal pelvis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8452107_3_5286", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "piritrexim"}, {"id": "8452107_3_5287", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_3_5288", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_3_5289", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "8452107_3_5290", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_3_5291", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_3_5292", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "transitional cell carcinoma of the renal pelvis"}, {"id": "8452107_3_5293", "context": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.", "question": "adverse event. Treatment, chemotherapy with piritrexim, a methotrexate analog. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_2_5294", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amiodarone"}, {"id": "2690546_2_5295", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_2_5296", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_2_5297", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_2_5298", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_2_5299", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_2_5300", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_2_5301", "context": "Amiodarone induced torsades de pointe.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2113320_1_5302", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Subject, A patient with Wegener's granulomatosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2113320_1_5303", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Subject, A patient with Wegener's granulomatosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2113320_1_5304", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Subject, A patient with Wegener's granulomatosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2113320_1_5305", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Subject, A patient with Wegener's granulomatosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2113320_1_5306", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Subject, A patient with Wegener's granulomatosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2113320_1_5307", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "2113320_1_5308", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2113320_1_5309", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2113320_1_5310", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2113320_1_5311", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2113320_1_5312", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2113320_1_5313", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wegener's granulomatosis"}, {"id": "2113320_1_5314", "context": "A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.", "question": "adverse event. Treatment, cyclophosphamide regimen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8733532_1_5315", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Subject, A case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8733532_1_5316", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Subject, A case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8733532_1_5317", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Subject, A case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8733532_1_5318", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Subject, A case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8733532_1_5319", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Subject, A case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "coagulation disorder"}, {"id": "8733532_1_5320", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minoxidil"}, {"id": "8733532_1_5321", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8733532_1_5322", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8733532_1_5323", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8733532_1_5324", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8733532_1_5325", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8733532_1_5326", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8733532_1_5327", "context": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.", "question": "adverse event. Treatment, minoxidil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11406880_1_5328", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methadone"}, {"id": "11406880_1_5329", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_1_5330", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_1_5331", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_1_5332", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_1_5333", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_1_5334", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "advanced cancer"}, {"id": "11406880_1_5335", "context": "Methadone-induced myoclonus in advanced cancer.", "question": "adverse event. Treatment, Methadone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_1_5336", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Subject, a patient with dermatomyositis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11984077_1_5337", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Subject, a patient with dermatomyositis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11984077_1_5338", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Subject, a patient with dermatomyositis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11984077_1_5339", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Subject, a patient with dermatomyositis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11984077_1_5340", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Subject, a patient with dermatomyositis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "dermatomyositis"}, {"id": "11984077_1_5341", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine; chemoradiotherapy"}, {"id": "11984077_1_5342", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_1_5343", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_1_5344", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_1_5345", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_1_5346", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_1_5347", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nasopharyngeal cancer"}, {"id": "11984077_1_5348", "context": "Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.", "question": "adverse event. Treatment, amifostine used with concurrent chemoradiotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "amifostine; chemoradiotherapy"}, {"id": "19260037_4_5349", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_4_5350", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_4_5351", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_4_5352", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_4_5353", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_4_5354", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_4_5355", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_4_5356", "context": "We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).", "question": "adverse event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_1_5357", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "LMWH"}, {"id": "19690222_1_5358", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19690222_1_5359", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_1_5360", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_1_5361", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_1_5362", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_1_5363", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_1_5364", "context": "CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.", "question": "adverse event. Treatment, LMWH. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17068466_1_5365", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Subject, These cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17068466_1_5366", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Subject, These cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17068466_1_5367", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Subject, These cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17068466_1_5368", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Subject, These cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17068466_1_5369", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Subject, These cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17068466_1_5370", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "moxifloxacin"}, {"id": "17068466_1_5371", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_1_5372", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17068466_1_5373", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17068466_1_5374", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_1_5375", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_1_5376", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_1_5377", "context": "CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.", "question": "adverse event. Treatment, moxifloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_4_5378", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine; penicillamine"}, {"id": "2568058_4_5379", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_4_5380", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_4_5381", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_4_5382", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2568058_4_5383", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_4_5384", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2568058_4_5385", "context": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11672959_1_5386", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Subject, A 34-year-old lady. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "34-year-old"}, {"id": "11672959_1_5387", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Subject, A 34-year-old lady. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "lady"}, {"id": "11672959_1_5388", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Subject, A 34-year-old lady. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11672959_1_5389", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Subject, A 34-year-old lady. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11672959_1_5390", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Subject, A 34-year-old lady. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11672959_1_5391", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulphasalazine"}, {"id": "11672959_1_5392", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11672959_1_5393", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11672959_1_5394", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11672959_1_5395", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11672959_1_5396", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "17th day"}, {"id": "11672959_1_5397", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ero-negative rheumatoid arthritis"}, {"id": "11672959_1_5398", "context": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "question": "adverse event. Treatment, a course of oral sulphasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18477279_3_5399", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin; fusidic acid"}, {"id": "18477279_3_5400", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18477279_3_5401", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18477279_3_5402", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18477279_3_5403", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 weeks later"}, {"id": "18477279_3_5404", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18477279_3_5405", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18477279_3_5406", "context": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis.", "question": "adverse event. Treatment, a course of fusidic acid at discharge in addition to his ongoing statin prescription. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "fusidic acid; statin"}, {"id": "10456689_2_5407", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Artelinic acid"}, {"id": "10456689_2_5408", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10456689_2_5409", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10456689_2_5410", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10456689_2_5411", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456689_2_5412", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10456689_2_5413", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multidrug resistant malaria"}, {"id": "10456689_2_5414", "context": "1.\nArtelinic acid (AL), a water-soluble artemisinin analogue for treatment of multidrug resistant malaria, is metabolized to the active metabolite dihydroqinghaosu (DQHS) solely by  CYP3A4/5.", "question": "potential therapeutic event. Treatment, Artelinic acid (AL), a water-soluble artemisinin analogue. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17331261_3_5415", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Subject, a patient with cystic fibrosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17331261_3_5416", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Subject, a patient with cystic fibrosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_3_5417", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Subject, a patient with cystic fibrosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_3_5418", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Subject, a patient with cystic fibrosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_3_5419", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Subject, a patient with cystic fibrosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_3_5420", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_3_5421", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_3_5422", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_3_5423", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "Inhaled"}, {"id": "17331261_3_5424", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_3_5425", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_3_5426", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "17331261_3_5427", "context": "Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.", "question": "adverse event. Treatment, Inhaled tobramycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_4_5428", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Subject, two children. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "15719254_4_5429", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Subject, two children. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15719254_4_5430", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Subject, two children. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "two"}, {"id": "15719254_4_5431", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Subject, two children. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15719254_4_5432", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Subject, two children. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15719254_4_5433", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "RA"}, {"id": "15719254_4_5434", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_4_5435", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15719254_4_5436", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15719254_4_5437", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_4_5438", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15719254_4_5439", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_4_5440", "context": "The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.", "question": "potential therapeutic event. Treatment, RA. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12665232_1_5441", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12665232_1_5442", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12665232_1_5443", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12665232_1_5444", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12665232_1_5445", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12665232_1_5446", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12665232_1_5447", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12665232_1_5448", "context": "Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.", "question": "adverse event. Treatment, pterygium excision and intraoperative mitomycin C. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16237130_1_5449", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Subject, five cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16237130_1_5450", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Subject, five cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16237130_1_5451", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Subject, five cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "16237130_1_5452", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Subject, five cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16237130_1_5453", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Subject, five cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16237130_1_5454", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Capecitabine"}, {"id": "16237130_1_5455", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16237130_1_5456", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16237130_1_5457", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16237130_1_5458", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16237130_1_5459", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16237130_1_5460", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16237130_1_5461", "context": "Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.", "question": "adverse event. Treatment, Capecitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15941649_3_5462", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vigabatrin"}, {"id": "15941649_3_5463", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_3_5464", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_3_5465", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_3_5466", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_3_5467", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_3_5468", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_3_5469", "context": "Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.", "question": "adverse event. Treatment, Vigabatrin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_1_5470", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Subject, elderly patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_1_5471", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Subject, elderly patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_1_5472", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Subject, elderly patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_1_5473", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Subject, elderly patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_1_5474", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Subject, elderly patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_1_5475", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "17667887_1_5476", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_1_5477", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_1_5478", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_1_5479", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_1_5480", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_1_5481", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_1_5482", "context": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports.", "question": "adverse event. Treatment, atypical antipsychotics; antidepressants. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "11903249_3_5483", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Subject, two patients with hepatitis C virus infection. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11903249_3_5484", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Subject, two patients with hepatitis C virus infection. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11903249_3_5485", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Subject, two patients with hepatitis C virus infection. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11903249_3_5486", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Subject, two patients with hepatitis C virus infection. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11903249_3_5487", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Subject, two patients with hepatitis C virus infection. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11903249_3_5488", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "11903249_3_5489", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11903249_3_5490", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11903249_3_5491", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11903249_3_5492", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11903249_3_5493", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11903249_3_5494", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C virus infection"}, {"id": "11903249_3_5495", "context": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.", "question": "adverse event. Treatment, interferon alfa and ribavirin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; ribavirin"}, {"id": "2523364_2_5496", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Subject, A 57-year-old man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "2523364_2_5497", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Subject, A 57-year-old man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "2523364_2_5498", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Subject, A 57-year-old man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2523364_2_5499", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Subject, A 57-year-old man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2523364_2_5500", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Subject, A 57-year-old man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2523364_2_5501", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bromocriptine"}, {"id": "2523364_2_5502", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2523364_2_5503", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2523364_2_5504", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2523364_2_5505", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2523364_2_5506", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2523364_2_5507", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2523364_2_5508", "context": "A 57-year-old man developed morphea while taking bromocriptine.", "question": "adverse event. Treatment, bromocriptine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_6_5509", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_6_5510", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_6_5511", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_6_5512", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_6_5513", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_6_5514", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_6_5515", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_6_5516", "context": "Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_2_5517", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_2_5518", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_2_5519", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_2_5520", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_2_5521", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_2_5522", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_2_5523", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_2_5524", "context": "Acute coronary syndromes complicating the first infusion of rituximab.", "question": "adverse event. Treatment, the first infusion of rituximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19690222_3_5525", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "low-molecular-weight heparin"}, {"id": "19690222_3_5526", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19690222_3_5527", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19690222_3_5528", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19690222_3_5529", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19690222_3_5530", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19690222_3_5531", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19690222_3_5532", "context": "Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.", "question": "adverse event. Treatment, low-molecular-weight heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_11_5533", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine"}, {"id": "10715308_11_5534", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_11_5535", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_11_5536", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_11_5537", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_11_5538", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_11_5539", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10715308_11_5540", "context": "There were no incremental increases in myelosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine.", "question": "potential therapeutic event. Treatment, tirapazamine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10715308_3_5541", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "10715308_3_5542", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_3_5543", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_3_5544", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_3_5545", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_3_5546", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_3_5547", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "non-small-cell lung cancer (NSCLC)"}, {"id": "10715308_3_5548", "context": "A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC).", "question": "potential therapeutic event. Treatment, tirapazamine plus cisplatin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "17316160_3_5549", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_3_5550", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_3_5551", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17316160_3_5552", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17316160_3_5553", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_3_5554", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17316160_3_5555", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_3_5556", "context": "Combination antimicrobial regimens (e.g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials.", "question": "potential therapeutic event. Treatment, Combination antimicrobial regimens (e.g., linezolid with rifampin). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "17667887_10_5557", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Subject, elderly patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_10_5558", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Subject, elderly patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_10_5559", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Subject, elderly patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_10_5560", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Subject, elderly patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_10_5561", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Subject, elderly patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_10_5562", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic antidepressants; atypical antipsychotics"}, {"id": "17667887_10_5563", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_10_5564", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_10_5565", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_10_5566", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_10_5567", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_10_5568", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_10_5569", "context": "Clinicians treating elderly patients with a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression should be aware of the potential for serotonin syndrome.", "question": "adverse event. Treatment, a combination of serotonergic antidepressants and atypical antipsychotics for psychotic depression. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "serotonergic antidepressants; atypical antipsychotics"}, {"id": "18472517_1_5570", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Enalaprilat"}, {"id": "18472517_1_5571", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18472517_1_5572", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18472517_1_5573", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18472517_1_5574", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18472517_1_5575", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18472517_1_5576", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18472517_1_5577", "context": "Enalaprilat induced acute parotitis.", "question": "adverse event. Treatment, Enalaprilat. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18477279_6_5578", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fusidic acid"}, {"id": "18477279_6_5579", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18477279_6_5580", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18477279_6_5581", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18477279_6_5582", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18477279_6_5583", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18477279_6_5584", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18477279_6_5585", "context": "We believe the most likely cause was hepatic inhibition of the CYP3A4 hepatic isoenzyme by fusidic acid resulting in an acute severe rise in plasma simvastatin level and extensive myocellular damage.", "question": "adverse event. Treatment, fusidic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18160579_2_5586", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18160579_2_5587", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18160579_2_5588", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18160579_2_5589", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18160579_2_5590", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18160579_2_5591", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetylsalicylic acid"}, {"id": "18160579_2_5592", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "18160579_2_5593", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18160579_2_5594", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18160579_2_5595", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18160579_2_5596", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18160579_2_5597", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "essential thrombocythemia"}, {"id": "18160579_2_5598", "context": "The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, low-dose acetylsalicylic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_7_5599", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy agents"}, {"id": "17083890_7_5600", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_7_5601", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_7_5602", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_7_5603", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_7_5604", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_7_5605", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_7_5606", "context": "This complex pattern of nail and skin changes is accounted by synergy or an additive effect of chemotherapy agents on cellular proliferation of nail compartments.", "question": "adverse event. Treatment, chemotherapy agents. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12625995_1_5607", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Subject, i. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12625995_1_5608", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Subject, i. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_1_5609", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Subject, i. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12625995_1_5610", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Subject, i. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_1_5611", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Subject, i. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_1_5612", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "12625995_1_5613", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_1_5614", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_1_5615", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_1_5616", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_1_5617", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_1_5618", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12625995_1_5619", "context": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1918672_1_5620", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Subject, a patient's. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1918672_1_5621", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Subject, a patient's. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1918672_1_5622", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Subject, a patient's. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1918672_1_5623", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Subject, a patient's. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1918672_1_5624", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Subject, a patient's. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1918672_1_5625", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "piroxicam"}, {"id": "1918672_1_5626", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1918672_1_5627", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1918672_1_5628", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1918672_1_5629", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1918672_1_5630", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1918672_1_5631", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ulcers"}, {"id": "1918672_1_5632", "context": "In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.", "question": "potential therapeutic event. Treatment, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9988365_2_5633", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9988365_2_5634", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9988365_2_5635", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9988365_2_5636", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9988365_2_5637", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9988365_2_5638", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_2_5639", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_2_5640", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9988365_2_5641", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9988365_2_5642", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_2_5643", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9988365_2_5644", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9988365_2_5645", "context": "Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3954165_2_5646", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Subject, a patient with status asthmaticus. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3954165_2_5647", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Subject, a patient with status asthmaticus. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3954165_2_5648", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Subject, a patient with status asthmaticus. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3954165_2_5649", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Subject, a patient with status asthmaticus. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3954165_2_5650", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Subject, a patient with status asthmaticus. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3954165_2_5651", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline; prednisone"}, {"id": "3954165_2_5652", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3954165_2_5653", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3954165_2_5654", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3954165_2_5655", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3954165_2_5656", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3954165_2_5657", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "status asthmaticus"}, {"id": "3954165_2_5658", "context": "We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.", "question": "adverse event. Treatment, theophylline and prednisone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "theophylline; prednisone"}, {"id": "17157086_5_5659", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "montelukast"}, {"id": "17157086_5_5660", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_5_5661", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_5_5662", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_5_5663", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_5_5664", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_5_5665", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_5_5666", "context": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast, which per se has well been studied as a hepatotoxic drug.", "question": "adverse event. Treatment, montelukast. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17157086_1_5667", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "food supplements; montelukast"}, {"id": "17157086_1_5668", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17157086_1_5669", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17157086_1_5670", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17157086_1_5671", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17157086_1_5672", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17157086_1_5673", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17157086_1_5674", "context": "Fatal liver failure following food supplements during chronic treatment with montelukast.", "question": "adverse event. Treatment, food supplements during chronic treatment with montelukast. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "food supplements; montelukast"}, {"id": "8627446_4_5675", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8627446_4_5676", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8627446_4_5677", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "one"}, {"id": "8627446_4_5678", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8627446_4_5679", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8627446_4_5680", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_4_5681", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_4_5682", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8627446_4_5683", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8627446_4_5684", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_4_5685", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8627446_4_5686", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nodules"}, {"id": "8627446_4_5687", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, withdrawal of methotrexate therapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8627446_4_5688", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient; the other. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8627446_4_5689", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient; the other. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8627446_4_5690", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient; the other. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "one"}, {"id": "8627446_4_5691", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient; the other. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8627446_4_5692", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Subject, one patient; the other. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8627446_4_5693", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydroxychloroquine"}, {"id": "8627446_4_5694", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_4_5695", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8627446_4_5696", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8627446_4_5697", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8627446_4_5698", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8627446_4_5699", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "nodules"}, {"id": "8627446_4_5700", "context": "The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.", "question": "potential therapeutic event. Treatment, the addition of hydroxychloroquine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12661801_2_5701", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony stimulating factor"}, {"id": "12661801_2_5702", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12661801_2_5703", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12661801_2_5704", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12661801_2_5705", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12661801_2_5706", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12661801_2_5707", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "carbimazole-induced agranulocytosis and sepsis"}, {"id": "12661801_2_5708", "context": "Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.", "question": "potential therapeutic event. Treatment, granulocyte colony stimulating factor. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3954165_1_5709", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Subject, large patient groups. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3954165_1_5710", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Subject, large patient groups. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3954165_1_5711", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Subject, large patient groups. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3954165_1_5712", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Subject, large patient groups. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3954165_1_5713", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Subject, large patient groups. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3954165_1_5714", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline; theophylline; steroids"}, {"id": "3954165_1_5715", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3954165_1_5716", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3954165_1_5717", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3954165_1_5718", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3954165_1_5719", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3954165_1_5720", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "asthma"}, {"id": "3954165_1_5721", "context": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.", "question": "adverse event. Treatment, theophylline and a combination of theophylline and steroids. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "theophylline; steroids"}, {"id": "9681092_10_5722", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Subject, our patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9681092_10_5723", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Subject, our patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9681092_10_5724", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Subject, our patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9681092_10_5725", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Subject, our patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9681092_10_5726", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Subject, our patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9681092_10_5727", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine; droperidol"}, {"id": "9681092_10_5728", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_10_5729", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_10_5730", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_10_5731", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "preoperative"}, {"id": "9681092_10_5732", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_10_5733", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_10_5734", "context": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration.", "question": "adverse event. Treatment, The combination of cyclobenzaprine and fluoxetine; preoperative droperidol administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine; droperidol"}, {"id": "7887138_2_5735", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7887138_2_5736", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7887138_2_5737", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7887138_2_5738", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7887138_2_5739", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7887138_2_5740", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "7887138_2_5741", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7887138_2_5742", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7887138_2_5743", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7887138_2_5744", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7887138_2_5745", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7887138_2_5746", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7887138_2_5747", "context": "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).", "question": "adverse event. Treatment, phenytoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9039216_3_5748", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_3_5749", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9039216_3_5750", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9039216_3_5751", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9039216_3_5752", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_3_5753", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9039216_3_5754", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9039216_3_5755", "context": "This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_3_5756", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Subject, Three patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15681911_3_5757", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Subject, Three patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15681911_3_5758", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Subject, Three patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "15681911_3_5759", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Subject, Three patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15681911_3_5760", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Subject, Three patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15681911_3_5761", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_3_5762", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_3_5763", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_3_5764", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "15681911_3_5765", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_3_5766", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_3_5767", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_3_5768", "context": "RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.", "question": "adverse event. Treatment, rofecoxib exposure. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_2_5769", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cytotoxic"}, {"id": "15112258_2_5770", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_2_5771", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_2_5772", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_2_5773", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_2_5774", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_2_5775", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_2_5776", "context": "Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas.", "question": "adverse event. Treatment, cytotoxic agents. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507211_1_5777", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Subject, 2 patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507211_1_5778", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Subject, 2 patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507211_1_5779", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Subject, 2 patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "16507211_1_5780", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Subject, 2 patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507211_1_5781", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Subject, 2 patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507211_1_5782", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "efalizumab; infliximab"}, {"id": "16507211_1_5783", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16507211_1_5784", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507211_1_5785", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507211_1_5786", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507211_1_5787", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507211_1_5788", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507211_1_5789", "context": "Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.", "question": "adverse event. Treatment, efalizumab and infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "efalizumab; infliximab"}, {"id": "12707728_1_5790", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12707728_1_5791", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12707728_1_5792", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12707728_1_5793", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12707728_1_5794", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12707728_1_5795", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12707728_1_5796", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12707728_1_5797", "context": "Intrathecal methotrexate-induced acute cerebellar syndrome.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7468565_1_5798", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Barbiturate"}, {"id": "7468565_1_5799", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_1_5800", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_1_5801", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_1_5802", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_1_5803", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_1_5804", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_1_5805", "context": "Barbiturate-induced submassive hepatic necrosis.", "question": "adverse event. Treatment, Barbiturate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9094821_1_5806", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "9094821_1_5807", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9094821_1_5808", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9094821_1_5809", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9094821_1_5810", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9094821_1_5811", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9094821_1_5812", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9094821_1_5813", "context": "The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_6_5814", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_6_5815", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_6_5816", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "2549018_6_5817", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_6_5818", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "neuroleptic-induced akathisia"}, {"id": "2549018_6_5819", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_6_5820", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_6_5821", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_6_5822", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_6_5823", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_6_5824", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_6_5825", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_6_5826", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_6_5827", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2549018_6_5828", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2549018_6_5829", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "2549018_6_5830", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2549018_6_5831", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Subject, Three patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "neuroleptic-induced akathisia"}, {"id": "2549018_6_5832", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "neuroleptic"}, {"id": "2549018_6_5833", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_6_5834", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_6_5835", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_6_5836", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_6_5837", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_6_5838", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_6_5839", "context": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "question": "adverse event. Treatment, neuroleptic. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8700794_2_5840", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_2_5841", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_2_5842", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8700794_2_5843", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "Intranasal"}, {"id": "8700794_2_5844", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_2_5845", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8700794_2_5846", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_2_5847", "context": "Intranasal desmopressin-induced hyponatremia.", "question": "adverse event. Treatment, Intranasal desmopressin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9934637_4_5848", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Subject, users. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9934637_4_5849", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Subject, users. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9934637_4_5850", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Subject, users. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9934637_4_5851", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Subject, users. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9934637_4_5852", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Subject, users. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9934637_4_5853", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "psoralen"}, {"id": "9934637_4_5854", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "9934637_4_5855", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_4_5856", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9934637_4_5857", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_4_5858", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_4_5859", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_4_5860", "context": "Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.", "question": "adverse event. Treatment, psoralen users because high doses or inappropriate use. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2204409_2_5861", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "folinic acid"}, {"id": "2204409_2_5862", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "2204409_2_5863", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2204409_2_5864", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2204409_2_5865", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_2_5866", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2204409_2_5867", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Methotrexate-induced leukoencephalopathy"}, {"id": "2204409_2_5868", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "potential therapeutic event. Treatment, high-dose folinic acid. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2204409_2_5869", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "2204409_2_5870", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2204409_2_5871", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2204409_2_5872", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2204409_2_5873", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2204409_2_5874", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2204409_2_5875", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2204409_2_5876", "context": "Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_5_5877", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Subject, 3 patients with lymphoproliferative disorders. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18765315_5_5878", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Subject, 3 patients with lymphoproliferative disorders. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18765315_5_5879", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Subject, 3 patients with lymphoproliferative disorders. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "18765315_5_5880", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Subject, 3 patients with lymphoproliferative disorders. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18765315_5_5881", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Subject, 3 patients with lymphoproliferative disorders. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18765315_5_5882", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_5_5883", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_5_5884", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_5_5885", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_5_5886", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_5_5887", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_5_5888", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "lymphoproliferative disorders"}, {"id": "18765315_5_5889", "context": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.", "question": "adverse event. Treatment, their initial infusion of rituximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_8_5890", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACE inhibitor"}, {"id": "14964753_8_5891", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_8_5892", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_8_5893", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_8_5894", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_8_5895", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_8_5896", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_8_5897", "context": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group.", "question": "adverse event. Treatment, ACE inhibitor. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11688826_3_5898", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Subject, a patient with pulmonary adenocarcinoma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11688826_3_5899", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Subject, a patient with pulmonary adenocarcinoma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11688826_3_5900", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Subject, a patient with pulmonary adenocarcinoma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11688826_3_5901", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Subject, a patient with pulmonary adenocarcinoma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11688826_3_5902", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Subject, a patient with pulmonary adenocarcinoma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11688826_3_5903", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin; vindesine"}, {"id": "11688826_3_5904", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11688826_3_5905", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11688826_3_5906", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11688826_3_5907", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11688826_3_5908", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11688826_3_5909", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary adenocarcinoma"}, {"id": "11688826_3_5910", "context": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).", "question": "adverse event. Treatment, systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "vindesine; cisplatin"}, {"id": "2196696_2_5911", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "2196696_2_5912", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2196696_2_5913", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2196696_2_5914", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2196696_2_5915", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 3 weeks"}, {"id": "2196696_2_5916", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2196696_2_5917", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2196696_2_5918", "context": "Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.", "question": "adverse event. Treatment, after 3 weeks of disulfiram. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17316160_1_5919", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Subject, a critically ill patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17316160_1_5920", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Subject, a critically ill patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17316160_1_5921", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Subject, a critically ill patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17316160_1_5922", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Subject, a critically ill patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17316160_1_5923", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Subject, a critically ill patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "critically ill"}, {"id": "17316160_1_5924", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_1_5925", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_1_5926", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17316160_1_5927", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17316160_1_5928", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_1_5929", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17316160_1_5930", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_1_5931", "context": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "potential therapeutic event. Treatment, concomitant linezolid and rifampin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "8329789_2_5932", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Subject, first five cases of; a pediatric population. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_2_5933", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Subject, first five cases of; a pediatric population. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_2_5934", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Subject, first five cases of; a pediatric population. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "8329789_2_5935", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Subject, first five cases of; a pediatric population. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_2_5936", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Subject, first five cases of; a pediatric population. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_2_5937", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "8329789_2_5938", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_2_5939", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_2_5940", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_2_5941", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_2_5942", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_2_5943", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_2_5944", "context": "OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.", "question": "adverse event. Treatment, amphotericin B overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_3_5945", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "11573852_3_5946", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_3_5947", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_3_5948", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_3_5949", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_3_5950", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_3_5951", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_3_5952", "context": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "question": "adverse event. Treatment, Amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12707728_2_5953", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12707728_2_5954", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12707728_2_5955", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12707728_2_5956", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12707728_2_5957", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12707728_2_5958", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "12707728_2_5959", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12707728_2_5960", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12707728_2_5961", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "12707728_2_5962", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12707728_2_5963", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12707728_2_5964", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12707728_2_5965", "context": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.", "question": "adverse event. Treatment, prophylactic intrathecal methotrexate administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11388112_1_5966", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Levofloxacin"}, {"id": "11388112_1_5967", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11388112_1_5968", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11388112_1_5969", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11388112_1_5970", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11388112_1_5971", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11388112_1_5972", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11388112_1_5973", "context": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.", "question": "adverse event. Treatment, Levofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_7_5974", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressants; analgesics"}, {"id": "25540831_7_5975", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_7_5976", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_7_5977", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_7_5978", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_7_5979", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_7_5980", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_7_5981", "context": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics.", "question": "adverse event. Treatment, antidepressants. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_7_5982", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "19071894_7_5983", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_7_5984", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_7_5985", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_7_5986", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_7_5987", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_7_5988", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_7_5989", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_7_5990", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluconazole"}, {"id": "19071894_7_5991", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_7_5992", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_7_5993", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_7_5994", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_7_5995", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_7_5996", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_7_5997", "context": "Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat.", "question": "adverse event. Treatment, fluconazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11319599_2_5998", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Subject, two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11319599_2_5999", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Subject, two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11319599_2_6000", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Subject, two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11319599_2_6001", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Subject, two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11319599_2_6002", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Subject, two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11319599_2_6003", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine"}, {"id": "11319599_2_6004", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11319599_2_6005", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11319599_2_6006", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11319599_2_6007", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11319599_2_6008", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11319599_2_6009", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11319599_2_6010", "context": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine-based non-myeloablative stem cell transplantation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_1_6011", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Subject, a person with Down syndrome. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8162401_1_6012", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Subject, a person with Down syndrome. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8162401_1_6013", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Subject, a person with Down syndrome. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8162401_1_6014", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Subject, a person with Down syndrome. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8162401_1_6015", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Subject, a person with Down syndrome. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "Down syndrome"}, {"id": "8162401_1_6016", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_1_6017", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_1_6018", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_1_6019", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_1_6020", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_1_6021", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_1_6022", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_1_6023", "context": "A case of fluoxetine induced seizures, in a person with Down syndrome, is described.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10405480_3_6024", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10405480_3_6025", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10405480_3_6026", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_3_6027", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10405480_3_6028", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_3_6029", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_3_6030", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_3_6031", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_3_6032", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_3_6033", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10405480_3_6034", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_3_6035", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_3_6036", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10414481_1_6037", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Diclofenac"}, {"id": "10414481_1_6038", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10414481_1_6039", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10414481_1_6040", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10414481_1_6041", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10414481_1_6042", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10414481_1_6043", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10414481_1_6044", "context": "Diclofenac-associated hepatitis.", "question": "adverse event. Treatment, Diclofenac. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12729371_1_6045", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12729371_1_6046", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12729371_1_6047", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12729371_1_6048", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12729371_1_6049", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12729371_1_6050", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12729371_1_6051", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12729371_1_6052", "context": "Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12540009_1_6053", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Subject, a nondiabetic young man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "12540009_1_6054", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Subject, a nondiabetic young man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12540009_1_6055", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Subject, a nondiabetic young man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12540009_1_6056", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Subject, a nondiabetic young man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12540009_1_6057", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Subject, a nondiabetic young man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12540009_1_6058", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Doxycycline"}, {"id": "12540009_1_6059", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12540009_1_6060", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12540009_1_6061", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12540009_1_6062", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12540009_1_6063", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12540009_1_6064", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12540009_1_6065", "context": "Doxycycline-induced hypoglycemia in a nondiabetic young man.", "question": "adverse event. Treatment, Doxycycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "968449_7_6066", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Subject, Case 2. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "968449_7_6067", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Subject, Case 2. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "968449_7_6068", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Subject, Case 2. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "968449_7_6069", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Subject, Case 2. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "968449_7_6070", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Subject, Case 2. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "968449_7_6071", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "968449_7_6072", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "968449_7_6073", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "968449_7_6074", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "968449_7_6075", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "40 months"}, {"id": "968449_7_6076", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "968449_7_6077", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "968449_7_6078", "context": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.", "question": "adverse event. Treatment, 40 months on chlorambucil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_3_6079", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "9792602_3_6080", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_3_6081", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9792602_3_6082", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9792602_3_6083", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "6 months"}, {"id": "9792602_3_6084", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9792602_3_6085", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anemia; urinary sediment; renal function"}, {"id": "9792602_3_6086", "context": "Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.", "question": "potential therapeutic event. Treatment, pranlukast. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16221163_1_6087", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Subject, kidney graft recipient.. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16221163_1_6088", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Subject, kidney graft recipient.. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16221163_1_6089", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Subject, kidney graft recipient.. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_1_6090", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Subject, kidney graft recipient.. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_1_6091", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Subject, kidney graft recipient.. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16221163_1_6092", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sirolimus"}, {"id": "16221163_1_6093", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_1_6094", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_1_6095", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_1_6096", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_1_6097", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_1_6098", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "kidney graft recipient"}, {"id": "16221163_1_6099", "context": "Sirolimus-associated hepatotoxicity in the kidney graft recipient.", "question": "adverse event. Treatment, Sirolimus. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12181031_1_6100", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_1_6101", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_1_6102", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_1_6103", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_1_6104", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_1_6105", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_1_6106", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukaemia"}, {"id": "12181031_1_6107", "context": "Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.", "question": "adverse event. Treatment, cladribine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19275460_6_6108", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Subject, patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "19275460_6_6109", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Subject, patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "19275460_6_6110", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Subject, patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "19275460_6_6111", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Subject, patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "19275460_6_6112", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Subject, patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "19275460_6_6113", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydration; broad-spectrum antibiotics"}, {"id": "19275460_6_6114", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19275460_6_6115", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19275460_6_6116", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "19275460_6_6117", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19275460_6_6118", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19275460_6_6119", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19275460_6_6120", "context": "Despite aggressive medical management, including intravenous hydration and broad-spectrum antibiotics, the patient continued to become more confused, agitated, and despondent over the subsequent 24 hours.", "question": "potential therapeutic event. Treatment, intravenous hydration and broad-spectrum antibiotics. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "hydration; broad-spectrum antibiotics"}, {"id": "17763133_1_6121", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine"}, {"id": "17763133_1_6122", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_1_6123", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17763133_1_6124", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17763133_1_6125", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_1_6126", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17763133_1_6127", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17763133_1_6128", "context": "Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, Cyclosporine is a potent inhibitor of simvastatin metabolism. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20180933_1_6129", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Subject, African children. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "20180933_1_6130", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Subject, African children. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20180933_1_6131", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Subject, African children. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20180933_1_6132", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Subject, African children. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "African"}, {"id": "20180933_1_6133", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Subject, African children. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20180933_1_6134", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "artemether; lumefantrine"}, {"id": "20180933_1_6135", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20180933_1_6136", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_1_6137", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "dispersible tablets; crushed; tablets"}, {"id": "20180933_1_6138", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_1_6139", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20180933_1_6140", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute uncomplicated Plasmodium falciparum malaria"}, {"id": "20180933_1_6141", "context": "The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.", "question": "potential therapeutic event. Treatment, artemether-lumefantrine crushed or dispersible tablets (Coartem). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "lumefantrine; artemether"}, {"id": "15827071_2_6142", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Subject, 2 cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15827071_2_6143", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Subject, 2 cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15827071_2_6144", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Subject, 2 cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "15827071_2_6145", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Subject, 2 cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15827071_2_6146", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Subject, 2 cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15827071_2_6147", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; serotonergic"}, {"id": "15827071_2_6148", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_2_6149", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_2_6150", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_2_6151", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_2_6152", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_2_6153", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_2_6154", "context": "To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports.", "question": "adverse event. Treatment, concomitant use of linezolid and serotonergic drugs. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "linezolid; serotonergic"}, {"id": "17952482_3_6155", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "17952482_3_6156", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_3_6157", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_3_6158", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_3_6159", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17952482_3_6160", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_3_6161", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17952482_3_6162", "context": "This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2357706_2_6163", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulpiride"}, {"id": "2357706_2_6164", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2357706_2_6165", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2357706_2_6166", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2357706_2_6167", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2357706_2_6168", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2357706_2_6169", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2357706_2_6170", "context": "Tardive dyskinesia induced by sulpiride.", "question": "adverse event. Treatment, sulpiride. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9758325_1_6171", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Subject, two patients with probable Alzheimer's disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9758325_1_6172", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Subject, two patients with probable Alzheimer's disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9758325_1_6173", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Subject, two patients with probable Alzheimer's disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9758325_1_6174", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Subject, two patients with probable Alzheimer's disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9758325_1_6175", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Subject, two patients with probable Alzheimer's disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9758325_1_6176", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metrifonate"}, {"id": "9758325_1_6177", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9758325_1_6178", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9758325_1_6179", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9758325_1_6180", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9758325_1_6181", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9758325_1_6182", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Alzheimer's disease"}, {"id": "9758325_1_6183", "context": "Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.", "question": "adverse event. Treatment, long-term treatment with metrifonate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_16_6184", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antithrombin III; heparin"}, {"id": "11597289_16_6185", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "High-dose"}, {"id": "11597289_16_6186", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11597289_16_6187", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11597289_16_6188", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_16_6189", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11597289_16_6190", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11597289_16_6191", "context": "High-dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin.", "question": "adverse event. Treatment, High-dose antithrombin III; heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "antithrombin III; heparin"}, {"id": "3513544_3_6192", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Subject, transplant patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3513544_3_6193", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Subject, transplant patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3513544_3_6194", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Subject, transplant patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3513544_3_6195", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Subject, transplant patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3513544_3_6196", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Subject, transplant patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "transplant"}, {"id": "3513544_3_6197", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine A"}, {"id": "3513544_3_6198", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3513544_3_6199", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3513544_3_6200", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3513544_3_6201", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3513544_3_6202", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3513544_3_6203", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3513544_3_6204", "context": "With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.", "question": "adverse event. Treatment, Cyclosporine A. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17473920_8_6205", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Subject, nine out of ten patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17473920_8_6206", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Subject, nine out of ten patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17473920_8_6207", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Subject, nine out of ten patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "nine out of ten"}, {"id": "17473920_8_6208", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Subject, nine out of ten patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17473920_8_6209", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Subject, nine out of ten patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17473920_8_6210", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nevirapine"}, {"id": "17473920_8_6211", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17473920_8_6212", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17473920_8_6213", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17473920_8_6214", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17473920_8_6215", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17473920_8_6216", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17473920_8_6217", "context": "After starting nevirapine treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and methadone dose had to be increased by 20% on average during the course of the study.", "question": "adverse event. Treatment, nevirapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19071894_4_6218", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B-deoxycholate; fluconazole"}, {"id": "19071894_4_6219", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19071894_4_6220", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19071894_4_6221", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19071894_4_6222", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19071894_4_6223", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19071894_4_6224", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19071894_4_6225", "context": "Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole.", "question": "adverse event. Treatment, amphotericin B-deoxycholate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16531969_3_6226", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Interferon-beta (IFN beta)"}, {"id": "16531969_3_6227", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16531969_3_6228", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16531969_3_6229", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16531969_3_6230", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16531969_3_6231", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16531969_3_6232", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16531969_3_6233", "context": "Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.", "question": "adverse event. Treatment, Interferon-beta. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18715650_2_6234", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18715650_2_6235", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18715650_2_6236", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18715650_2_6237", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18715650_2_6238", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18715650_2_6239", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "18715650_2_6240", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18715650_2_6241", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18715650_2_6242", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18715650_2_6243", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18715650_2_6244", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18715650_2_6245", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18715650_2_6246", "context": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16368918_1_6247", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lopinavir; ritonavir; valproic acid"}, {"id": "16368918_1_6248", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16368918_1_6249", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16368918_1_6250", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16368918_1_6251", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16368918_1_6252", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16368918_1_6253", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16368918_1_6254", "context": "OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.", "question": "adverse event. Treatment, interaction between lopinavir/ritonavir and valproic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "valproic acid; lopinavir; ritonavir"}, {"id": "6597713_4_6255", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Subject, a 70 year old female with a two year history of primary biliary cirrhosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "70 year old"}, {"id": "6597713_4_6256", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Subject, a 70 year old female with a two year history of primary biliary cirrhosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "6597713_4_6257", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Subject, a 70 year old female with a two year history of primary biliary cirrhosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6597713_4_6258", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Subject, a 70 year old female with a two year history of primary biliary cirrhosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6597713_4_6259", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Subject, a 70 year old female with a two year history of primary biliary cirrhosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6597713_4_6260", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine"}, {"id": "6597713_4_6261", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_4_6262", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_4_6263", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_4_6264", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_4_6265", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_4_6266", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "primary biliary cirrhosis"}, {"id": "6597713_4_6267", "context": "The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.", "question": "adverse event. Treatment, cholestyramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_4_6268", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Subject, a neutropenic patient with a history of chronic lymphocytic leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19423476_4_6269", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Subject, a neutropenic patient with a history of chronic lymphocytic leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19423476_4_6270", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Subject, a neutropenic patient with a history of chronic lymphocytic leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19423476_4_6271", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Subject, a neutropenic patient with a history of chronic lymphocytic leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19423476_4_6272", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Subject, a neutropenic patient with a history of chronic lymphocytic leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19423476_4_6273", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_4_6274", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_4_6275", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_4_6276", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_4_6277", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_4_6278", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_4_6279", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocytic leukemia"}, {"id": "19423476_4_6280", "context": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab.", "question": "adverse event. Treatment, alemtuzumab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_6_6281", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Subject, the patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_6_6282", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Subject, the patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_6_6283", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Subject, the patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_6_6284", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Subject, the patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_6_6285", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Subject, the patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_6_6286", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "leucovorin; methotrexate; carboxypeptidase G2"}, {"id": "22550162_6_6287", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "a dose"}, {"id": "22550162_6_6288", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_6_6289", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_6_6290", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_6_6291", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_6_6292", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_6_6293", "context": "Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2.", "question": "potential therapeutic event. Treatment, Aggressive hydration, urinary alkalinization, and leucovorin; elevated methotrexate; course of hemodialysis and a dose of carboxypeptidase G2. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2924444_1_6294", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-thyroxine"}, {"id": "2924444_1_6295", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2924444_1_6296", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2924444_1_6297", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2924444_1_6298", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2924444_1_6299", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2924444_1_6300", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2924444_1_6301", "context": "Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.", "question": "adverse event. Treatment, L-thyroxine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_7_6302", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_7_6303", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_7_6304", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_7_6305", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_7_6306", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_7_6307", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "DT-PACE; DCEP-T"}, {"id": "12149193_7_6308", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_7_6309", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_7_6310", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_7_6311", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_7_6312", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_7_6313", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12149193_7_6314", "context": "Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT.", "question": "adverse event. Treatment, DT-PACE but not DCEP-T. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17316160_5_6315", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Subject, a critically ill patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17316160_5_6316", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Subject, a critically ill patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17316160_5_6317", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Subject, a critically ill patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17316160_5_6318", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Subject, a critically ill patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17316160_5_6319", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Subject, a critically ill patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "critically ill"}, {"id": "17316160_5_6320", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; rifampin"}, {"id": "17316160_5_6321", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17316160_5_6322", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17316160_5_6323", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17316160_5_6324", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316160_5_6325", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17316160_5_6326", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17316160_5_6327", "context": "To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin.", "question": "adverse event. Treatment, concomitant linezolid and rifampin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "linezolid; rifampin"}, {"id": "8700794_4_6328", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Subject, her. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8700794_4_6329", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Subject, her. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "her"}, {"id": "8700794_4_6330", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Subject, her. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8700794_4_6331", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Subject, her. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8700794_4_6332", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Subject, her. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8700794_4_6333", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "desmopressin"}, {"id": "8700794_4_6334", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8700794_4_6335", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8700794_4_6336", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8700794_4_6337", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8700794_4_6338", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "24 hours"}, {"id": "8700794_4_6339", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8700794_4_6340", "context": "Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.", "question": "potential therapeutic event. Treatment, 24 hours of fluid restriction and cessation of desmopressin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1450506_1_6341", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "1450506_1_6342", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_1_6343", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_1_6344", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_1_6345", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_1_6346", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_1_6347", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_1_6348", "context": "An adverse reaction to IFN was strongly suspected as the cause of CHF.", "question": "adverse event. Treatment, IFN. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16164579_1_6349", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Subject, A 51-year old physically fit woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "51-year old"}, {"id": "16164579_1_6350", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Subject, A 51-year old physically fit woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16164579_1_6351", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Subject, A 51-year old physically fit woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16164579_1_6352", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Subject, A 51-year old physically fit woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16164579_1_6353", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Subject, A 51-year old physically fit woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16164579_1_6354", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "irbesartan"}, {"id": "16164579_1_6355", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16164579_1_6356", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16164579_1_6357", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "16164579_1_6358", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16164579_1_6359", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16164579_1_6360", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16164579_1_6361", "context": "A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.", "question": "adverse event. Treatment, irbesartan ingestion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_3_6362", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "platinum agents"}, {"id": "15823103_3_6363", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_3_6364", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_3_6365", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_3_6366", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_3_6367", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_3_6368", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_3_6369", "context": "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.", "question": "adverse event. Treatment, total dose of previously administered platinum agents. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_4_6370", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Lansoprazole"}, {"id": "11978156_4_6371", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_4_6372", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_4_6373", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_4_6374", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_4_6375", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_4_6376", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_4_6377", "context": "Lansoprazole-induced thrombocytopenia.", "question": "adverse event. Treatment, Lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15965422_2_6378", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "15965422_2_6379", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15965422_2_6380", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15965422_2_6381", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15965422_2_6382", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15965422_2_6383", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15965422_2_6384", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15965422_2_6385", "context": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.", "question": "adverse event. Treatment, interferon alfa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_1_6386", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "droperidol; cytochrome P450"}, {"id": "9681092_1_6387", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_1_6388", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_1_6389", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_1_6390", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_1_6391", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_1_6392", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_1_6393", "context": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.", "question": "adverse event. Treatment, droperidol; cytochrome P450. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17952482_2_6394", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sulfasalazine"}, {"id": "17952482_2_6395", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17952482_2_6396", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17952482_2_6397", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17952482_2_6398", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17952482_2_6399", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17952482_2_6400", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17952482_2_6401", "context": "Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.", "question": "adverse event. Treatment, Sulfasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11335880_4_6402", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Subject, a patient with the specific genetic susceptibility associated with the thyroid disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_4_6403", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Subject, a patient with the specific genetic susceptibility associated with the thyroid disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_4_6404", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Subject, a patient with the specific genetic susceptibility associated with the thyroid disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_4_6405", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Subject, a patient with the specific genetic susceptibility associated with the thyroid disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_4_6406", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Subject, a patient with the specific genetic susceptibility associated with the thyroid disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "specific genetic susceptibility"}, {"id": "11335880_4_6407", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "11335880_4_6408", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_4_6409", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_4_6410", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_4_6411", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_4_6412", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_4_6413", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic viral C hepatitis"}, {"id": "11335880_4_6414", "context": "OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha (IFN-alpha) treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_2_6415", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_2_6416", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_2_6417", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_2_6418", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_2_6419", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_2_6420", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_2_6421", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_2_6422", "context": "Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_1_6423", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "linezolid; Serotonin"}, {"id": "15827071_1_6424", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15827071_1_6425", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15827071_1_6426", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15827071_1_6427", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_1_6428", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15827071_1_6429", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15827071_1_6430", "context": "Serotonin toxicity associated with concomitant use of linezolid.", "question": "adverse event. Treatment, concomitant use of linezolid; Serotonin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "Serotonin; linezolid"}, {"id": "16221163_3_6431", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Subject, the case of a 30-year-old male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "30-year-old"}, {"id": "16221163_3_6432", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Subject, the case of a 30-year-old male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "16221163_3_6433", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Subject, the case of a 30-year-old male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_3_6434", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Subject, the case of a 30-year-old male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_3_6435", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Subject, the case of a 30-year-old male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16221163_3_6436", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "steroids; cyclosporin A; SRL"}, {"id": "16221163_3_6437", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_3_6438", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_3_6439", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_3_6440", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_3_6441", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_3_6442", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_3_6443", "context": "We report the case of a 30-year-old male after kidney transplantation, treated with steroids, cyclosporin A and SRL, with steroid-resistant acute rejection in anamnesis.", "question": "adverse event. Treatment, kidney transplantation, treated with steroids, cyclosporin A and SRL. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "steroids; cyclosporin A; SRL"}, {"id": "8933322_2_6444", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Subject, Infants. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "Infants"}, {"id": "8933322_2_6445", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Subject, Infants. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8933322_2_6446", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Subject, Infants. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8933322_2_6447", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Subject, Infants. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8933322_2_6448", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Subject, Infants. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8933322_2_6449", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrate"}, {"id": "8933322_2_6450", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8933322_2_6451", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8933322_2_6452", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8933322_2_6453", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8933322_2_6454", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8933322_2_6455", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8933322_2_6456", "context": "Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.", "question": "adverse event. Treatment, nitrate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16580907_2_6457", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Subject, A 72-year-old woman with renal insufficiency. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "72-year-old"}, {"id": "16580907_2_6458", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Subject, A 72-year-old woman with renal insufficiency. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16580907_2_6459", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Subject, A 72-year-old woman with renal insufficiency. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16580907_2_6460", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Subject, A 72-year-old woman with renal insufficiency. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16580907_2_6461", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Subject, A 72-year-old woman with renal insufficiency. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal insufficiency"}, {"id": "16580907_2_6462", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pilsicainide; cetirizine"}, {"id": "16580907_2_6463", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "150 mg/d; 20 mg/d"}, {"id": "16580907_2_6464", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16580907_2_6465", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral; oral"}, {"id": "16580907_2_6466", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 days"}, {"id": "16580907_2_6467", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16580907_2_6468", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16580907_2_6469", "context": "A 72-year-old woman with renal insufficiency who was taking oral pilsicainide (150 mg/d) complained of feeling faint 3 days after she was prescribed oral cetirizine (20 mg/d).", "question": "adverse event. Treatment, taking oral pilsicainide (150 mg/d); 3 days after she was prescribed oral cetirizine (20 mg/d). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cetirizine; pilsicainide"}, {"id": "16615675_2_6470", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxychloroquine"}, {"id": "16615675_2_6471", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_2_6472", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_2_6473", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_2_6474", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_2_6475", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16615675_2_6476", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16615675_2_6477", "context": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.", "question": "adverse event. Treatment, Chronic hydroxychloroquine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10610018_3_6478", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10610018_3_6479", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10610018_3_6480", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10610018_3_6481", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10610018_3_6482", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10610018_3_6483", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine; risperidone"}, {"id": "10610018_3_6484", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10610018_3_6485", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10610018_3_6486", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10610018_3_6487", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10610018_3_6488", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10610018_3_6489", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "elevated serum triglyceride levels"}, {"id": "10610018_3_6490", "context": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.", "question": "adverse event. Treatment, clozapine was switched to risperidone and vice versa. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12763355_2_6491", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12763355_2_6492", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12763355_2_6493", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12763355_2_6494", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12763355_2_6495", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12763355_2_6496", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "12763355_2_6497", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12763355_2_6498", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12763355_2_6499", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12763355_2_6500", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12763355_2_6501", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12763355_2_6502", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12763355_2_6503", "context": "Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.", "question": "adverse event. Treatment, 5-aminosalicylic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_7_6504", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Subject, patient 1 (the only survivor). What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8329789_7_6505", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Subject, patient 1 (the only survivor). What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8329789_7_6506", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Subject, patient 1 (the only survivor). What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8329789_7_6507", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Subject, patient 1 (the only survivor). What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8329789_7_6508", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Subject, patient 1 (the only survivor). What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8329789_7_6509", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Hydrocortisone; verapamil"}, {"id": "8329789_7_6510", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8329789_7_6511", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8329789_7_6512", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8329789_7_6513", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_7_6514", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8329789_7_6515", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_7_6516", "context": "Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor).", "question": "potential therapeutic event. Treatment, Hydrocortisone prophylaxis and verapamil therapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "160443_2_6517", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clioquinol"}, {"id": "160443_2_6518", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "160443_2_6519", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "160443_2_6520", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "160443_2_6521", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "160443_2_6522", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "160443_2_6523", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "160443_2_6524", "context": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.", "question": "adverse event. Treatment, clioquinol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12729371_2_6525", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Subject, a case of AILD in an 80-year-old male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "80-year-old"}, {"id": "12729371_2_6526", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Subject, a case of AILD in an 80-year-old male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "12729371_2_6527", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Subject, a case of AILD in an 80-year-old male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12729371_2_6528", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Subject, a case of AILD in an 80-year-old male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12729371_2_6529", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Subject, a case of AILD in an 80-year-old male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "AILD"}, {"id": "12729371_2_6530", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "12729371_2_6531", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12729371_2_6532", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12729371_2_6533", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12729371_2_6534", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12729371_2_6535", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12729371_2_6536", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12729371_2_6537", "context": "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.", "question": "adverse event. Treatment, doxycycline administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16092915_2_6538", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Subject, an adolescent girl with a mitochondrial disorder and depression. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "16092915_2_6539", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Subject, an adolescent girl with a mitochondrial disorder and depression. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "16092915_2_6540", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Subject, an adolescent girl with a mitochondrial disorder and depression. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16092915_2_6541", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Subject, an adolescent girl with a mitochondrial disorder and depression. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16092915_2_6542", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Subject, an adolescent girl with a mitochondrial disorder and depression. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16092915_2_6543", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "16092915_2_6544", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16092915_2_6545", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16092915_2_6546", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16092915_2_6547", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16092915_2_6548", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16092915_2_6549", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "mitochondrial disorder; depression"}, {"id": "16092915_2_6550", "context": "OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.", "question": "adverse event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9733234_1_6551", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Subject, Young children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "Young; children"}, {"id": "9733234_1_6552", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Subject, Young children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9733234_1_6553", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Subject, Young children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9733234_1_6554", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Subject, Young children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9733234_1_6555", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Subject, Young children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9733234_1_6556", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "9733234_1_6557", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9733234_1_6558", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9733234_1_6559", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9733234_1_6560", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9733234_1_6561", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9733234_1_6562", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9733234_1_6563", "context": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.", "question": "adverse event. Treatment, undergoing cisplatin chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12692521_1_6564", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor"}, {"id": "12692521_1_6565", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12692521_1_6566", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12692521_1_6567", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12692521_1_6568", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12692521_1_6569", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12692521_1_6570", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12692521_1_6571", "context": "Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).", "question": "adverse event. Treatment, granulocyte colony-stimulating factor (G-CSF). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_2_6572", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Subject, Two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_2_6573", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Subject, Two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_2_6574", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Subject, Two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "16449538_2_6575", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Subject, Two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_2_6576", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Subject, Two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_2_6577", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_2_6578", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_2_6579", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_2_6580", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "16449538_2_6581", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_2_6582", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_2_6583", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_2_6584", "context": "CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.", "question": "adverse event. Treatment, ifosfamide-containing chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_3_6585", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrine"}, {"id": "10456487_3_6586", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_3_6587", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10456487_3_6588", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10456487_3_6589", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_3_6590", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10456487_3_6591", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10456487_3_6592", "context": "One of the monohydroxy-metabolites has been incriminated with tacrine-induced hepatotoxicity.", "question": "adverse event. Treatment, tacrine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20020238_1_6593", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Subject, chronic hepatitis C patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20020238_1_6594", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Subject, chronic hepatitis C patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20020238_1_6595", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Subject, chronic hepatitis C patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20020238_1_6596", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Subject, chronic hepatitis C patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20020238_1_6597", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Subject, chronic hepatitis C patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20020238_1_6598", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ribavirin; pegylated interferon"}, {"id": "20020238_1_6599", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20020238_1_6600", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20020238_1_6601", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20020238_1_6602", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20020238_1_6603", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20020238_1_6604", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "20020238_1_6605", "context": "BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.", "question": "adverse event. Treatment, pegylated interferon and ribavirin combination therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "ribavirin; pegylated interferon"}, {"id": "12149193_1_6606", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Subject, myeloma patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_1_6607", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Subject, myeloma patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_1_6608", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Subject, myeloma patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_1_6609", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Subject, myeloma patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_1_6610", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Subject, myeloma patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_1_6611", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin; thalidomide"}, {"id": "12149193_1_6612", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_1_6613", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_1_6614", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_1_6615", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_1_6616", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_1_6617", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12149193_1_6618", "context": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.", "question": "adverse event. Treatment, doxorubicin; thalidomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_2_6619", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Subject, end stage renal disease (ESRD) patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_2_6620", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Subject, end stage renal disease (ESRD) patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_2_6621", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Subject, end stage renal disease (ESRD) patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_2_6622", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Subject, end stage renal disease (ESRD) patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_2_6623", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Subject, end stage renal disease (ESRD) patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15053046_2_6624", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_2_6625", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_2_6626", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_2_6627", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_2_6628", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_2_6629", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "prolonged"}, {"id": "15053046_2_6630", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "end stage renal disease (ESRD)"}, {"id": "15053046_2_6631", "context": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.", "question": "adverse event. Treatment, prolonged vancomycin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_4_6632", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_4_6633", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_4_6634", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_4_6635", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_4_6636", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "a short course"}, {"id": "8551001_4_6637", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_4_6638", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_4_6639", "context": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.", "question": "adverse event. Treatment, a short course of azathioprine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3967536_1_6640", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nifedipine"}, {"id": "3967536_1_6641", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3967536_1_6642", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3967536_1_6643", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3967536_1_6644", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3967536_1_6645", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3967536_1_6646", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary hypertension"}, {"id": "3967536_1_6647", "context": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension.", "question": "adverse event. Treatment, nifedipine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9709726_1_6648", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Subject, children and adolescents with chronic hematologic and oncologic diseases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children; adolescents"}, {"id": "9709726_1_6649", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Subject, children and adolescents with chronic hematologic and oncologic diseases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9709726_1_6650", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Subject, children and adolescents with chronic hematologic and oncologic diseases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9709726_1_6651", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Subject, children and adolescents with chronic hematologic and oncologic diseases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9709726_1_6652", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Subject, children and adolescents with chronic hematologic and oncologic diseases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9709726_1_6653", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diphenhydramine"}, {"id": "9709726_1_6654", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9709726_1_6655", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9709726_1_6656", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9709726_1_6657", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9709726_1_6658", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9709726_1_6659", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hematologic and oncologic diseases"}, {"id": "9709726_1_6660", "context": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.", "question": "adverse event. Treatment, diphenhydramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_1_6661", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_1_6662", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_1_6663", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_1_6664", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_1_6665", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_1_6666", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_1_6667", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic nephrogenic diabetes insipidus"}, {"id": "8739289_1_6668", "context": "Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8636829_1_6669", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Subject, a boy with systemic juvenile rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8636829_1_6670", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Subject, a boy with systemic juvenile rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "8636829_1_6671", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Subject, a boy with systemic juvenile rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8636829_1_6672", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Subject, a boy with systemic juvenile rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8636829_1_6673", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Subject, a boy with systemic juvenile rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8636829_1_6674", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8636829_1_6675", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8636829_1_6676", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8636829_1_6677", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8636829_1_6678", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8636829_1_6679", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8636829_1_6680", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "systemic juvenile rheumatoid arthritis"}, {"id": "8636829_1_6681", "context": "A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.", "question": "adverse event. Treatment, methotrexate toxicity. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_1_6682", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6507240_1_6683", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6507240_1_6684", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6507240_1_6685", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6507240_1_6686", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6507240_1_6687", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_1_6688", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_1_6689", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_1_6690", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_1_6691", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_1_6692", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_1_6693", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_1_6694", "context": "Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.", "question": "adverse event. Treatment, lorcainide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8186884_2_6695", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_2_6696", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_2_6697", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_2_6698", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8186884_2_6699", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_2_6700", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_2_6701", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8186884_2_6702", "context": "Electrical proarrhythmia with procainamide: a new ICD-drug interaction.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_2_6703", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_2_6704", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_2_6705", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_2_6706", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_2_6707", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_2_6708", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_2_6709", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_2_6710", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, concomitant cyclobenzaprine and fluoxetine administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_2_6711", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "droperidol"}, {"id": "9681092_2_6712", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_2_6713", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_2_6714", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_2_6715", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_2_6716", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_2_6717", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_2_6718", "context": "To report a case of QT prolongation associated with concomitant cyclobenzaprine and fluoxetine administration followed by torsade de pointes potentiated by droperidol.", "question": "adverse event. Treatment, droperidol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_3_6719", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine"}, {"id": "6597713_3_6720", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_3_6721", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6597713_3_6722", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6597713_3_6723", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_3_6724", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6597713_3_6725", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_3_6726", "context": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.", "question": "adverse event. Treatment, cholestyramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_1_6727", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "8551001_1_6728", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_1_6729", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_1_6730", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_1_6731", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_1_6732", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_1_6733", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_1_6734", "context": "Azathioprine can cause severe myelosuppression.", "question": "adverse event. Treatment, Azathioprine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7789881_1_6735", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7789881_1_6736", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7789881_1_6737", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7789881_1_6738", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7789881_1_6739", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7789881_1_6740", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "7789881_1_6741", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7789881_1_6742", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7789881_1_6743", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7789881_1_6744", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7789881_1_6745", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7789881_1_6746", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "7789881_1_6747", "context": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.", "question": "adverse event. Treatment, tamoxifen for breast cancer. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_4_6748", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_4_6749", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_4_6750", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_4_6751", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_4_6752", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_4_6753", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_4_6754", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_4_6755", "context": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.", "question": "adverse event. Treatment, capecitabine or the intermediate metabolite. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10465148_1_6756", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "10465148_1_6757", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10465148_1_6758", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10465148_1_6759", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "10465148_1_6760", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10465148_1_6761", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10465148_1_6762", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10465148_1_6763", "context": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "question": "adverse event. Treatment, intrathecal methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19512997_1_6764", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Divalproex sodium"}, {"id": "19512997_1_6765", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19512997_1_6766", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19512997_1_6767", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19512997_1_6768", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19512997_1_6769", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19512997_1_6770", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19512997_1_6771", "context": "Divalproex sodium-induced eosinophilic pleural effusion.", "question": "adverse event. Treatment, Divalproex sodium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10405480_1_6772", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Subject, A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "26-year-old"}, {"id": "10405480_1_6773", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Subject, A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "10405480_1_6774", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Subject, A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_1_6775", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Subject, A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Japanese"}, {"id": "10405480_1_6776", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Subject, A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_1_6777", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_1_6778", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_1_6779", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_1_6780", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_1_6781", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "one day"}, {"id": "10405480_1_6782", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_1_6783", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_1_6784", "context": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_1_6785", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Subject, a patient with AIDS. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11573852_1_6786", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Subject, a patient with AIDS. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11573852_1_6787", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Subject, a patient with AIDS. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_1_6788", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Subject, a patient with AIDS. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11573852_1_6789", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Subject, a patient with AIDS. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "AIDS"}, {"id": "11573852_1_6790", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "11573852_1_6791", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_1_6792", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_1_6793", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_1_6794", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_1_6795", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_1_6796", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_1_6797", "context": "Amphotericin B-induced seizures in a patient with AIDS.", "question": "adverse event. Treatment, Amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2154663_2_6798", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Subject, this patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2154663_2_6799", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Subject, this patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2154663_2_6800", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Subject, this patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2154663_2_6801", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Subject, this patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2154663_2_6802", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Subject, this patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2154663_2_6803", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aminoglutethimide; irradiation"}, {"id": "2154663_2_6804", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2154663_2_6805", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2154663_2_6806", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2154663_2_6807", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2154663_2_6808", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2154663_2_6809", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2154663_2_6810", "context": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.", "question": "adverse event. Treatment, Concomitant irradiation; aminoglutethimide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "irradiation; aminoglutethimide"}, {"id": "8996514_1_6811", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Subject, A 59-year-old man with known neurocysticercosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "59-year-old"}, {"id": "8996514_1_6812", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Subject, A 59-year-old man with known neurocysticercosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "8996514_1_6813", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Subject, A 59-year-old man with known neurocysticercosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8996514_1_6814", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Subject, A 59-year-old man with known neurocysticercosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8996514_1_6815", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Subject, A 59-year-old man with known neurocysticercosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8996514_1_6816", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "8996514_1_6817", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8996514_1_6818", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8996514_1_6819", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8996514_1_6820", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8996514_1_6821", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8996514_1_6822", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neurocysticercosis"}, {"id": "8996514_1_6823", "context": "CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.", "question": "adverse event. Treatment, during praziquantel therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12181031_3_6824", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Subject, a 73-year-old woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "73-year-old"}, {"id": "12181031_3_6825", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Subject, a 73-year-old woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12181031_3_6826", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Subject, a 73-year-old woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12181031_3_6827", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Subject, a 73-year-old woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12181031_3_6828", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Subject, a 73-year-old woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12181031_3_6829", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_3_6830", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_3_6831", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_3_6832", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_3_6833", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_3_6834", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_3_6835", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12181031_3_6836", "context": "We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17083890_8_6837", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adriamycin; vincristine"}, {"id": "17083890_8_6838", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17083890_8_6839", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17083890_8_6840", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17083890_8_6841", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17083890_8_6842", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17083890_8_6843", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17083890_8_6844", "context": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy, which further pointed out towards adriamycin and vincristine as possible etiologic agents.", "question": "adverse event. Treatment, adriamycin and vincristine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "adriamycin; vincristine"}, {"id": "24679099_7_6845", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab; irinotecan"}, {"id": "24679099_7_6846", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "24679099_7_6847", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "24679099_7_6848", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "24679099_7_6849", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24679099_7_6850", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "24679099_7_6851", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "24679099_7_6852", "context": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.", "question": "adverse event. Treatment, bevacizumab and irinotecan. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "bevacizumab; irinotecan"}, {"id": "3609047_2_6853", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3609047_2_6854", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3609047_2_6855", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3609047_2_6856", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3609047_2_6857", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3609047_2_6858", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3609047_2_6859", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3609047_2_6860", "context": "Torsade de pointes represents a potential complication of chronic amiodarone therapy.", "question": "adverse event. Treatment, chronic amiodarone therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9988365_1_6861", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_1_6862", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_1_6863", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9988365_1_6864", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9988365_1_6865", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_1_6866", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9988365_1_6867", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9988365_1_6868", "context": "Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).", "question": "adverse event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_3_6869", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Subject, a 69-year-old man who was admitted for depression with psychosis. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "69-year-old"}, {"id": "17667887_3_6870", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Subject, a 69-year-old man who was admitted for depression with psychosis. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "17667887_3_6871", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Subject, a 69-year-old man who was admitted for depression with psychosis. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17667887_3_6872", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Subject, a 69-year-old man who was admitted for depression with psychosis. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17667887_3_6873", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Subject, a 69-year-old man who was admitted for depression with psychosis. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17667887_3_6874", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "trazodone; risperidone; sertraline"}, {"id": "17667887_3_6875", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_3_6876", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17667887_3_6877", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17667887_3_6878", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_3_6879", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17667887_3_6880", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "depression with psychosis"}, {"id": "17667887_3_6881", "context": "The first case is a 69-year-old man who was admitted for depression with psychosis and treated with trazodone, risperidone, and sertraline.", "question": "potential therapeutic event. Treatment, trazodone, risperidone, and sertraline. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "risperidone; sertraline; trazodone"}, {"id": "6221046_2_6882", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "6221046_2_6883", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6221046_2_6884", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6221046_2_6885", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6221046_2_6886", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6221046_2_6887", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6221046_2_6888", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6221046_2_6889", "context": "Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.", "question": "adverse event. Treatment, propylthiouracil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_15_6890", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrine"}, {"id": "10456487_15_6891", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_15_6892", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10456487_15_6893", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10456487_15_6894", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_15_6895", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10456487_15_6896", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10456487_15_6897", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "adverse event. Treatment, tacrine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10456487_15_6898", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluvoxamine"}, {"id": "10456487_15_6899", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10456487_15_6900", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10456487_15_6901", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10456487_15_6902", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10456487_15_6903", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10456487_15_6904", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "tacrine-induced hepatotoxicity"}, {"id": "10456487_15_6905", "context": "Whether concomitant fluvoxamine treatment reduces tacrine-induced hepatotoxicity needs further study.", "question": "potential therapeutic event. Treatment, concomitant fluvoxamine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3718111_3_6906", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Subject, a patient with radiation pneumonitis and glaucoma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3718111_3_6907", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Subject, a patient with radiation pneumonitis and glaucoma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3718111_3_6908", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Subject, a patient with radiation pneumonitis and glaucoma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3718111_3_6909", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Subject, a patient with radiation pneumonitis and glaucoma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3718111_3_6910", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Subject, a patient with radiation pneumonitis and glaucoma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "glaucoma"}, {"id": "3718111_3_6911", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "3718111_3_6912", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_3_6913", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_3_6914", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_3_6915", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_3_6916", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_3_6917", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "radiation pneumonitis"}, {"id": "3718111_3_6918", "context": "Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.", "question": "adverse event. Treatment, prednisone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_2_6919", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pancrease MT 16; enzymes"}, {"id": "9651465_2_6920", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_2_6921", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_2_6922", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_2_6923", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 to 2 hours"}, {"id": "9651465_2_6924", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_2_6925", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_2_6926", "context": "She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.", "question": "adverse event. Treatment, enzymes. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_2_6927", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Subject, two clinical case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15701285_2_6928", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Subject, two clinical case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15701285_2_6929", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Subject, two clinical case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15701285_2_6930", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Subject, two clinical case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15701285_2_6931", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Subject, two clinical case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15701285_2_6932", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gliadel wafers"}, {"id": "15701285_2_6933", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_2_6934", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_2_6935", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "implantation"}, {"id": "15701285_2_6936", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_2_6937", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_2_6938", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15701285_2_6939", "context": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.", "question": "adverse event. Treatment, implantation of Gliadel wafers. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_4_6940", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antifungal agent"}, {"id": "15279668_4_6941", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_4_6942", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_4_6943", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15279668_4_6944", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15279668_4_6945", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_4_6946", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_4_6947", "context": "At this point, a new antifungal agent had been commenced, suggesting a possible drug interaction enhancing the risk of known neurological toxicity with this regime.", "question": "adverse event. Treatment, a new antifungal agent. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15941649_2_6948", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Subject, pediatric patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "15941649_2_6949", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Subject, pediatric patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15941649_2_6950", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Subject, pediatric patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15941649_2_6951", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Subject, pediatric patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15941649_2_6952", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Subject, pediatric patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15941649_2_6953", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "VGB"}, {"id": "15941649_2_6954", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15941649_2_6955", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15941649_2_6956", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15941649_2_6957", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15941649_2_6958", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15941649_2_6959", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15941649_2_6960", "context": "The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.", "question": "adverse event. Treatment, VGB. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19097599_2_6961", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Subject, patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19097599_2_6962", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Subject, patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19097599_2_6963", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Subject, patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19097599_2_6964", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Subject, patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19097599_2_6965", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Subject, patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19097599_2_6966", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "19097599_2_6967", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19097599_2_6968", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19097599_2_6969", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19097599_2_6970", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10-day"}, {"id": "19097599_2_6971", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19097599_2_6972", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "BCR-ABL (ela2) positive acute lymphoblastic leukemia"}, {"id": "19097599_2_6973", "context": "We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.", "question": "adverse event. Treatment, 10-day treatment with imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9792602_2_6974", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pranlukast"}, {"id": "9792602_2_6975", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9792602_2_6976", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9792602_2_6977", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9792602_2_6978", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9792602_2_6979", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9792602_2_6980", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9792602_2_6981", "context": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.", "question": "adverse event. Treatment, pranlukast. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23471710_2_6982", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; omeprazole"}, {"id": "23471710_2_6983", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23471710_2_6984", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23471710_2_6985", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23471710_2_6986", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23471710_2_6987", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23471710_2_6988", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a Helicobacter pylori infection"}, {"id": "23471710_2_6989", "context": "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone.", "question": "adverse event. Treatment, clarithromycin and omeprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; omeprazole"}, {"id": "14660304_4_6990", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Subject, first two patients in our institution. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "two"}, {"id": "14660304_4_6991", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Subject, first two patients in our institution. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14660304_4_6992", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Subject, first two patients in our institution. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14660304_4_6993", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Subject, first two patients in our institution. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14660304_4_6994", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Subject, first two patients in our institution. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14660304_4_6995", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone; dexamethasone"}, {"id": "14660304_4_6996", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "10 mg/m"}, {"id": "14660304_4_6997", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "day"}, {"id": "14660304_4_6998", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14660304_4_6999", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 weeks"}, {"id": "14660304_4_7000", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14660304_4_7001", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14660304_4_7002", "context": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.", "question": "adverse event. Treatment, treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_4_7003", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glyburide; chlorpropamide"}, {"id": "6510223_4_7004", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_4_7005", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_4_7006", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_4_7007", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_4_7008", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_4_7009", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6510223_4_7010", "context": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia.", "question": "adverse event. Treatment, glyburide and chlorpropamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; chlorpropamide"}, {"id": "10586009_1_7011", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Subject, neonate. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "neonate"}, {"id": "10586009_1_7012", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Subject, neonate. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10586009_1_7013", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Subject, neonate. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10586009_1_7014", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Subject, neonate. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10586009_1_7015", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Subject, neonate. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10586009_1_7016", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Codeine"}, {"id": "10586009_1_7017", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10586009_1_7018", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10586009_1_7019", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10586009_1_7020", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10586009_1_7021", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10586009_1_7022", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10586009_1_7023", "context": "Codeine intoxication in the neonate.", "question": "adverse event. Treatment, Codeine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9760614_1_7024", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tPA"}, {"id": "9760614_1_7025", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9760614_1_7026", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9760614_1_7027", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injections"}, {"id": "9760614_1_7028", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9760614_1_7029", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9760614_1_7030", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9760614_1_7031", "context": "However, 1 eye had vitreous hemorrhage after repeated injections of tPA.", "question": "adverse event. Treatment, repeated injections of tPA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1389744_2_7032", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adrenaline"}, {"id": "1389744_2_7033", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "chronic overuse"}, {"id": "1389744_2_7034", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1389744_2_7035", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "inhaler"}, {"id": "1389744_2_7036", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1389744_2_7037", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1389744_2_7038", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1389744_2_7039", "context": "Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.", "question": "adverse event. Treatment, chronic overuse of an adrenaline inhaler. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14530108_3_7040", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FK506"}, {"id": "14530108_3_7041", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14530108_3_7042", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14530108_3_7043", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14530108_3_7044", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14530108_3_7045", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14530108_3_7046", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14530108_3_7047", "context": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.", "question": "adverse event. Treatment, FK506 after any organ transplantation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6826112_2_7048", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Subject, Thirty patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6826112_2_7049", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Subject, Thirty patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6826112_2_7050", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Subject, Thirty patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Thirty"}, {"id": "6826112_2_7051", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Subject, Thirty patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6826112_2_7052", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Subject, Thirty patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6826112_2_7053", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclofenil"}, {"id": "6826112_2_7054", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6826112_2_7055", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6826112_2_7056", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6826112_2_7057", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6826112_2_7058", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6826112_2_7059", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6826112_2_7060", "context": "Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.", "question": "adverse event. Treatment, cyclofenil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19275460_3_7061", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "serotonergic drug"}, {"id": "19275460_3_7062", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19275460_3_7063", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19275460_3_7064", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19275460_3_7065", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19275460_3_7066", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19275460_3_7067", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19275460_3_7068", "context": "Though serotonin syndrome is most often associated with ingestion of more than one serotonergic drug, many other mechanisms have been associated with serotonergic excess.", "question": "adverse event. Treatment, ingestion of more than one serotonergic drug. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2276822_1_7069", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillin G; gentamicin; cefazolin"}, {"id": "2276822_1_7070", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2276822_1_7071", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2276822_1_7072", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2276822_1_7073", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2276822_1_7074", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2276822_1_7075", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2276822_1_7076", "context": "Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.", "question": "adverse event. Treatment, penicillin G; gentamicin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "penicillin G; gentamicin"}, {"id": "15944830_4_7077", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_4_7078", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_4_7079", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_4_7080", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_4_7081", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_4_7082", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_4_7083", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_4_7084", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_4_7085", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_4_7086", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_4_7087", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_4_7088", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_4_7089", "context": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.", "question": "adverse event. Treatment, IFN. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_6_7090", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_6_7091", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_6_7092", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_6_7093", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_6_7094", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_6_7095", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "18562412_6_7096", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_6_7097", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_6_7098", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_6_7099", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_6_7100", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_6_7101", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_6_7102", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18562412_6_7103", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_6_7104", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_6_7105", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_6_7106", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_6_7107", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Subject, The third patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_6_7108", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_6_7109", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_6_7110", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_6_7111", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18562412_6_7112", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_6_7113", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_6_7114", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "akathisia"}, {"id": "18562412_6_7115", "context": "The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.", "question": "adverse event. Treatment, switching to olanzapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_1_7116", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Chlorpropamide"}, {"id": "6510223_1_7117", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_1_7118", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_1_7119", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_1_7120", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_1_7121", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_1_7122", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6510223_1_7123", "context": "Chlorpropamide-induced hemolytic anemia.", "question": "adverse event. Treatment, Chlorpropamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_3_7124", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine; phenytoin"}, {"id": "16099004_3_7125", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_3_7126", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_3_7127", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_3_7128", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_3_7129", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_3_7130", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16099004_3_7131", "context": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use.", "question": "adverse event. Treatment, quinine treatment in the context of concurrent phenytoin use. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "15719254_2_7132", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "RA"}, {"id": "15719254_2_7133", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_2_7134", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_2_7135", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_2_7136", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_2_7137", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_2_7138", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_2_7139", "context": "It is likely that RA contributed to the deterioration in renal function in these patients.", "question": "adverse event. Treatment, RA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6303138_1_7140", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "marijuana; nortriptyline"}, {"id": "6303138_1_7141", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6303138_1_7142", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6303138_1_7143", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6303138_1_7144", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6303138_1_7145", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6303138_1_7146", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6303138_1_7147", "context": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.", "question": "adverse event. Treatment, marijuana and nortriptyline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "marijuana; nortriptyline"}, {"id": "17373180_1_7148", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab; Infliximab"}, {"id": "17373180_1_7149", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17373180_1_7150", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17373180_1_7151", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17373180_1_7152", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17373180_1_7153", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17373180_1_7154", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17373180_1_7155", "context": "Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.", "question": "adverse event. Treatment, infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14723711_1_7156", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "14723711_1_7157", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14723711_1_7158", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14723711_1_7159", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14723711_1_7160", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14723711_1_7161", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14723711_1_7162", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14723711_1_7163", "context": "A new type of minocycline-induced cutaneous hyperpigmentation.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_3_7164", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_3_7165", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_3_7166", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_3_7167", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9491301_3_7168", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_3_7169", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_3_7170", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_3_7171", "context": "Stroke is an infrequent but recognized complication of heroin addiction.", "question": "adverse event. Treatment, heroin addiction. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2461837_1_7172", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Subject, an AIDS patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2461837_1_7173", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Subject, an AIDS patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2461837_1_7174", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Subject, an AIDS patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2461837_1_7175", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Subject, an AIDS patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2461837_1_7176", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Subject, an AIDS patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2461837_1_7177", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "2461837_1_7178", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2461837_1_7179", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2461837_1_7180", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2461837_1_7181", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2461837_1_7182", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2461837_1_7183", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "2461837_1_7184", "context": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.", "question": "adverse event. Treatment, bleomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_1_7185", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Subject, Case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6625005_1_7186", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Subject, Case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6625005_1_7187", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Subject, Case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6625005_1_7188", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Subject, Case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6625005_1_7189", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Subject, Case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6625005_1_7190", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amoxapine"}, {"id": "6625005_1_7191", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_1_7192", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_1_7193", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_1_7194", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_1_7195", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_1_7196", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_1_7197", "context": "Case report of withdrawal dyskinesia associated with amoxapine.", "question": "adverse event. Treatment, amoxapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21350204_2_7198", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Subject, patients with ischemic stroke. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21350204_2_7199", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Subject, patients with ischemic stroke. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21350204_2_7200", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Subject, patients with ischemic stroke. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21350204_2_7201", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Subject, patients with ischemic stroke. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21350204_2_7202", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Subject, patients with ischemic stroke. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21350204_2_7203", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; ntravenous tissue plasminogen activator"}, {"id": "21350204_2_7204", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21350204_2_7205", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21350204_2_7206", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21350204_2_7207", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21350204_2_7208", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21350204_2_7209", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ischemic stroke"}, {"id": "21350204_2_7210", "context": "Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.", "question": "adverse event. Treatment, receiving intravenous tissue plasminogen activator; preadmission warfarin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; ntravenous tissue plasminogen activator"}, {"id": "7035691_1_7211", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7035691_1_7212", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7035691_1_7213", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7035691_1_7214", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7035691_1_7215", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7035691_1_7216", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "angiotensin I-converting enzyme inhibitor"}, {"id": "7035691_1_7217", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_1_7218", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7035691_1_7219", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7035691_1_7220", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_1_7221", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7035691_1_7222", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal artery stenosis of the solitary kidney"}, {"id": "7035691_1_7223", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "adverse event. Treatment, angiotensin I-converting enzyme inhibitor (SQ 14225). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7035691_1_7224", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7035691_1_7225", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7035691_1_7226", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7035691_1_7227", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7035691_1_7228", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Subject, a patient with renal artery stenosis of the solitary kidney. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7035691_1_7229", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7035691_1_7230", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_1_7231", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7035691_1_7232", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7035691_1_7233", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_1_7234", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7035691_1_7235", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Transient anuria"}, {"id": "7035691_1_7236", "context": "Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.", "question": "potential therapeutic event. Treatment, renal autotransplantation. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9517515_1_7237", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9517515_1_7238", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9517515_1_7239", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9517515_1_7240", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9517515_1_7241", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9517515_1_7242", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa; pentostatin"}, {"id": "9517515_1_7243", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9517515_1_7244", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9517515_1_7245", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9517515_1_7246", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9517515_1_7247", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9517515_1_7248", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukemia"}, {"id": "9517515_1_7249", "context": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.", "question": "adverse event. Treatment, interferon alfa and pentostatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "interferon alfa; pentostatin"}, {"id": "12399645_1_7250", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Subject, A case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12399645_1_7251", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Subject, A case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12399645_1_7252", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Subject, A case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_1_7253", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Subject, A case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_1_7254", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Subject, A case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_1_7255", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_1_7256", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_1_7257", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_1_7258", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_1_7259", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_1_7260", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_1_7261", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_1_7262", "context": "A case of SIADH induced by mizoribin administration.", "question": "adverse event. Treatment, mizoribin administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_4_7263", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor; vancomycin"}, {"id": "15053046_4_7264", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_4_7265", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15053046_4_7266", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15053046_4_7267", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_4_7268", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15053046_4_7269", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15053046_4_7270", "context": "The agranulocytosis was rapidly resolved by granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF) therapy and by the discontinuation of vancomycin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11406880_3_7271", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Subject, A patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11406880_3_7272", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Subject, A patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11406880_3_7273", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Subject, A patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11406880_3_7274", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Subject, A patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11406880_3_7275", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Subject, A patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11406880_3_7276", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methadone"}, {"id": "11406880_3_7277", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11406880_3_7278", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11406880_3_7279", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11406880_3_7280", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11406880_3_7281", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11406880_3_7282", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cancer-associated pain"}, {"id": "11406880_3_7283", "context": "A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.", "question": "adverse event. Treatment, methadone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9224230_1_7284", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Subject, 3 of these patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9224230_1_7285", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Subject, 3 of these patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9224230_1_7286", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Subject, 3 of these patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "9224230_1_7287", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Subject, 3 of these patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9224230_1_7288", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Subject, 3 of these patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9224230_1_7289", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "9224230_1_7290", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9224230_1_7291", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9224230_1_7292", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9224230_1_7293", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9224230_1_7294", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "first month"}, {"id": "9224230_1_7295", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9224230_1_7296", "context": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.", "question": "adverse event. Treatment, first month of treatment with prednisone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_5_7297", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Subject, she. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16816519_5_7298", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Subject, she. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "16816519_5_7299", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Subject, she. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16816519_5_7300", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Subject, she. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16816519_5_7301", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Subject, she. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16816519_5_7302", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "16816519_5_7303", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_5_7304", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_5_7305", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_5_7306", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Five days"}, {"id": "16816519_5_7307", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_5_7308", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_5_7309", "context": "Five days after the fourth dose of vincristine, she presented with bilateral ptosis.", "question": "adverse event. Treatment, Five days after the fourth dose of vincristine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_7_7310", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "19249953_7_7311", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_7_7312", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_7_7313", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_7_7314", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_7_7315", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_7_7316", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_7_7317", "context": "As it had been 10 months since her last dosage adjustment of diltiazem, it was unlikely that the statin-induced rhabdomyolysis was precipitated by diltiazem.", "question": "adverse event. Treatment, diltiazem. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "278642_2_7318", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Subject, the patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "278642_2_7319", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Subject, the patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "278642_2_7320", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Subject, the patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "278642_2_7321", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Subject, the patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "278642_2_7322", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Subject, the patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "278642_2_7323", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "278642_2_7324", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "278642_2_7325", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "278642_2_7326", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "278642_2_7327", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "278642_2_7328", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "278642_2_7329", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "278642_2_7330", "context": "After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.", "question": "adverse event. Treatment, chlorambucil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_7_7331", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Subject, She. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16816519_7_7332", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Subject, She. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "16816519_7_7333", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Subject, She. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16816519_7_7334", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Subject, She. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16816519_7_7335", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Subject, She. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16816519_7_7336", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristin"}, {"id": "16816519_7_7337", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "3.8 mg"}, {"id": "16816519_7_7338", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_7_7339", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_7_7340", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_7_7341", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_7_7342", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_7_7343", "context": "She received 3.8 mg cumulative dose of vincristin before development of ptosis.", "question": "adverse event. Treatment, 3.8 mg cumulative dose of vincristin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_3_7344", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_3_7345", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_3_7346", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_3_7347", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_3_7348", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_3_7349", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_3_7350", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_3_7351", "context": "In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_2_7352", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9527943_2_7353", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_2_7354", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9527943_2_7355", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_2_7356", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_2_7357", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "9527943_2_7358", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_2_7359", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_2_7360", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_2_7361", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_2_7362", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_2_7363", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_2_7364", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_2_7365", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, One patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9527943_2_7366", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, One patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_2_7367", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, One patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "9527943_2_7368", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, One patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_2_7369", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Subject, One patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_2_7370", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "9527943_2_7371", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_2_7372", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_2_7373", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_2_7374", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_2_7375", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_2_7376", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9527943_2_7377", "context": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.", "question": "adverse event. Treatment, propranolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7685228_2_7378", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Subject, an RA patient treated with gold salts. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7685228_2_7379", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Subject, an RA patient treated with gold salts. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7685228_2_7380", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Subject, an RA patient treated with gold salts. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7685228_2_7381", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Subject, an RA patient treated with gold salts. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7685228_2_7382", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Subject, an RA patient treated with gold salts. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "RA"}, {"id": "7685228_2_7383", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "granulocyte colony-stimulating factor"}, {"id": "7685228_2_7384", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_2_7385", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7685228_2_7386", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7685228_2_7387", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_2_7388", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7685228_2_7389", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe neutropenia"}, {"id": "7685228_2_7390", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "potential therapeutic event. Treatment, granulocyte colony-stimulating factor (G-CSF). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7685228_2_7391", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold salts"}, {"id": "7685228_2_7392", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7685228_2_7393", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7685228_2_7394", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7685228_2_7395", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7685228_2_7396", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7685228_2_7397", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "7685228_2_7398", "context": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.", "question": "adverse event. Treatment, gold salts. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10907391_1_7399", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Subject, A third patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10907391_1_7400", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Subject, A third patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10907391_1_7401", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Subject, A third patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10907391_1_7402", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Subject, A third patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10907391_1_7403", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Subject, A third patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10907391_1_7404", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "10907391_1_7405", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10907391_1_7406", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10907391_1_7407", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10907391_1_7408", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10907391_1_7409", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10907391_1_7410", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10907391_1_7411", "context": "A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.", "question": "adverse event. Treatment, paclitaxel. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_5_7412", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12702914_5_7413", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "40 mg/day"}, {"id": "12702914_5_7414", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12702914_5_7415", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12702914_5_7416", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_5_7417", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12702914_5_7418", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatic dysfunction"}, {"id": "12702914_5_7419", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "adverse event. Treatment, 40 mg/day of prednisolone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12702914_5_7420", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12702914_5_7421", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "40 mg/day"}, {"id": "12702914_5_7422", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12702914_5_7423", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12702914_5_7424", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12702914_5_7425", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12702914_5_7426", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hepatic dysfunction"}, {"id": "12702914_5_7427", "context": "While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.", "question": "potential therapeutic event. Treatment, 40 mg/day of prednisolone. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15463865_2_7428", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Subject, patients; elderly. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "15463865_2_7429", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Subject, patients; elderly. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15463865_2_7430", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Subject, patients; elderly. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15463865_2_7431", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Subject, patients; elderly. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15463865_2_7432", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Subject, patients; elderly. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15463865_2_7433", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_2_7434", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_2_7435", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_2_7436", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_2_7437", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_2_7438", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_2_7439", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15463865_2_7440", "context": "Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "95811_1_7441", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Subject, 61-year-old man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "61-year-old"}, {"id": "95811_1_7442", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Subject, 61-year-old man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "95811_1_7443", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Subject, 61-year-old man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "95811_1_7444", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Subject, 61-year-old man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "95811_1_7445", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Subject, 61-year-old man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "95811_1_7446", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "95811_1_7447", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "95811_1_7448", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "95811_1_7449", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "95811_1_7450", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "95811_1_7451", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "26 months"}, {"id": "95811_1_7452", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "95811_1_7453", "context": "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.", "question": "adverse event. Treatment, 26 months of procainamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_4_7454", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Subject, a 2-year-old child. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "2-year-old child"}, {"id": "10510017_4_7455", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Subject, a 2-year-old child. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10510017_4_7456", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Subject, a 2-year-old child. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10510017_4_7457", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Subject, a 2-year-old child. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10510017_4_7458", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Subject, a 2-year-old child. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10510017_4_7459", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "10510017_4_7460", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_4_7461", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10510017_4_7462", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10510017_4_7463", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_4_7464", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10510017_4_7465", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10510017_4_7466", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10510017_4_7467", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, a 2-year-old child. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "2-year-old child"}, {"id": "10510017_4_7468", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, a 2-year-old child. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10510017_4_7469", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, a 2-year-old child. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10510017_4_7470", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, a 2-year-old child. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10510017_4_7471", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Subject, a 2-year-old child. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10510017_4_7472", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Danaparoid"}, {"id": "10510017_4_7473", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10510017_4_7474", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10510017_4_7475", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10510017_4_7476", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10510017_4_7477", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10510017_4_7478", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "heparin-induced thrombocytopenia and subsequent hemorrhagic complications"}, {"id": "10510017_4_7479", "context": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "question": "potential therapeutic event. Treatment, Danaparoid (orgaran). What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18775393_2_7480", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acenocoumarol; topical econazole"}, {"id": "18775393_2_7481", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18775393_2_7482", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18775393_2_7483", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18775393_2_7484", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18775393_2_7485", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18775393_2_7486", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18775393_2_7487", "context": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.", "question": "adverse event. Treatment, acenocoumarol; topical econazole lotion. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "acenocoumarol; topical econazole"}, {"id": "24927617_2_7488", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Subject, A 46-year old man with a chronic hepatitis C virus infection. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "46-year old"}, {"id": "24927617_2_7489", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Subject, A 46-year old man with a chronic hepatitis C virus infection. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "24927617_2_7490", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Subject, A 46-year old man with a chronic hepatitis C virus infection. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24927617_2_7491", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Subject, A 46-year old man with a chronic hepatitis C virus infection. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24927617_2_7492", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Subject, A 46-year old man with a chronic hepatitis C virus infection. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24927617_2_7493", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ribavirin; pegylated interferon; telaprevir"}, {"id": "24927617_2_7494", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24927617_2_7495", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24927617_2_7496", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24927617_2_7497", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24927617_2_7498", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24927617_2_7499", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "a chronic hepatitis C virus infection"}, {"id": "24927617_2_7500", "context": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "question": "potential therapeutic event. Treatment, triple therapy with ribavirin, pegylated interferon and telaprevir. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "ribavirin; pegylated interferon; telaprevir"}, {"id": "17176478_2_7501", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "corticosteroid"}, {"id": "17176478_2_7502", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17176478_2_7503", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17176478_2_7504", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17176478_2_7505", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17176478_2_7506", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17176478_2_7507", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17176478_2_7508", "context": "Leishmania infantum leishmaniasis in corticosteroid--treated patients.", "question": "adverse event. Treatment, corticosteroid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15028328_3_7509", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Subject, The patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15028328_3_7510", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Subject, The patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15028328_3_7511", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Subject, The patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15028328_3_7512", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Subject, The patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15028328_3_7513", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Subject, The patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15028328_3_7514", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PPA"}, {"id": "15028328_3_7515", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_3_7516", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_3_7517", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_3_7518", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_3_7519", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_3_7520", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_3_7521", "context": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.", "question": "adverse event. Treatment, extremely elevated levels of PPA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_2_7522", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "atypical antipsychotics"}, {"id": "17329303_2_7523", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_2_7524", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17329303_2_7525", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17329303_2_7526", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_2_7527", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17329303_2_7528", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "childhood behavioural disorders"}, {"id": "17329303_2_7529", "context": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission.", "question": "potential therapeutic event. Treatment, atypical antipsychotics; as monotherapy or in combination with other medications. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15468380_1_7530", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15468380_1_7531", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15468380_1_7532", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15468380_1_7533", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15468380_1_7534", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15468380_1_7535", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15468380_1_7536", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "15468380_1_7537", "context": "Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.", "question": "adverse event. Treatment, infliximab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17710018_2_7538", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_2_7539", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17710018_2_7540", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_2_7541", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17710018_2_7542", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_2_7543", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_2_7544", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_2_7545", "context": "Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.", "question": "adverse event. Treatment, etoposide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17959575_12_7546", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Subject, the patient was again admitted for worsening CHF. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17959575_12_7547", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Subject, the patient was again admitted for worsening CHF. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17959575_12_7548", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Subject, the patient was again admitted for worsening CHF. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17959575_12_7549", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Subject, the patient was again admitted for worsening CHF. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17959575_12_7550", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Subject, the patient was again admitted for worsening CHF. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17959575_12_7551", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "dobutamine"}, {"id": "17959575_12_7552", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17959575_12_7553", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "continuous"}, {"id": "17959575_12_7554", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "infusion"}, {"id": "17959575_12_7555", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17959575_12_7556", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17959575_12_7557", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17959575_12_7558", "context": "On March 13 the patient was again admitted for worsening CHF and was started on continuous dobutamine infusion.", "question": "potential therapeutic event. Treatment, continuous dobutamine infusion. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7559", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "22550162_1_7560", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7561", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7562", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7563", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7564", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7565", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_1_7566", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, omeprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7567", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Subject, methotrexate-experienced patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_1_7568", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Subject, methotrexate-experienced patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_1_7569", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Subject, methotrexate-experienced patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_1_7570", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Subject, methotrexate-experienced patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_1_7571", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Subject, methotrexate-experienced patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_1_7572", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carboxypeptidase G2"}, {"id": "22550162_1_7573", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7574", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7575", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7576", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7577", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7578", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "methotrexate toxicity"}, {"id": "22550162_1_7579", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "potential therapeutic event. Treatment, carboxypeptidase G2. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22550162_1_7580", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "22550162_1_7581", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22550162_1_7582", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22550162_1_7583", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22550162_1_7584", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_1_7585", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22550162_1_7586", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22550162_1_7587", "context": "Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.", "question": "adverse event. Treatment, methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16688722_2_7588", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Subject, a 53-year-old-man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "53-year-old"}, {"id": "16688722_2_7589", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Subject, a 53-year-old-man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16688722_2_7590", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Subject, a 53-year-old-man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16688722_2_7591", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Subject, a 53-year-old-man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16688722_2_7592", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Subject, a 53-year-old-man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16688722_2_7593", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "16688722_2_7594", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16688722_2_7595", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16688722_2_7596", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16688722_2_7597", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 months"}, {"id": "16688722_2_7598", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16688722_2_7599", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypercholesterolemia"}, {"id": "16688722_2_7600", "context": "We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.", "question": "adverse event. Treatment, 2 months after starting simvastatin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6597713_1_7601", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Subject, she. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6597713_1_7602", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Subject, she. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6597713_1_7603", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Subject, she. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6597713_1_7604", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Subject, she. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6597713_1_7605", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Subject, she. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6597713_1_7606", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cholestyramine II"}, {"id": "6597713_1_7607", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6597713_1_7608", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "6597713_1_7609", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "sachets"}, {"id": "6597713_1_7610", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6597713_1_7611", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "two months"}, {"id": "6597713_1_7612", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6597713_1_7613", "context": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.", "question": "adverse event. Treatment, cholestyramine II sachets twice daily for two months. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_2_7614", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_2_7615", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_2_7616", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_2_7617", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_2_7618", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_2_7619", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_2_7620", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2429270_2_7621", "context": "Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_2_7622", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Subject, myeloma patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12149193_2_7623", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Subject, myeloma patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12149193_2_7624", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Subject, myeloma patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12149193_2_7625", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Subject, myeloma patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12149193_2_7626", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Subject, myeloma patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12149193_2_7627", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12149193_2_7628", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_2_7629", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_2_7630", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "12149193_2_7631", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_2_7632", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_2_7633", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "12149193_2_7634", "context": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT).", "question": "adverse event. Treatment, any type of chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12399645_3_7635", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Subject, the first case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12399645_3_7636", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Subject, the first case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12399645_3_7637", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Subject, the first case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_3_7638", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Subject, the first case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_3_7639", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Subject, the first case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_3_7640", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_3_7641", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_3_7642", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_3_7643", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_3_7644", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12399645_3_7645", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_3_7646", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12399645_3_7647", "context": "In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.", "question": "adverse event. Treatment, mizoribin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_3_7648", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isoniazid; ethambutol"}, {"id": "3115809_3_7649", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_3_7650", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_3_7651", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_3_7652", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_3_7653", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_3_7654", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_3_7655", "context": "Isoniazid and ethambutol as a cause of optic neuropathy.", "question": "adverse event. Treatment, Isoniazid and ethambutol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "Isoniazid; ethambutol"}, {"id": "12452753_3_7656", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_3_7657", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_3_7658", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_3_7659", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_3_7660", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_3_7661", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_3_7662", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_3_7663", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "adverse event. Treatment, capecitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_3_7664", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Fluorouracil"}, {"id": "12452753_3_7665", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_3_7666", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12452753_3_7667", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12452753_3_7668", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12452753_3_7669", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12452753_3_7670", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "allergic reactions to capecitabine"}, {"id": "12452753_3_7671", "context": "Fluorouracil for allergic reactions to capecitabine.", "question": "potential therapeutic event. Treatment, Fluorouracil. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4018433_2_7672", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Subject, an infant. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "infant"}, {"id": "4018433_2_7673", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Subject, an infant. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4018433_2_7674", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Subject, an infant. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4018433_2_7675", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Subject, an infant. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4018433_2_7676", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Subject, an infant. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4018433_2_7677", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridoxine"}, {"id": "4018433_2_7678", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4018433_2_7679", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4018433_2_7680", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4018433_2_7681", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4018433_2_7682", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4018433_2_7683", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "convulsions"}, {"id": "4018433_2_7684", "context": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.", "question": "adverse event. Treatment, pyridoxine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11059196_1_7685", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Subject, a child with idiopathic ulcerative colitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "11059196_1_7686", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Subject, a child with idiopathic ulcerative colitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11059196_1_7687", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Subject, a child with idiopathic ulcerative colitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11059196_1_7688", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Subject, a child with idiopathic ulcerative colitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11059196_1_7689", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Subject, a child with idiopathic ulcerative colitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11059196_1_7690", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-aminosalicylic acid"}, {"id": "11059196_1_7691", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11059196_1_7692", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11059196_1_7693", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11059196_1_7694", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11059196_1_7695", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "long-term"}, {"id": "11059196_1_7696", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic ulcerative colitis"}, {"id": "11059196_1_7697", "context": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.", "question": "adverse event. Treatment, long-term 5-aminosalicylic acid therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_2_7698", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "antithrombin III"}, {"id": "11597289_2_7699", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "High-dose"}, {"id": "11597289_2_7700", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11597289_2_7701", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11597289_2_7702", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_2_7703", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11597289_2_7704", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe sepsis"}, {"id": "11597289_2_7705", "context": "High-dose antithrombin III in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, High-dose antithrombin III. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7459812_1_7706", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorambucil"}, {"id": "7459812_1_7707", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "7459812_1_7708", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7459812_1_7709", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7459812_1_7710", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7459812_1_7711", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7459812_1_7712", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocyte leukemia"}, {"id": "7459812_1_7713", "context": "Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.", "question": "adverse event. Treatment, high-dose intermittent chlorambucil therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "647693_3_7714", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "647693_3_7715", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "647693_3_7716", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "647693_3_7717", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "647693_3_7718", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "647693_3_7719", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "647693_3_7720", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "647693_3_7721", "context": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20171144_1_7722", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lacosamide"}, {"id": "20171144_1_7723", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg/day"}, {"id": "20171144_1_7724", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20171144_1_7725", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20171144_1_7726", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20171144_1_7727", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20171144_1_7728", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20171144_1_7729", "context": "Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).", "question": "adverse event. Treatment, lacosamide doses up to 600 mg/day. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_2_7730", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Subject, elderly patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "17667887_2_7731", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Subject, elderly patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17667887_2_7732", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Subject, elderly patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17667887_2_7733", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Subject, elderly patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17667887_2_7734", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Subject, elderly patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17667887_2_7735", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "17667887_2_7736", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_2_7737", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_2_7738", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_2_7739", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_2_7740", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_2_7741", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psychotic depression"}, {"id": "17667887_2_7742", "context": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants.", "question": "adverse event. Treatment, atypical antipsychotics and antidepressants. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "atypical antipsychotics; antidepressants"}, {"id": "8452107_1_7743", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Piritrexim"}, {"id": "8452107_1_7744", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8452107_1_7745", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8452107_1_7746", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8452107_1_7747", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8452107_1_7748", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8452107_1_7749", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8452107_1_7750", "context": "Piritrexim-induced pulmonary toxicity.", "question": "adverse event. Treatment, Piritrexim. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_6_7751", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib mesylate"}, {"id": "15338554_6_7752", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_6_7753", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_6_7754", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_6_7755", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_6_7756", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_6_7757", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15338554_6_7758", "context": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.", "question": "adverse event. Treatment, imatinib mesylate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19648225_3_7759", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Subject, three palliative care patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19648225_3_7760", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Subject, three palliative care patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19648225_3_7761", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Subject, three palliative care patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "19648225_3_7762", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Subject, three palliative care patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19648225_3_7763", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Subject, three palliative care patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19648225_3_7764", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ketamine"}, {"id": "19648225_3_7765", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19648225_3_7766", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19648225_3_7767", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19648225_3_7768", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19648225_3_7769", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19648225_3_7770", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19648225_3_7771", "context": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.", "question": "adverse event. Treatment, ketamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19058340_1_7772", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Subject, A 52 year-old male patient diagnosed of ankylosing spondylitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "52 year-old"}, {"id": "19058340_1_7773", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Subject, A 52 year-old male patient diagnosed of ankylosing spondylitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "19058340_1_7774", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Subject, A 52 year-old male patient diagnosed of ankylosing spondylitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19058340_1_7775", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Subject, A 52 year-old male patient diagnosed of ankylosing spondylitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19058340_1_7776", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Subject, A 52 year-old male patient diagnosed of ankylosing spondylitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19058340_1_7777", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "19058340_1_7778", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19058340_1_7779", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19058340_1_7780", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19058340_1_7781", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "ten-month"}, {"id": "19058340_1_7782", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19058340_1_7783", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ankylosing spondylitis"}, {"id": "19058340_1_7784", "context": "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.", "question": "adverse event. Treatment, a ten-month treatment of methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19423476_6_7785", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alemtuzumab"}, {"id": "19423476_6_7786", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19423476_6_7787", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19423476_6_7788", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19423476_6_7789", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19423476_6_7790", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19423476_6_7791", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19423476_6_7792", "context": "The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.", "question": "adverse event. Treatment, immunosuppressive therapy with alemtuzumab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681092_13_7793", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "9681092_13_7794", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681092_13_7795", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681092_13_7796", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681092_13_7797", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681092_13_7798", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681092_13_7799", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681092_13_7800", "context": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine, monitor for other cytochrome P450 inhibitors, and avoid concomitant drugs known to prolong the QT interval.", "question": "adverse event. Treatment, cyclobenzaprine and fluoxetin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclobenzaprine; fluoxetine"}, {"id": "10405480_2_7801", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10405480_2_7802", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10405480_2_7803", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10405480_2_7804", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10405480_2_7805", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Subject, a patient with ulcerative colitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10405480_2_7806", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "10405480_2_7807", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10405480_2_7808", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10405480_2_7809", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10405480_2_7810", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10405480_2_7811", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10405480_2_7812", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ulcerative colitis"}, {"id": "10405480_2_7813", "context": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "question": "adverse event. Treatment, salazosulfapyridine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17627694_1_7814", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Acetic acid"}, {"id": "17627694_1_7815", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17627694_1_7816", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17627694_1_7817", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17627694_1_7818", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17627694_1_7819", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17627694_1_7820", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17627694_1_7821", "context": "CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.", "question": "adverse event. Treatment, Acetic acid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16244351_3_7822", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Subject, a healthy patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16244351_3_7823", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Subject, a healthy patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16244351_3_7824", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Subject, a healthy patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16244351_3_7825", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Subject, a healthy patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16244351_3_7826", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Subject, a healthy patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16244351_3_7827", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vardenafil"}, {"id": "16244351_3_7828", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16244351_3_7829", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16244351_3_7830", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16244351_3_7831", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16244351_3_7832", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16244351_3_7833", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16244351_3_7834", "context": "We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.", "question": "adverse event. Treatment, vardenafil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7362333_1_7835", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Subject, patients undergoing cardiopulmonary bypass. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7362333_1_7836", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Subject, patients undergoing cardiopulmonary bypass. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7362333_1_7837", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Subject, patients undergoing cardiopulmonary bypass. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7362333_1_7838", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Subject, patients undergoing cardiopulmonary bypass. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7362333_1_7839", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Subject, patients undergoing cardiopulmonary bypass. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "cardiopulmonary bypass"}, {"id": "7362333_1_7840", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propranolol"}, {"id": "7362333_1_7841", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7362333_1_7842", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7362333_1_7843", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7362333_1_7844", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7362333_1_7845", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7362333_1_7846", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7362333_1_7847", "context": "Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.", "question": "adverse event. Treatment, Propranolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15681911_1_7848", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "15681911_1_7849", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15681911_1_7850", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15681911_1_7851", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "exposure"}, {"id": "15681911_1_7852", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15681911_1_7853", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15681911_1_7854", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15681911_1_7855", "context": "CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16507380_13_7856", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16507380_13_7857", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16507380_13_7858", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16507380_13_7859", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16507380_13_7860", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16507380_13_7861", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa; gemfibrozil"}, {"id": "16507380_13_7862", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg; 11 MU"}, {"id": "16507380_13_7863", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "BID; TIW"}, {"id": "16507380_13_7864", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_13_7865", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_13_7866", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_13_7867", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507380_13_7868", "context": "A possible drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID was reported in a patient undergoing treatment for IFN-induced hypertriglyceridemia.", "question": "adverse event. Treatment, drug-drug interaction between IFN alfa 11 MU TIW and gemfibrozil 600 mg BID. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "IFN alfa; gemfibrozil"}, {"id": "12181031_2_7869", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cladribine"}, {"id": "12181031_2_7870", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12181031_2_7871", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12181031_2_7872", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12181031_2_7873", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12181031_2_7874", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12181031_2_7875", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hairy cell leukaemia"}, {"id": "12181031_2_7876", "context": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.", "question": "adverse event. Treatment, cladribine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_2_7877", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Quinine"}, {"id": "11126885_2_7878", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_2_7879", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11126885_2_7880", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11126885_2_7881", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_2_7882", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11126885_2_7883", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "night leg cramps"}, {"id": "11126885_2_7884", "context": "Quinine is universally used for the very common symptom of night leg cramps.", "question": "potential therapeutic event. Treatment, Quinine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8864370_3_7885", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "8864370_3_7886", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "8864370_3_7887", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8864370_3_7888", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8864370_3_7889", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8864370_3_7890", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8864370_3_7891", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8864370_3_7892", "context": "However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.", "question": "adverse event. Treatment, low-dose MTX. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11597289_5_7893", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Subject, severely ill patients. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11597289_5_7894", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Subject, severely ill patients. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11597289_5_7895", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Subject, severely ill patients. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11597289_5_7896", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Subject, severely ill patients. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11597289_5_7897", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Subject, severely ill patients. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11597289_5_7898", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Antithrombin III"}, {"id": "11597289_5_7899", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11597289_5_7900", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11597289_5_7901", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11597289_5_7902", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11597289_5_7903", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11597289_5_7904", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multiorgan failure; severely ill"}, {"id": "11597289_5_7905", "context": "Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.", "question": "potential therapeutic event. Treatment, Antithrombin III; multiorgan failure. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7235792_3_7906", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Subject, In the second case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7235792_3_7907", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Subject, In the second case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7235792_3_7908", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Subject, In the second case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7235792_3_7909", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Subject, In the second case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7235792_3_7910", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Subject, In the second case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7235792_3_7911", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_3_7912", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_3_7913", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_3_7914", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_3_7915", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "several hours after"}, {"id": "7235792_3_7916", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_3_7917", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "complex ventricular ectopy"}, {"id": "7235792_3_7918", "context": "In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.", "question": "adverse event. Treatment, several hours after beginning a trial of bretylium maintenance therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_3_7919", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_3_7920", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_3_7921", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_3_7922", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_3_7923", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_3_7924", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_3_7925", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_3_7926", "context": "The association of central diabetes insipidus (CDI) with lithium use is rare.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_2_7927", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "teicoplanin"}, {"id": "17426073_2_7928", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_2_7929", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_2_7930", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_2_7931", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "11 days"}, {"id": "17426073_2_7932", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_2_7933", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_2_7934", "context": "However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.", "question": "adverse event. Treatment, 11 days after teicoplanin initiation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7448830_4_7935", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Subject, patients with breast cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7448830_4_7936", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Subject, patients with breast cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7448830_4_7937", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Subject, patients with breast cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7448830_4_7938", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Subject, patients with breast cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7448830_4_7939", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Subject, patients with breast cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7448830_4_7940", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hycanthone"}, {"id": "7448830_4_7941", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "lower doses"}, {"id": "7448830_4_7942", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7448830_4_7943", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7448830_4_7944", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7448830_4_7945", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7448830_4_7946", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "7448830_4_7947", "context": "In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.", "question": "adverse event. Treatment, hycanthone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_3_7948", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Subject, adolescent patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "11008259_3_7949", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Subject, adolescent patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11008259_3_7950", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Subject, adolescent patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11008259_3_7951", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Subject, adolescent patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11008259_3_7952", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Subject, adolescent patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11008259_3_7953", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_3_7954", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_3_7955", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_3_7956", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_3_7957", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_3_7958", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_3_7959", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_3_7960", "context": "This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.", "question": "adverse event. Treatment, tiagabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "180258_2_7961", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Subject, Two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "180258_2_7962", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Subject, Two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "180258_2_7963", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Subject, Two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "180258_2_7964", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Subject, Two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "180258_2_7965", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Subject, Two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "180258_2_7966", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "180258_2_7967", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "114 g; 30.6; g"}, {"id": "180258_2_7968", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "180258_2_7969", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "180258_2_7970", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "180258_2_7971", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "180258_2_7972", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "180258_2_7973", "context": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.", "question": "adverse event. Treatment, the ingestion of 30.6 and 114 g metronidazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_3_7974", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Subject, two young patients with cystic fibrosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "15463865_3_7975", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Subject, two young patients with cystic fibrosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15463865_3_7976", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Subject, two young patients with cystic fibrosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15463865_3_7977", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Subject, two young patients with cystic fibrosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15463865_3_7978", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Subject, two young patients with cystic fibrosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15463865_3_7979", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_3_7980", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_3_7981", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_3_7982", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15463865_3_7983", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2-3 weeks"}, {"id": "15463865_3_7984", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_3_7985", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "15463865_3_7986", "context": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.", "question": "adverse event. Treatment, 2-3 weeks of oral ciprofloxacin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15827071_8_7987", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Subject, A 37-year-old male with multiple myeloma. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "37-year-old"}, {"id": "15827071_8_7988", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Subject, A 37-year-old male with multiple myeloma. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "male"}, {"id": "15827071_8_7989", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Subject, A 37-year-old male with multiple myeloma. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15827071_8_7990", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Subject, A 37-year-old male with multiple myeloma. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15827071_8_7991", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Subject, A 37-year-old male with multiple myeloma. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "multiple myeloma"}, {"id": "15827071_8_7992", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "citalopram; trazodone"}, {"id": "15827071_8_7993", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "40 mg/day; 150 mg/day"}, {"id": "15827071_8_7994", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15827071_8_7995", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15827071_8_7996", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15827071_8_7997", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15827071_8_7998", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anxiety-related disorders"}, {"id": "15827071_8_7999", "context": "A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders.", "question": "potential therapeutic event. Treatment, citalopram 40 mg/day and trazodone 150 mg/day. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "citalopram; trazodone"}, {"id": "11335880_3_8000", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Subject, a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11335880_3_8001", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Subject, a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11335880_3_8002", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Subject, a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11335880_3_8003", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Subject, a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11335880_3_8004", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Subject, a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "specific genetic susceptibility to the thyroid disease"}, {"id": "11335880_3_8005", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "11335880_3_8006", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11335880_3_8007", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11335880_3_8008", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11335880_3_8009", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11335880_3_8010", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11335880_3_8011", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11335880_3_8012", "context": "Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.", "question": "adverse event. Treatment, interferon-alpha. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9039216_2_8013", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_2_8014", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9039216_2_8015", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9039216_2_8016", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9039216_2_8017", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_2_8018", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9039216_2_8019", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9039216_2_8020", "context": "Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.", "question": "adverse event. Treatment, minocycline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16092915_1_8021", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Subject, mitochondrial disorder in this adolescent. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "16092915_1_8022", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Subject, mitochondrial disorder in this adolescent. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16092915_1_8023", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Subject, mitochondrial disorder in this adolescent. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16092915_1_8024", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Subject, mitochondrial disorder in this adolescent. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16092915_1_8025", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Subject, mitochondrial disorder in this adolescent. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "mitochondrial disorder"}, {"id": "16092915_1_8026", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "16092915_1_8027", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16092915_1_8028", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16092915_1_8029", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16092915_1_8030", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16092915_1_8031", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16092915_1_8032", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16092915_1_8033", "context": "CONCLUSIONS: This observation of \"on-off\" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.", "question": "adverse event. Treatment, risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11008259_2_8034", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tiagabine"}, {"id": "11008259_2_8035", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11008259_2_8036", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11008259_2_8037", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11008259_2_8038", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11008259_2_8039", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11008259_2_8040", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11008259_2_8041", "context": "The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.", "question": "adverse event. Treatment, reduction in tiagabine dosages. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17426073_1_8042", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17426073_1_8043", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17426073_1_8044", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17426073_1_8045", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17426073_1_8046", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17426073_1_8047", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin; teicoplanin"}, {"id": "17426073_1_8048", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17426073_1_8049", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17426073_1_8050", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17426073_1_8051", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17426073_1_8052", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17426073_1_8053", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17426073_1_8054", "context": "CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "teicoplanin; vancomycin"}, {"id": "19058340_2_8055", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "19058340_2_8056", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19058340_2_8057", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19058340_2_8058", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19058340_2_8059", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19058340_2_8060", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19058340_2_8061", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19058340_2_8062", "context": "Methotrexate induced sprue-like syndrome.", "question": "adverse event. Treatment, Methotrexate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_9_8063", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin; warfarin"}, {"id": "22010004_9_8064", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_9_8065", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_9_8066", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_9_8067", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_9_8068", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_9_8069", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_9_8070", "context": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions, there is a potential for synergistic coagulopathy when combined with warfarin therapy.", "question": "adverse event. Treatment, niacin; combined with warfarin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; niacin"}, {"id": "8186884_3_8071", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_3_8072", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_3_8073", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_3_8074", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8186884_3_8075", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_3_8076", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_3_8077", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8186884_3_8078", "context": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_5_8079", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, The former patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_5_8080", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, The former patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_5_8081", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, The former patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_5_8082", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, The former patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_5_8083", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, The former patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_5_8084", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_5_8085", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_5_8086", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_5_8087", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_5_8088", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_5_8089", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_5_8090", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_5_8091", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15944830_5_8092", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15944830_5_8093", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15944830_5_8094", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15944830_5_8095", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15944830_5_8096", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15944830_5_8097", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN"}, {"id": "15944830_5_8098", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15944830_5_8099", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15944830_5_8100", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15944830_5_8101", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15944830_5_8102", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15944830_5_8103", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15944830_5_8104", "context": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.", "question": "adverse event. Treatment, IFN therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11573852_4_8105", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotercin B"}, {"id": "11573852_4_8106", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_4_8107", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_4_8108", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11573852_4_8109", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_4_8110", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_4_8111", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_4_8112", "context": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "question": "adverse event. Treatment, amphotercin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_3_8113", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Subject, a patient who presented with bloody diarrhoea; osteoarthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11247558_3_8114", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Subject, a patient who presented with bloody diarrhoea; osteoarthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11247558_3_8115", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Subject, a patient who presented with bloody diarrhoea; osteoarthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11247558_3_8116", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Subject, a patient who presented with bloody diarrhoea; osteoarthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11247558_3_8117", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Subject, a patient who presented with bloody diarrhoea; osteoarthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11247558_3_8118", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_3_8119", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "15 mg"}, {"id": "11247558_3_8120", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "11247558_3_8121", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11247558_3_8122", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11247558_3_8123", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "10 days"}, {"id": "11247558_3_8124", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteoarthritis"}, {"id": "11247558_3_8125", "context": "We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.", "question": "adverse event. Treatment, 15 mg meloxicam daily for 10 days. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7235792_2_8126", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Subject, first patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7235792_2_8127", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Subject, first patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7235792_2_8128", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Subject, first patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7235792_2_8129", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Subject, first patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7235792_2_8130", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Subject, first patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7235792_2_8131", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_2_8132", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_2_8133", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_2_8134", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7235792_2_8135", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "close temporal sequence"}, {"id": "7235792_2_8136", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_2_8137", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_2_8138", "context": "In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.", "question": "adverse event. Treatment, close temporal sequence with administering bretylium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3030084_1_8139", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin"}, {"id": "3030084_1_8140", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3030084_1_8141", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3030084_1_8142", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3030084_1_8143", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3030084_1_8144", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3030084_1_8145", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3030084_1_8146", "context": "Transient phenytoin induced IgA deficiency and permanent IgE increase.", "question": "adverse event. Treatment, phenytoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15701285_1_8147", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gliadel"}, {"id": "15701285_1_8148", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15701285_1_8149", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15701285_1_8150", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15701285_1_8151", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15701285_1_8152", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15701285_1_8153", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15701285_1_8154", "context": "Cerebral edema associated with Gliadel wafers: two case studies.", "question": "adverse event. Treatment, Gliadel wafers. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8305778_4_8155", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clonazepam"}, {"id": "8305778_4_8156", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "0.5 mg qhs"}, {"id": "8305778_4_8157", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8305778_4_8158", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8305778_4_8159", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8305778_4_8160", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8305778_4_8161", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "restless leg syndrome"}, {"id": "8305778_4_8162", "context": "Following the development of restless leg syndrome, therapy with clonazepam 0.5 mg qhs was initiated.", "question": "potential therapeutic event. Treatment, clonazepam 0.5 mg qhs. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15362597_2_8163", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Subject, a case of a diabetic patient taking glyburide. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15362597_2_8164", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Subject, a case of a diabetic patient taking glyburide. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15362597_2_8165", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Subject, a case of a diabetic patient taking glyburide. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15362597_2_8166", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Subject, a case of a diabetic patient taking glyburide. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15362597_2_8167", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Subject, a case of a diabetic patient taking glyburide. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15362597_2_8168", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "15362597_2_8169", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15362597_2_8170", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15362597_2_8171", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15362597_2_8172", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15362597_2_8173", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15362597_2_8174", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic"}, {"id": "15362597_2_8175", "context": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "glyburide; ciprofloxacin"}, {"id": "12399645_4_8176", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Subject, a 74-year-old man with rheumatoid arthritis (RA). What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "74-year-old"}, {"id": "12399645_4_8177", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Subject, a 74-year-old man with rheumatoid arthritis (RA). What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12399645_4_8178", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Subject, a 74-year-old man with rheumatoid arthritis (RA). What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12399645_4_8179", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Subject, a 74-year-old man with rheumatoid arthritis (RA). What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12399645_4_8180", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Subject, a 74-year-old man with rheumatoid arthritis (RA). What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12399645_4_8181", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mizoribin"}, {"id": "12399645_4_8182", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12399645_4_8183", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12399645_4_8184", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12399645_4_8185", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1.5 months after"}, {"id": "12399645_4_8186", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12399645_4_8187", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "12399645_4_8188", "context": "We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.", "question": "adverse event. Treatment, 1.5 months after commencement of mizoribin prescription. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16682062_2_8189", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_2_8190", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16682062_2_8191", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_2_8192", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_2_8193", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16682062_2_8194", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_2_8195", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16682062_2_8196", "context": "To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.", "question": "adverse event. Treatment, ivermectin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_3_8197", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "10348150_3_8198", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_3_8199", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_3_8200", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_3_8201", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_3_8202", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_3_8203", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10348150_3_8204", "context": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "question": "adverse event. Treatment, hydroxyurea. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17301517_1_8205", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Subject, A 32-year-old man with a family history of type 2 diabetes mellitus. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "32-year-old"}, {"id": "17301517_1_8206", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Subject, A 32-year-old man with a family history of type 2 diabetes mellitus. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "17301517_1_8207", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Subject, A 32-year-old man with a family history of type 2 diabetes mellitus. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17301517_1_8208", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Subject, A 32-year-old man with a family history of type 2 diabetes mellitus. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17301517_1_8209", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Subject, A 32-year-old man with a family history of type 2 diabetes mellitus. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "type 2 diabetes mellitus"}, {"id": "17301517_1_8210", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "perospirone hydrochloride"}, {"id": "17301517_1_8211", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17301517_1_8212", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17301517_1_8213", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17301517_1_8214", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 9 days"}, {"id": "17301517_1_8215", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17301517_1_8216", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17301517_1_8217", "context": "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.", "question": "adverse event. Treatment, 9 days of treatment with perospirone hydrochloride. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16615675_3_8218", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "HCQ"}, {"id": "16615675_3_8219", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16615675_3_8220", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16615675_3_8221", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16615675_3_8222", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16615675_3_8223", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "16615675_3_8224", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatic diseases"}, {"id": "16615675_3_8225", "context": "CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.", "question": "adverse event. Treatment, chronic use of HCQ. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3400849_1_8226", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine."}, {"id": "3400849_1_8227", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3400849_1_8228", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3400849_1_8229", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3400849_1_8230", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3400849_1_8231", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3400849_1_8232", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3400849_1_8233", "context": "Myoclonic spasms following intrathecal morphine.", "question": "adverse event. Treatment, intrathecal morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6324592_2_8234", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cefmenoxime"}, {"id": "6324592_2_8235", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6324592_2_8236", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6324592_2_8237", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6324592_2_8238", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6324592_2_8239", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6324592_2_8240", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6324592_2_8241", "context": "This is the first report of a disulfiram-like reaction with cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_2_8242", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; niacin"}, {"id": "22010004_2_8243", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22010004_2_8244", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_2_8245", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_2_8246", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_2_8247", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_2_8248", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_2_8249", "context": "To report a case of a probable interaction between warfarin and extended-release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio (INR) in patients taking these drugs concomitantly.", "question": "adverse event. Treatment, warfarin and extended-release niacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "niacin; warfarin"}, {"id": "19838099_2_8250", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Dasatinib"}, {"id": "19838099_2_8251", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19838099_2_8252", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19838099_2_8253", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19838099_2_8254", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19838099_2_8255", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19838099_2_8256", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19838099_2_8257", "context": "Dasatinib-induced pleural effusions: a lymphatic network disorder?", "question": "adverse event. Treatment, Dasatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9819544_3_8258", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Subject, an otherwise healthy patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9819544_3_8259", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Subject, an otherwise healthy patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9819544_3_8260", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Subject, an otherwise healthy patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9819544_3_8261", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Subject, an otherwise healthy patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9819544_3_8262", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Subject, an otherwise healthy patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9819544_3_8263", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "naproxen"}, {"id": "9819544_3_8264", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9819544_3_8265", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9819544_3_8266", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9819544_3_8267", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9819544_3_8268", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "brief course"}, {"id": "9819544_3_8269", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9819544_3_8270", "context": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.", "question": "adverse event. Treatment, a brief course of naproxen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_1_8271", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "steroid; PTU"}, {"id": "9695308_1_8272", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_1_8273", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9695308_1_8274", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9695308_1_8275", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_1_8276", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9695308_1_8277", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9695308_1_8278", "context": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.", "question": "potential therapeutic event. Treatment, steroid; PTU. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18562412_5_8279", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Subject, The second patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18562412_5_8280", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Subject, The second patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18562412_5_8281", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Subject, The second patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18562412_5_8282", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Subject, The second patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18562412_5_8283", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Subject, The second patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18562412_5_8284", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18562412_5_8285", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18562412_5_8286", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18562412_5_8287", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18562412_5_8288", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18562412_5_8289", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18562412_5_8290", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18562412_5_8291", "context": "The second patient exhibited sudden PLMS following olanzapine injection.", "question": "adverse event. Treatment, olanzapine injection. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11428480_2_8292", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adenosine"}, {"id": "11428480_2_8293", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11428480_2_8294", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11428480_2_8295", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11428480_2_8296", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11428480_2_8297", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11428480_2_8298", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11428480_2_8299", "context": "However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.", "question": "adverse event. Treatment, adenosine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19249953_5_8300", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "19249953_5_8301", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_5_8302", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_5_8303", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_5_8304", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_5_8305", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19249953_5_8306", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_5_8307", "context": "A cardiology consultation performed on the day of admission determined that a markedly elevated creatine kinase-myocardial band isoenzyme level and borderline-high troponin I level were diagnostic of rhabdomyolysis secondary to statin use.", "question": "adverse event. Treatment, statin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9651465_1_8308", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Viokase; Pancrease MT 16"}, {"id": "9651465_1_8309", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9651465_1_8310", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9651465_1_8311", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9651465_1_8312", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9651465_1_8313", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9651465_1_8314", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9651465_1_8315", "context": "METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.", "question": "adverse event. Treatment, Viokase and Pancrease MT 16. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "Viokase; Pancrease MT 16"}, {"id": "25204404_2_8316", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Subject, men with metastatic castration-resistant prostate cancer (mCRPC). What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25204404_2_8317", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Subject, men with metastatic castration-resistant prostate cancer (mCRPC). What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "men"}, {"id": "25204404_2_8318", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Subject, men with metastatic castration-resistant prostate cancer (mCRPC). What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "25204404_2_8319", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Subject, men with metastatic castration-resistant prostate cancer (mCRPC). What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25204404_2_8320", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Subject, men with metastatic castration-resistant prostate cancer (mCRPC). What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "25204404_2_8321", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Abiraterone acetate"}, {"id": "25204404_2_8322", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25204404_2_8323", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25204404_2_8324", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25204404_2_8325", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25204404_2_8326", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25204404_2_8327", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "metastatic castration-resistant prostate cancer"}, {"id": "25204404_2_8328", "context": "Abiraterone acetate, an androgen biosynthesis inhibitor, prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) in the pre- and post-chemotherapy setting as demonstrated by the pivotal phase III studies COU-AA-301 and COU-AA-302.", "question": "potential therapeutic event. Treatment, Abiraterone acetate, an androgen biosynthesis inhibitor. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12455453_2_8329", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "12455453_2_8330", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "Reduction"}, {"id": "12455453_2_8331", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12455453_2_8332", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12455453_2_8333", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12455453_2_8334", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12455453_2_8335", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "glycemia"}, {"id": "12455453_2_8336", "context": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.", "question": "potential therapeutic event. Treatment, Reduction of methylprednisolone dosage rather than insulin therapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17725438_1_8337", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "RFP"}, {"id": "17725438_1_8338", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17725438_1_8339", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17725438_1_8340", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17725438_1_8341", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17725438_1_8342", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17725438_1_8343", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17725438_1_8344", "context": "Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, RFP. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_9_8345", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14964753_9_8346", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14964753_9_8347", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14964753_9_8348", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14964753_9_8349", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14964753_9_8350", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_9_8351", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_9_8352", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_9_8353", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_9_8354", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_9_8355", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_9_8356", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_9_8357", "context": "Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.", "question": "adverse event. Treatment, ramipril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8186884_1_8358", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Subject, A 78-year-old man with a transvenous cardioverter defibrillator system. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "78-year-old"}, {"id": "8186884_1_8359", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Subject, A 78-year-old man with a transvenous cardioverter defibrillator system. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "8186884_1_8360", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Subject, A 78-year-old man with a transvenous cardioverter defibrillator system. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8186884_1_8361", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Subject, A 78-year-old man with a transvenous cardioverter defibrillator system. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8186884_1_8362", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Subject, A 78-year-old man with a transvenous cardioverter defibrillator system. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8186884_1_8363", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "8186884_1_8364", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8186884_1_8365", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8186884_1_8366", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "8186884_1_8367", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8186884_1_8368", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8186884_1_8369", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a transvenous cardioverter defibrillator system"}, {"id": "8186884_1_8370", "context": "A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.", "question": "adverse event. Treatment, during oral procainamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_2_8371", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Subject, A 53 year old Greenlandic male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "53 year old"}, {"id": "11590881_2_8372", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Subject, A 53 year old Greenlandic male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11590881_2_8373", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Subject, A 53 year old Greenlandic male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11590881_2_8374", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Subject, A 53 year old Greenlandic male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Greenlandic"}, {"id": "11590881_2_8375", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Subject, A 53 year old Greenlandic male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11590881_2_8376", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11590881_2_8377", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "10 g and 4 g"}, {"id": "11590881_2_8378", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11590881_2_8379", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "11590881_2_8380", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_2_8381", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11590881_2_8382", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_2_8383", "context": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.", "question": "adverse event. Treatment, ingestion of 10 g and 4 g of carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15112258_14_8384", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "other common agents"}, {"id": "15112258_14_8385", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_14_8386", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_14_8387", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_14_8388", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_14_8389", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_14_8390", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_14_8391", "context": "In contrast, other common agents for the most part trigger cutaneous inflammation.", "question": "adverse event. Treatment, other common agents for the most part. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10619721_1_8392", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Subject, both patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10619721_1_8393", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Subject, both patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10619721_1_8394", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Subject, both patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "10619721_1_8395", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Subject, both patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10619721_1_8396", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Subject, both patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10619721_1_8397", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pyridostigmine"}, {"id": "10619721_1_8398", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10619721_1_8399", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10619721_1_8400", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10619721_1_8401", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10619721_1_8402", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10619721_1_8403", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10619721_1_8404", "context": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.", "question": "adverse event. Treatment, pyridostigmine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8175330_2_8405", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Subject, three patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8175330_2_8406", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Subject, three patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8175330_2_8407", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Subject, three patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "8175330_2_8408", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Subject, three patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8175330_2_8409", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Subject, three patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8175330_2_8410", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium valproate; carbamazepine"}, {"id": "8175330_2_8411", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8175330_2_8412", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8175330_2_8413", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8175330_2_8414", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8175330_2_8415", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8175330_2_8416", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8175330_2_8417", "context": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.", "question": "adverse event. Treatment, antiepileptic agents sodium valproate and carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "sodium valproate; carbamazepine"}, {"id": "3620420_4_8418", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Subject, a case with bilateral Mooren's ulcer. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_4_8419", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Subject, a case with bilateral Mooren's ulcer. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_4_8420", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Subject, a case with bilateral Mooren's ulcer. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_4_8421", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Subject, a case with bilateral Mooren's ulcer. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_4_8422", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Subject, a case with bilateral Mooren's ulcer. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_4_8423", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "corticosteroids; silver nitrate; corticosteroids; cyclophosphamide; azathioprine"}, {"id": "3620420_4_8424", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_4_8425", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_4_8426", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "topical"}, {"id": "3620420_4_8427", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_4_8428", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_4_8429", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "bilateral Mooren's ulcer"}, {"id": "3620420_4_8430", "context": "We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine.", "question": "potential therapeutic event. Treatment, local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "corticosteroids; silver nitrate; corticosteroids; cyclophosphamide; azathioprine"}, {"id": "12635752_2_8431", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbimazole"}, {"id": "12635752_2_8432", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_2_8433", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12635752_2_8434", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12635752_2_8435", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_2_8436", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12635752_2_8437", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration"}, {"id": "12635752_2_8438", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "potential therapeutic event. Treatment, carbimazole. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12635752_2_8439", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "12635752_2_8440", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12635752_2_8441", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12635752_2_8442", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12635752_2_8443", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12635752_2_8444", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12635752_2_8445", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12635752_2_8446", "context": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.", "question": "adverse event. Treatment, propylthiouracil. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8638872_1_8447", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "8638872_1_8448", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8638872_1_8449", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8638872_1_8450", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8638872_1_8451", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8638872_1_8452", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8638872_1_8453", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8638872_1_8454", "context": "Jaundice induced by streptokinase.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16355099_4_8455", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "16355099_4_8456", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16355099_4_8457", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16355099_4_8458", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16355099_4_8459", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16355099_4_8460", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16355099_4_8461", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16355099_4_8462", "context": "When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3620420_8_8463", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Subject, patients with severe sight threatening Mooren's ulcer. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "3620420_8_8464", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Subject, patients with severe sight threatening Mooren's ulcer. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "3620420_8_8465", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Subject, patients with severe sight threatening Mooren's ulcer. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3620420_8_8466", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Subject, patients with severe sight threatening Mooren's ulcer. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3620420_8_8467", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Subject, patients with severe sight threatening Mooren's ulcer. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "3620420_8_8468", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cyclosporin"}, {"id": "3620420_8_8469", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3620420_8_8470", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3620420_8_8471", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3620420_8_8472", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3620420_8_8473", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3620420_8_8474", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Mooren's ulcer"}, {"id": "3620420_8_8475", "context": "The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.", "question": "potential therapeutic event. Treatment, cyclosporin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8329789_9_8476", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Subject, children and infants. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children; infants"}, {"id": "8329789_9_8477", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Subject, children and infants. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_9_8478", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Subject, children and infants. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_9_8479", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Subject, children and infants. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_9_8480", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Subject, children and infants. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_9_8481", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "8329789_9_8482", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_9_8483", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_9_8484", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_9_8485", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_9_8486", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_9_8487", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_9_8488", "context": "CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.", "question": "adverse event. Treatment, Amphotericin B overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "369675_1_8489", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Subject, diagnosis of myeloma; patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "369675_1_8490", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Subject, diagnosis of myeloma; patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "369675_1_8491", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Subject, diagnosis of myeloma; patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "369675_1_8492", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Subject, diagnosis of myeloma; patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "369675_1_8493", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Subject, diagnosis of myeloma; patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "369675_1_8494", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "369675_1_8495", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "369675_1_8496", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "369675_1_8497", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "369675_1_8498", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "369675_1_8499", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "369675_1_8500", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myeloma"}, {"id": "369675_1_8501", "context": "Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.", "question": "adverse event. Treatment, cyclophosphamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_2_8502", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "G-CSF"}, {"id": "9681211_2_8503", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_2_8504", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_2_8505", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_2_8506", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9681211_2_8507", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_2_8508", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9681211_2_8509", "context": "Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.", "question": "adverse event. Treatment, chemotherapy and G-CSF. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9426968_1_8510", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Subject, a patient with chronic active hepatitis C. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9426968_1_8511", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Subject, a patient with chronic active hepatitis C. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9426968_1_8512", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Subject, a patient with chronic active hepatitis C. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9426968_1_8513", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Subject, a patient with chronic active hepatitis C. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9426968_1_8514", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Subject, a patient with chronic active hepatitis C. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9426968_1_8515", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alpha-interferon"}, {"id": "9426968_1_8516", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9426968_1_8517", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9426968_1_8518", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9426968_1_8519", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9426968_1_8520", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9426968_1_8521", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic active hepatitis C"}, {"id": "9426968_1_8522", "context": "Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.", "question": "adverse event. Treatment, alpha-interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1759924_2_8523", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Subject, a man aged 70. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "aged 70"}, {"id": "1759924_2_8524", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Subject, a man aged 70. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "1759924_2_8525", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Subject, a man aged 70. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1759924_2_8526", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Subject, a man aged 70. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1759924_2_8527", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Subject, a man aged 70. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1759924_2_8528", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "1759924_2_8529", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1759924_2_8530", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "six-hourly"}, {"id": "1759924_2_8531", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "1759924_2_8532", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 12 hours"}, {"id": "1759924_2_8533", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1759924_2_8534", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1759924_2_8535", "context": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.", "question": "adverse event. Treatment, six-hourly intravenous metoclopramide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17331261_1_8536", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Subject, a patient with CF; beginning at 16 months of age. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "16 months"}, {"id": "17331261_1_8537", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Subject, a patient with CF; beginning at 16 months of age. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_1_8538", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Subject, a patient with CF; beginning at 16 months of age. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_1_8539", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Subject, a patient with CF; beginning at 16 months of age. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_1_8540", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Subject, a patient with CF; beginning at 16 months of age. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_1_8541", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_1_8542", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_1_8543", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_1_8544", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "inhalation"}, {"id": "17331261_1_8545", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_1_8546", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_1_8547", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CF"}, {"id": "17331261_1_8548", "context": "CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.", "question": "adverse event. Treatment, repeated administration of preservative-free tobramycin by inhalation. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_1_8549", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Subject, two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9491301_1_8550", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Subject, two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_1_8551", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Subject, two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "9491301_1_8552", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Subject, two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_1_8553", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Subject, two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9491301_1_8554", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_1_8555", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9491301_1_8556", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_1_8557", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9491301_1_8558", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_1_8559", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_1_8560", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_1_8561", "context": "Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.", "question": "adverse event. Treatment, intravenous heroin overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7468565_3_8562", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Subject, A case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7468565_3_8563", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Subject, A case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7468565_3_8564", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Subject, A case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7468565_3_8565", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Subject, A case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7468565_3_8566", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Subject, A case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7468565_3_8567", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "barbiturate"}, {"id": "7468565_3_8568", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7468565_3_8569", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7468565_3_8570", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7468565_3_8571", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7468565_3_8572", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7468565_3_8573", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7468565_3_8574", "context": "A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.", "question": "adverse event. Treatment, barbiturate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3967572_5_8575", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; theophylline"}, {"id": "3967572_5_8576", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3967572_5_8577", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3967572_5_8578", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3967572_5_8579", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3967572_5_8580", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3967572_5_8581", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3967572_5_8582", "context": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "question": "adverse event. Treatment, phenytoin is added; theophylline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; theophylline"}, {"id": "2549018_3_8583", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Fluoxetine"}, {"id": "2549018_3_8584", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_3_8585", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_3_8586", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_3_8587", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_3_8588", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_3_8589", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_3_8590", "context": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "question": "adverse event. Treatment, Fluoxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_1_8591", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Lansoprazole"}, {"id": "16001348_1_8592", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_1_8593", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_1_8594", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_1_8595", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16001348_1_8596", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_1_8597", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16001348_1_8598", "context": "Lansoprazole-associated collagenous colitis: a case report.", "question": "adverse event. Treatment, Lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2863342_2_8599", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfasalazine"}, {"id": "2863342_2_8600", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2863342_2_8601", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2863342_2_8602", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2863342_2_8603", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2863342_2_8604", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2863342_2_8605", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2863342_2_8606", "context": "We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.", "question": "adverse event. Treatment, sulfasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15961942_2_8607", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Subject, an Asian patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15961942_2_8608", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Subject, an Asian patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15961942_2_8609", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Subject, an Asian patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15961942_2_8610", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Subject, an Asian patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Asian"}, {"id": "15961942_2_8611", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Subject, an Asian patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15961942_2_8612", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alfa-interferon"}, {"id": "15961942_2_8613", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15961942_2_8614", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15961942_2_8615", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15961942_2_8616", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15961942_2_8617", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15961942_2_8618", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "15961942_2_8619", "context": "OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.", "question": "adverse event. Treatment, alfa-interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_10_8620", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "10715308_10_8621", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_10_8622", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10715308_10_8623", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10715308_10_8624", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_10_8625", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10715308_10_8626", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10715308_10_8627", "context": "The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting.", "question": "adverse event. Treatment, tirapazamine-plus-cisplatin regimen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "12665232_2_8628", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C"}, {"id": "12665232_2_8629", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single intraoperative application"}, {"id": "12665232_2_8630", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12665232_2_8631", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12665232_2_8632", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12665232_2_8633", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12665232_2_8634", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12665232_2_8635", "context": "To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.", "question": "adverse event. Treatment, a single intraoperative application of mitomycin C. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3259776_2_8636", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "streptokinase"}, {"id": "3259776_2_8637", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3259776_2_8638", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3259776_2_8639", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3259776_2_8640", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3259776_2_8641", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3259776_2_8642", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary emboli."}, {"id": "3259776_2_8643", "context": "Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.", "question": "adverse event. Treatment, streptokinase. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7986915_1_8644", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Subject, case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7986915_1_8645", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Subject, case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7986915_1_8646", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Subject, case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7986915_1_8647", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Subject, case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7986915_1_8648", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Subject, case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7986915_1_8649", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "7986915_1_8650", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7986915_1_8651", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7986915_1_8652", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7986915_1_8653", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7986915_1_8654", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7986915_1_8655", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7986915_1_8656", "context": "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.", "question": "adverse event. Treatment, metronidazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16521231_3_8657", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16521231_3_8658", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16521231_3_8659", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16521231_3_8660", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16521231_3_8661", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16521231_3_8662", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16521231_3_8663", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16521231_3_8664", "context": "Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?", "question": "adverse event. Treatment, infliximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18715650_1_8665", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18715650_1_8666", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18715650_1_8667", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18715650_1_8668", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18715650_1_8669", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18715650_1_8670", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "temozolomide"}, {"id": "18715650_1_8671", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18715650_1_8672", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18715650_1_8673", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18715650_1_8674", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18715650_1_8675", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18715650_1_8676", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18715650_1_8677", "context": "Disseminated salmonellosis in a patient treated with temozolomide.", "question": "adverse event. Treatment, temozolomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16221163_2_8678", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Subject, a kidney graft recipient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16221163_2_8679", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Subject, a kidney graft recipient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16221163_2_8680", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Subject, a kidney graft recipient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16221163_2_8681", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Subject, a kidney graft recipient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16221163_2_8682", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Subject, a kidney graft recipient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "kidney graft"}, {"id": "16221163_2_8683", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "16221163_2_8684", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_2_8685", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_2_8686", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_2_8687", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_2_8688", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_2_8689", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_2_8690", "context": "The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.", "question": "adverse event. Treatment, sirolimus (SRL). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3744305_1_8691", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrofurantoin"}, {"id": "3744305_1_8692", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3744305_1_8693", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3744305_1_8694", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3744305_1_8695", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3744305_1_8696", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3744305_1_8697", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3744305_1_8698", "context": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.", "question": "adverse event. Treatment, nitrofurantoin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17937473_3_8699", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Subject, patients with RA. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17937473_3_8700", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Subject, patients with RA. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17937473_3_8701", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Subject, patients with RA. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17937473_3_8702", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Subject, patients with RA. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17937473_3_8703", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Subject, patients with RA. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17937473_3_8704", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "17937473_3_8705", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_3_8706", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_3_8707", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_3_8708", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_3_8709", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_3_8710", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "17937473_3_8711", "context": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.", "question": "adverse event. Treatment, leflunomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6102186_5_8712", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "serine"}, {"id": "6102186_5_8713", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low; dose"}, {"id": "6102186_5_8714", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6102186_5_8715", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "6102186_5_8716", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 h"}, {"id": "6102186_5_8717", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6102186_5_8718", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6102186_5_8719", "context": "In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.", "question": "adverse event. Treatment, one low oral dose of serine; 5 h later. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16939867_1_8720", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "16939867_1_8721", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16939867_1_8722", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16939867_1_8723", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16939867_1_8724", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16939867_1_8725", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16939867_1_8726", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16939867_1_8727", "context": "Localized purpura associated with lamotrigine.", "question": "adverse event. Treatment, lamotrigine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20065266_1_8728", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20065266_1_8729", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20065266_1_8730", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20065266_1_8731", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20065266_1_8732", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20065266_1_8733", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "20065266_1_8734", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20065266_1_8735", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20065266_1_8736", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20065266_1_8737", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20065266_1_8738", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20065266_1_8739", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20065266_1_8740", "context": "Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.", "question": "adverse event. Treatment, trimethoprim-sulfamethoxazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "trimethoprim; sulfamethoxazole"}, {"id": "16352777_3_8741", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Torsemide"}, {"id": "16352777_3_8742", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16352777_3_8743", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16352777_3_8744", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16352777_3_8745", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16352777_3_8746", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16352777_3_8747", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16352777_3_8748", "context": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.", "question": "adverse event. Treatment, Torsemide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2863342_1_8749", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Subject, adults. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "adults"}, {"id": "2863342_1_8750", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Subject, adults. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2863342_1_8751", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Subject, adults. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2863342_1_8752", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Subject, adults. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2863342_1_8753", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Subject, adults. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2863342_1_8754", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sulfasalazine"}, {"id": "2863342_1_8755", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2863342_1_8756", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2863342_1_8757", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2863342_1_8758", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2863342_1_8759", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2863342_1_8760", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2863342_1_8761", "context": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.", "question": "adverse event. Treatment, Sulfasalazine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10348150_1_8762", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10348150_1_8763", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10348150_1_8764", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10348150_1_8765", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10348150_1_8766", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Subject, a patient with essential thrombocythemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10348150_1_8767", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Hydroxyurea"}, {"id": "10348150_1_8768", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10348150_1_8769", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10348150_1_8770", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10348150_1_8771", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10348150_1_8772", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10348150_1_8773", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "essential thrombocythemia"}, {"id": "10348150_1_8774", "context": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "question": "adverse event. Treatment, Hydroxyurea. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_9_8775", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Subject, patients with microscopic colitis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16001348_9_8776", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Subject, patients with microscopic colitis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16001348_9_8777", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Subject, patients with microscopic colitis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16001348_9_8778", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Subject, patients with microscopic colitis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16001348_9_8779", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Subject, patients with microscopic colitis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "microscopic colitis"}, {"id": "16001348_9_8780", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "16001348_9_8781", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_9_8782", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_9_8783", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_9_8784", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16001348_9_8785", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_9_8786", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16001348_9_8787", "context": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.", "question": "adverse event. Treatment, proton pump inhibitor lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "644545_3_8788", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "644545_3_8789", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "644545_3_8790", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "644545_3_8791", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "644545_3_8792", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "644545_3_8793", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "644545_3_8794", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "644545_3_8795", "context": "The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.", "question": "adverse event. Treatment, cyclophosphamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16001348_2_8796", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Subject, 57-year-old man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "16001348_2_8797", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Subject, 57-year-old man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16001348_2_8798", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Subject, 57-year-old man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16001348_2_8799", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Subject, 57-year-old man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16001348_2_8800", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Subject, 57-year-old man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16001348_2_8801", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole; lansoprazole"}, {"id": "16001348_2_8802", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16001348_2_8803", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16001348_2_8804", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16001348_2_8805", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "four weeks"}, {"id": "16001348_2_8806", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16001348_2_8807", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastroesophageal reflux disease"}, {"id": "16001348_2_8808", "context": "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.", "question": "adverse event. Treatment, four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lansoprazole; lansoprazole"}, {"id": "10327035_2_8809", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Subject, patient with gastric cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10327035_2_8810", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Subject, patient with gastric cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10327035_2_8811", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Subject, patient with gastric cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10327035_2_8812", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Subject, patient with gastric cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10327035_2_8813", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Subject, patient with gastric cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10327035_2_8814", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "10327035_2_8815", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "moderate-dose"}, {"id": "10327035_2_8816", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10327035_2_8817", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10327035_2_8818", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10327035_2_8819", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10327035_2_8820", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastric cancer"}, {"id": "10327035_2_8821", "context": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "question": "adverse event. Treatment, moderate-dose MTX. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18672645_1_8822", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Subject, The patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18672645_1_8823", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Subject, The patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18672645_1_8824", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Subject, The patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18672645_1_8825", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Subject, The patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18672645_1_8826", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Subject, The patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18672645_1_8827", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "18672645_1_8828", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18672645_1_8829", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18672645_1_8830", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18672645_1_8831", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18672645_1_8832", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "seven cycles"}, {"id": "18672645_1_8833", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18672645_1_8834", "context": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.", "question": "adverse event. Treatment, seven cycles of treatment; drug toxicity of bleomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12149193_8_8835", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; doxorubicin"}, {"id": "12149193_8_8836", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12149193_8_8837", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12149193_8_8838", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12149193_8_8839", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12149193_8_8840", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12149193_8_8841", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12149193_8_8842", "context": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis.", "question": "adverse event. Treatment, combination chemotherapy including doxorubicin (P =.02). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; doxorubicin"}, {"id": "2417800_3_8843", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxygen"}, {"id": "2417800_3_8844", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2417800_3_8845", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2417800_3_8846", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2417800_3_8847", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2417800_3_8848", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2417800_3_8849", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2417800_3_8850", "context": "Bleomycin pneumonitis potentiated by oxygen administration.", "question": "adverse event. Treatment, oxygen administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12455453_1_8851", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Subject, boys. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12455453_1_8852", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Subject, boys. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "boys"}, {"id": "12455453_1_8853", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Subject, boys. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12455453_1_8854", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Subject, boys. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12455453_1_8855", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Subject, boys. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12455453_1_8856", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "12455453_1_8857", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12455453_1_8858", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12455453_1_8859", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "12455453_1_8860", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12455453_1_8861", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "After five and six weeks"}, {"id": "12455453_1_8862", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12455453_1_8863", "context": "After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.", "question": "adverse event. Treatment, After five and six weeks of continuous oral administration of methylprednisolone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18775393_1_8864", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Subject, elderly patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "18775393_1_8865", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Subject, elderly patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18775393_1_8866", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Subject, elderly patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18775393_1_8867", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Subject, elderly patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18775393_1_8868", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Subject, elderly patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18775393_1_8869", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "econazole; acenocoumarol"}, {"id": "18775393_1_8870", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18775393_1_8871", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18775393_1_8872", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical; lotion"}, {"id": "18775393_1_8873", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18775393_1_8874", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18775393_1_8875", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18775393_1_8876", "context": "CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.", "question": "adverse event. Treatment, a probable interaction between topical econazole lotion 1% and acenocoumarol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "econazole; acenocoumarol"}, {"id": "15529178_1_8877", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "15529178_1_8878", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15529178_1_8879", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15529178_1_8880", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15529178_1_8881", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15529178_1_8882", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15529178_1_8883", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15529178_1_8884", "context": "Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.", "question": "adverse event. Treatment, etanercept. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16459502_2_8885", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCG"}, {"id": "16459502_2_8886", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16459502_2_8887", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16459502_2_8888", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16459502_2_8889", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16459502_2_8890", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16459502_2_8891", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16459502_2_8892", "context": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.", "question": "adverse event. Treatment, BCG. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_5_8893", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statins"}, {"id": "14712320_5_8894", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_5_8895", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_5_8896", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_5_8897", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_5_8898", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_5_8899", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_5_8900", "context": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin.", "question": "adverse event. Treatment, statins; other drugs that are themselves myotoxic or that elevate the concentration of the statin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4044222_2_8901", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amiodarone"}, {"id": "4044222_2_8902", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4044222_2_8903", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4044222_2_8904", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4044222_2_8905", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4044222_2_8906", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4044222_2_8907", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4044222_2_8908", "context": "Amiodarone-induced dysthyroidism.", "question": "adverse event. Treatment, Amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_2_8909", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergot"}, {"id": "6108450_2_8910", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_2_8911", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_2_8912", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_2_8913", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_2_8914", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_2_8915", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_2_8916", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_2_8917", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Subject, Two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6108450_2_8918", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Subject, Two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6108450_2_8919", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Subject, Two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "6108450_2_8920", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Subject, Two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6108450_2_8921", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Subject, Two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "ergot-induced arteriospasm"}, {"id": "6108450_2_8922", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergot"}, {"id": "6108450_2_8923", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_2_8924", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_2_8925", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_2_8926", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_2_8927", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_2_8928", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_2_8929", "context": "Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.", "question": "adverse event. Treatment, ergot. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18765315_1_8930", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "18765315_1_8931", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18765315_1_8932", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18765315_1_8933", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18765315_1_8934", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18765315_1_8935", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18765315_1_8936", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18765315_1_8937", "context": "Acute coronary syndromes can be associated with the infusion of rituximab.", "question": "adverse event. Treatment, infusion of rituximab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9466030_2_8938", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9466030_2_8939", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9466030_2_8940", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9466030_2_8941", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9466030_2_8942", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9466030_2_8943", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "9466030_2_8944", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9466030_2_8945", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9466030_2_8946", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "nebulised"}, {"id": "9466030_2_8947", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "15 min"}, {"id": "9466030_2_8948", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9466030_2_8949", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9466030_2_8950", "context": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.", "question": "adverse event. Treatment, nebulised morphine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_1_8951", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_1_8952", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_1_8953", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2549018_1_8954", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2549018_1_8955", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_1_8956", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2549018_1_8957", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Akathisia"}, {"id": "2549018_1_8958", "context": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "question": "potential therapeutic event. Treatment, beta-adrenergic antagonist propranolol. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9934637_1_8959", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "psoralens"}, {"id": "9934637_1_8960", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9934637_1_8961", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9934637_1_8962", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9934637_1_8963", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9934637_1_8964", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9934637_1_8965", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9934637_1_8966", "context": "An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.", "question": "adverse event. Treatment, use of drugs that contain psoralens.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11984077_3_8967", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11984077_3_8968", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11984077_3_8969", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11984077_3_8970", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11984077_3_8971", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11984077_3_8972", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amifostine"}, {"id": "11984077_3_8973", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11984077_3_8974", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11984077_3_8975", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11984077_3_8976", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11984077_3_8977", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11984077_3_8978", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11984077_3_8979", "context": "The patient suffered a life-threatening anaphylactoid reaction to amifostine.", "question": "adverse event. Treatment, amifostine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16313549_2_8980", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16313549_2_8981", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16313549_2_8982", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "16313549_2_8983", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16313549_2_8984", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Subject, patients with multiple myeloma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16313549_2_8985", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisphosphonate"}, {"id": "16313549_2_8986", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16313549_2_8987", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16313549_2_8988", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "i.v."}, {"id": "16313549_2_8989", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16313549_2_8990", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16313549_2_8991", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "multiple myeloma"}, {"id": "16313549_2_8992", "context": "We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.", "question": "adverse event. Treatment, i.v. bisphosphonate treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1829999_2_8993", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1829999_2_8994", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1829999_2_8995", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1829999_2_8996", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1829999_2_8997", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1829999_2_8998", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "1829999_2_8999", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1829999_2_9000", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1829999_2_9001", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous; intraperitoneal"}, {"id": "1829999_2_9002", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1829999_2_9003", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1829999_2_9004", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1829999_2_9005", "context": "We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.", "question": "adverse event. Treatment, intravenous and intraperitoneal administration of tobramycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "95811_2_9006", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "95811_2_9007", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "95811_2_9008", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "95811_2_9009", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "95811_2_9010", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "95811_2_9011", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "95811_2_9012", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "95811_2_9013", "context": "Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.", "question": "adverse event. Treatment, procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8645078_4_9014", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Subject, Patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8645078_4_9015", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Subject, Patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8645078_4_9016", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Subject, Patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8645078_4_9017", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Subject, Patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8645078_4_9018", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Subject, Patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8645078_4_9019", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril; captopril"}, {"id": "8645078_4_9020", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8645078_4_9021", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8645078_4_9022", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8645078_4_9023", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8645078_4_9024", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8645078_4_9025", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8645078_4_9026", "context": "Patients treated with captopril who develop \"atypical cholangitis\" should be suspected of having captopril-associated liver damage.", "question": "adverse event. Treatment, captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10586009_2_9027", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Subject, in the neonate; for cough control during an emergency department visit. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "neonate"}, {"id": "10586009_2_9028", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Subject, in the neonate; for cough control during an emergency department visit. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10586009_2_9029", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Subject, in the neonate; for cough control during an emergency department visit. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10586009_2_9030", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Subject, in the neonate; for cough control during an emergency department visit. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10586009_2_9031", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Subject, in the neonate; for cough control during an emergency department visit. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10586009_2_9032", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "codeine"}, {"id": "10586009_2_9033", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10586009_2_9034", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10586009_2_9035", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10586009_2_9036", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10586009_2_9037", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10586009_2_9038", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cough"}, {"id": "10586009_2_9039", "context": "We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.", "question": "adverse event. Treatment, codeine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17763133_2_9040", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "simvastatin; cyclosporine"}, {"id": "17763133_2_9041", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_2_9042", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17763133_2_9043", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17763133_2_9044", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_2_9045", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17763133_2_9046", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "rhabdomyolysis"}, {"id": "17763133_2_9047", "context": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.", "question": "potential therapeutic event. Treatment, Discontinuation of simvastatin and cyclosporine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15028328_2_9048", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Phenylpropanolamine"}, {"id": "15028328_2_9049", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15028328_2_9050", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15028328_2_9051", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15028328_2_9052", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15028328_2_9053", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15028328_2_9054", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15028328_2_9055", "context": "Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.", "question": "adverse event. Treatment, Phenylpropanolamine (PPA). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22010004_1_9056", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22010004_1_9057", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22010004_1_9058", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22010004_1_9059", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22010004_1_9060", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22010004_1_9061", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; niacin"}, {"id": "22010004_1_9062", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "increase in; dose"}, {"id": "22010004_1_9063", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22010004_1_9064", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22010004_1_9065", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22010004_1_9066", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22010004_1_9067", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22010004_1_9068", "context": "Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.", "question": "adverse event. Treatment, warfarin; increase in extended-release niacin dose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_5_9069", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Subject, He. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17329303_5_9070", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Subject, He. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "17329303_5_9071", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Subject, He. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17329303_5_9072", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Subject, He. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_5_9073", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Subject, He. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_5_9074", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate; risperidone"}, {"id": "17329303_5_9075", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_5_9076", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_5_9077", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_5_9078", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_5_9079", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_5_9080", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_5_9081", "context": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment.", "question": "adverse event. Treatment, methylphenidate after the discontinuation of risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12390172_4_9082", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "12390172_4_9083", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12390172_4_9084", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12390172_4_9085", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12390172_4_9086", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12390172_4_9087", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12390172_4_9088", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12390172_4_9089", "context": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.", "question": "adverse event. Treatment, rifabutin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3290702_1_9090", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Subject, a 32-year-old New Zealand woman with idiopathic hypopituitarism. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "32-year-old"}, {"id": "3290702_1_9091", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Subject, a 32-year-old New Zealand woman with idiopathic hypopituitarism. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "3290702_1_9092", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Subject, a 32-year-old New Zealand woman with idiopathic hypopituitarism. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3290702_1_9093", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Subject, a 32-year-old New Zealand woman with idiopathic hypopituitarism. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "New Zealand"}, {"id": "3290702_1_9094", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Subject, a 32-year-old New Zealand woman with idiopathic hypopituitarism. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3290702_1_9095", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "human growth hormone"}, {"id": "3290702_1_9096", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3290702_1_9097", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3290702_1_9098", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3290702_1_9099", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3290702_1_9100", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3290702_1_9101", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic hypopituitarism"}, {"id": "3290702_1_9102", "context": "A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.", "question": "adverse event. Treatment, human growth hormone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_2_9103", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Quinine"}, {"id": "16099004_2_9104", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_2_9105", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16099004_2_9106", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16099004_2_9107", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_2_9108", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16099004_2_9109", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "falciparum malaria"}, {"id": "16099004_2_9110", "context": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world.", "question": "potential therapeutic event. Treatment, Quinine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17068466_3_9111", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoroquinolone"}, {"id": "17068466_3_9112", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17068466_3_9113", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17068466_3_9114", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17068466_3_9115", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17068466_3_9116", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17068466_3_9117", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17068466_3_9118", "context": "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.", "question": "adverse event. Treatment, topical fluoroquinolone therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12452753_6_9119", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "12452753_6_9120", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12452753_6_9121", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12452753_6_9122", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12452753_6_9123", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 hours"}, {"id": "12452753_6_9124", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12452753_6_9125", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12452753_6_9126", "context": "She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.", "question": "adverse event. Treatment, approximately 4 hours after the first dose of capecitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8162401_2_9127", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "8162401_2_9128", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8162401_2_9129", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8162401_2_9130", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8162401_2_9131", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8162401_2_9132", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8162401_2_9133", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8162401_2_9134", "context": "Seizures associated with fluoxetine therapy are uncommon.", "question": "adverse event. Treatment, fluoxetine therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10337682_1_9135", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Subject, A 14-year-old girl with newly diagnosed SLE. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "14-year-old"}, {"id": "10337682_1_9136", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Subject, A 14-year-old girl with newly diagnosed SLE. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "10337682_1_9137", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Subject, A 14-year-old girl with newly diagnosed SLE. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10337682_1_9138", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Subject, A 14-year-old girl with newly diagnosed SLE. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10337682_1_9139", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Subject, A 14-year-old girl with newly diagnosed SLE. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10337682_1_9140", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "10337682_1_9141", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10337682_1_9142", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10337682_1_9143", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10337682_1_9144", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10337682_1_9145", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10337682_1_9146", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "SLE"}, {"id": "10337682_1_9147", "context": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "question": "adverse event. Treatment, prednisone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8175330_1_9148", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine; Sodium valproate"}, {"id": "8175330_1_9149", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8175330_1_9150", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8175330_1_9151", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8175330_1_9152", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8175330_1_9153", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8175330_1_9154", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8175330_1_9155", "context": "Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.", "question": "adverse event. Treatment, Sodium valproate and carbamazepine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_1_9156", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cisplatin; Tirapazamine"}, {"id": "10715308_1_9157", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10715308_1_9158", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10715308_1_9159", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10715308_1_9160", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10715308_1_9161", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_1_9162", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "advanced non-small-cell lung cancer"}, {"id": "10715308_1_9163", "context": "Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group.", "question": "potential therapeutic event. Treatment, Tirapazamine plus cisplatin. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "cisplatin; Tirapazamine"}, {"id": "1829999_1_9164", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin sulfate"}, {"id": "1829999_1_9165", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1829999_1_9166", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1829999_1_9167", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1829999_1_9168", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1829999_1_9169", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1829999_1_9170", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1829999_1_9171", "context": "Exfoliative dermatitis secondary to tobramycin sulfate.", "question": "adverse event. Treatment, tobramycin sulfate.. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20110001_3_9172", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20110001_3_9173", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20110001_3_9174", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20110001_3_9175", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20110001_3_9176", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20110001_3_9177", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib mesylate"}, {"id": "20110001_3_9178", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20110001_3_9179", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20110001_3_9180", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20110001_3_9181", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20110001_3_9182", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20110001_3_9183", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "20110001_3_9184", "context": "Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.", "question": "adverse event. Treatment, imatinib mesylate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6303138_2_9185", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Subject, young patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "6303138_2_9186", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Subject, young patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6303138_2_9187", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Subject, young patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6303138_2_9188", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Subject, young patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6303138_2_9189", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Subject, young patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6303138_2_9190", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nortriptyline"}, {"id": "6303138_2_9191", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6303138_2_9192", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6303138_2_9193", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6303138_2_9194", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6303138_2_9195", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6303138_2_9196", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6303138_2_9197", "context": "A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.", "question": "adverse event. Treatment, nortriptyline. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3501467_2_9198", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "3501467_2_9199", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3501467_2_9200", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3501467_2_9201", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3501467_2_9202", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3501467_2_9203", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3501467_2_9204", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3501467_2_9205", "context": "Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.", "question": "adverse event. Treatment, gold therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6614033_3_9206", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Subject, five patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6614033_3_9207", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Subject, five patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6614033_3_9208", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Subject, five patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "6614033_3_9209", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Subject, five patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6614033_3_9210", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Subject, five patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6614033_3_9211", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "6614033_3_9212", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6614033_3_9213", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6614033_3_9214", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6614033_3_9215", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6614033_3_9216", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6614033_3_9217", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6614033_3_9218", "context": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.", "question": "adverse event. Treatment, amphotericin B therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15529178_2_9219", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Subject, four patients with rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15529178_2_9220", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Subject, four patients with rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15529178_2_9221", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Subject, four patients with rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "four"}, {"id": "15529178_2_9222", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Subject, four patients with rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15529178_2_9223", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Subject, four patients with rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15529178_2_9224", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "15529178_2_9225", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15529178_2_9226", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15529178_2_9227", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15529178_2_9228", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15529178_2_9229", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15529178_2_9230", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "15529178_2_9231", "context": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.", "question": "adverse event. Treatment, institution of etanercept therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17331261_2_9232", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17331261_2_9233", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17331261_2_9234", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17331261_2_9235", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17331261_2_9236", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17331261_2_9237", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tobramycin"}, {"id": "17331261_2_9238", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17331261_2_9239", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17331261_2_9240", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "inhalation; ntravenous administration."}, {"id": "17331261_2_9241", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17331261_2_9242", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17331261_2_9243", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17331261_2_9244", "context": "CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.", "question": "adverse event. Treatment, use of tobramycin by inhalation or by intravenous administration. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_4_9245", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Subject, 4 patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_4_9246", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Subject, 4 patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_4_9247", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Subject, 4 patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "4"}, {"id": "16449538_4_9248", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Subject, 4 patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_4_9249", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Subject, 4 patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_4_9250", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_4_9251", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_4_9252", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_4_9253", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_4_9254", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_4_9255", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_4_9256", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_4_9257", "context": "NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18487000_3_9258", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Subject, obese woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18487000_3_9259", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Subject, obese woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18487000_3_9260", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Subject, obese woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18487000_3_9261", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Subject, obese woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18487000_3_9262", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Subject, obese woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18487000_3_9263", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sibutramine"}, {"id": "18487000_3_9264", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18487000_3_9265", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18487000_3_9266", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18487000_3_9267", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18487000_3_9268", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18487000_3_9269", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obese"}, {"id": "18487000_3_9270", "context": "We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.", "question": "adverse event. Treatment, sibutramine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19448237_1_9271", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tranexamic acid"}, {"id": "19448237_1_9272", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19448237_1_9273", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19448237_1_9274", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "19448237_1_9275", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19448237_1_9276", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19448237_1_9277", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19448237_1_9278", "context": "Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.", "question": "adverse event. Treatment, accidental injection of tranexamic acid in spinal anesthesia. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14712320_3_9279", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Hydroxymethylglutaryl coenzyme A reductase inhibitors"}, {"id": "14712320_3_9280", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_3_9281", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_3_9282", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_3_9283", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_3_9284", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_3_9285", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_3_9286", "context": "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been associated with myopathy and rhabdomyolysis.", "question": "adverse event. Treatment, Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4051280_2_9287", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Propranolol"}, {"id": "4051280_2_9288", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4051280_2_9289", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4051280_2_9290", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4051280_2_9291", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4051280_2_9292", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4051280_2_9293", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4051280_2_9294", "context": "Propranolol-induced hypertension in treatment of cocaine intoxication.", "question": "adverse event. Treatment, Propranolol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10970989_1_9295", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10970989_1_9296", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10970989_1_9297", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10970989_1_9298", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10970989_1_9299", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10970989_1_9300", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "stavudine; lamivudine"}, {"id": "10970989_1_9301", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10970989_1_9302", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10970989_1_9303", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10970989_1_9304", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10970989_1_9305", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10970989_1_9306", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10970989_1_9307", "context": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine.", "question": "adverse event. Treatment, stavudine and lamivudine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "lamivudine; stavudine"}, {"id": "7035691_2_9308", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Subject, a patient with renal artery stenosis who had only 1 kidney. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7035691_2_9309", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Subject, a patient with renal artery stenosis who had only 1 kidney. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7035691_2_9310", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Subject, a patient with renal artery stenosis who had only 1 kidney. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7035691_2_9311", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Subject, a patient with renal artery stenosis who had only 1 kidney. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7035691_2_9312", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Subject, a patient with renal artery stenosis who had only 1 kidney. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal artery stenosis who had only 1 kidney"}, {"id": "7035691_2_9313", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "7035691_2_9314", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7035691_2_9315", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7035691_2_9316", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7035691_2_9317", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7035691_2_9318", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7035691_2_9319", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7035691_2_9320", "context": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.", "question": "adverse event. Treatment, the administration of captopril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11795358_1_9321", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Subject, women with breast cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11795358_1_9322", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Subject, women with breast cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "women"}, {"id": "11795358_1_9323", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Subject, women with breast cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11795358_1_9324", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Subject, women with breast cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11795358_1_9325", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Subject, women with breast cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11795358_1_9326", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "11795358_1_9327", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11795358_1_9328", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11795358_1_9329", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11795358_1_9330", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11795358_1_9331", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11795358_1_9332", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "11795358_1_9333", "context": "However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17763133_3_9334", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Simvastatin; cyclosporine"}, {"id": "17763133_3_9335", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17763133_3_9336", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17763133_3_9337", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17763133_3_9338", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17763133_3_9339", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17763133_3_9340", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "uveitis"}, {"id": "17763133_3_9341", "context": "Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.", "question": "adverse event. Treatment, cyclosporine treatment; Simvastatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "cyclosporine; Simvastatin"}, {"id": "12663440_2_9342", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Subject, adult patients (15-60 years old). What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "adult; 15-60 years old"}, {"id": "12663440_2_9343", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Subject, adult patients (15-60 years old). What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12663440_2_9344", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Subject, adult patients (15-60 years old). What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12663440_2_9345", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Subject, adult patients (15-60 years old). What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12663440_2_9346", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Subject, adult patients (15-60 years old). What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12663440_2_9347", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinine"}, {"id": "12663440_2_9348", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12663440_2_9349", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12663440_2_9350", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12663440_2_9351", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12663440_2_9352", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12663440_2_9353", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "de novo acute myelogenous leukemia (AML)"}, {"id": "12663440_2_9354", "context": "Based on our previous demonstration that quinine could be used clinically to reverse P-glycoprotein-mediated resistance, we designed a multicenter, randomized trial aiming to determine whether quinine would improve the survival of adult patients (15-60 years old) with de novo acute myelogenous leukemia (AML).", "question": "potential therapeutic event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16816519_1_9355", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vincristine"}, {"id": "16816519_1_9356", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_1_9357", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16816519_1_9358", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16816519_1_9359", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_1_9360", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16816519_1_9361", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_1_9362", "context": "Vincristine induced cranial polyneuropathy.", "question": "adverse event. Treatment, Vincristine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17697264_1_9363", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "17697264_1_9364", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17697264_1_9365", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17697264_1_9366", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17697264_1_9367", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17697264_1_9368", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17697264_1_9369", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17697264_1_9370", "context": "Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.", "question": "adverse event. Treatment, azathioprine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_2_9371", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Subject, TTP patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19260037_2_9372", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Subject, TTP patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19260037_2_9373", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Subject, TTP patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19260037_2_9374", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Subject, TTP patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19260037_2_9375", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Subject, TTP patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "TTP"}, {"id": "19260037_2_9376", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_2_9377", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_2_9378", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_2_9379", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_2_9380", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_2_9381", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_2_9382", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_2_9383", "context": "A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.", "question": "adverse event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18306483_1_9384", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Subject, patients with disseminated extranodal marginal zone B cell lymphoma. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18306483_1_9385", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Subject, patients with disseminated extranodal marginal zone B cell lymphoma. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18306483_1_9386", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Subject, patients with disseminated extranodal marginal zone B cell lymphoma. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18306483_1_9387", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Subject, patients with disseminated extranodal marginal zone B cell lymphoma. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18306483_1_9388", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Subject, patients with disseminated extranodal marginal zone B cell lymphoma. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18306483_1_9389", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rituximab-CHOP"}, {"id": "18306483_1_9390", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18306483_1_9391", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18306483_1_9392", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18306483_1_9393", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18306483_1_9394", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18306483_1_9395", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "disseminated extranodal marginal zone B cell lymphoma"}, {"id": "18306483_1_9396", "context": "Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.", "question": "adverse event. Treatment, Rituximab-CHOP. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2234880_2_9397", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Nitrendipine"}, {"id": "2234880_2_9398", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2234880_2_9399", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2234880_2_9400", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2234880_2_9401", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2234880_2_9402", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2234880_2_9403", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2234880_2_9404", "context": "Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.", "question": "adverse event. Treatment, Nitrendipine is an experimental calcium channel blocking agent. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18950384_1_9405", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18950384_1_9406", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18950384_1_9407", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18950384_1_9408", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18950384_1_9409", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18950384_1_9410", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mianserin; aripiprazole"}, {"id": "18950384_1_9411", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18950384_1_9412", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18950384_1_9413", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18950384_1_9414", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18950384_1_9415", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18950384_1_9416", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18950384_1_9417", "context": "The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.", "question": "adverse event. Treatment, corticosteroid and psychotropic treatment such as mianserin and aripiprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "mianserin; aripiprazole"}, {"id": "12625995_2_9418", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Subject, children with schizophrenia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "12625995_2_9419", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Subject, children with schizophrenia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12625995_2_9420", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Subject, children with schizophrenia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12625995_2_9421", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Subject, children with schizophrenia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12625995_2_9422", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Subject, children with schizophrenia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12625995_2_9423", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Clozapine"}, {"id": "12625995_2_9424", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12625995_2_9425", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12625995_2_9426", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12625995_2_9427", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12625995_2_9428", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12625995_2_9429", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "12625995_2_9430", "context": "Clozapine-induced akathisia in children with schizophrenia.", "question": "adverse event. Treatment, Clozapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10715308_4_9431", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Subject, Patients with previously untreated NSCLC. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10715308_4_9432", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Subject, Patients with previously untreated NSCLC. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10715308_4_9433", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Subject, Patients with previously untreated NSCLC. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10715308_4_9434", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Subject, Patients with previously untreated NSCLC. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10715308_4_9435", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Subject, Patients with previously untreated NSCLC. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10715308_4_9436", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tirapazamine; cisplatin; cisplatin"}, {"id": "10715308_4_9437", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "390 mg/m(2); 75 mg/m(2); 75 mg/m(2)"}, {"id": "10715308_4_9438", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "every 3 weeks for a maximum of eight cycles"}, {"id": "10715308_4_9439", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "infused"}, {"id": "10715308_4_9440", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "over 2 hours; over 1 hour"}, {"id": "10715308_4_9441", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10715308_4_9442", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "NSCLC"}, {"id": "10715308_4_9443", "context": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles.", "question": "potential therapeutic event. Treatment, either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "tirapazamine; cisplatin"}, {"id": "11720625_3_9444", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "erythomycin; pharmacologic agents; macrolide antibiotics"}, {"id": "11720625_3_9445", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11720625_3_9446", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11720625_3_9447", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11720625_3_9448", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11720625_3_9449", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11720625_3_9450", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11720625_3_9451", "context": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.", "question": "adverse event. Treatment, Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "erythomycin; pharmacologic agents"}, {"id": "20180933_5_9452", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Subject, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "infants and children"}, {"id": "20180933_5_9453", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Subject, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20180933_5_9454", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Subject, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "899"}, {"id": "20180933_5_9455", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Subject, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20180933_5_9456", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Subject, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20180933_5_9457", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "AL"}, {"id": "20180933_5_9458", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "six doses"}, {"id": "20180933_5_9459", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20180933_5_9460", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "crushed tablets; dispersible tablets"}, {"id": "20180933_5_9461", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20180933_5_9462", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "3 days"}, {"id": "20180933_5_9463", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Plasmodium falciparum malaria"}, {"id": "20180933_5_9464", "context": "In a randomised, investigator-blinded, multicentre phase III efficacy trial, 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets.", "question": "potential therapeutic event. Treatment, six doses of AL according to body weight over 3 days either as crushed tablets (Coartem) or as dispersible tablets. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1389744_1_9465", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Subject, A patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1389744_1_9466", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Subject, A patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1389744_1_9467", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Subject, A patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1389744_1_9468", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Subject, A patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1389744_1_9469", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Subject, A patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1389744_1_9470", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adrenaline"}, {"id": "1389744_1_9471", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overusing"}, {"id": "1389744_1_9472", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1389744_1_9473", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "inhaler"}, {"id": "1389744_1_9474", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1389744_1_9475", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1389744_1_9476", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1389744_1_9477", "context": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.", "question": "adverse event. Treatment, many years of overusing an adrenaline inhaler. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6625005_2_9478", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amoxapine"}, {"id": "6625005_2_9479", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6625005_2_9480", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6625005_2_9481", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6625005_2_9482", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6625005_2_9483", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6625005_2_9484", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6625005_2_9485", "context": "Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.", "question": "adverse event. Treatment, amoxapine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_1_9486", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10442258_1_9487", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10442258_1_9488", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10442258_1_9489", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10442258_1_9490", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10442258_1_9491", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paroxetine"}, {"id": "10442258_1_9492", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_1_9493", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_1_9494", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_1_9495", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_1_9496", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_1_9497", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_1_9498", "context": "Hair loss associated with paroxetine treatment: a case report.", "question": "adverse event. Treatment, paroxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_4_9499", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Subject, a 22-year-old Thai woman with Graves' disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "22-year-old"}, {"id": "15760792_4_9500", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Subject, a 22-year-old Thai woman with Graves' disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15760792_4_9501", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Subject, a 22-year-old Thai woman with Graves' disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15760792_4_9502", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Subject, a 22-year-old Thai woman with Graves' disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Thai"}, {"id": "15760792_4_9503", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Subject, a 22-year-old Thai woman with Graves' disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15760792_4_9504", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15760792_4_9505", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_4_9506", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_4_9507", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_4_9508", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "after 3 years"}, {"id": "15760792_4_9509", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_4_9510", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Graves' disease"}, {"id": "15760792_4_9511", "context": "RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.", "question": "adverse event. Treatment, after 3 years of therapy with PTU. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6578007_1_9512", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "melphalan; busulfan"}, {"id": "6578007_1_9513", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6578007_1_9514", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6578007_1_9515", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6578007_1_9516", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6578007_1_9517", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6578007_1_9518", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6578007_1_9519", "context": "Additive pulmonary toxicity with melphalan and busulfan therapy.", "question": "adverse event. Treatment, melphalan and busulfan therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "melphalan; busulfan"}, {"id": "16682062_3_9520", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Subject, 20-year-old woman originally from Cameroon who was infected by the L. loa parasite. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "20-year-old"}, {"id": "16682062_3_9521", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Subject, 20-year-old woman originally from Cameroon who was infected by the L. loa parasite. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16682062_3_9522", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Subject, 20-year-old woman originally from Cameroon who was infected by the L. loa parasite. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16682062_3_9523", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Subject, 20-year-old woman originally from Cameroon who was infected by the L. loa parasite. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "Cameroon"}, {"id": "16682062_3_9524", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Subject, 20-year-old woman originally from Cameroon who was infected by the L. loa parasite. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16682062_3_9525", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_3_9526", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "single dose"}, {"id": "16682062_3_9527", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_3_9528", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_3_9529", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 month"}, {"id": "16682062_3_9530", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_3_9531", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "infected by the L. loa parasite"}, {"id": "16682062_3_9532", "context": "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.", "question": "adverse event. Treatment, 1 month after a single dose of ivermectin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8739289_5_9533", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_5_9534", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_5_9535", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_5_9536", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_5_9537", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_5_9538", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_5_9539", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_5_9540", "context": "To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11795358_2_9541", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Subject, healthy population. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11795358_2_9542", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Subject, healthy population. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11795358_2_9543", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Subject, healthy population. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11795358_2_9544", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Subject, healthy population. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11795358_2_9545", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Subject, healthy population. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11795358_2_9546", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "11795358_2_9547", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11795358_2_9548", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11795358_2_9549", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11795358_2_9550", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11795358_2_9551", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11795358_2_9552", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11795358_2_9553", "context": "In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.", "question": "adverse event. Treatment, tamoxifen. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7235792_4_9554", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bretylium"}, {"id": "7235792_4_9555", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7235792_4_9556", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7235792_4_9557", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "7235792_4_9558", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7235792_4_9559", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7235792_4_9560", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7235792_4_9561", "context": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.", "question": "adverse event. Treatment, intravenous bretylium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11978156_5_9562", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Subject, a case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11978156_5_9563", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Subject, a case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11978156_5_9564", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Subject, a case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11978156_5_9565", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Subject, a case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11978156_5_9566", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Subject, a case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11978156_5_9567", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lansoprazole"}, {"id": "11978156_5_9568", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11978156_5_9569", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11978156_5_9570", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11978156_5_9571", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11978156_5_9572", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11978156_5_9573", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11978156_5_9574", "context": "OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.", "question": "adverse event. Treatment, lansoprazole. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_1_9575", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Subject, A patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3115809_1_9576", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Subject, A patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3115809_1_9577", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Subject, A patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3115809_1_9578", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Subject, A patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3115809_1_9579", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Subject, A patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3115809_1_9580", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid; ethambutol"}, {"id": "3115809_1_9581", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_1_9582", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_1_9583", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_1_9584", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_1_9585", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_1_9586", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_1_9587", "context": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol.", "question": "adverse event. Treatment, isoniazid and ethambutol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "isoniazid; ethambutol"}, {"id": "18622319_3_9588", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Subject, a 52-year-old white woman. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "52-year-old"}, {"id": "18622319_3_9589", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Subject, a 52-year-old white woman. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "18622319_3_9590", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Subject, a 52-year-old white woman. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18622319_3_9591", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Subject, a 52-year-old white woman. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "18622319_3_9592", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Subject, a 52-year-old white woman. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18622319_3_9593", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bevacizumab"}, {"id": "18622319_3_9594", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18622319_3_9595", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18622319_3_9596", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18622319_3_9597", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18622319_3_9598", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18622319_3_9599", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18622319_3_9600", "context": "This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.", "question": "adverse event. Treatment, antiangiogenic drug, bevacizumab. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2104570_5_9601", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, Two cases are reported of patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2104570_5_9602", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, Two cases are reported of patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2104570_5_9603", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, Two cases are reported of patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "2104570_5_9604", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, Two cases are reported of patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2104570_5_9605", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, Two cases are reported of patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2104570_5_9606", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoglucid; doxorubicin; mitomycin C"}, {"id": "2104570_5_9607", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_5_9608", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_5_9609", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical chemotherapy"}, {"id": "2104570_5_9610", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2104570_5_9611", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_5_9612", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "superficial bladder cancer"}, {"id": "2104570_5_9613", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, etoglucid, doxorubicin, and mitomycin C; several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "mitomycin C; doxorubicin; etoglucid"}, {"id": "17937473_1_9614", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Subject, Eleven patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17937473_1_9615", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Subject, Eleven patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17937473_1_9616", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Subject, Eleven patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Eleven"}, {"id": "17937473_1_9617", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Subject, Eleven patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17937473_1_9618", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Subject, Eleven patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17937473_1_9619", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "17937473_1_9620", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17937473_1_9621", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17937473_1_9622", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17937473_1_9623", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17937473_1_9624", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17937473_1_9625", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17937473_1_9626", "context": "Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).", "question": "adverse event. Treatment, leflunomide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11247558_2_9627", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "meloxicam"}, {"id": "11247558_2_9628", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11247558_2_9629", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11247558_2_9630", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11247558_2_9631", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "1 week"}, {"id": "11247558_2_9632", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11247558_2_9633", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Symptoms and endoscopic lesions"}, {"id": "11247558_2_9634", "context": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.", "question": "potential therapeutic event. Treatment, within 1 week of meloxicam withdrawal. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14712320_1_9635", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; danazol"}, {"id": "14712320_1_9636", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14712320_1_9637", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14712320_1_9638", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14712320_1_9639", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14712320_1_9640", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14712320_1_9641", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14712320_1_9642", "context": "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.", "question": "adverse event. Treatment, drug interaction between simvastatin and danazol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "simvastatin; danazol"}, {"id": "1450506_2_9643", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha-interferon"}, {"id": "1450506_2_9644", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1450506_2_9645", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1450506_2_9646", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1450506_2_9647", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1450506_2_9648", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1450506_2_9649", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1450506_2_9650", "context": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.", "question": "adverse event. Treatment, first administration of recombinant alpha-interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_1_9651", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Subject, multiple platinum-treated patients with recurrent ovarian cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_1_9652", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Subject, multiple platinum-treated patients with recurrent ovarian cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_1_9653", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Subject, multiple platinum-treated patients with recurrent ovarian cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_1_9654", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Subject, multiple platinum-treated patients with recurrent ovarian cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_1_9655", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Subject, multiple platinum-treated patients with recurrent ovarian cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_1_9656", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel; carboplatin; platinum"}, {"id": "15823103_1_9657", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "15823103_1_9658", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_1_9659", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_1_9660", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_1_9661", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_1_9662", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "recurrent ovarian cancer"}, {"id": "15823103_1_9663", "context": "Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.", "question": "adverse event. Treatment, low-dose paclitaxel/carboplatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "paclitaxel; carboplatin"}, {"id": "2104570_2_9664", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2104570_2_9665", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2104570_2_9666", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2104570_2_9667", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2104570_2_9668", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2104570_2_9669", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoglucid; doxorubicin; mitomycin C"}, {"id": "2104570_2_9670", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2104570_2_9671", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2104570_2_9672", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical"}, {"id": "2104570_2_9673", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "several years after"}, {"id": "2104570_2_9674", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2104570_2_9675", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "superficial bladder cancer"}, {"id": "2104570_2_9676", "context": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.", "question": "adverse event. Treatment, several years after intravesical chemotherapy; with etoglucid, doxorubicin, and mitomycin C. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "mitomycin C; doxorubicin; etoglucid"}, {"id": "11573852_2_9677", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Subject, A 46-year-old African-American man. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "46-year-old"}, {"id": "11573852_2_9678", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Subject, A 46-year-old African-American man. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "11573852_2_9679", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Subject, A 46-year-old African-American man. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11573852_2_9680", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Subject, A 46-year-old African-American man. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": "African-American"}, {"id": "11573852_2_9681", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Subject, A 46-year-old African-American man. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11573852_2_9682", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "11573852_2_9683", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11573852_2_9684", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11573852_2_9685", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous infusion"}, {"id": "11573852_2_9686", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11573852_2_9687", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11573852_2_9688", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11573852_2_9689", "context": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "question": "adverse event. Treatment, intravenous infusion of amphotericin B. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16948177_2_9690", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16948177_2_9691", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16948177_2_9692", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16948177_2_9693", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16948177_2_9694", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16948177_2_9695", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16948177_2_9696", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16948177_2_9697", "context": "Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.", "question": "adverse event. Treatment, rituximab therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1624172_4_9698", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Subject, Two cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1624172_4_9699", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Subject, Two cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1624172_4_9700", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Subject, Two cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "1624172_4_9701", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Subject, Two cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1624172_4_9702", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Subject, Two cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1624172_4_9703", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant alpha interferon"}, {"id": "1624172_4_9704", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1624172_4_9705", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1624172_4_9706", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1624172_4_9707", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1624172_4_9708", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1624172_4_9709", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic hepatitis C"}, {"id": "1624172_4_9710", "context": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.", "question": "adverse event. Treatment, recombinant alpha interferon. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15760792_2_9711", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Subject, young woman with Graves' disease. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "15760792_2_9712", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Subject, young woman with Graves' disease. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15760792_2_9713", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Subject, young woman with Graves' disease. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15760792_2_9714", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Subject, young woman with Graves' disease. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15760792_2_9715", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Subject, young woman with Graves' disease. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15760792_2_9716", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "15760792_2_9717", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15760792_2_9718", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15760792_2_9719", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15760792_2_9720", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15760792_2_9721", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15760792_2_9722", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Graves' disease"}, {"id": "15760792_2_9723", "context": "OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_2_9724", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Subject, An obese patient, not diabetic. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11468878_2_9725", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Subject, An obese patient, not diabetic. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11468878_2_9726", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Subject, An obese patient, not diabetic. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11468878_2_9727", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Subject, An obese patient, not diabetic. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11468878_2_9728", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Subject, An obese patient, not diabetic. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11468878_2_9729", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_2_9730", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_2_9731", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_2_9732", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_2_9733", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_2_9734", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "some weeks"}, {"id": "11468878_2_9735", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "obese"}, {"id": "11468878_2_9736", "context": "An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.", "question": "adverse event. Treatment, metformin for some weeks. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2690546_1_9737", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "2690546_1_9738", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2690546_1_9739", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2690546_1_9740", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2690546_1_9741", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2690546_1_9742", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2690546_1_9743", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2690546_1_9744", "context": "Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.", "question": "adverse event. Treatment, amiodarone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_2_9745", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, one patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_2_9746", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, one patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_2_9747", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, one patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_2_9748", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, one patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_2_9749", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, one patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_2_9750", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBDCA"}, {"id": "15823103_2_9751", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_2_9752", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_2_9753", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_2_9754", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_2_9755", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_2_9756", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_2_9757", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_2_9758", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, four patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_2_9759", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, four patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_2_9760", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, four patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15823103_2_9761", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, four patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_2_9762", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Subject, four patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_2_9763", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBDCA"}, {"id": "15823103_2_9764", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15823103_2_9765", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15823103_2_9766", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15823103_2_9767", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_2_9768", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_2_9769", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15823103_2_9770", "context": "However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.", "question": "adverse event. Treatment, CBDCA. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17329303_3_9771", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Subject, three cases of children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "17329303_3_9772", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Subject, three cases of children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17329303_3_9773", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Subject, three cases of children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "17329303_3_9774", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Subject, three cases of children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17329303_3_9775", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Subject, three cases of children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17329303_3_9776", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone; methylphenidate"}, {"id": "17329303_3_9777", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17329303_3_9778", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17329303_3_9779", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17329303_3_9780", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17329303_3_9781", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17329303_3_9782", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17329303_3_9783", "context": "This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate.", "question": "adverse event. Treatment, during switching from risperidone to methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10414481_2_9784", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Subject, This patient, who had a history of osteoarthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10414481_2_9785", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Subject, This patient, who had a history of osteoarthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10414481_2_9786", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Subject, This patient, who had a history of osteoarthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10414481_2_9787", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Subject, This patient, who had a history of osteoarthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10414481_2_9788", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Subject, This patient, who had a history of osteoarthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10414481_2_9789", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diclofenac"}, {"id": "10414481_2_9790", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10414481_2_9791", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10414481_2_9792", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10414481_2_9793", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 weeks"}, {"id": "10414481_2_9794", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10414481_2_9795", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "increasing pain in the joints"}, {"id": "10414481_2_9796", "context": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "question": "adverse event. Treatment, 5 weeks after being started on diclofenac. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16816519_4_9797", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Subject, She. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16816519_4_9798", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Subject, She. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "She"}, {"id": "16816519_4_9799", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Subject, She. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16816519_4_9800", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Subject, She. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16816519_4_9801", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Subject, She. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16816519_4_9802", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16816519_4_9803", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16816519_4_9804", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16816519_4_9805", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "16816519_4_9806", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16816519_4_9807", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16816519_4_9808", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16816519_4_9809", "context": "She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII.", "question": "potential therapeutic event. Treatment, chemotherapy. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9039216_1_9810", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Subject, A 17-year-old female patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "17-year-old"}, {"id": "9039216_1_9811", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Subject, A 17-year-old female patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "9039216_1_9812", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Subject, A 17-year-old female patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9039216_1_9813", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Subject, A 17-year-old female patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9039216_1_9814", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Subject, A 17-year-old female patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9039216_1_9815", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "minocycline"}, {"id": "9039216_1_9816", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "50 mg"}, {"id": "9039216_1_9817", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "9039216_1_9818", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "9039216_1_9819", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9039216_1_9820", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "3 weeks"}, {"id": "9039216_1_9821", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acne"}, {"id": "9039216_1_9822", "context": "A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.", "question": "adverse event. Treatment, oral minocycline (50 mg twice daily) for 3 weeks. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12880504_3_9823", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Subject, two children. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "12880504_3_9824", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Subject, two children. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12880504_3_9825", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Subject, two children. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "12880504_3_9826", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Subject, two children. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12880504_3_9827", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Subject, two children. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12880504_3_9828", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Risperidone"}, {"id": "12880504_3_9829", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12880504_3_9830", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12880504_3_9831", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12880504_3_9832", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12880504_3_9833", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12880504_3_9834", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12880504_3_9835", "context": "Risperidone-induced obsessive-compulsive symptoms in two children.", "question": "adverse event. Treatment, Risperidone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11642488_2_9836", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dipivefrin; antiglaucoma drugs"}, {"id": "11642488_2_9837", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11642488_2_9838", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11642488_2_9839", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11642488_2_9840", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11642488_2_9841", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11642488_2_9842", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11642488_2_9843", "context": "CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.", "question": "adverse event. Treatment, antiglaucoma drugs including dipivefrin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2429270_1_9844", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Subject, A patient with the Wolff-Parkinson-White syndrome. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2429270_1_9845", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Subject, A patient with the Wolff-Parkinson-White syndrome. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2429270_1_9846", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Subject, A patient with the Wolff-Parkinson-White syndrome. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2429270_1_9847", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Subject, A patient with the Wolff-Parkinson-White syndrome. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2429270_1_9848", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Subject, A patient with the Wolff-Parkinson-White syndrome. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2429270_1_9849", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "2429270_1_9850", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2429270_1_9851", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2429270_1_9852", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2429270_1_9853", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2429270_1_9854", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2429270_1_9855", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wolff-Parkinson-White syndrome"}, {"id": "2429270_1_9856", "context": "A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.", "question": "adverse event. Treatment, initiation of procainamide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12439602_3_9857", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Subject, patients presenting with hyperacute changes on ECG. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12439602_3_9858", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Subject, patients presenting with hyperacute changes on ECG. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12439602_3_9859", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Subject, patients presenting with hyperacute changes on ECG. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12439602_3_9860", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Subject, patients presenting with hyperacute changes on ECG. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12439602_3_9861", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Subject, patients presenting with hyperacute changes on ECG. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "hyperacute changes on ECG"}, {"id": "12439602_3_9862", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carboplatin"}, {"id": "12439602_3_9863", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12439602_3_9864", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12439602_3_9865", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12439602_3_9866", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12439602_3_9867", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12439602_3_9868", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12439602_3_9869", "context": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.", "question": "adverse event. Treatment, carboplatin therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_2_9870", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ethambutol"}, {"id": "3115809_2_9871", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_2_9872", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_2_9873", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_2_9874", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_2_9875", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_2_9876", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_2_9877", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, ethambutol. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3115809_2_9878", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "3115809_2_9879", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3115809_2_9880", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3115809_2_9881", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3115809_2_9882", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3115809_2_9883", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3115809_2_9884", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3115809_2_9885", "context": "A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.", "question": "adverse event. Treatment, isoniazid. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11554897_4_9886", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lamotrigine"}, {"id": "11554897_4_9887", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11554897_4_9888", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11554897_4_9889", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11554897_4_9890", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11554897_4_9891", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11554897_4_9892", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11554897_4_9893", "context": "PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.", "question": "adverse event. Treatment, acute lamotrigine poisoning. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6108450_1_9894", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergotamine"}, {"id": "6108450_1_9895", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6108450_1_9896", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6108450_1_9897", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6108450_1_9898", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6108450_1_9899", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6108450_1_9900", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6108450_1_9901", "context": "Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.", "question": "adverse event. Treatment, ergotamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17667887_9_9902", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressant; antipsychotic"}, {"id": "17667887_9_9903", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17667887_9_9904", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17667887_9_9905", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17667887_9_9906", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17667887_9_9907", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17667887_9_9908", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17667887_9_9909", "context": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment.", "question": "adverse event. Treatment, combinations of antidepressant and atypical antipsychotic treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "antidepressant; antipsychotic"}, {"id": "18991509_2_9910", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Subject, a human immunodeficiency virus type 1 (HIV-1)-infected individual. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18991509_2_9911", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Subject, a human immunodeficiency virus type 1 (HIV-1)-infected individual. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18991509_2_9912", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Subject, a human immunodeficiency virus type 1 (HIV-1)-infected individual. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18991509_2_9913", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Subject, a human immunodeficiency virus type 1 (HIV-1)-infected individual. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18991509_2_9914", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Subject, a human immunodeficiency virus type 1 (HIV-1)-infected individual. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18991509_2_9915", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone; ritonavir"}, {"id": "18991509_2_9916", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18991509_2_9917", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18991509_2_9918", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "epidural; injections"}, {"id": "18991509_2_9919", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18991509_2_9920", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18991509_2_9921", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "human immunodeficiency virus type 1"}, {"id": "18991509_2_9922", "context": "We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.", "question": "adverse event. Treatment, combination antiretroviral therapy, which included ritonavir; epidural triamcinolone injections. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "ritonavir; triamcinolone"}, {"id": "6324592_1_9923", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cefmenoxime"}, {"id": "6324592_1_9924", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6324592_1_9925", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6324592_1_9926", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6324592_1_9927", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6324592_1_9928", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6324592_1_9929", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6324592_1_9930", "context": "Disulfiram-like reactions with newer cephalosporins: cefmenoxime.", "question": "adverse event. Treatment, cefmenoxime. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11590881_4_9931", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Subject, patients over the age of 50. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "over the age of 50"}, {"id": "11590881_4_9932", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Subject, patients over the age of 50. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11590881_4_9933", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Subject, patients over the age of 50. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11590881_4_9934", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Subject, patients over the age of 50. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11590881_4_9935", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Subject, patients over the age of 50. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11590881_4_9936", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "11590881_4_9937", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11590881_4_9938", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11590881_4_9939", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11590881_4_9940", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11590881_4_9941", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11590881_4_9942", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11590881_4_9943", "context": "We recommend routine follow up by ECG of patients over the age of 50 treated with carbamazepine.", "question": "potential therapeutic event. Treatment, routine follow up by ECG. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3149484_1_9944", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Subject, A 10-year-old girl with Lennox-Gastaut syndrome. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "10-year-old"}, {"id": "3149484_1_9945", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Subject, A 10-year-old girl with Lennox-Gastaut syndrome. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "girl"}, {"id": "3149484_1_9946", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Subject, A 10-year-old girl with Lennox-Gastaut syndrome. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "3149484_1_9947", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Subject, A 10-year-old girl with Lennox-Gastaut syndrome. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "3149484_1_9948", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Subject, A 10-year-old girl with Lennox-Gastaut syndrome. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "Lennox-Gastaut syndrome"}, {"id": "3149484_1_9949", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lorazepam"}, {"id": "3149484_1_9950", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3149484_1_9951", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3149484_1_9952", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "3149484_1_9953", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3149484_1_9954", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3149484_1_9955", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "atypical absence status seizures"}, {"id": "3149484_1_9956", "context": "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.", "question": "potential therapeutic event. Treatment, intravenous lorazepam. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10485779_10_9957", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Subject, patients receiving ritonavir medication. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10485779_10_9958", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Subject, patients receiving ritonavir medication. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10485779_10_9959", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Subject, patients receiving ritonavir medication. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10485779_10_9960", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Subject, patients receiving ritonavir medication. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10485779_10_9961", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Subject, patients receiving ritonavir medication. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10485779_10_9962", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fentanyl; Ritonavir"}, {"id": "10485779_10_9963", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10485779_10_9964", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10485779_10_9965", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10485779_10_9966", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10485779_10_9967", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10485779_10_9968", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10485779_10_9969", "context": "Ritonavir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.", "question": "adverse event. Treatment, fentanyl. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "fentanyl; Ritonavir"}, {"id": "8739289_7_9970", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Subject, This case. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8739289_7_9971", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Subject, This case. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8739289_7_9972", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Subject, This case. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8739289_7_9973", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Subject, This case. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8739289_7_9974", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Subject, This case. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8739289_7_9975", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "8739289_7_9976", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8739289_7_9977", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8739289_7_9978", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8739289_7_9979", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8739289_7_9980", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8739289_7_9981", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8739289_7_9982", "context": "This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.", "question": "adverse event. Treatment, lithium. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17710018_1_9983", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Subject, A patient with chronic myelomonocytic leukemia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17710018_1_9984", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Subject, A patient with chronic myelomonocytic leukemia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17710018_1_9985", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Subject, A patient with chronic myelomonocytic leukemia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17710018_1_9986", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Subject, A patient with chronic myelomonocytic leukemia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17710018_1_9987", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Subject, A patient with chronic myelomonocytic leukemia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronic myelomonocytic leukemia"}, {"id": "17710018_1_9988", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etoposide"}, {"id": "17710018_1_9989", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low dose"}, {"id": "17710018_1_9990", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17710018_1_9991", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "17710018_1_9992", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17710018_1_9993", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17710018_1_9994", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17710018_1_9995", "context": "A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.", "question": "adverse event. Treatment, using low dose oral etoposide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10442258_2_9996", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "psychotropic"}, {"id": "10442258_2_9997", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10442258_2_9998", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10442258_2_9999", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10442258_2_10000", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10442258_2_10001", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10442258_2_10002", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10442258_2_10003", "context": "Alopecia and hair loss are rare side effects of psychotropic drugs.", "question": "adverse event. Treatment, psychotropic drugs. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11126885_1_10004", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "11126885_1_10005", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11126885_1_10006", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11126885_1_10007", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11126885_1_10008", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11126885_1_10009", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11126885_1_10010", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11126885_1_10011", "context": "Occult quinine-induced thrombocytopenia.", "question": "adverse event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_3_10012", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Subject, a 17-year-old male. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "17-year-old"}, {"id": "19296063_3_10013", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Subject, a 17-year-old male. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "19296063_3_10014", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Subject, a 17-year-old male. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19296063_3_10015", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Subject, a 17-year-old male. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19296063_3_10016", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Subject, a 17-year-old male. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19296063_3_10017", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_3_10018", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single dose"}, {"id": "19296063_3_10019", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_3_10020", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_3_10021", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_3_10022", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_3_10023", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_3_10024", "context": "We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.", "question": "adverse event. Treatment, a single dose of methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9925865_2_10025", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Subject, In patients with swallowing dysfunction and pneumonia. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9925865_2_10026", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Subject, In patients with swallowing dysfunction and pneumonia. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9925865_2_10027", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Subject, In patients with swallowing dysfunction and pneumonia. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9925865_2_10028", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Subject, In patients with swallowing dysfunction and pneumonia. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9925865_2_10029", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Subject, In patients with swallowing dysfunction and pneumonia. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9925865_2_10030", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mineral oil"}, {"id": "9925865_2_10031", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9925865_2_10032", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9925865_2_10033", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9925865_2_10034", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9925865_2_10035", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9925865_2_10036", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9925865_2_10037", "context": "In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.", "question": "adverse event. Treatment, a history of mineral oil use. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15053046_1_10038", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Subject, ESRD patient on CAPD. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15053046_1_10039", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Subject, ESRD patient on CAPD. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15053046_1_10040", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Subject, ESRD patient on CAPD. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15053046_1_10041", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Subject, ESRD patient on CAPD. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15053046_1_10042", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Subject, ESRD patient on CAPD. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "ESRD"}, {"id": "15053046_1_10043", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "15053046_1_10044", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15053046_1_10045", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15053046_1_10046", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15053046_1_10047", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15053046_1_10048", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15053046_1_10049", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15053046_1_10050", "context": "Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.", "question": "adverse event. Treatment, vancomycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16682062_1_10051", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ivermectin"}, {"id": "16682062_1_10052", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16682062_1_10053", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16682062_1_10054", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16682062_1_10055", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16682062_1_10056", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16682062_1_10057", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16682062_1_10058", "context": "First case of ivermectin-induced severe hepatitis.", "question": "adverse event. Treatment, ivermectin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2549018_4_10059", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "2549018_4_10060", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2549018_4_10061", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2549018_4_10062", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2549018_4_10063", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2549018_4_10064", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2549018_4_10065", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2549018_4_10066", "context": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "question": "adverse event. Treatment, fluoxetine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19755414_10_10067", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Subject, patients receiving multiple doses of oxycodone for pain relief. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19755414_10_10068", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Subject, patients receiving multiple doses of oxycodone for pain relief. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19755414_10_10069", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Subject, patients receiving multiple doses of oxycodone for pain relief. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19755414_10_10070", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Subject, patients receiving multiple doses of oxycodone for pain relief. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19755414_10_10071", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Subject, patients receiving multiple doses of oxycodone for pain relief. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19755414_10_10072", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "telithromycin"}, {"id": "19755414_10_10073", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19755414_10_10074", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19755414_10_10075", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19755414_10_10076", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19755414_10_10077", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19755414_10_10078", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19755414_10_10079", "context": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects.", "question": "adverse event. Treatment, telithromycin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17195428_1_10080", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Subject, a 16-year-old girl with cystic fibrosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "16-year-old"}, {"id": "17195428_1_10081", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Subject, a 16-year-old girl with cystic fibrosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "17195428_1_10082", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Subject, a 16-year-old girl with cystic fibrosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17195428_1_10083", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Subject, a 16-year-old girl with cystic fibrosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17195428_1_10084", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Subject, a 16-year-old girl with cystic fibrosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "cystic fibrosis"}, {"id": "17195428_1_10085", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metoclopramide"}, {"id": "17195428_1_10086", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17195428_1_10087", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17195428_1_10088", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17195428_1_10089", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17195428_1_10090", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17195428_1_10091", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17195428_1_10092", "context": "A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.", "question": "adverse event. Treatment, metoclopramide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16099004_4_10093", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; quinine"}, {"id": "16099004_4_10094", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16099004_4_10095", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16099004_4_10096", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16099004_4_10097", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16099004_4_10098", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16099004_4_10099", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malaria"}, {"id": "16099004_4_10100", "context": "Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.", "question": "adverse event. Treatment, phenytoin; quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; quinine"}, {"id": "16688722_1_10101", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin"}, {"id": "16688722_1_10102", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16688722_1_10103", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16688722_1_10104", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16688722_1_10105", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16688722_1_10106", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16688722_1_10107", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16688722_1_10108", "context": "Sporadic rippling muscle disease unmasked by simvastatin.", "question": "adverse event. Treatment, simvastatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_1_10109", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_1_10110", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_1_10111", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_1_10112", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_1_10113", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_1_10114", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_1_10115", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_1_10116", "context": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15719254_1_10117", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cis-retinoic acid"}, {"id": "15719254_1_10118", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15719254_1_10119", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15719254_1_10120", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15719254_1_10121", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15719254_1_10122", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15719254_1_10123", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15719254_1_10124", "context": "Cis-retinoic acid (RA) may further increase the risk of developing BMTN.", "question": "adverse event. Treatment, Cis-retinoic acid (RA). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12546343_3_10125", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Subject, He. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12546343_3_10126", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Subject, He. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "12546343_3_10127", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Subject, He. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12546343_3_10128", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Subject, He. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12546343_3_10129", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Subject, He. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12546343_3_10130", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "12546343_3_10131", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12546343_3_10132", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12546343_3_10133", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12546343_3_10134", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12546343_3_10135", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12546343_3_10136", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12546343_3_10137", "context": "He was later skin tested to confirm allergy to MTX.", "question": "adverse event. Treatment, MTX. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11319599_1_10138", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine"}, {"id": "11319599_1_10139", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11319599_1_10140", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11319599_1_10141", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11319599_1_10142", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11319599_1_10143", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11319599_1_10144", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11319599_1_10145", "context": "Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.", "question": "adverse event. Treatment, fludarabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19296063_1_10146", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "19296063_1_10147", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19296063_1_10148", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19296063_1_10149", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19296063_1_10150", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19296063_1_10151", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19296063_1_10152", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19296063_1_10153", "context": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate.", "question": "adverse event. Treatment, methylphenidate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9527943_3_10154", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Subject, three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "premature infants (mean gestational age 27 weeks)"}, {"id": "9527943_3_10155", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Subject, three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9527943_3_10156", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Subject, three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "9527943_3_10157", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Subject, three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9527943_3_10158", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Subject, three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9527943_3_10159", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "9527943_3_10160", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9527943_3_10161", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9527943_3_10162", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9527943_3_10163", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9527943_3_10164", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9527943_3_10165", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bronchopulmonary dysplasia."}, {"id": "9527943_3_10166", "context": "STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.", "question": "adverse event. Treatment, during dexamethasone treatment for bronchopulmonary dysplasia. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2063999_1_10167", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Subject, A case of the Rett syndrome. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2063999_1_10168", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Subject, A case of the Rett syndrome. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2063999_1_10169", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Subject, A case of the Rett syndrome. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2063999_1_10170", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Subject, A case of the Rett syndrome. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2063999_1_10171", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Subject, A case of the Rett syndrome. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2063999_1_10172", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hopantenate"}, {"id": "2063999_1_10173", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2063999_1_10174", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2063999_1_10175", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2063999_1_10176", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2063999_1_10177", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2063999_1_10178", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Rett syndrome"}, {"id": "2063999_1_10179", "context": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.", "question": "adverse event. Treatment, calcium hopantenate treatment. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25540831_1_10180", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tramadol; selective serotonin reuptake inhibitor"}, {"id": "25540831_1_10181", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25540831_1_10182", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25540831_1_10183", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25540831_1_10184", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25540831_1_10185", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25540831_1_10186", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25540831_1_10187", "context": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.", "question": "adverse event. Treatment, concurrent use of tramadol and selective serotonin reuptake inhibitor. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "tramadol; selective serotonin reuptake inhibitor"}, {"id": "16507380_3_10188", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN alfa-2b"}, {"id": "16507380_3_10189", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16507380_3_10190", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16507380_3_10191", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16507380_3_10192", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16507380_3_10193", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16507380_3_10194", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16507380_3_10195", "context": "Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms.", "question": "adverse event. Treatment, IFN alfa-2b. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_2_10196", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "procainamide"}, {"id": "7474364_2_10197", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7474364_2_10198", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_2_10199", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7474364_2_10200", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7474364_2_10201", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_2_10202", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7474364_2_10203", "context": "Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.", "question": "adverse event. Treatment, Sustained-release procainamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9681211_3_10204", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Subject, a patient with M4 AML. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9681211_3_10205", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Subject, a patient with M4 AML. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9681211_3_10206", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Subject, a patient with M4 AML. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9681211_3_10207", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Subject, a patient with M4 AML. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9681211_3_10208", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Subject, a patient with M4 AML. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9681211_3_10209", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chemotherapy; G-CSF"}, {"id": "9681211_3_10210", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9681211_3_10211", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9681211_3_10212", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9681211_3_10213", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "day 8"}, {"id": "9681211_3_10214", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9681211_3_10215", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "M4 AML"}, {"id": "9681211_3_10216", "context": "We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.", "question": "adverse event. Treatment, standard chemotherapy followed by G-CSF. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "chemotherapy; G-CSF"}, {"id": "7797283_2_10217", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Subject, two patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7797283_2_10218", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Subject, two patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7797283_2_10219", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Subject, two patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "7797283_2_10220", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Subject, two patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7797283_2_10221", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Subject, two patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7797283_2_10222", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "7797283_2_10223", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7797283_2_10224", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7797283_2_10225", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7797283_2_10226", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7797283_2_10227", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7797283_2_10228", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7797283_2_10229", "context": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.", "question": "adverse event. Treatment, omeprazole therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17660778_1_10230", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Bisphosphonate"}, {"id": "17660778_1_10231", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17660778_1_10232", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17660778_1_10233", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17660778_1_10234", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17660778_1_10235", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17660778_1_10236", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17660778_1_10237", "context": "Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.", "question": "adverse event. Treatment, Bisphosphonate. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15338554_4_10238", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Subject, 3 patients with CML. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15338554_4_10239", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Subject, 3 patients with CML. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15338554_4_10240", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Subject, 3 patients with CML. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "15338554_4_10241", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Subject, 3 patients with CML. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15338554_4_10242", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Subject, 3 patients with CML. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15338554_4_10243", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imatinib"}, {"id": "15338554_4_10244", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15338554_4_10245", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15338554_4_10246", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15338554_4_10247", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15338554_4_10248", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15338554_4_10249", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CML"}, {"id": "15338554_4_10250", "context": "OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.", "question": "adverse event. Treatment, imatinib. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8627446_3_10251", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Subject, a few nodules at diagnosis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8627446_3_10252", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Subject, a few nodules at diagnosis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8627446_3_10253", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Subject, a few nodules at diagnosis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8627446_3_10254", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Subject, a few nodules at diagnosis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8627446_3_10255", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Subject, a few nodules at diagnosis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "a few nodules"}, {"id": "8627446_3_10256", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8627446_3_10257", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8627446_3_10258", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8627446_3_10259", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8627446_3_10260", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 to 4 months"}, {"id": "8627446_3_10261", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8627446_3_10262", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8627446_3_10263", "context": "Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.", "question": "adverse event. Treatment, methotrexate therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16449538_3_10264", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Subject, a patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16449538_3_10265", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Subject, a patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16449538_3_10266", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Subject, a patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16449538_3_10267", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Subject, a patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16449538_3_10268", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Subject, a patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16449538_3_10269", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "16449538_3_10270", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16449538_3_10271", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16449538_3_10272", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16449538_3_10273", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16449538_3_10274", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16449538_3_10275", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16449538_3_10276", "context": "CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.", "question": "adverse event. Treatment, ifosfamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6507240_3_10277", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorcainide"}, {"id": "6507240_3_10278", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6507240_3_10279", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6507240_3_10280", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6507240_3_10281", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6507240_3_10282", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6507240_3_10283", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6507240_3_10284", "context": "It is concluded that SIADH is an important side effect of lorcainide therapy.", "question": "adverse event. Treatment, lorcainide therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16221163_8_10285", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SRL"}, {"id": "16221163_8_10286", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16221163_8_10287", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16221163_8_10288", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16221163_8_10289", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16221163_8_10290", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16221163_8_10291", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16221163_8_10292", "context": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.", "question": "adverse event. Treatment, SRL therapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19260037_1_10293", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Subject, 12/12 patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19260037_1_10294", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Subject, 12/12 patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19260037_1_10295", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Subject, 12/12 patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "12/12"}, {"id": "19260037_1_10296", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Subject, 12/12 patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19260037_1_10297", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Subject, 12/12 patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19260037_1_10298", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "19260037_1_10299", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19260037_1_10300", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19260037_1_10301", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19260037_1_10302", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19260037_1_10303", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19260037_1_10304", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19260037_1_10305", "context": "A previous study of patients with \"quinine-associated TTP/HUS\" found that ADAMTS13 activities were not abnormal in 12/12 patients.", "question": "adverse event. Treatment, quinine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9695308_3_10306", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Subject, A teenage girl with crescentic glomerulonephritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "teenage"}, {"id": "9695308_3_10307", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Subject, A teenage girl with crescentic glomerulonephritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "9695308_3_10308", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Subject, A teenage girl with crescentic glomerulonephritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9695308_3_10309", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Subject, A teenage girl with crescentic glomerulonephritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9695308_3_10310", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Subject, A teenage girl with crescentic glomerulonephritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "crescentic glomerulonephritis"}, {"id": "9695308_3_10311", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "9695308_3_10312", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9695308_3_10313", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9695308_3_10314", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9695308_3_10315", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9695308_3_10316", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9695308_3_10317", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperthyroidism without cutaneous vasculitis"}, {"id": "9695308_3_10318", "context": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.", "question": "adverse event. Treatment, propylthiouracil (PTU). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11468878_3_10319", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11468878_3_10320", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11468878_3_10321", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11468878_3_10322", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11468878_3_10323", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11468878_3_10324", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "11468878_3_10325", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11468878_3_10326", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11468878_3_10327", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11468878_3_10328", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11468878_3_10329", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11468878_3_10330", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11468878_3_10331", "context": "Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?", "question": "adverse event. Treatment, metformin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18492617_1_10332", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Subject, patients without a history of seizures. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18492617_1_10333", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Subject, patients without a history of seizures. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18492617_1_10334", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Subject, patients without a history of seizures. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18492617_1_10335", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Subject, patients without a history of seizures. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18492617_1_10336", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Subject, patients without a history of seizures. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18492617_1_10337", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pregabalin"}, {"id": "18492617_1_10338", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18492617_1_10339", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18492617_1_10340", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18492617_1_10341", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18492617_1_10342", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18492617_1_10343", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18492617_1_10344", "context": "Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.", "question": "adverse event. Treatment, pregabalin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8551001_5_10345", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "8551001_5_10346", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8551001_5_10347", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8551001_5_10348", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8551001_5_10349", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8551001_5_10350", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8551001_5_10351", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8551001_5_10352", "context": "We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.", "question": "adverse event. Treatment, azathioprine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15823103_4_10353", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Subject, patients with recurrent ovarian cancer. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15823103_4_10354", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Subject, patients with recurrent ovarian cancer. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15823103_4_10355", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Subject, patients with recurrent ovarian cancer. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "15823103_4_10356", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Subject, patients with recurrent ovarian cancer. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15823103_4_10357", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Subject, patients with recurrent ovarian cancer. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15823103_4_10358", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel; CBDCA; carboplatin; platinum"}, {"id": "15823103_4_10359", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose; 60 mg/m2"}, {"id": "15823103_4_10360", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": "weekly"}, {"id": "15823103_4_10361", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15823103_4_10362", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15823103_4_10363", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15823103_4_10364", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "recurrent ovarian cancer"}, {"id": "15823103_4_10365", "context": "We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.", "question": "adverse event. Treatment, weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy; multiple platinum-based chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "paclitaxel; CBDCA; platinum"}, {"id": "22550162_3_10366", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Subject, The patient. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22550162_3_10367", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Subject, The patient. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22550162_3_10368", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Subject, The patient. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22550162_3_10369", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Subject, The patient. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22550162_3_10370", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Subject, The patient. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22550162_3_10371", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "methotrexate; methotrexate; omeprazole"}, {"id": "22550162_3_10372", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "22550162_3_10373", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22550162_3_10374", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22550162_3_10375", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22550162_3_10376", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22550162_3_10377", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "stress ulcer"}, {"id": "22550162_3_10378", "context": "The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate.", "question": "potential therapeutic event. Treatment, methotrexate. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19249953_6_10379", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Subject, the patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19249953_6_10380", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Subject, the patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19249953_6_10381", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Subject, the patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19249953_6_10382", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Subject, the patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19249953_6_10383", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Subject, the patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19249953_6_10384", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lovastatin; lovastatin"}, {"id": "19249953_6_10385", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19249953_6_10386", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19249953_6_10387", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19249953_6_10388", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19249953_6_10389", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": "12 years"}, {"id": "19249953_6_10390", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19249953_6_10391", "context": "Because the patient had been taking lovastatin for the past 12 years, the possibility that the rhabdomyolysis may have been caused by a drug interaction between lovastatin and a concomitant drug was evaluated.", "question": "adverse event. Treatment, lovastatin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8104147_1_10392", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ibopamine"}, {"id": "8104147_1_10393", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8104147_1_10394", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8104147_1_10395", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8104147_1_10396", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8104147_1_10397", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8104147_1_10398", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "congestive heart failure"}, {"id": "8104147_1_10399", "context": "Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.", "question": "adverse event. Treatment, Ibopamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7474364_1_10400", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Subject, A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "71-year-old"}, {"id": "7474364_1_10401", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Subject, A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "7474364_1_10402", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Subject, A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7474364_1_10403", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Subject, A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7474364_1_10404", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Subject, A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "anterior myocardial infarction"}, {"id": "7474364_1_10405", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sustained-release procainamide"}, {"id": "7474364_1_10406", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "750 mg/day"}, {"id": "7474364_1_10407", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7474364_1_10408", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "7474364_1_10409", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "8 days"}, {"id": "7474364_1_10410", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7474364_1_10411", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "paroxysmal atrial fibrillation"}, {"id": "7474364_1_10412", "context": "A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).", "question": "adverse event. Treatment, oral sustained-release procainamide (750 mg/day). What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18957000_2_10413", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Subject, patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18957000_2_10414", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Subject, patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18957000_2_10415", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Subject, patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18957000_2_10416", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Subject, patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18957000_2_10417", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Subject, patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18957000_2_10418", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "18957000_2_10419", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18957000_2_10420", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18957000_2_10421", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18957000_2_10422", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18957000_2_10423", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18957000_2_10424", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18957000_2_10425", "context": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.", "question": "adverse event. Treatment, heparin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17725438_2_10426", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rifampin"}, {"id": "17725438_2_10427", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17725438_2_10428", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17725438_2_10429", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17725438_2_10430", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17725438_2_10431", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17725438_2_10432", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17725438_2_10433", "context": "Rifampin-induced hypothyroidism without underlying thyroid disease.", "question": "adverse event. Treatment, Rifampin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3149484_2_10434", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Subject, child with atypical absence seizures. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "3149484_2_10435", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Subject, child with atypical absence seizures. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3149484_2_10436", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Subject, child with atypical absence seizures. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3149484_2_10437", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Subject, child with atypical absence seizures. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3149484_2_10438", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Subject, child with atypical absence seizures. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3149484_2_10439", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lorazepam"}, {"id": "3149484_2_10440", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3149484_2_10441", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3149484_2_10442", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3149484_2_10443", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3149484_2_10444", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3149484_2_10445", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "absence seizures"}, {"id": "3149484_2_10446", "context": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.", "question": "adverse event. Treatment, lorazepam. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2568058_2_10447", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Subject, a 70-year-old woman with rheumatoid arthritis. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "70-year-old"}, {"id": "2568058_2_10448", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Subject, a 70-year-old woman with rheumatoid arthritis. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "2568058_2_10449", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Subject, a 70-year-old woman with rheumatoid arthritis. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2568058_2_10450", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Subject, a 70-year-old woman with rheumatoid arthritis. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2568058_2_10451", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Subject, a 70-year-old woman with rheumatoid arthritis. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2568058_2_10452", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillamine"}, {"id": "2568058_2_10453", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2568058_2_10454", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2568058_2_10455", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2568058_2_10456", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 year"}, {"id": "2568058_2_10457", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2568058_2_10458", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "2568058_2_10459", "context": "Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.", "question": "adverse event. Treatment, penicillamine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14964753_1_10460", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ramipril"}, {"id": "14964753_1_10461", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14964753_1_10462", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14964753_1_10463", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14964753_1_10464", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14964753_1_10465", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14964753_1_10466", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14964753_1_10467", "context": "Cutaneous vasculitis secondary to ramipril.", "question": "adverse event. Treatment, ramipril. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15463865_5_10468", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "15463865_5_10469", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15463865_5_10470", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15463865_5_10471", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15463865_5_10472", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15463865_5_10473", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15463865_5_10474", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15463865_5_10475", "context": "Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.", "question": "adverse event. Treatment, ciprofloxacin. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25295553_4_10476", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Subject, 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. What is the age of the subject?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "25295553_4_10477", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Subject, 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. What is the gender of the subject?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "25295553_4_10478", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Subject, 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. What is the number of subjects?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "2"}, {"id": "25295553_4_10479", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Subject, 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. What is the race of the subject?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "25295553_4_10480", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Subject, 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. What is the disorder of the subject?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "25295553_4_10481", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clozapine; Pregabalin"}, {"id": "25295553_4_10482", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "25295553_4_10483", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "25295553_4_10484", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "25295553_4_10485", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25295553_4_10486", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "25295553_4_10487", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "anxiety symptoms; schizophrenia"}, {"id": "25295553_4_10488", "context": "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.", "question": "potential therapeutic event. Treatment, Pregabalin was added to clozapine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Pregabalin; clozapine"}, {"id": "3718111_2_10489", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "timolol"}, {"id": "3718111_2_10490", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3718111_2_10491", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3718111_2_10492", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3718111_2_10493", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3718111_2_10494", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3718111_2_10495", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3718111_2_10496", "context": "Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.", "question": "adverse event. Treatment, timolol; a topically applied beta-adrenergic antagonist. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8329789_1_10497", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Subject, pediatric patients. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "8329789_1_10498", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Subject, pediatric patients. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8329789_1_10499", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Subject, pediatric patients. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8329789_1_10500", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Subject, pediatric patients. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8329789_1_10501", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Subject, pediatric patients. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8329789_1_10502", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "8329789_1_10503", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8329789_1_10504", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8329789_1_10505", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8329789_1_10506", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8329789_1_10507", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8329789_1_10508", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8329789_1_10509", "context": "Amphotericin B overdose in pediatric patients with associated cardiac arrest.", "question": "adverse event. Treatment, Amphotericin B overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15279668_3_10510", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FLA; Ara-C"}, {"id": "15279668_3_10511", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15279668_3_10512", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15279668_3_10513", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "15279668_3_10514", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "sixth course"}, {"id": "15279668_3_10515", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15279668_3_10516", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15279668_3_10517", "context": "Of particular interest is that toxicity only occurred during the second course of FLA and sixth course of Ara-C containing chemotherapy.", "question": "adverse event. Treatment, second course of FLA and sixth course of Ara-C containing chemotherapy. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": "FLA; Ara-C"}, {"id": "15112258_8_10518", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Subject, 12 cases. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15112258_8_10519", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Subject, 12 cases. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15112258_8_10520", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Subject, 12 cases. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "12"}, {"id": "15112258_8_10521", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Subject, 12 cases. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15112258_8_10522", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Subject, 12 cases. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15112258_8_10523", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "15112258_8_10524", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15112258_8_10525", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15112258_8_10526", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15112258_8_10527", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15112258_8_10528", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15112258_8_10529", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15112258_8_10530", "context": "The literature search found 12 cases of radiation recall caused by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9491301_4_10531", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Subject, Two heroin addicts, aged 34 and 19 years. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "aged 34 and 19 years"}, {"id": "9491301_4_10532", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Subject, Two heroin addicts, aged 34 and 19 years. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9491301_4_10533", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Subject, Two heroin addicts, aged 34 and 19 years. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "9491301_4_10534", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Subject, Two heroin addicts, aged 34 and 19 years. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9491301_4_10535", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Subject, Two heroin addicts, aged 34 and 19 years. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "heroin addicts"}, {"id": "9491301_4_10536", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heroin"}, {"id": "9491301_4_10537", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "9491301_4_10538", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9491301_4_10539", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "9491301_4_10540", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9491301_4_10541", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9491301_4_10542", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9491301_4_10543", "context": "Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.", "question": "adverse event. Treatment, intravenous heroin overdose. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9988365_3_10544", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What are the drugs used in the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9988365_3_10545", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What is the dosage of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9988365_3_10546", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What is the frequency of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9988365_3_10547", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What is the route of the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9988365_3_10548", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9988365_3_10549", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. How long did the treatment last?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9988365_3_10550", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What is the disorder targeted by the treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "eosinophilia"}, {"id": "9988365_3_10551", "context": "Successful challenge with clozapine in a history of eosinophilia.", "question": "potential therapeutic event. Treatment, clozapine. What are the drugs used in combination?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16352777_1_10552", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Subject, A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "16352777_1_10553", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Subject, A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "16352777_1_10554", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Subject, A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16352777_1_10555", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Subject, A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16352777_1_10556", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Subject, A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": "cardiomyopathy; \"sulfa\" (trimethoprim/sulfamethoxazole) allergy"}, {"id": "16352777_1_10557", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "furosemide"}, {"id": "16352777_1_10558", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16352777_1_10559", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16352777_1_10560", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16352777_1_10561", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16352777_1_10562", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16352777_1_10563", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16352777_1_10564", "context": "CASE SUMMARY: A 57-year-old female with cardiomyopathy and \"sulfa\" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.", "question": "adverse event. Treatment, furosemide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6510223_2_10565", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Subject, a diabetic patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6510223_2_10566", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Subject, a diabetic patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6510223_2_10567", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Subject, a diabetic patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6510223_2_10568", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Subject, a diabetic patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6510223_2_10569", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Subject, a diabetic patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6510223_2_10570", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorpropamide"}, {"id": "6510223_2_10571", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6510223_2_10572", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6510223_2_10573", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6510223_2_10574", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6510223_2_10575", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6510223_2_10576", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic"}, {"id": "6510223_2_10577", "context": "Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.", "question": "adverse event. Treatment, chlorpropamide. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17505739_1_10578", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Subject, the patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17505739_1_10579", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Subject, the patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17505739_1_10580", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Subject, the patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17505739_1_10581", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Subject, the patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17505739_1_10582", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Subject, the patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17505739_1_10583", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone"}, {"id": "17505739_1_10584", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17505739_1_10585", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17505739_1_10586", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": "Intravitreal"}, {"id": "17505739_1_10587", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17505739_1_10588", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17505739_1_10589", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17505739_1_10590", "context": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.", "question": "adverse event. Treatment, Intravitreal triamcinolone. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8961730_2_10591", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Subject, patient. What is the age of the subject?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8961730_2_10592", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Subject, patient. What is the gender of the subject?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8961730_2_10593", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Subject, patient. What is the number of subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8961730_2_10594", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Subject, patient. What is the race of the subject?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8961730_2_10595", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Subject, patient. What is the disorder of the subject?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8961730_2_10596", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What are the drugs used in the treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "8961730_2_10597", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What is the dosage of the treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8961730_2_10598", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What is the frequency of the treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8961730_2_10599", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What is the route of the treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8961730_2_10600", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. How long has elapsed from the treatment to the occurence of the event?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 months"}, {"id": "8961730_2_10601", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. How long did the treatment last?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8961730_2_10602", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What is the disorder targeted by the treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "8961730_2_10603", "context": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.", "question": "adverse event. Treatment, 4 months of isoniazid prophylaxis. What are the drugs used in combination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}]}